A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1240

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1240
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 1291

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1291
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/system/core/Exceptions.php:271)

Filename: controllers/Trial.php

Line Number: 1333

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1333
Function: header

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/system/core/Exceptions.php:271)

Filename: controllers/Trial.php

Line Number: 1334

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1334
Function: header

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/system/core/Exceptions.php:271)

Filename: controllers/Trial.php

Line Number: 1335

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/application/controllers/Trial.php
Line: 1335
Function: header

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/circ/index.php
Line: 315
Function: require_once

ࡱ;                ! " # $ % & ' (  Oh+'0t X`8 T `l Office 2007 XLSX Test Document Office 2007 XLSX Test DocumentMaarten Balliauwoffice 2007 openxml phpDTest document for Office 2007 XLSX, generated using PHP classes.Maarten Balliauw@QX߃@QX߃՜.+,0 PXt | Test result file  Worksheet Feuilles de calcul  B=%r8X"1Calibri                83ffff̙̙3f3fff3f3f33333f33333TrialDBg C$(_thV00000000000(6R\O:00000000QHr cO'Ye,gOOS :e.s_PMID_URLn0eW[R0J0OD0n00000n00000kk00000Y00S0h0g0PubMedn00000Ng0M0~0Y00TrialtfnameCompactSummaryu`'YR^e.s_000zvhe.s_gezvh e.s_PMID_URL 1+1 TrialD;biQ000000n0wD0NTICDo0_[;bn0iQ09eUW0 ;bwk0vS_n0X'YL0000_0k00K0K000Z0 NiR\ORo0XRW0j0K0c0_00 Nte2004t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/15326069?report=DocSum&format=html3V FFR-FRIENDSThree-vessel Fractional Flow Reserve for the Assessment of Total Physiologic Atherosclerotic Burden and Its Clinical Impact in Patients with Coronary Artery Disease[3V-FFRutvk0UOU00_0RlxSburdenn0cjg0B003gn0FFR$Pn0T n0聊^va0i*</sup>0_ NhQ Nte2016t^04gNhttp://www.ncbi.nlm.nih.gov/pubmed/27029350,27029349?report=DocSum&format=htmlAATAC-AFLAblation vs Amiodarone for Treatment of AFib in Patients with CHF and an ICD<EFf"40%0NYHA__jR^II-III^0c}'`AFn0NTICD0CRTD i0`k0J0Q00wgAFQzvN2Rg02015t^03gABACASsAdjunctive Balloon Angioplasty after Intravascular Ultrasound-guided Optimal Directional Coronary Atherectomy StudyDDCAXSrh0DCA 0000Rb5_n0Qrzk0[Y00Rg0k0g\@{_n09eU kX[rzb6RRgDCA 0000Rb5_DCA*01999t^10gEhttp://www.ncbi.nlm.nih.gov/pubmed/10520785?report=DocSum&format=htmlAbbate A, et al.=%`'`_K{h^XAMI K0012Bf^60e_n0h^XN@{IRA x0n0PCIk000 __jJ00s0uX[sL0 gak09eUW0_000000000000000 CABG ABC`Alpha-Glucosidase-Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT-0000000;[n0_K{h^XN!kN2n0i0 |?\u Z@'`_u`2005t^09gABCD.Appropriate Blood Pressure Control in Diabetes<!--2L-N-->;-N1XJT=S12</sub>bbprasugreln0MRbN@{ q_MR PCIeLBf h0^MRbNPCIeLBfn00 n0 gR'`0kY0007e_n0_@{{k _K{h^XMI 3RS-N }%`Q@LQ^S GP IIb/IIIa;[bNn0T0000000MRbNR"^MRbN0TIMI'YQ@000MRbN^MRbN*02013t^09g2014t^12gWhttp://www.ncbi.nlm.nih.gov/pubmed/23991622,23991623,25524333?report=DocSum&format=htmlA Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with Non-ST-elevation MIPCIeLN[n0^ST NfW%`'`QuPNSTE-ACS `k0J0D0f0 b@\g000000prasugrel 0:eBfh0hTSgk0bNY00MRbNg0o0 8^n0hTSg1VbNk0O00y0 7e_n0TIMI'YQ@000L0XRW0 _@{0000n0b6R0000j0K0c0_00 ACCOMPLISHhAvoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension_ACE;[benazepril CabbamlodipineuO(ubNo0benazepril )R?\hydrochlorothiazideuO(ubN00_@{{k _@{00000 gak0b6R02015t^02g{http://www.ncbi.nlm.nih.gov/pubmed/19052124,19052130,15363822,25529596,23219284,20620720,20170948?report=DocSum&format=htmlhAvoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension3ؚ000ؚ@'W`k0J0Q00uO(uM'WlBvn0kACE;[ Cabb vs ACE;[ )R?\ 0ACCORD1Action to Control Cardiovascular Risk in DiabetesTSA Coronary Disease Trial Investigating Outcome with Nifedipinepwg\O(uWCabbnifedipinen00^0i0M'WRgnifedipine0000*0hQ{kN %`'`_K{h^X 㖻l'`r_u eU'`_ NhQ [0kY03RS-N +gh@{@LQ^SnifedipineR"000002005t^03gNhttp://www.ncbi.nlm.nih.gov/pubmed/15351192,15716708?report=DocSum&format=htmlKA Coronary Disease Trial Investigating Outcome with Nifedipine ؚ@'W`00㉐g 0_@{0000b6RRgo0 140/90mmHg*gnk0ky0140/90mmHgN Nn0eL0ؚD002005t^06gCA Coronary Disease Trial Investigating Outcome with Nifedipine GITS6uP'`n0[[r_uk0J0D0f0 br_ulBv Cabbnifedipineo0r_u e_ NhQ 3RS-N0b6R0 ACTIV in CHF\Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure]00000002S[SObbtolvaptano024Bf_n0SO͑NO Nso0tolvaptan 60mg90mg30mg00000_ NhQ`StolvaptanR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/15113814?report=DocSum&format=html ACTIV IN CHF^Acute and Chronic Therapeutic Impact of a Vasopressin 2 Antagonist in Congestive Heart FailureSF0c0@'`_ NhQ`k0J0D0f0 jnlBv 00000002S[SObbtolvaptank000 %`'`gn0SO͑L0 gak0NO NW0 ba'`gn0_ NhQ`So00000k0 ga]j0W002003t^11gACTIVATE6ACAT Intrvascular Atherosclerosis Treatment Evaluationoacyl-coenzyme A: cholesterol acyltransferase ACAT ;[pactimiben000000'`RlxS2U\b6RRg0i000000ϑn0 YSpactimibeR"000002006t^03gEhttp://www.ncbi.nlm.nih.gov/pubmed/16554527?report=DocSum&format=htmlhEffect of ACAT Inhibition on the Progression of Coronary Atherosclerosis: A Randomized, Controlled TrialACAT;[k0RlxS2U\b6RRgo0000Z002005t^11gACTIVE AYAtrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events Anclopidogreln0aspirinx0n0RbNn0 gR'`0aspirinh0kY000 ;N@{0000b6RRgclopidogrel aspirinaspirin*0yrk03RS-NN2RgL0ؚD0L0Q@000L0X'Y02009t^05g2010t^10g`http://www.ncbi.nlm.nih.gov/pubmed/19336502,19439748,16781218,20979470?report=DocSum&format=htmlYAtrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events0APwarfarin Ni_n03RS-N000n0ؚD0_?b0}R`k0J0D0f0 clopidogreln0aspirinx0n0RbNo03RS-N0 gak0b6RW0_0L0 Q@000L0X'Y02009t^03gACTIVE IWAtrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular EventsiARB irbesartann0_@{0000b6RRg0iY0003RS-N _K{h^X @{{kn0T0000000 3RS-N _K{h^X @{{k _ NhQk000eQbn0T0000000irbesartanR"00000ؚ@'W NteEhttp://www.ncbi.nlm.nih.gov/pubmed/21388310?report=DocSum&format=htmlACTIVE-I;S.~g@'Wg"110mmHgn0_?b0}R`k0J0D0f0 irbesartano00000k0ky0_@{0000zvu0b6RW0j0D00ACTIVE Web@\gclopidogrel aspirinuO(ubNn0@{0000b6RRgL0L}SbQVk0R0j0D0S0h00i<03RS-N ^-Ng^yL}|hQ'`^Xhu _K{h^X @{{kb6RRgbQVb@\g*02006t^06gNhttp://www.ncbi.nlm.nih.gov/pubmed/16765759,18036454?report=DocSum&format=htmlACTIVE-W9_?b0}R`n0@{0000N2k0J0D0f0bQVwarfarin o0clopidogrel aspirin0QP00ACUITY=Acute Catheterization and Urgent Intervention Triage Strategy^b00000bivalirudink000bQVBvl0i0Z@'`0000 ͑'Yj0Q@b6RRgbivalirudin GP IIb/IIIaR"heparin GP IIb/IIIa02016t^12ghttp://www.ncbi.nlm.nih.gov/pubmed/17124018,27978944,24561145,22483327,22575311,21658558,20359590,20142447,20026777,19460609,19298914,19171852,19022155,18755342,18452778,18436116,18056903,17394970,17368152,17299194?report=DocSum&format=html<Acute Catheterization and Urgent Intervention Triage Settinga%`'`QuPk0J0D0f0 b00000bivalirudinXSrbNo0heparin GP IIb/IIIa reductase;[k0ky030e_n0 g[000004O0j0D0uX[s0 gak0 Nf0ACUTEVAnalysis of Coronary Ultrasound Thrombolysis Endpoints in Acute Myocardial Infarction3L}vL}{vQRl@hnBvln0聊^S'`0i0QLpAmbRTIMI grade 3 o087%01997t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/9118507?report=DocSum&format=htmlBAssessment of Cardioversion Using Transesophageal Echocardiographyj_egn0d0}R[eMR31n0bQVBvlh0L}ߘS_000k000wgn0bQVBvln0 gR'`0k0^Xh0000_eglBvR"L}ߘS_000 Q@0000b6R d0}R~0g0n0Bfw.~RgL}ߘS_000_eglBv*02001t^05gWhttp://www.ncbi.nlm.nih.gov/pubmed/11346805,15063433,14607452?report=DocSum&format=htmlADAPT2-Hour Accelerated Diagnostic Protocol to Assess Patients with Chest Pain Symptoms Using Contemporary Troponins as the Only BiomarkerMŏ:e000000ADPTIMI0000 ECGk0Z@'` YSj0W0 @n00000Ick8^{Vn03d0n0Wn g0egbL0Sj0NO000`0yr[g0M0002012t^06gNhttp://www.ncbi.nlm.nih.gov/pubmed/22578923,22651866?report=DocSum&format=html ADAPT-DES@Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents2dRuO(u< b@\gBvl[e-Nn0@\gS_'`h0聊^0^n0O0iY000clopidogrelbN Nn0@\gS_'`ؚ$Po0 1t^_n00000@hu _K{h^X000n0X'Y 聊^vk0OULh0j00Q@000n0NO Nh0 gak0#W0_0L0 {kNh0o0#[0Z00Ne aspirinbN Nn0ؚ$Po0 Q@000n0NO Nh0#W0_0L0 ]0n0Nn00^h0n0#o0000Z002015t^09gahttp://www.ncbi.nlm.nih.gov/pubmed/23890998,,23890996,26314532,24281330?report=DocSum&format=html AdaptResponse@]00000 gY00_ NhQ`k0J0Q00AdaptivCRT000000-d 0000k000_[Q TgBvle,gSRn0NLuqQ Txvz 2014t^07gADDITION-EuropenAnglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care-Europen0000000g02W|?\uL0zvU00_0Bfp :eBfK00n0YVP[7_SNeQk000_@{u`0b6Rg0M00K00iY000egn0YVP[7_S{tk000_@{0000J00s0{kNb6RRgo0\U0O0 jnlBvh0ky0f0 ga]o0000j0K0c0_002011t^07gWhttp://www.ncbi.nlm.nih.gov/pubmed/21705063,21705070,21340624?report=DocSum&format=html2011t^06gADEG*Antiarrhythmic Drug Evaluation Group studycb Nteflecainide, propafenone, amiodaronen0wgvj0Rg0k0 gR'` 00000000amiodaroneflecainide, propafenone01992t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/1396837?report=DocSum&format=htmlADMIRALqAbciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up@\gGPIIb/IIIaS[SObbabciximab h00000n0uO(uBvlL0 0000XSrn04XTh0kW0f0 gRg0B00K00i030eNQn0{kN Qh^X jv@{n0}%`@LQ^Sb6RRg TIMI grade 3n0TbRgabciximab0000*02001t^06g2005t^12gNhttp://www.ncbi.nlm.nih.gov/pubmed/11419426,16249219?report=DocSum&format=htmlADOPT%Atrial Dynamic Overdrive Pacing TrialzAF Suppression Algorithm DDDRn0 gR'`J00s0[hQ'`0i0uP'`AFc}sAFzvuepe/epe AF Suppression Algorithm DDDRk000v[NO Nso025%g0B0c0_0L0 v}[vj0]o0\U0D002003t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/12932592?report=DocSum&format=html<Apixaban Dosing to Optimize Protection from Thrombosis TrialeQbgJ00s0b_wgn0Y@h^XhuVTE N2bNh0W0f0 L}Svc,{XaVP[;[apixabann0^wbNh0NORP[ϑheparinenoxaparin wgbNh00k30en0lBvg-Nn0VTE#{k hQVTE ^uP'` NяMOmY@hu n0T0000000apixabanR"enoxaparin0ؚ@'W ]0n0N2011t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/22077144?report=DocSum&format=html6Apixaban Dosing to Optimize Protection from Thrombosis%`'`u`k000eQb`n0mY@huVTE 000o0b_k0X'YY000b_0}}Y00vc,{XaVP[;[000000apixaban n0wgN2bNk000VTE VTE{kn0b6Ro0 00bNgn0wD0enoxaparinh0 TI{g0 Q@000L0X'Y0 ADORE"Aggressive Diagnosis of Restenosis2001t^03gADVANCEKAdditional Value of NIR Stents for Treatment of Long Coronary Lesions StudyYwD0u Ywk0J0D0f0 0000k000iP}g0__0_n0R0000provisional stenting n0 gR'`0i0;Nj0 g[_0000b6RRgR0000R"[gq02002t^02g2004t^07gNhttp://www.ncbi.nlm.nih.gov/pubmed/11823075,15234398?report=DocSum&format=htmlV^yL}f[v0000n0yr_0㉐gY000L}00000v'YR_ncSTAVR _n03RS-Nzvuso0eg `gh00k0NOK0c0_00^yL}f[v0000n0N,nVP[o0zvuBfgk000puj0c0_00]0n0N uf[2015t^07gNhttp://www.ncbi.nlm.nih.gov/pubmed/26184612,26184613?report=DocSum&format=htmlI_y i__jOk0J0D0f0 \W][܈R_tňnHVAD i0n0180e_n0bRsuX[ y i[e __jV_k00000001 o0_egn00n0h0 TI{0XAction in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled EvaluationK2W|?\u`k0J0D0f0 ACE;[perindopril /000000|)R?\indapamidek000M'Wo0 {kN _@{00000 gak0b6R02007t^09gAAssessing Diagnostic Value of Non-invasive FFRCT in Coronary Care0QR00k0J0Q00^OrvQ@AmNPϑkFFRCT n0:eO$Pn0UOe,gSRn0NLuqQ Txvz ADVANCE IIILAvoid Delivering Therapies for Non-sustained Arrhythmias in ICD Patients IIIk_[;biQ-[0000000jnvj018/24K0030/40k0^wW0_04XTk0 b;b00000ATP 0000L0n\Y00K00iY000ATP 0000n0}peb6RRg000000^wjn000000*02013t^05gNhttp://www.ncbi.nlm.nih.gov/pubmed/23652522,23652525?report=DocSum&format=htmlADVANCE-@'W000000f[@'W000000k000'Y@{J00s00}\@{u`x0n0 gR'`0iY000'Y@{u` 0}\@{u`b6RRgACE;[perindopril-)R?\indapamide0000*02014t^10ghttp://www.ncbi.nlm.nih.gov/pubmed/17765963,25234206,23926207,19470869,19282274,19225038,15975103,17579315?report=DocSum&format=htmlADVANCE-@|000000fdS*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/26794722?report=DocSum&format=htmlKurL0[[W0f0D0080skN Nn0NSTE-ACS`k0J0D0f0OrvlBvQR q__ lBv0zl[ o0irk000QyvlBvk0O00y00^L09eUY00K00i0AGATHA*A Global Atherothrombosis Assessment StudyX00000@hu0;NVh0Y00RlxS'`u`o02d0N Nn0MOg0zvuY00S0h00YO0 {- NU@'WkABI o0qSzVP[000000 00000@hun0MOJ00s0 z^h0#W0_002006t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/16820367?report=DocSum&format=htmlAgeno W, et al.%_@{u`n0qSzVP[o0Y@h^XhuVTE zvu000n0 Nfh0#Y000AGENT&Adenovirus FGF Angiogenic Gene TherapyAIDA;Amsterdam Investigator-Initiated Absorb Strategy All-Comers[hQ'`n0a_K00000[hQ'`000000YTOL0RJTW0_0eg1XJTPCIeLOg0n0jv@{ NhQk0J0D0f0 everolimusnQuSO8TS'`00000000BVS h0ё^\0000k0 ga]o0j0K0c0_00W0K0W0 BVSo02t^n00000@hun0ؚzvush0#W0_002017t^06gEhttp://www.ncbi.nlm.nih.gov/pubmed/28402237?report=DocSum&format=html AIDA STEMIcAbciximab Intracoronary versus Intravenously Drug Application in ST-Elevation Myocardial InfarctionyPCI0eLY00ST NfW_K{h^X`k0J0D0f0 hTSgn0@\gGP IIb/IIIaS[SObbabciximabQRQ0000bNo0jnvj00000Ylk0ky0 90e_n0hQ{kN Qh^X eF0c0@'`_ NhQn0T00000000b6RW0j0D00AIM-HIGHxAtherothrombosis Intervention in Metabolic Syndrome with Low HDL/High0Triglycerides and Impact on Global Health Outcomes]LDL-C70mg/dLn000000'`RlxS`k0J0D0f0 36K0gn0niacinn00000x0n0Rk000HDL-CJ00s0TGo09eUW0_0L0 0^k0[Y00 NWN[0Rgo0000j0K0c0_00 Z@'`_u` 3_t2013t^10g`http://www.ncbi.nlm.nih.gov/pubmed/22085343,22085318,23916935,23973688?report=DocSum&format=html-00000n0simvastatinx0n0Ro0_@{u``k0J0Q00@{00000b6R[0Z002011t^11gAIMS"APSAC Intervention Mortality Study+@hn㉬APSACn01t^uX[sk0[Y00 g(u'`0i0uX[sAPSAC0000*01990t^02gDhttp://www.ncbi.nlm.nih.gov/pubmed/1968167?report=D< ocSum&format=htmlAIPRI0ACE Inhibitionin Progressive Renal InsufficiencyQACE;[benazepriln0[hQ'`J00s0kX[N_jOwRg0i00000000000000L030^45mL/Rn0-NI{^n0N[uOg00N_jn0Owk0 gR0N_j[1999t^Ehttp://www.ncbi.nlm.nih.gov/pubmed/10028949?report=DocSum&format=htmlAir PAMI0Air Primary Angioplasty in Myocardial Infarction<PTCA Nj0ubg0n0gon0QLpAml0i030e_n0;Nj0_0000b6RRgprimary PTCA@hnBvl02002t^06gNhttp://www.ncbi.nlm.nih.gov/pubmed/12039480,14522475?report=DocSum&format=htmlAIRCRAFTOAustralian Intervention Randomized Control of Rate in Atrial Fibrillation TrialZ__j0?b[cT萢0000000 00000AVJAP h0 dRk000_bpe000000h00k012K0g_n0EF 000000wfk000KRBfAVJAPR"irBvl02003t^05gEhttp://www.ncbi.nlm.nih.gov/pubmed/12767649?report=DocSum&format=htmlAIRE(Acute Infarction Ramipril Efficacy Study3ACE;[ramipriln0hQ{kNk0[Y00Rg0i0hQ{kNb6RRgramipril0000*0 Z@'`_u` _ NhQ1997t^05gThttp://www.ncbi.nlm.nih.gov/pubmed/8104270,9049514,9167457?report=DocSum&format=htmlAKDNAlberta Kidney Disease Network'0000n0ig$P0O(uW0_0Y͑N,n000k000b_n0͑^CKD0N,ng0M0002017t^11gEhttp://www.ncbi.nlm.nih.gov/pubmed/29136443?report=DocSum&format=htmlALBIONxAssessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis TrialwaspirinI{n0jnlBvk0b@\gclopidogrelRbNW0_04XTn0Rgn0iclopidogrel 300mgN N600mg 900mg g0bN0YY00h0 @\gQƖ;[RgL0ؚO0 24Bf_~0g0n0@\g;m'`0NO NY000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16949482?report=DocSum&format=htmlALCADIAKAutologous Human Cardiac-derived Stem Cell To Treat Ischemic CardiomyopathyCABG0eLY00Z@'`_K{u`k0[Y00]_Ӂy^0}ހCSC y ih0iXW'`}}0}ހXkVP[basic fibroblast growth factorbFGF _>e000Nk000000000KbS*o0[hQg0 ][ƙQsL09eUW022.6!34.7% gR'`n0S'`L0:yU000,{1vf: 6Oe60g 02012t^11gAldo-DHF8Aldosterone Receptor Blockade in Diastolic Heart FailureXb5_'`_ NhQ`k0J0D0f0 0000000S[SObb00000000spironolactone o0 120g_n0b5__j09eUW0_0L0 KRRo09eU[0Z0,{IIbvf 0 AleCardioj%`'`QuPzvu_n02W|?\u`k0J0D0f0 eL}SPPAR-/00000 00000000aleglitazar n0jnlBvx0n0Rk000_@{000NO No0000Z0 S'`n0N_j[ ÀxQ@L0XR02014t^03gALERTEffects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance with Coronary Artery Disease(0000 i0uOk0J0Q00ߘ_N@|9eUacarbosen0N!kN2Rgn0i0 Z@'`_u` |?\uvcv000;[ aliskiren valsartanThe Direct Renin Inhibitor Aliskiren in Combination with the Angiotensin Receptor Blocker Valsartan Provides Additional Blood Pressure-Lowering Effects Compared with Either Agent Alone in Patients with Hypertension.@^^-NI{^n0ؚ@'W`k0J0D0f0 aliskiren valsartanh00k0o}Yk0M'WW0_0L0 uO(ubNk0vRRgL0:yUU00_002007t^03gALIVENAmiodarone versus Lidocaine in Prehospital Ventricular Fibrillation EvaluationRlvd0}Rn0܈RBvlh0W0f0n0b Nten0 gR'`0lidocaineh0amiodaroneh0g0k0uX[W0f0eQbY00Rgamiodaronelidocaine02002t^03gEhttp://www.ncbi.nlm.nih.gov/pubmed/11907287?report=DocSum&format=html*Azimilide Post Infarct Survival EvaluationMIIIb Nteazimiliden0hQ{kNJ00s0{kV%Rn0b6RRg0i0azimilideo0_K{h^X_n0{kNs09eUY00S0h00`SU0[00S0h00j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/14967728,15063432?report=DocSum&format=html*Azimilide post-infarct Survival EvaluationR_K{h^X_n0z6q{k000OJ00s0z6q{kؚ000Ok0J0D0f0 Iks/Ikr0b6RY00IIIb Nteazimilide 100mgn0{kNb6RRgo0000j0K0c0_00 ALKK-StudyIStudy of the Arbeitsgemeinschaft Leitende Kardiologische KrankenhausarzteOL}vv@LQ^Sh0irBvlh00k01t^_n00000Qh^X QPTCA CABG B00D0o0͑^r_uk000QeQb 04O0j0D0uX[sPTCAirBvl0Nhttp://www.ncbi.nlm.nih.gov/pubmed/12939210,15936604?report=DocSum&format=html&All-Japan Utstein Registry of the FDMAEAll-Japan Utstein Registry of the Fire and Disaster Management AgencyAlQqQn04Xx0n0RSOYd0}RhVAED n0-nk000_S'`bY_\PbkK001K0g_n0^yL}f[v[L0B0c0f00^n0uX[sL0 NfW0f0D0002016t^10gihttp://www.ncbi.nlm.nih.gov/pubmed/20237345,27783922,26197185,20606122,20202679?report=DocSum&format=htmlALLAY)Aliskiren in Left Ventricular HypertrophyvcvL}S000;[aliskiren ARB losartanuO(ubNn0]['Y.~Rgo0 losartanXSrbN00*Q0f0D00K00i0aliskirenn0][K{.~Rgo0losartanh0 TI{g0B00L0 aliskiren losartanuO(ubNk000losartanXSrbN0QP0M'WRgh0o0rzW0_0 gaj0.~Rgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/19153265?report=DocSum&format=html4Aliskiren Left Ventricular Assessment of Hypertrophy-NSO͑n0]['Yؚ@'W`k0J0D0f0vcv000;[aliskirenn0 g(u'`L0:yU0000ALLHATKAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialCabbamlodipine ACE;[lisinoprilk000M'WBvln0{k'`CHD ^{k'`_K{h^Xb6RRgo0)R?\< chlorthalidonelBvh0 TI{nedoxazosinn0fo02000t^1gk0-Nbk 0HMG-CoA reductase;[pravastatinn0{kNb6Ro08^lBvh0ky0f0 ga]j0W00 ؚ@'W pu8^u2017t^01ghttp://www.ncbi.nlm.nih.gov/pubmed/12479763,12479764,10789664,11208751,12925554,27893045,24779706,22396585,22431578,21969009,19926008,19001024,18212314,18227370,17101936,16461961,16651474,16864749,15983290,15851647,15967849,15811979?report=DocSum&format=html ALLHAT (CHDO)cAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 000000BfCHDO;24%=g0n0i Q{kv~0_0o0^{kv_K{h^XB00D0o0hQ{kNB00D0o0+ggN[n0b6RRgk0J0D0f0 CHDn0 g!q0OU0Z0amlodipineh0lisinoprilk0 ga]j0W00ALLHAT (000000000000) Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial |?\uO0dO020,198OK00000}1YO0dD0_00n00000000000000;MetS=*8013O ^MetS;non-MetS=9502Og0i0amlodipine vs lisinopril vs chlorthalidone F000000000000n0 g!q0OU0Z0amlodipine lisinopril chlorthalidonen00^o0 Tig0B0c0_00EAntihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackҞNk0J0D0f0o0 )R?\0M'WlBvn0,{Nxbh0Y00y0M0g0B000ALLIANCE>Aggressive Lipid-Lowering Initiation Abates New Cardiac EventscHMG-CoA reductase;[atorvastatink000MzuivNO NBvlh08^lBvh00k0MzuivlBvn0LDL-Co095mg/dLk0 gak0NO N00000b6RRgMzui8^*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15519006?report=DocSum&format=htmlBThe Aggressive Lipid-Lowering Initiation Abates New Cardiac EventsVQR_u`0 gY00ؚ@u`k0J0D0f0 HMG-CoA reductase;[atorvastatink000Mzuivj0NO NBvlo0_Ӂ{k _K{h^X 3RS-N eQb0b6R0ALPHA/T-Wave Alternans in Patients With Heart FailureYTlNNTWA ign0pu8^On0_Ӂ{k {k'` Nten0000o0ck8^On04 Pg0B000TWAigg0ck8^h0:eU00_0uOn0N_o0o}Yg0 ICDlBvn00000o0{0h00i0j0D0h0`0000Ehttp://www.ncbi.nlm.nih.gov/pubmed/17980258?report=DocSum&format=html/T-wave ALternans in Patients with Heart FAilure2^Z@'`_K{u`g0TlNNlign0pu8^uOn0_Ӂ{k u}Tk0K0K000 Nten0000o0ck8^uOn03 P0 Alpha OmegadNO(uϑn0Z1uegn0n-3|xEPA DHA iir1uegn0n-3|x-0000x[ALA] n0_@{OwRg0iY000EPA-DHA ALAD0Z000;N_@{00000b6RW0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20929341?report=DocSum&format=html ALPHA OMEGAUEffect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patientsQ_K{h^Xe_Ok0J0D0f0 Zl1uegn0000-3-n-3| xk0 iir1uegn0n-3|x-0000x 0RW0_04XTn0_@{u`k0[Y00 gR'`o0000Z002010t^08gALPHABET<Arterial Pulmonary Hypertension and Beraprost European TrialX000000000\SOberaprostn0121L}SbNn0KR[ ur _@LRKak0NH00RgJ00s0[hQ'`0i0beraprosto0KR[J00s0ur09eUY000Ehttp://www.ncbi.nlm.nih.gov/pubmed/11985913?report=DocSum&format=htmlALPHEEDose Ranging Study of Celivarone with Amiodarone as Calibrator for the Prevention of Implantable Caridoverter Defibrillator Interventions or Death*eb Ntecelivaronek0ICD\OR0z6q{kn0N2Rgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/22082672?report=DocSum&format=htmlDouble blind placebo controlled dose ranging study of the efficacy and safety of celivarone 50, 100, or 300mg od with amiodarone as calibrator for the prevention of ICD interventions or death]NO][ƙQsEFf"40% ICD i0`k0J0D0f0 b Nte00000celivarone 1e1VL}SbNk0 _['`;b _[0}Rk0[Y00ICD\OR z6q{kN2Rgo0000Z00ALPINEUAntihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation^Oj0)R?\hydrochlorothiazide ne h000ؚOj0AIIS[SObbcandesartan Cabb n0wgv gR'`0kY00wgvk0o0ؚOj0M'WlBvg00 Nx0n0q_0naY00h0wgvk0o00000000000`0h0`0000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12872052?report=DocSum&format=htmlALPS-JlAzelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis:elective PCIeLn0ؚ@'W`k0J0Q00Cabbazelnidipinen0wgbNk000bRlxSn0i02006t^02gALTITUDE>Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpointsw;egB}N=vcv000;[aliskirenRk000 gR'`J00s0[hQ'`0i<0_@{u`{k z6q{kK00n0u {kv0^{kv_K{h^X {kv0^{kv3RS-N _ NhQk000N[Yn0eQb N0000aliskirenR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/23121378?report=DocSum&format=html?Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints~_@{0N0000ؚ000n02W|?\u`k0J0D0f0 ARB/ACE;[x0n0vc000;[000000aliskiren Rk000_eN0000b6Rn0 NWN[0Rgo0:yU00Z0 g[NaXRn0_002011t^12gk0N[00eO0B}NW0_0fn0NPP}g 0ALTITUDE Survival`000000L0wguX[sk0S|0Y0q_J00s00000Bvl_n0uX[s0`000000Og0UO0[聊^k0J0Q00uX[so0 聊^fn01XJTh0 Y00j0D00`0000000Lc0_0`n0uX[so0o}Y`0L0 0000k0000000Bvl00_00W0_0 Nteo0{kN000n0X'Yh0#0Whttp://www.ncbi.nlm.nih.gov/pubmed/23810882,21098452,21098454?report=DocSum&format=htmlAMADEOWTelmisartan vs Losartan in Hypertensive Type-2 Diabetic Patients wit< h Overt NephropathyKARB telmisartanh0losartann0NOwRg0kY000M'Wo0!N Tig0B00L0 ?\ˆ}vn\Rgo0telmisartann0eL0'YM0D002008t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/18496508?report=DocSum&format=htmlAmadeus;m'`S,{XVP[;[dRidraparinuxn0V[(uϑv Nln0@h^XhuN2n0 gR'`J00s0[hQ'`0 0000Kbbn0te(uϑL}SbNh0kY00^R'`f0idraparinuxk000wglBvo0 gR'`hQ3RS-N hQ'`^Xhu n0pg00000Kbbk0R0j0K0c0_0L0 Q@n0 gaj0XRk0d0j0L0c0_002013t^12gNhttp://www.ncbi.nlm.nih.gov/pubmed/18294998,23966309?report=DocSum&format=htmlAMBITIONJAmbrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertensionk000000S[SObbn0ambrisentanh0PDE-5;[n0tadalafilk000RguO(uBvln0 gR'`h0[hQ'`0 ]00^00n0XSdRbNh0k0聊^v NbR000NOnuO(uXSdR<sup>*</sup>02015t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/26308684?report=DocSum&format=htmlAMI-SKImproved Reperfusion and Clinical Outcome With Enoxaparin as an Adjunct to Streptokinase Trombolysis in Acute Myocardial InfarctionAMIGO8Atherectomy before Multilink Improves lumen Gain OutcomeAMIHOT:Acute myocardial Infarction with Hyperoxemic Therapy Triallaqueous oxygenAO k000ؚx }@mQLpAmL0__j _\_t@Am09eUW0 h^X0000.~\Y00K00i0[hQ'` _['`L0ؚD00n0n0 @\@bXKR ST YSn0m1Y gB}h^X000n09eUo0000j0K0c0_002007t^07gEhttp://www.ncbi.nlm.nih.gov/pubmed/17662390?report=DocSum&format=htmlAMIO-CATsRecurrence of Arrhythmia Following Short-term Oral Amiodarone after Catheter Ablation for Atrial Fibrillation Trial^egn0 NteQzvN20vvh0W0_0b Nteamiodaronen0wgbNk000 `gn0 NteQzvL0n\Y00K00iY0003K0g_n0_?b'`;'` NteamiodaroneR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/25182250?report=DocSum&format=htmlAMIOVIRTJAmiodarone Versus Implantable Cardioverter-Defibrillator: Randomized TrialcIIIb Nteamiodaroneh0 i0Wd0}RhVICD n0hQ{kNsk0S|0Y0Rg0k0uX[samiodaroneR"ICD0 Nte^zvuuX[samiodaroneICDp0.8 0Nhttp://www.ncbi.nlm.nih.gov/pubmed/12767651,12767652?report=DocSum&format=htmlAmiodarone vs Implantable Defibrillator in Patients with Nonischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia6^Z@'`_K{uJ00s0!quP'`n0^c}'`_[;b0 gY00`k0J0Q00ICDh0amiodaronen0Rgn0k02000t^11gAMIS#Aspirin Myocardial Infarction Study6aspirinn0hQ{kN QRu`zvun0NO NRg0i0{kNs QRu`zvusaspirinR"000001980t^02gDhttp://www.ncbi.nlm.nih.gov/pubmed/6985998?report=DocSum&format=htmlAMISTAD.Acute Myocardial Infarction Study of Adenosine@adenosine0@hnBvlk0RW0_04XT h^X000L0.~\Y00K0i0h^X0009eUMRXh^Xg0000000000*01999t^11gEhttp://www.ncbi.nlm.nih.gov/pubmed/10577561?report=DocSum&format=html AMISTAD II1Acute Myocardial Infarction Study of Adenosine IIQLpAmBvlk0adenosineYl0RW0_04XTn0聊^0^J00s0h^X000k0[Y00q_0i06K0gn0hQ{kN F0c0@'`_ NhQCHF k000gRn0QeQb 0000S_24Bfn0en0CHFzvuadenosine 50J00s070g/kg/RR"0000070g/kg/Rg0h^X000L0 gak0.~\0Nhttp://www.ncbi.nlm.nih.gov/pubmed/15936605,16782719?report=DocSum&format=htmlAMORIS%Apolipoprotein-related Mortality Risk0000ˆ}vBapoB 0000ˆ}vA-IapoA-) apoB/apoA-IkL0%`'`_K{h^X{kJ00s0z6q{kn0N,nVP[h0j00K00i0apoB apoB/apoA-Ik apoA-I0_000n07_D0N,n0000g0B00S0h0L0:yUU0000LDL-CL0ck8^OB00D0o0NO$POg00 N,vj0pu8^0 gY007usYn0:eJ00s0lBvk0J0D0f0apoB apoA-Io0g0͑0uf[2001t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/11755609?report=DocSum&format=htmlAMPLIFYhApixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line TherapyqL}S,{XaVP[;[apixabann0 gR'`h0[hQ'`0_eglBvenoxaparin warfarin h0kY000apixabano0VTEQzv VTE#{kn0b6Rk0J0D0f0_eglBvk0[W0f0^R'`g0 Q@000L0 gak0NOK0c0_002013t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/23808982?report=DocSum&format=html AMPLIFY-EXTApixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-line Therapy-Extended Treatmentc6^12K0gn0bQVBvl0B}NW0_0uOk0J0D0f0 L}S,{XaVP[;[apixaban 2.5mg 5mgk000bQVBvln01t^n0^wo0 D0Z000'YQ@n00000XRY00S0h0j0O0Qzv0000b6R02013t^02gNhttp://www.ncbi.nlm.nih.gov/pubmed/23216615,23425170?report=DocSum&format=htmlANBP(Australian National Blood Pressure Study9M'WlBvn0 gR'`0i0{kN ^{k'`0000000n0b6RRg[chlorothiazide 0000*01980t^06gDhttp://www.ncbi.nlm.nih.gov/pubmed/6104081?report=DocSum&format=htmlANBP2/Second Australian National Blood Pressure StudyKACE;[h0)R?\h0n0hQ_@{0000~0_0o0hQ{kNb6RRg0kY000M'WACE;[R")R?\0b6RRgACE;[)R?\p0.005 02003t^02g2007t^06gNhttp://www.ncbi.nlm.nih.gov/pubmed/12584366,17470723?report=DocSum&format=html1Second Australian National Blood Pressure Study ANDROMEDA]Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decre< aseamiodaroneh0lutf[vyr_o0^*</sup> 3t^_n0_ NhQ _?b0}R d0}Rk000eQbSafeRR"DDD02015t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/25179761?report=DocSum&format=htmlfAntiarrhythmic Effects Of n-3 Polyunsaturated Fatty Acids in Survivors of Ventricular Tachyarrhythmias6_['`;b'` Ntee_Ok0J0D0f0 n-3|n0YO NTxn-3 PUFA k0b NteRgo0000Z00ANTIBIO6Antibiotic Therapy After an Acute Myocarial InfarctionO000000|buirroxithromycinL0TuOuzvusJ00s0{kNs0NO NU0[00K00i012K0g_n0{kNsroxithromycinR"000002003t^03gEhttp://www.ncbi.nlm.nih.gov/pubmed/12628944?report=DocSum&format=htmlANTIPAF;Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation;hVꌄv_u`n0j0D0zv\O'`_?b0}RAF `k0J0D0f0 ARB olmesartank000AFQzvb6RRgo0000Z00Antithrombotic trialists' (ATT)^aspirinn0_@{u`N!kN2Rgo0000000^X'`0000b6R / 000͑'Yj0Q@ k0naY00h0 }Tvj0 g(u'`o0x[g0M0j0K0c0_00s(W2L-Nn000000n0P}gL0__0000APAF1Ablation for Paroxysmal Atrial Fibrillation TrialEY0000000CPVA h0b NtelBvADT n0Rg0k01t^n0_?b'`;'` Nten0Qzvb6RRgCPVAADT*02006t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/17161267?report=DocSum&format=html+Ablation for Paroxysmal Atrial Fibrillation,YhTV0000000(CPVA)o0irBvlk0ky0f0 zv\O'`_?b0}R0 gak0b6RW0_000APCSC: Asia Pacific Cohort Studies CollaborationG000*Ys^ m0WWk0J0D0f0 @'W Nfk000_@{u`000n0X'Yo0 MRؚ@'WJ00s0d[z'`b5_gؚ@'W0+T0Y0y0f0n0ؚ@'W00000g0000_00M'WlBv APCSC and OACJNn0pu8^04O0j0D0NOHDL-C@uXSrNOHDL-C@u o0000Nk0kvYD0eW0D0000n0pu8^ug0B00 QRu`000 Nfh0#Y000APEXWAcute Medically Ill Venous Thromboembolism Prevention with Extended Duration BetrixabanL}Svc,{XaVP[;[0000000betrixaban n0wgbNn0@hN2Rg0iY000D000p NfOg0n0,{32^47en0!quP'`n0яMODVT ,{1^42en0uP'`n0яMO/`MODVT uP'`n0^{kvPE VTE{kn0T0000000betrixabanR"enoxaparin02016t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/27232649?report=DocSum&format=htmlAPEX AMI7Assesment of Pexelizumab in Acute Myocardial InfarctionQPCIk0܈SOC5k0[Y00000000000bSOpexelizumab0uO(uW0_04XTn0 gR'`0i030e_n0}{kNb6RRgpexelizumabR"000002007t^01gNhttp://www.ncbi.nlm.nih.gov/pubmed/17200474,19417195?report=DocSum&format=htmlDST NfW%`'`_K{h^X_n0PCI0eLuOk0J0D0f0 ܈SOC5k0[Y000000000bSOpexelizumabn0{kNb6RRgo0000Z00APOLLOA study to evaluate the efficacy of Rosuvastatin for patients with coronary plaque utilizing aggressive lipid lowering treatmentEQR00000 gY00`k0J0Q00HMG-CoA reductase;[ rosuvastatink000MzuivNO NBvln0 gR'`n0UO pu8^u Z@'`_u`2008t^07g APPRAISE-22Apixaban for Prevention of Acute Ischemic Events 2[eg-Nbk]L}Svc,{XaVP[;[apixaban0jnvb@\gBvlk0RW0_04XT Z@0000Qzvb6RRgL0Q@0000 NV0K00i<0apixabang0聊^vk0͑j0Q@0000L0XRW0 ]0n00000vkY00Z@0000b6RRgL0000j0K0c0_002011t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/21780946?report=DocSum&format=htmlAPPROACHLAlberta Provincial Project for Outcomes Assessment in Coronary Heart Disease@LQ^S^eLOk0ky0 CABGo0N_j0OU0Z0o}Yj0uX[s00_00W0_0Ne PCIo0SgqJ00s0@mgOX[Og0o0{kN0000NO NU0[0_0L0 @mg^OX[`n0{kNso0b6RW0j0K0c0_00Nu`0gx0n0OX[o0@LQ^S yrk0CABGk0d0D0f0n0[h0o0j00j0D002013t^07g`http://www.ncbi.nlm.nih.gov/pubmed/15451786,23833076,21242477,16843175?report=DocSum&format=htmlThe Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History00000bb'`9eUg0B00000000000|dRrosiglitazonen0QR00000'`RlxS2U\k0[Y00Rg000000?\ }n0glipizideh0k00000000000eLW0f0D0j0D0QRk0J0Q0000000[MzsrosiglitazoneR"glipizide0Nhttp://www.ncbi.nlm.nih.gov/pubmed/20194881,20194886?report=DocSum&format=htmlAssessment on the Prevention of Progression by Rosiglitazone on Atherrosclerosis in Diabetes Patients with Cardiovascular HistoryR_@{u`e_0 gY002W|?\u`k0J0Q0000000bb'`9eUrosiglitazonen000000'`RlxS2U\b6RRgo0SUglipizideh0]o0j0D002008t^11gAPPROVALtImpact of Different Ablation Approaches on Long-term Procedure Outcome in Coexistent Atrial Fibrillation and Flutter_AFh0AFLAFAFL 0000000n0QzvN2J00s0QOL9eURg0 AFLn00n00000000h0kY000 NteQzvb6RRgAFAFL0000000AFL0000000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23572499?report=DocSum&format=htmlAPPROVe%Adenomatous Polyp Prevention on Vioxx'Yxzk`k0J0Q00COX-2;[rofecoxibn0'Yxk v'`0000n0Qzvb6RRg0iY00fg0B0c0_0L0 _@{k'`n0zvsk00c0f0lBvL0-NbkU00_0_0< 0 hQuOk0J0D0f0lBv-NbkK001t^N N_n0_@{0^0i0rofecoxibo0_@{00000XRU0[0 lBvegn0000 Nfo0lBv-Nbk_1t^c}W0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/18922570,18922571?report=DocSum&format=htmlAPRICOTIAntithrombotics in the Prevention of Reocclusion in Coronary Thrombolysiszaspirin warfarin heparing0@hnBvlbR_n0Q^Xh0Z@Qzvn0N2Rg0k0Q^Xso0k0 ga]j0W00@LQ^Sb6RRgaspirin0000*00000b6RRgaspirinwarfarin 0000*01993t^05gDhttp://www.ncbi.nlm.nih.gov/pubmed/8491007?report=DocSum&format=html APRICOT-2Yaspirink000b@hBvlh0܈Rvj0prolonged bQVBvln0uO(un0 Q^XJ00s0Z@0000Qzvn0N2Rg0i0aspirin coumarinaspirin*02002t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/12163424?report=DocSum&format=htmlAPSI2Acebutolol et Prevention Secondaire de l'Infarctus/neacebutolollBvn0 gR'`0i0{kNsNO No0acebutolol0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9068513?report=DocSum&format=htmlAPSIS#Angina Prognosis Study in Stockholmlnemetoprolol~0_0o0Cabbverapamiln0wglBvk000hQ_@{0000000h0_tVP[k0[Y00Rg0i0hQ_@{0000b6R _tVP[k0[Y00RgmetoprololR"verapamil01996t^01g2000t^06gMhttp://www.ncbi.nlm.nih.gov/pubmed/8682134,10806014?report=DocSum&format=htmlAPTH7Ambulatory Blood Pressure and Treatment of HypertensionQƖVs^GW$P00{QW0_0T/Pkh0 P0g0{QW0_0T/Pkn0s^GW$Pn0D0Z00L0M'Wn0UOk0iW0f0D00K00i0hQOn0T/Pko0]SGWI{j0R^0:yU0Z00Qs'`o0 No01995t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/7490153?report=DocSum&format=htmlAQUARIUSPAliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound StudyMRؚ@'WSBP 125-139mmHg DBP90mmHg n0uP'`QRu`20%rzs50% g0 U00k02d0n0qSzVP[0 gY00`k0J0D0f0 vc000;[aliskiren Rk000721_n000000'`RlxSu2U\n0 gaj0b6Ro0000Z00ARBITERXArterial Biology for the Investigation of the Treatment Effects of Reducing CholesterolT;-N1XJT=HMG-CoA reductase;[pravastatin atorvastatinn0LDL-CNO NRg 8Rn000000RlxS2U\b6RRg0k0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11231429?report=DocSum&format=html ARBITER 2YArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2+NOHDL-Ck0 gRj0niacin0RbNk00000000'`RlxSn02U\L0E^W0_002004t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/15537681?report=DocSum&format=html3HDL-CL0NO0n0QRu``k0J0D0f0 00000 0000o000000'`RlxSn02U\0b6RW0_00ARBITER 6-HALTSzArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies}0000x0n0 NWN[0Rg0HDL-C0 NfU0[000000x_>edRniacin h0LDL-C0NO NU0[00000000000000000;[ezetimibeh0g0k014K0g_n0}8RQ--NS.~0000x_>edRezetimibe*02009t^11gihttp://www.ncbi.nlm.nih.gov/pubmed/19915217,19915216,19915218,22564353,20399059?report=DocSum&format=htmlX0000wgbNOn08RQ--NS.~Rgo0 0000x_>edR (niacin) RbNL0\x000000000000000;[ezetimibeRbN00'YM0D00ARCH&Amiodarone Reduction in Coronary Heart`b Nteamiodaronen0NO(uϑYlL0 _S_n0_?b0}RJ00s0eQbgk0S|0Y0Rg0i0_?b0}Rb6RRgamiodarone0000*0eQbgamiodaroneR"000001999t^08gEhttp://www.ncbi.nlm.nih.gov/pubmed/10440143?report=DocSum&format=htmlARCTICA Randomized Trial of Bedside Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus Standard of Care in Patients Undergoing Drug Eluting Stent Implantation: The ARCTIC StudyIdRnQ'`0000 i0`k0J0D0f0 @\g_jigk000000000h0]00k000teW0_0b@\glBvk0001t^_n0_@{0^n09eUo0000Z00ARCTIC-InterruptionAssessment by a double Randomisation of a Conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment Interruption versus Continuation one year after stenting-InterruptionfhQ{kN _K{h^X 3RS-N/TIA }%`@LQ^S 0000@hun0T00000002dRuO(ub@\gBvlDAPT 0U00k06K0gN N}}DAPT}[ego018K0g R"DAPT-Nbk12K0g 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25037988?report=DocSum&format=htmlARIC)Atherosclerosis Risk in Communities StudyA00000'`RlxSn0SV0iY00f0i0j0000VP[ lBv J00s0N.z '` E\OO4X@b y`gk0J0Q00聊^L}Nk0d0D0f0i02018t^05g<http://www.ncbi.nlm.nih.gov/pubmed/2646917,29386202,28399252,27881564,27550968,27185168,27590090,26659948,26746175,22271752,26152706,26085454,26022911,25918127,25149362,25104519,25027141,24344084,23487436,22871870,21646496,21346180,20200384,20082929,19153274,19064831,19064828,18212291,18420100,17631213,16894039,16061739,16043740,15920070,15735206,15632337,14757686,14757692,14517173,12570944,12351467,12118905,12103252,11879113,11597667,11535564,11450679,11034936,10982537,10912737,10783222,10790343,10807384,10821330,10738048,10449696,10347984?report=DocSum&f< ormat=html#Atherosclerosis Risk In CommunitiesARISE1Aggressive Reduction of Inflammation Stops Events@gяzvuW0_0ؚ000n0ACS`k0J0D0f0 ebxSg0B00succinobucoln0_@{0000b6RRgo0000j0K0c0_00 ARISTOTLEWApixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial FibrillationeL}SbQVg0B00vc,{XaVP[;[000000apixaban n03RS-NJ00s0hQ'`^XhuN2Rg0jnlBv(uϑtewarfarin h0kY0003RS-N hQ'`^XhuN2k0J0Q00apixabann0warfarink0[Y00*Q'`L0000 Q@ {kN0000NOK0c0_00http://www.ncbi.nlm.nih.gov/pubmed/21870978,21870977,26106009,25301455,25294786,24561548,24211508,24055845,24144788,23563134,23036896?report=DocSum&format=htmlrApixaban Compared with Warfarin in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack@apixabano0warfarink0O00y0f03RS-N~0_0o0hQ'`^Xhun0Qzv024% 'YQ@027% -˄QQ@063%b6RW0_002012t^02g3RS-Nn0qSzVP[0 gY00_?b0}R`n03RS-N hQ'`^Xhub6Rk0J0D0f0 eL}SQVg0B00vcXaVP[;[000000apixaban n0warfarink0[Y00*Q'`L000000Q@J00s0{kN0000apixabann0{0F0L0NOK0c0_0e,gSRn0VqQ Txvz 0 ARISTOTLE-JYApixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation-Je,gN_?b0}R`k0J0Q00eL}SbQVg0B00,{XaVP[;[000000apixaban 2.5mg2V/e 5mg2V/en0121bNn0_['`o0o}Yg0B000 e,gN0+T0NLuqQ T,{IIIvfL02L-N<sup>*</sup>g0B00 <sup>*</sup> }Ɩl,gP}gL02011t^ESCg0zvhU00e.sSU00_0ARISTOTLE-J 0ARMS*Anistreplase Reocclusion Multicenter Study7@hn㉬APSACbN90R_n0Q^XJ00s0bN_24BfNQn0QRX['`0i0NOQ^XsL0000_001991t^08gDhttp://www.ncbi.nlm.nih.gov/pubmed/1858670?report=DocSum&format=htmlARMYDABAtorvastatin for Reduction of Myocardial Damage during Angioplasty6HMG-CoA reductase;[atorvastatinn0SMRbNo0eSk000_K{P[0 gak0NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15277322?report=DocSum&format=htmlARMYDA-2JAntiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty]b@\gclopidogrelؚ(uϑn0MRbNk000_K{0000b6RRg0i030e_n0{kN _K{h^X jv@{@LQ^Sb6RRgؚ(uϑ600mg jn(uϑ300mg *0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15750189?report=DocSum&format=htmlARMYDA-3JAtorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac SurgeryPHMG-CoA reductase;[atorvastatinn0S_n0_?b0}RAF b6RRg0i0AFb6RRgatorvastatin0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17000910?report=DocSum&format=htmlJAtorvastatin for Reduction of Myocardial Dysrhythmia after Cardiac SurgeryJN]_O(un0_ӁKbSOk0J0D0f0 HMG-CoA reductase;[atorvastatinn0SMRbNk000S_n0_?b0}RL0 gak0b6RU00_00ARMYDA-5 PRELOADTAntiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-5 Preload~QR q__ PCIeLBfn0_Ӂ00000[in-lab k0J0Q00b@\gclopidogrel 600mg000000MRbNn0 gR'`00000n0000000MRbNpre-load h0k030e_n0MACEin-labR"pre-load0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20688209?report=DocSum&format=html ARMYDA-ACS[Atorvastatin for Reduction of Myocardial Damage During Angioplasty-Acute Coronary SyndromesPHMG-CoA reductase;[atorvastatinn0 gR'`0i030e_n0;N g[_0000b6RRgatorvastatin0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17394957?report=DocSum&format=htmlCPCI0eLY00ACSk0J0D0f0 atorvastatinMRbNk000hTSgn0_K{h^XL0b6RU0030e_n0;Nj0_0000zvusL0NO N0ARMYDA-RECAPTUREMAtorvastatin for Reduction of Myocardial Damage During Angioplasty- RECAPTUREHPCIeLMRn0atorvastatinn0RbNn0 gR'`0iY00030e_n0 g[_0000b6RRgatorvastatin0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/19643320?report=DocSum&format=htmlARMYDA RECAPTURELAtorvastatin for Reduction of MYocardial Damage during Angioplasty RECAPTURE-0000ba'`bNOk0J0D0f0 PCIeLMRbN0vMRn0RbNk000_@{u`L0b6RU0000 ARMYDA-RELOADJAntiplatelet therapy for Reduction of MYocardial Damage during AngioplastySclopidogrel0bNU00f0D00PCIeLOx0n0KbbMRRbNk000 ^ST NfWACSg0o0 g[_0000L0 gak0b6RU00_0L0 [[uOg0o0 gR'`o0000Z002008t^04g ARREST-AF>Aggressive Risk Factor Reduction Study for Atrial Fibrillation7Mzuivj0qSzVP[n0{tk000_?b0}RAF n0wJ00s0͑u^L0NO NW0 AF0000000_n0wg0^o09eU0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25456757?report=DocSum&format=htmlART Arterial Revascularisation Trial?CABGk0J0Q00!NtPQR0000o0 GrtPQR0000h0ky0f030e_ 1t^_n0{kN _@{000 eQbepe0X'Y[0Z00ARTISNAntiplatelet Therapy in Combination with Rt-PA Thrombolysis in Ischemic StrokeV;egB}N=aspirinYleguO(un0 gR'`0i03K0g_n0o}Yj00^mRs000 aspirinuO(uR"jnlBv0aspirinuO(ug0-˄QQ@000L0 Nf0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22748820?report=DocSum&format=htmlARTISTkResults of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis TrialWrotational atherectomy 0000ROTA h00000XSrPTCA h00k0< 6K0g_n0@{ q_P}go0ROTAk0ky0PTCAn0eL0 gak0o}Y0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11827923?report=DocSum&format=htmlcCompariosn of Effect of Carvedilol Compared to Bisoprolol on Central Pulse Pressure in Hypertensionؚ@'W`k0J0Q00nen0'Wx0n0q_n0i0ARTS*Arterial Revascularization Therapies Study:0000h00000n0 gR'`h00000k01t^g00000o0000000@LQ^Sn0QeLso0ؚD0L0 ;SBvo0NOD002001t^04grhttp://www.ncbi.nlm.nih.gov/pubmed/11297702,16098418,14993134,11849851,11723020,11479249?report=DocSum&format=htmlARTS II2Arterial Revascularization Therapies Study Part II?Ygu``k0J0D0f0 1t^_n0 g[_3@{0000so0sirolimusnQ0000n0eL0ARTS ICABG 00NOD003Arterial Revascularization Therapies Study Part II -Ygu`k0J0D0f0 sirolimusnQ0000o0ARTS In0CABG000*Q0f0D000ARUBABA Randomised Trial of Unruptured Brain Arteriovenous Malformationsf;egB}N=QyvlBvo0QyvlBv N2vNeQlBvk0O00y0{kNJ00s0uP'`3RS-Nn0b6Rk0*Q00K00iY000hQ{kN uP'`3RS-Nn0T0000000b6RRgQyvlBvQyvlBv N2vNeQlBv*02014t^02gNhttp://www.ncbi.nlm.nih.gov/pubmed/24268105,24529458?report=DocSum&format=htmlASAAC0Acetylsalicylic Acid versus Anticoagulants StudyHNO(uϑaspirinh0bQVheparing0QR0000S_n00000^Xk0[Y00Rg0k0^X9eURgaspirinR"heparin01990t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/2251993?report=DocSum&format=htmlASAN-MAIN Registry8ASAN medical center-left main revascularization RegistryPӗVn0@LQ^eLuOn0{v2xvz0PCIn0wg{kN {kN Qlh^X 3RS-No0CABGh0 TI{g0B00L0 0000o0DESg00@LQ^Sn0QeLsL0CABG00ؚD00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20946993?report=DocSum&format=htmlAsan-Multivessel Registry:Asan Medical Center-Multivessel Revascularization RegistryPDES i0Oh0CABGeLOk0J0D0f0 wg0^0kY0005t^_n0{kNJ00s0_@{0^o0 TI{g0B0c0_0L0 Q@LQ^Sn0eLso0DES i0On0{0F0L0ؚK0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/21211683?report=DocSum&format=htmlASAP9Antioxidant Supplementation in Atherosclerosis PreventionT6t^n00000EJ00s0Cn0܈EQBvlk00000000'`8RlxSun02U\N2Rg0i0}8RQ -NSb6RRg܈EQBvl0000*sY'`g0o0 ga]j0W0 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12600905?report=DocSum&format=html:Atorvastatin vs Simvastatin on Atherosclerosis ProgressionHMG-CoA reductase;[k0007_RNO NBvlatorvastatinؚ(uϑ L0sLn0lBvsimvastatin 000RlxSn02U\0b6RY00K00i08RQ -NSn\Rg LDL-CNO NRgؚ(uϑatorvastatinsimvastatin*02001t^02g2003t^01gNhttp://www.ncbi.nlm.nih.gov/pubmed/11558482,12535822?report=DocSum&format=html-Azimilide Supraventricular Arrhythmia ProgrampIIIb Nteazimiliden0 gR'`0%R0k0L00_04fSVA-1^4 g0i0!quP'`_?b0}RAf o0uP'`Afe_0 gY00*glBv`g0W0p0W0p0zvuW0 azimilideo0!quP'`Af0b6RY00S'`L0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12615792?report=DocSum&format=htmlASCB!Asymptomatic Cervical Bruit StudyOaspirin n0@{0000b6RRg0i0͑{j08Rrzo0@{0000n0000VP[0ؚ^rzuOk0aspirino0Rgj0W00!quP'`rzn06qtk00Dhttp://www.ncbi.nlm.nih.gov/pubmed/9109874?report=DocSum&format=htmlASCEND,A Study of Cardiovascular Events iN Diabetes`ewn0CVDn0j0D0|?\u`k0[Y00NO(uϑaspirinbNo0, Rzvn0͑{j0CV00000000NOnY00L0, 'YQ@0000n0XRk000aspirinn0v}[v000000o0'YE^k0vkU00002018t^10gEhttp://www.ncbi.nlm.nih.gov/pubmed/30146931?report=DocSum&format=html ASCEND-HFRAcute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure@{b5_\O(u0 gY00D}cH000BW00000)R?\0000nesiritiden0jnlBvx0RW0_04XTn0|T8TV eQb {kNx0n0q_0i0QeQb hQ{kNnesiritideR"0000 6Bf_J00s024Bf_n0|T8TVn09eUnesiritide0000*0ihttp://www.ncbi.nlm.nih.gov/pubmed/21732835,21732841,28641792,22497823,23747790?report=DocSum&format=htmlSAcute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure \%`'`NQ'`_ NhQ`k0J0D0f0 jnlBvx0n000BW00000)R?\0000g0B0000000nesiritide n0Ro030e_n0_ NhQk000QeQb {kN0b6R[0Z0vs 0000 0ASCENTAACS Multilink Stent Clinical Equivalence in De Novo Lesions TrialG,{2NN0000ML h0jn0000PS n0 gR'`J00s0[hQ'`0k0kX[rzb6RRg {kN0_K{h^X0@LQ^Sn0b6RRgMLPS02001t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/11152831?report=DocSum&format=htmlASCERTdACCF and STS Database Collaboration on the Comparative Effectiveness of Revascularization StrategiesrPCIJ00s0_ӁKbSn0000000h0OzˊBl0000(uD0f0PCIh0CABG0kؚb74sk n0Ygu Y`n0wguX[so0 CABGOn0{0F0L0PCIO000o}Y/ 000K00\ObW0_0000o0CABG_n0{kN0000o}Yk0N,n02012t^04gWhttp://www.ncbi.nlm.nih.gov/pubmed/22452338,22452337,22361330?report=DocSum&format=html`ACCF-STS Database Collaboration on the Comparative Effectiveness of Revascularization Strategies&Ygu Yk0[Y00@LQ^4t^_n0uX[so0 CABGn0{0F0L0PCI000ؚD00ASCOT)Anglo-Scandinavian Cardiac Outcomes Trial&_egn0000000k0CRP0RH0f00_@{0000000d\%Rn09eUo0\U0D00QRu`CHD J00s03RS-N000< 065%NO N0 ASCOT-BPLAEAnglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering ArmQRu`CHD n0N!kN2Rg0 Cabbamlodipine0000h0Y00en0M'WBvlACE;[perindopril0uO(uAm(+P) h0neatenolol0000h0Y00_egn0M'WBvl000000|)R?\bendroflumethiazide0uO(uAt(+T) h0g0k0At(+T)g0{kNOL0YO0fo0N[00eO0-Nbk0^{kv_K{h^XJ00s0{kvCHDb6RRgAm(+P)At(+T)0rhttp://www.ncbi.nlm.nih.gov/pubmed/16154016,20226988,20413040,18786484,18559700,16476843?report=DocSum&format=htmlzAnglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm ezvu|?\uamlodipine000L0atenolol000k0ky0000L034%NO N n0㉐g06000000Bfn0zzyBf@|$P BMI M'WlBv HDL-C 0000000L0e|?\uzvun0N,nVP[g0B000IThe Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm_@{0000n0qSzVP[03d0N N gY00ؚ@'W`k0J0D0f0 wBf\O(uWCabbamlodipine0000h0W0_0ACE;[perindoprilh0n0uO(uBvlo0neatenolol0000h0W0_0)R?\thiazideh0n0uO(uBvl000;N_@{0000 hQ{kN e|?\uzvu0b6R0SAnglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm of the Trial Vؚ@'W`k0J0D0f0 amlodipine/perindoprillBvo0;N_@{0000 {kN e|?\uzvub6RRgg0atenolol/thiazide000*Q0f0D0_00 ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm)^{kv_K{h^Xh0{kvCHDb6RRgatorvastatin0000*02011t^10g{http://www.ncbi.nlm.nih.gov/pubmed/11403364,12686036,21873710,19103995,18175773,17145722,15855581?report=DocSum&format=html<Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering ArmH0000000L0s^GW$P00NOD0ؚ@'W`k0J0D0f0 HMG-CoA reductase;[atorvastatinlBvk000_@{000L0NO N0 Asian TAVR9The Asian Transcatheter Aortic Valve Replacement Registry)000n0L}00000v'YR_ncSTAVR {v2xvze,gSRn0NLuqQ Txvz ASIS Angina and Silent Ischemia Studyonepropranolol-LA Cabbdiltiazem-SR nifedipineg0!quP'`_K{Z@n0zvs;^h0zv\Oc}Bfn0NO Nk0 gRj0XSdRBvl0i0Z@n0zvsb6RRgpropranolol0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/2122926?report=DocSum&format=htmlASISTAtenolol Silent Ischemia StudyBneatenololn0t^0000zvusk0S|0Y0Rg0i0{kN0_['` Nte0_K{h^Xb6RRgatenolol0000*01994t^08gDhttp://www.ncbi.nlm.nih.gov/pubmed/8044945?report=DocSum&format=htmlASKAustralian Streptokinase Trial@hn㉬streptokinaseSK L0n0y`J00s0{kNb6RRg0i zvu_3BfNQh03BfNMn0SKbNn0N_0k0{kNb6RSKR"00000@kzvusSK0000*03BfNQbNo0SKk0N_9eUPT03BfN_bNo0SKg0{kNXR01996t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/8805730?report=DocSum&format=htmlASPECTKAnticoagulants in the Secondary Prevention of Events in Coronary ThrombosisM{kNsh0@{n0y`sk0[Y00L}SbQVn0wgbNn0Rg0i0{kNb6RbQV00000_K{h^XQzv03@{0000b6RRgbQV0000*01994t^02gDhttp://www.ncbi.nlm.nih.gov/pubmed/7906757?report=DocSum&format=html-Asian Paclitaxel-Eluting Stent Clinical Trialpbk vpaclitaxelg0000000W0_00000n0QrzN2RgJ00s0[hQ'`0i0_egn0b@\gBvl0uO(uW0_0paclitaxelnQ0000o0 jn0000h0 Tin0[hQ'`g0 rzh0euQb_b0Rgvk0b6RW0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/12700373,17174179,12566359?report=DocSum&format=htmlASPECT-2NAntithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2L}SbQV7_S000000XSr L}SbQV-NI{^000000 aspirin aspirinXSrn0D0Z00L0wgvk0 gRK007_S000000XSr aspirin -NI{^000000000000o0 aspirinXSr000_@{0000J00s0{kNn0b6Rk0 gRg0B0c0_002002t^07gEhttp://www.ncbi.nlm.nih.gov/pubmed/12126819?report=DocSum&format=htmlASPECTS'Alberta Stroke Programme Early CT ScoreE%`'`MR3h^Xk0J0Q00CTn0[ϑv000Sn0 gR'` O<'` g(u'`0i<0@hnBvl0eLW0f00zn0V_n00L0NOD0uO0N,ng0M0002000t^05gEhttp://www.ncbi.nlm.nih.gov/pubmed/10905241?report=DocSum&format=htmlASPIRE@AutoPulse Assisted Prehospital International Resuscitation Trialhjnvj0Qe%`;SBv0000k000(uKbv_ulCPR h0 Rw͑w000LDB k000CPRLDB-CRP n00^0k0Qe%`1XK004Bf_n0zv_tn0V_W0_0uX[sCRPR"LDB-CRP0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16772625?report=DocSum&format=htmlASPIRE 3Aspirin to Prevent Recurrent Venous Thromboembolism8yrzv'`Y@h^XhuRzv`k0J0D0f0 RVbQVBvlB}N_n0aspirink000 gaj0N!kN2Rgo0000Z008Aliskiren study in Post-MI Patients to Reduce Remodeling9%`'`_K{h^X_n0ilBvk0vc000;[aliskiren0 NWN[0W0f00 ][000000b6RRgo0000Z00 &aspirinn0SO͑j00s0k0(uϑk000@{0000J00s0Lv000k0[Y00Rglaspirinn0@{0000N2Rgo0 (uϑ SO͑k000puj00S0h0L0:yU00_00aspirinn0 TN(uϑQeone-dose-fits-all00000o0iRg0o0j0D0S'`L0ؚO0 N_o000 P%RSlBv&beuL0_h0j0002018t^08gASSENT-2=Assessment of the Safety and Efficacy of a New Thrombolytic-2r@hn㉬tenecteplaseh0 alteplasen0 gR'`J00s0[hQ'`0k0{kN0-˄QQ@b6RtenecteplaseR"alteplase03NYn0Q@TuOub6RRgtenecteplasealteplase*0ihttp://www.ncbi.nlm.nih.gov/pubmed/10475182,15827313,12788302,11728350,11723014?report=DocSum&format=htmlASSENT-3EAssessment of the Safet< y and Efficacy of a New Thrombolytic Regimen-3@hn㉬tenecteplaseJ00s0uO(uh0W0f0NORP[ϑheparinenoxaparin @\gGPIIb/IIIaS[SObbabciximab ^R;uheparinn0 gR'`h0[hQ'`0k0tenecteplase enoxaparinB00D0o0abciximabo0AMIn0Z@'`TuOu0b6RW0_02001t^08g2011t^05gihttp://www.ncbi.nlm.nih.gov/pubmed/11530146,21570513,15234403,14522476,12919776?report=DocSum&format=html ASSENT-3 PLUS[Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 PLUS Randomized TrialeQbMRn0lBvh0W0f0@hn㉬tenecteplaseJ00s0NORP[ϑheparinenoxaparinENOX ^R;uheparinUFH uO(un0 gR'`h0[hQ'`0i0ENOXg030eNQn0{kN eQb-Nn0Qh^X eQb-Nn0lBvbb'`Z@0b6RPT0sBfpg0o0tenecteplase UFHL0eQbMRk0J0Q000000n0QLpAmBvlh0W0f0chYU0000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12847070?report=DocSum&format=html ASSENT-3PLUS`Assessment of the Safety and Efficacy of a New Thrombolytic Regimen in the Pre-Hospital Setting0 ASSENT-4PCIiAssessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Interventiont@hn㉬tenecteplasen0MRbN0LF0facilitated PCIh0primary PCIn0 gR'`0k090eNQn0{kN F0c0@'`_ NhQ 0000b6RRgprimary PCIfacilitated PCI*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/16488800,21545942?report=DocSum&format=html ASSENT-PlusHAssessment of the Safety and Efficacy of a New Thrombolytic Regimen Plus@hn㉬alteplasen0uO(uh0W0f0NORP[ϑheparinLMWH h0^R;uheparinUFH n0 gR'`J00s0[hQ'`0k0TIMI grade 3LMWHR"UFH0LMWHn0uO(uo0egn0QR^XJ00s0Qh^Xn00000NO NU0[00h0`000L0 lBv-Nbk_egn00000000L0 Nf0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12714021?report=DocSum&format=htmlASSERTSAortic Stentless versus Stented Valve Assessed by Echocardiography Randomized Triala00000000'YR_h00000NM000'YR_n0 gR'`0k0SbMzh0'YR_'W]o0000000_n0eL0 gak0o}Yg0B0c0_0k00K0K000Z0 6K0g_n0][͑ϑn0NO No0!N Tig0B0c0_002005t^10gEhttp://www.ncbi.nlm.nih.gov/pubmed/16230487?report=DocSum&format=htmlAsymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial'!quP'`_?b'`;o0ؚ;^k0zvuW0 3h^X~0_0o0hQ'`^Xhun0000g0B0c0_002012t^01gNhttp://www.ncbi.nlm.nih.gov/pubmed/22236222,22236229?report=DocSum&format=htmlcApo A1 Synthesis Stimulation Evaluation in Patients Requiring Treatment for Coronary Artery Diseaseq0000lBv-Nn0[[QRu``k0J0D0f0 0000ˆ}vA-1 (ApoA-1) Tb0zvW0HDL-C0 NfU0[00eL}SRVX-208k000(uϑOX[vk0 gak0ApoA-1L0 NfW0_0L0 0000h0n0k0o0 ga]o0j0K0c0_00ASSET.Anglo-Scandinavian Study of Early Thrombolysis>@hn㉬rt-PAalteplase n0{kNs TuOun0zvusk0[Y00Rg0i0{kNb6RRgrt-PA0000*01990t^05gDhttp://www.ncbi.nlm.nih.gov/pubmed/1971034?report=DocSum&format=htmlASSORT?AdminiStration of Statin On Acute Ischemic stRoke patienT Trial%`'`Z@'`3RS-N`k0[Y000000lBvASSUREdApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression EvaluationhHDL-C$Pn0NOD0uP'`QRu``k0J0D0f0 0000ˆ}vA-1n0Tb0zvY00eL}SRVX-208n0261_n00000[Mzso0000000k0kW0f0n\PT0:yW0_00n0n0 0000h0n0 ga]o0j0W00ASTAMICAutologous Stem-Cell Transplantation in Acute Myocardial Infarction;ꁶ[Ě0}ހBMC n0QRQleQk000][_j9eURg0i0EF b5_B}+gg[Mz h^X000BMCR"[gq0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16990383?report=DocSum&format=htmlEffects of Left Ventricular Function by Intracoronary Injections of Autologous Mononuclear Bone Marrow Cells in Acute Anterior Wall Myocardial Infarction-%`'`MRXh^X`k0J0D0f0 ]Ě1ueg0}ހn0QRQleQk000][_jn09eUo0000Z00ASTEROIDkA Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma BurdennHMG-CoA reductase;[rosuvastatink000^8^k07_Rj0NO NBvlk000 LDL-Co060.8mg/dL~0g0NO N HDL-CL014.7%XR0 gaj000000'`RlxSn02U\b6RL0000_002006t^04g2008t^05gNhttp://www.ncbi.nlm.nih.gov/pubmed/16533939,18378607?report=DocSum&format=html3rosuvastatink000QRn000000'`RlxS.~RgL0rzO@{ q_ g0000000MQRu``k0J0D0f0 HMG-CoA reductase;[rosuvastatink0007_RNO NBvlk00000000'`RlxSL0 gak0.~W0_00 ASTRONAUT&Aliskiren Trial on Acute Heart FailureSjnvj0lBvk0vcv000;[aliskiren0RW0f00 b_6K0g_J00s012K0g~0g0n0_@{{k _ NhQk000QeQbn0T0000000o0b6RU00j0K0c0_002013t^03gNhttp://www.ncbi.nlm.nih.gov/pubmed/23478743,23999456?report=DocSum&format=html/Aliskiren Trial on Acute Heart Failure Outcomesk][S.~n0NO NW0_0ba'`_ NhQeQb`k0J0D0f0 jnvj0lBvk0vcv000;[aliskiren0RW0f00 b_6K0g_J00s012K0g~0g0n0_@{{k _ NhQk000QeQbn0T0000000o0b6RU00j0K0c0_00 ASTRONOMERJAortic Stenosis Progression Observation: Measuring Effects of RosuvastatinTHMG-CoA reductase;[rosuvastatink000'YR_rzuAS 2U\b6RRg0iY000ASn02U\rosuvastatinR"000002010t^01g2012t^07gNhtt< p://www.ncbi.nlm.nih.gov/pubmed/20048204,22789885?report=DocSum&format=htmlATACH-2:Antihypertensive Treatment of Acute Cerebral Hemorrhage IIAŏj0MzuivM'Wn0[hQ'` gR'`0iY0003K0g_n0[ {kNvjSBP 110^139mmHgR"140^179mmHg02016t^09gEhttp://www.ncbi.nlm.nih.gov/pubmed/27276234?report=DocSum&format=htmlATACS2Antithrombotic Therapy in Acute Coronary SyndromesPb@\gaspirin bQVn0uO(uBvlh0aspirinXSrbN0k0_K{Z@J00s0hQZ@'`0000b6RRgaspirin bQVaspirin*01994t^01gDhttp://www.ncbi.nlm.nih.gov/pubmed/8281698?report=DocSum&format=htmlATHENAA Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter_eIIIb NtedronedaroneL0_@{0000k000eQbJ00s0{kN0b6RY00K00iY000_@{0000k000RVeQb hQ{kNb6RRgdronedarone0000*02010t^07gWhttp://www.ncbi.nlm.nih.gov/pubmed/19213680,20436046,19752319?report=DocSum&format=html atHome StudyComparison of the Safety and Efficacy of the Management of Pacemaker Patients Followed-up via Home Monitoring vs. Conventional In-office Follow-ups0000000`k0J0Q00`000000n0[hQ'`h0 gR'`0ATLANTIC;Angina Treatments-Lasers and Normal Therapies in ComparisonA000_K{Q@LQ^STMR irlBvuO(uh0irXSrlBv0k0KR[Bf0CCSR^9eUTMR irlBvirlBv*01999t^09gEhttp://www.ncbi.nlm.nih.gov/pubmed/10489946?report=DocSum&format=htmlATLANTIS2Acute Noninterventional Therapy in Ischemic StrokeQ@hn㉬rt-PAn0 gR'`J00s0[hQ'`0i0zvu_3^5Bfn0uOx0n0rt-PAbNn090evn0N_9eURgj0W00rt-PAg0uP'`-˄QQ@n0000 Nf01999t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/10591384?report=DocSum&format=htmlATLASKAcolysis During Treatment of Lesions Affecting Saphenous Vein Bypass Grafts20000u Yx0n0l@hnBvlo0 QR q_ Nn00^o0 Nog0 %`'`Z@'`TuOun0zvu0XRW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12732601?report=DocSum&format=html4Assessment of Treatment with Lisinopril and SurvivalS{kNJ00s0eQbn0000k0[Y00ACE;[n0 gR'`h0[hQ'`0 ؚ(uϑ NO(uϑg0k0{kN000ؚ(uϑg0NO N0{kNJ00s0eQb000 _ NhQk000eQbؚ(uϑg0NO N*02000t^08gNhttp://www.ncbi.nlm.nih.gov/pubmed/10587334,10931799?report=DocSum&format=htmlATLAS ACS 2 -TIMI 51Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51vzvuK007eNQn0%`'`QuP`k0J0D0f0 vc,{XaVP[;[00000000rivaroxaban NO(uϑn0jnlBvx0n0RbNk000 _@{{k _K{h^X 3RS-NT0000000000L0NO NW0_0L0 Q@ -˄QQ@000L0X'Y0`http://www.ncbi.nlm.nih.gov/pubmed/22077192,22077849,23602776,23500262?report=DocSum&format=htmlAnti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-thrombolysis in Myocardial Infarction 51 vzvuK007eNQn0%`'`QuP`k0J0D0f0 vc,{XaVP[;[0000000rivaroxaban NO(uϑn0jnlBvx0n0RbNk000 _@{{k _K{h^X 3RS-NT0000000000L0NO NW0_0L0 Q@ -˄QQ@000L0X'Y0 ATLAS ACS-TIMI 46Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin with or without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome- Thrombolysis in Myocardial Infarction 46 TrialvL}Svc\O(uWXaVP[;[rivaroxabann0[hQ'`h0 gR'`0UOW0 gi(uϑh0bNl0iY00phase IIf0;Nj0Z@'`0000o0b6RW0_0L0 Q@000L0(uϑOX[vk0X'YW0_00NO(uϑg0n0phase IIIfL02L-N02009t^06g2009t^07gNhttp://www.ncbi.nlm.nih.gov/pubmed/19539361,19539362?report=DocSum&format=htmlRandomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes]%`'`QuPACS k0J0D0f0 L}Svc\O(uW,{XaVP[;[rivaroxabano0(uϑOX['`n0Q@000 NfL0000 ;N_@{u`n0 gaj0b6RRgo0000Z0phase II 0ATLASTuAntiplatelet Therapy versus Lovenox plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosisbb@\gBvlk0NORP[ϑheparin enoxaparin 0RbNW0_04XTn0 gR'`J00s0[hQ'`0i00^ _['`o0oK0c0_0L0 egn01=s \Q@L0enoxaparing0 gak0ؚK0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11704394?report=DocSum&format=html ATMOSPHERECAliskiren Trial to Minimize Outcomes in Patients with Heart Failure000;[aliskirenh0ACE;[enalapriln0uO(un0enalaprilk0[Y00*Q'` j00s0k0aliskirenXSdRn0enalaprilk0[Y00*Q'`J00s0^R'`0i12</sub>;[bN-Nn0_?b0}R`k0J0D0f0 apixaban0+T0b@hBvlaspirin^uO(u o0 VKAJ00s0/~0_0o0aspirin0+T0b@hBvlk0O00y0 Q@J00s0eQb0b6RW0_002019t^04gEhttp://www.ncbi.nlm.nih.gov/pubmed/30883055?report=DocSum&format=htmlAune D, et al.NSO͑J00s0no0hQ{kN000 Nfh0#0000L0g0NOK0c0_0BMI$Po0^UYq23-24kg/m&sup2 ^UYqeeP^22-23kg/m&sup2; gg"20t^n0^UYq20.0-22kg/m&sup2h0 JW[Wn0O0BMINO$POg0n0{kN000X'Yo0 *g:eu`n0kYONa}n0S'`L0:yU00_00UYqtk TuO0*g:eu` gn0egn0q_0dYW0j0D0h0 BMIh0{kNn0Oo0UW[Wk0яe0O002016t^05gAUREC2Austrian Study on Recurrent Venous Thromboembolism000000g0L00f0D00MRTM00000xvz0Nhttp://www.ncbi.nlm.nih.gov/pubmed/17372172,15201412?report=DocSum&format=htmlAURORAOA Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis.@mg-Nn0+ggNu`k0J0Q000000|dRrosuvastatinn0 gR'`o0000Z00AusDiab1Australian Diabetes, Obesity, and Lifestyle Study0000000n0|?\uy`rlJ00s0]0n0#VP[n0u;mca 0iW0f0D000000[xvz0 0|Npu8^o0hQ{kN yrk0_@{{kh07_O0#00SO;mRh02Bf@|$Po0 gak0vW0_0L0zzyBf@|$Ph0o0v[0Z0000000/000ko0qSzVP[n0 T[k0 g(u00|?\u0|Npu8^L0%`X0ihttp://www.ncbi.nlm.nih.gov/pubmed/20065160,17130191,14641796,11978676,17576864?report=DocSum&format=html AVALON-AWCVAmlodipine in Patients with Elevated Lipids and Hypertension- Arterial Wall ComplianceTؚ@'W0ؚ@u`k0J0D0f0 Cabbamlodipine/HMG-CoA reductase;[atorvastatinn0TdRo0@{Qv_j0XSrbN0009eU02005t^05gAVERROESApixaban versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment]en0bQVg0B00vc,{XaVP[;[apixabann0[hQ'`h0 gR'`0aspirinh0kY0003RS-N hQ'`^Xhun0T0000000b6RRgapixabanaspirin*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21309657?report=DocSum&format=html=Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokesm3RS-N000n0ؚD00000KbbBvl Ni_n0_?b0}R`k0J0D0f0 en0L}S,{XaVP[;[000000apixaban o0aspirink0ky03RS-N~0_0o0hQ'`^Xhun00000 gak0b6RW0 Q@0000X'Y[0Z00AVERT/Atorvas< tatin versus Revascularization TreatmentHMG-CoA reductase;[atorvastatink000Mzuivj0NO NBvlh0 L}vvQR@LQ^Sn0Z@'`0000n0zvub6RRg0k0Z@'`0000b6RRgatorvastatin@LQ^S0Z@'`0000Rzv~0g0n0Bfo0atorvastating0^w*01999t^07gMhttp://www.ncbi.nlm.nih.gov/pubmed/9359537,10395630?report=DocSum&format=htmlM%`'`gzvu_f"24Bf n00000Yn0 gR'`08^n000h0k03RS-N_3K0gn0o}Yj00^8^00%`'`g0000<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25892679?report=DocSum&format=html]Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer PatientsF@hu0000 gY00YegL00`x0n0apixabanbNo00000k0O00y0Y@h^Xhu0 gak0b6RW0_0Ne 'YQ@00000zvuso0XR02018t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/30511879?report=DocSum&format=htmlAVID1Antiarrhythmics versus Implantable Defibrillators.b NteBvlh0 i0Wd0}RhVICD n0Rg0k0{kNN2RgICDb Nte*01997t^11ghttp://www.ncbi.nlm.nih.gov/pubmed/9411221,12849664,11980684,11827924,11136492,11319196,11208684,11263614,11704386,11496849,10520795,10520799,10551706,10440140?report=DocSum&format=htmlAVIT-J`Assessment Study on Validity of the Intervention Therapies for Coronary Artery Disease in Japan.'QRu`CAD lBvk0J0Q00000000000Bvln0YS_'`k0d0D0f0n0i0AVOID6Aliskiren in the Evaluation of Proteinuria in Diabeteszij0M'WlBv ARB losartang'YchY(uϑ k0vcvL}S000;[aliskiren0RbNW0_0RAASn0 dual ;[k000NOwRg [hQ'`0i0?\-N00000/000000kn0NO Naliskiren0000*0 ؚ@'W |?\u N_j[Nhttp://www.ncbi.nlm.nih.gov/pubmed/18525041,20693353?report=DocSum&format=html7Air Versus Oxygen In ST-elevation myocarDial infarctionvzvu_12Bf*gng0x }T^g"94%n0STEMI`63sk k0J0D0f0 x }Bvlo0^x }Bvlk0O00y0 CKg0UOW0_072Bf_n0_K{P[ bBfn0MIQzv ;N NteL0YO0 _ӁMRIg0UOW0_060g_n0h^X000L0'YM0K0c0_00 AVROlA Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects with Recent Onset Atrial Fibrillationveb Ntevernakalantn0Yln0 gR'`h0[hQ'`L0IIIb Nteamiodarone0 NV0K00i12</sub>;[o0clopidogrelk0ky0f0PCI_n0{kN0 gak0b6R0000/000000ko0yrk0PCI0eLW0_0ST NfW_K{h^XOg0o}Yg0B0c0_00BELLO*Balloon Elution and Late Loss Optimizationopaclitaxel0000000W0_0dRnQ'`0000DEB n0Qrzb6RRgL0paclitaxelnQ0000PES k0R0j0D0S0h00i~ 聊^0^0 N\_Oh0kW0_001t^J00s02t^_n0hQ{kNN\_OR" N\_O02017t^05gEhttp://www.ncbi.nlm.nih.gov/pubmed/28330793?report=DocSum&format=html BIO-RESORT^8^k0D000000n0euR'`00000O(uW0_0 dRnQ^0ϑj0i0L0puj002.z^n00000everolimusnQ0000 sirolimusnQ0000 n0 eNNEN'`00000000zotarolimusnQ0000k0[Y0012K0g_n0[hQ'` gR'`k0J0Q00^R'`L0:yU00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27806902?report=DocSum&format=html BIOFLOW VU12K0g_n0jvu Y NhQk0J0D0f0 Wn0uSO8TS'`0000O(un0sirolimusnQ0000n0EN'`0000everolimusnQ0000k0[Y00^R'`L0:yU00_002017t^10gEhttp://www.ncbi.nlm.nih.gov/pubmed/28851504?report=DocSum&format=html BIOSCIENCEW00000h0uR'`00000O(uW0_0en0sirolimusnQ0000Orsiro n0[hQ'` gR'`0 W00000n0EN'`0000everolimusnQ0000h0kY00012K0g_n0jvu Y NhQk0d0D0f0uR'`0000sirolimusnQ0000n0EN'`0000everolimusnQ0000k0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/25189359?report=DocSum&format=html BIOSOLVE IIt,{NNNn0uSO8TS'`dRsirolimus nQё^\00000000n0[hQ'` '`0UOY00first-in-manf06K0g_n0s^GW00000Q`g d1Y_o00.27mmg0 [eS [hQ'`J00s0< '`o0o}Yj0S0h0L0:yU00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/26470647?report=DocSum&format=htmlBIP!Bezafibrate Infarction Prevention`ؚ@u(ubezafibratebNL0 QRu`CAD k000{kNs CADuOn0^{k'`_K{h^XMI 0NO NU0[00K0i0bezafibratek0MIJ00s0z6q{kn0NO NPT00_00`http://www.ncbi.nlm.nih.gov/pubmed/10880410,18222357,11923036,11739302?report=DocSum&format=htmlBLOCK HFcBiventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block[!N[00000k000{kN _ NhQn0Qe%`lBv g[j0][000000L0S[00000k0O00y0n\Y00K00i*</sup>0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23614585,27151347?report=DocSum&format=htmlvBiventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular BlockV?b[00000EF50%n0_[000000Y00`k0J0D0f0 !N[00000o0S[00000k0O00y0{kN _ NhQk000}%`lBv ][S.~+gg[MzOpen0XR0 gak0b6R0 BPLTTCuACE;[ AIIS[SObbARB k0003RS-N QRu` _ NhQ000k0[Y00@'WOX['`b6RRgo0 T z^g0B0c0_00ACE;[k000;NQRu`0000k0[Y00@'W^OX['`b6RRgL0000_0L0 ARBg0o0000j0K0c0_002007t^05gBBlood Pressure Lowering Treatment Trialists CollaborationBPLTTC Mc{|tSOoNϑL0B00 z^NO NW0_0`k0J0D0f0 M'WlBvk000@'Wn0NO No0_@{0000n0b6Rk0 gRg0B0c0_0L0 M'Wn0000k000]o0000j0K0c0_00BBlood Pressure Lowering Treatment Trialists Collaboration: BPLTTC/yr[n0M'Wn0xbL0 n`h0u[0_0`h0g0puj000^00_00Y0h0D0F0~k0[NW0F00K0i0kX[rz0Qrzb6RsDCAPTCA*00000zvusDCAR"PTCA0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9468205?report=DocSum&format=htmlBoekholdt SM, et al.h0000lBv`g0o0 ^8^k0NOD0LDL-C$PTbOk0J0D0f00 HDL-CJ00s0ApoA-Io0CVD000NO Nh07_O0#W0_00ApoA-I Nfo0CVD000NO Nh0#W0_0Neg0 HDL-C Nfo0#W0j0K0c0_00NO NlBv}0000lBvk000LDL-C non-HDL-C apoBn0NO No0 PN YRL0'YM0O0 ؚ(uϑ0000bNOn040%L0LDL-C70mg/dL0Tbg0M0j0D00LDL-C50mg/dLTbOn0CVDNO No075-100mg/dLO000 gak0'YM0D002014t^08gBogalusa Heart StudyFfxj0community-basedn0[a0|^\gK00Rt^g0L}f0t^d\bNk00~0g0gW0 _@{u`n0000VP[n0Yi'`0iY00uf[0http://www.ncbi.nlm.nih.gov/pubmed/25301461,21953798,21126976,16769996,15837946,15616245,16053958,14600185,11710784,11281231,11130771,10933568,2028978?report=DocSum&format=htmlBOOSTGBone Marrow Transfer to Enhance ST-elevation Infarct Regeneration Trial9ꁶ[Ě0}ހBMC n0QQy iL0][_j09eUY00K00i0EF9eU^BMC[gq*p0.0026 0Nhttp://www.ncbi.nlm.nih.gov/pubmed/15246726,16520413?report=DocSum&format=htmlBoussageon R, et al.R7_S@|M NBvln0hQ{kN _@{{kb6RRgo0000Z00 0Z0K0k0:yU00_0^{kv_K{h^X _ϑ00000?\b6RRg0͑uNO@|n0XRk000vkU000S'`L0B000Boutitie F, et al.ZY@h^Xhun0Qzv000o0bQVBvl030gg0B}NW0_04XTh0]00N N}}W0_04XTh0o0 TI{g0 yrzv'`n0яMOtPmY@hu ^Xhuo0bQVBvln0B}NBfg0OU0Z0Qzv000L0ؚD001puj00M'Wk00c0f0TbW0_0M'Wk000_@{0000b6RRgo065skN Nh065sk*gnh0k0]o0j0D00aM'Wg0TbU000_@{000n0v[NO No0 000000Bfn0_@{0000000OU0Z0 M'WlBvk000v}[000NO No0ؚ000uO{0i0'YM0D00M'WlBvn0zl[k0J0Q00_@{000n0 g(u'`L0:yU00_00BRAVE,Bavarian Reperfusion Alternatives Evaluationr@hn㉬reteplase @\gGPIIb/IIIaS[SObbabciximabn0MRbNo0 abciximabXSrbNh0ky0 gRK0&TK00i0h^X000reteplase abciximabR"abciximabXSrbN02004t^02gEhttp://www.ncbi.nlm.nih.gov/pubmed/14982910?report=DocSum&format=htmlnPCIprimary coronary intervention eLN[n0%`'`_K{h^XAMI `k0J0D0f0 reteplase abciximabn0MRbNo0h^X000b6Rg0abciximabXSrbN0QR0j0K0c0_00BRAVE-28Beyond 12 Hours Reperfusion Alternative Evaluation Trial8primary PCI0000 GP IIb/IIIaS[SObb o0_eglBv00h^X0000 gak0.~\0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15956631?report=DocSum&format=htmlBRAVOJBlockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular OcclusionxL}SGPIIB/IIIaS[SObblotrafibann0{kN _K{h^XMI 3RS-N eQb0Y00Z@Qzv }%`@LQ^Sb6RRg0ilotrafibanR"00000{kNsL0lotrafibang0 gak0YK0c0_0_00fo0-Nbk0< Ehttp://www.ncbi.nlm.nih.gov/pubmed/12874182?report=DocSum&format=html BREATHE-1:Bosentan Randomized Trial of Endothelin Antagonist Therapy?000000S[SObbbosentann0KR[x0n0Rg0i06RikLݍ^wRgbosentan0000*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/11907289,12706935?report=DocSum&format=htmlBRIDGEBridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery;000000bQVBvl^[eo0000000[ek0[W0f0R@h^XhuN2g0^R'`g0B00 'YQ@000L0 gak0NOK0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/26095867?report=DocSum&format=html BRIDGE-ACSP%`'`QuPk0[Y00ꌒ09eUY00YbvNeQYenjen0MN }0SQ0_0000000000 000000 [j0i0 k00000000k0We0D0_0lBvn0[eL0XR0 BRIEF-PCIVBrief Infusion of Eptifibatide Following Successful Percutaneous Coronary Intervention*__jvPCIeL_n0eptifibatidebNo02Bf*gnk0w.~W0f00[hQg0B000Briel M, et al.BHDL-C$P0 NfU0[0f00_@{u`000o0NO NW0j0D00 pu8^ulBvn0,{Nn000000o0LDL-Cn0NO Ng0B00S0h0L0/ecU00_00BRIGHTPBivalirudin in Acute Myocardial Infarction vs Heparin and GPI plus Heparin Trialbivalirudinn0 gR'`h0[hQ'`0heparinXSdR~0_0o0heparin GPIIb/IIIa;[tirofibanh0k030e_n0MACCE BARCWnQ@n0T0000000b6RRgbivalirudinheparin heparin tirofiban<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25775052?report=DocSum&format=htmlBritish Regional Heart Study_0000hQWn0:u0kY00h0Z@'`_u`{kk02 Pn0]L0B00S0h0K00 tXJ00s0>yOL}n000K00_@{{kn0Yi'` 000VP[0i0TVP[h0n0vNOJ00s00Wtvj0UD0h0n0#0iY000 Z@'`_u` uf[Vhttp://www.ncbi.nlm.nih.gov/pubmed/12628945,11956120,6789956?report=DocSum&format=htmlBrugts JJ, et al.ZE^^D0@{u``k0J0D0f0 ACE;[perindopril )R?\indapamideh0n0uO(u 0000h0W0_0lBvk000NW0_0{kN ;N_@{0000b6RRgL0000_007qSzVP[0 gY00^_@{u``k0J0D0f0 0000|dRo0 gak0uX[s09eUW0 ;N_@{00000b6RW0_00BRUISE CONTROLJBridge or Continue Coumadin for Device Surgery Randomized Controlled TrialY;egB}N=hTSgn0warfarin}}h0heparinncn0[hQ'` gR'`0kY000聊^vk0OULh0j000000Q@kb6RRgwarfarin}}heparinnc*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23659733?report=DocSum&format=html:Bruneck Ischemic Heart Disease and Stroke Prevention Study!quP'`8RlxSn0y`sJ00s0000VP[0iY00uf[0_http://www.ncbi.nlm.nih.gov/pubmed/12663606,10484534,10588212,8485116?report=DocSum&format=htmlBurke MC, et al.T[hQv N i0Wd0}RhVo0_['`;b/_[0}Rk0[W0ؚD0 gR'`0:yW0_00TuOuh0 NiRj00000n0zvuso0000000000000000Sn0L}n0XRk04OD0NO NW0_00Bypassing the Blues trialHTelephone-Delivered Collaborative Care for Treating Post-CABG DepressionCABG_ ww+^n0qk000F0d0u00n0 gR'`L0:yU0000C-PORT6Atlantic Cardiovascular Patient Outcomes Research Teams_ӁYyKbS-P PCI programn0j0D0e-g0[eW0_0primary PCIn0 gR'`L0@hnBvlk0*Q0K0 *Q0j00]0n0 gR'`L0c}Y00K00i0primary PCIo0 MI_6K0gn00^9eUh0eQbepew.~00_00W0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11960536?report=DocSum&format=htmlC-SIRIUS5Canadian Sirolimus-Eluting Stent in Coronary Lesions :0000Qrzؚ000u Yk0J0D0f0 sirolimusnQ0000o0jnn0^n00000k0ky0Qrz0 gak0b6R0CABADASwPrevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole, and Acenocoumarol / Phenoprocoumon StudyvQR0000S_1t^n0Y0000n0^XN2k0J0Q00 b@\gNO(uϑaspirin 0000 NO(uϑaspirin dipyridamoleA D L}SbQVn0Q^XN2Rgh0[hQ'`0k0A Dn0 g(u'`o0000j0K0c0_001993t^07gLhttp://www.ncbi.nlm.nih.gov/pubmed/8101300,7930237?report=DocSum&format=html CABG Patch"Coronary Artery Bypass Graft Patch7QR0000SBfn0N2vj0d0}RhVICD i0n0u}TN_9eURg0i0{kNpeICD i0R"^ i00 Nte,Z@'`_u` Z@'`_u` NteVhttp://www.ncbi.nlm.nih.gov/pubmed/9371853,11028466,10567289?report=DocSum&format=htmlCABG Surgery Study1COX-2;[valdecoxibJ00s0parecoxibbNk000_@{0000L0 gak0XR0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15713945?report=DocSum&format=htmlafety of Parecoxib and Valdecoxib in the Treatment of Postoperative Pain Following Coronary Artery Bypass Graft Surgery or Major General Surgery5CABGeL_n0COX-2;[parecoxib valdecoxibn0bNk000_@{0000L0XR0CABRIBCoronary Angioplasty versus Bypass Revascularisation Investigation9CABGh0PTCAn0Rg0k0{kNN2RgCABGPTCA0@LQ^SQeLb6RRgCABGPTCA*01995t^11g1999t^05gMhttp://www.ncbi.nlm.nih.gov/pubmed/7475656,10208785?report=DocSum&format=htmlCACTUSWCoronary Bifurcations: Application of Crushing Technique Using Sirolimus-Eluting StentsusirolimusnQ0000Yun&beuh0W0f0 000000000lh0,gy^n00x0n00000 f[vtPgT0000h00kY000tPgx0n00000L0_j0uOo01/3 z^0000000000h0f[v0000n0@{ q_ 聊^0^o0 TI{k0 gR02009t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/19103990?report=DocSum&format=htmlCADILLACVControlled Abciximab and Device Investigation to Lower < Late Angioplasty Complicationsprimary PTCAk00000 @\gGPIIb/IIIaS[SObb0uO(uW0_04XTn0 gR'`0i06K0gn0hQ{kN Qh^X Z@k000jv@{n0@LQ^SQeL Nw0Y003RS-Nb6RRg0000 PTCA abciximabprimary PTCA*0http://www.ncbi.nlm.nih.gov/pubmed/11919304,20650362,16516077,15862409,15811868,15708696,15353506,15093869,15364322,15261923,15358018,12939213,14610016,13678914?report=DocSum&format=htmlCAFA2Canadian Atrial Fibrillation Anticoagulation Study}bQVwarfarinbNk000hQ'`@h^Xhun0zvsb6RRgh0]0n0lBvk04OF0Q@000k0d0D0f0i0Q@zvub6RRg0000warfarin0^000h^X0^-Ng^yL}|hQ'`^Xhu0{k'`Q@0-˄QQ@b6RRgwarfarin00000Dhttp://www.ncbi.nlm.nih.gov/pubmed/1856403?report=DocSum&format=htmlCAFE"Conduit Artery Function Evaluation)-N_R'WL00^n0zl[VP[k0j00S'`L0:yU0000ASCOT-BPLAn000㉐g0Caixeta A, et al.ASESg0o0BMSk0ky0 {kN _K{h^X 0000@hun00000X'YY00S0h0j0O0 5t^_n0jv@{@LQ^S0 gak0b6RW0_00CALIBERRCardiovascular Research Using Linked Bespoke Studies and Electronic Health Recordshؚ@'WL0_@{u`k0S|0Y0q_o0u` t^bk000puj000SBPo0r_u _K{h^X +gh@{u`x0n0 DBPo0y'YR$vx0n0q_L0'YM0D0030skBfn0uX[ d1Yt^peL0J0J0M0D0n0o0r_u 80skBfo0_ NhQh0r_u0uf[ ؚ@'Whttp://www.ncbi.nlm.nih.gov/pubmed/28432148,24881994,24881978,28254179,28331015,27334486,26429079,26429080,26419648,25466521,26330414?report=DocSum&format=htmlCALM+Candesartan and Lisinopril MicroalbuminuriaARB candesartanh0ACE;[lisinopril J00s0uO(uBvln0 gR'`0kY000candesartann0M'W _ϑ00000b6RRgo0lisinoprilh0 Tig0B000candesartanh0lisinopriln0uO(ubNn0_['`o0o}Yg0 M'W^o0XSrbN00'YM0D00 ؚ@'W N_j[ |?\u2000t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/11110735?report=DocSum&format=htmlCAMELLIA-TIMI 61}Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients  Thrombolysis in Myocardial Infarction 61CCVؚ000ƖVk0J0D0f0u;mcaNeQx0n0lorcaserinn0Rk000 ;NCV0000XR04O0Z0k0c}vj0SO͑n\L0}cU00_00pu8^u |?\u Z@'`_u`Ehttp://www.ncbi.nlm.nih.gov/pubmed/30145941?report=DocSum&format=htmlCAMELOTIComparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis_@{0000b6RRg0Cabbamlodipine ACE;[enalapril 0000g0k0M'WRg!N[0000*0_@{0000b6RRgamlodipine0000* enalapril 0000 amlodipineenalapril ga]j0W0 0amlodipinek000000'`RlxSn02U\b6RRgL0000_00`http://www.ncbi.nlm.nih.gov/pubmed/15536108,22520542,17161053,16904557?report=DocSum&format=htmlCAMIAT:Canadian Amiodarone Myocardial Infarction Arrhythmia Trial7u}TN_k0[Y00b Nteamiodaronen0Rg0i0_NEeb6RRgamiodarone0000*0Mhttp://www.ncbi.nlm.nih.gov/pubmed/9078198,10226092?report=DocSum&format=htmlCANHEART Aortic Stenosis studyLCardiovascular Health in Ambulatory Care Research Team Aortic Stenosis studyo_@{u`e_n0j0D0ؚbk0J0Q00qSzVP[h0͑^'YR_rzuAS zvuh0n0wgk00_00O0i<0ؚ@'W |?\u pu8^uh0ASzvuk0rzW0_0(uϑOX[vj0#L0000 S0003VP[o0͑^ASn0J00]03Rn010`S0_002017t^03gEhttp://www.ncbi.nlm.nih.gov/pubmed/28335833?report=DocSum&format=htmlCANHEART Immigrant@Cardiovascular Health in Ambulatory Care Research Team Immigrant:Yleylk0J0Q00CV0000zvusk0o0UWj0]L0000_00S0n0]0SxQvqSzVP[n00g0fY00S0h0o0g0M0j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/26324719,27810046?report=DocSum&format=htmlCANPAPdCanadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failurenc}lS}'WBvlcontinuous positive airway pressureCPAP k000-NgWaw wBf!q|T8Tn0wglBvL0{kNJ00s0_y i0b6RY00K00i0hQ{kN _y iCPAPR"[gqirBvl 0Nhttp://www.ncbi.nlm.nih.gov/pubmed/16282177,17562959?report=DocSum&format=htmlCANTOS5Canakinumab Antiinflammatory Thrombosis Outcome Study[3K0gT0h0n0[hQ00WbIL-10000000bSOg0B00canakinumab 150mgk000bpulBvo0 NO Nh0o0rzW0f00000k0O00y0CV0000Qzv0 gak0NO NW0_002017t^09gihttp://www.ncbi.nlm.nih.gov/pubmed/28845751,28844177,30165610,29146124,28855077?report=DocSum&format=htmlCANVAS Program5Canagliflozin Cardiovascular Assessment Study Programcanagliflozinn0_@{k0[Y00[hQ'`h0 gR'`0i0000<sup>*</sup>0canagliflozing0 NRe000L0 Nf02017t^08g`http://www.ncbi.nlm.nih.gov/pubmed/28605608,29941478,29526832,29133604?report=DocSum&format=htmlCAPARES0Coronary Angioplasty Amlodipine Restenosis Study[PTCAeL`k0J0D0f0 Cabbamlodipinen0QrzJ00s0N_k0S|0Y0Rg0i0{kN _K{h^X CABGB00D0o0QPTCAn0b6RRgamlodipine0000*02000t^03gEhttp://www.ncbi.nlm.nih.gov/pubmed/10716459?report=DocSum&format=htmlCAPASaCutting Balloon Angioplasty vs Plain Old Balloon Angioplasty Randomized Study in Type B/C LesionsKcutting<  balloonCBA h0_egn00000PTCA n0Qrzb6RRg0k090e_n050%N Nn0Qrzb6RRgCBAPTCA*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11685163?report=DocSum&format=htmlCAPE)Circadian Anti-Ischemia Program in Europec_K{Z@n0ie0000k0[Y00Cabbamlodipinen0\O(u0i0ST NM0STZ@bMzNO NRg r_ub6RRg nitroglycerinO(uϑNO NRgamlodipine0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7930276?report=DocSum&format=htmlCAPE II,Circadian Anti-ischemia Program in Europe IICabbamlodipineh0diltiazemn0_K{Z@k0[Y00 gR'`0k0XSdR TXn0]o0j0D0L0 OBfn0Z@b6RRgo0amlodipinediltiazem*0Z@b6R}cRgamlodipine neatenololdiltiazem ]xx02002t^09gEhttp://www.ncbi.nlm.nih.gov/pubmed/12225716?report=DocSum&format=html CAPITAL AMItCombined Angioplasty and Pharmacological Intervention versus Thrombolysis Alone in Acute Myocardial Infarction Study9tenecteplasebNbNv_n0PCIk000 K0g_n0{kN MIQzv N[[Z@Qzv 3RS-Nn0000L0NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16053952?report=DocSum&format=html CAPITAL-RCTaCarvedilol Post-Intervention Long-Term Administration in Large-scale Randomized Controlled Trial1PCI0eLW0_0ST NfW_K{h^X`k0J0Q00necarvediloln0wgN_9eURgn0iCapodanno D, et al.D];Ny^u Yk0[Y001t^_n0;N g[_0000{kN _K{h^X jv@{@LQ^S 3RS-N o0 PCIh0CABGg0 gaj0UD0o0j0K0c0_00CAPPPCaptopril Prevention Project`ACE;[h0N,vlBvn03_@{TuOuN2Rg0kY0003RS-N hQ_K{h^X Nn0_@{{kN2RgACE;[R"N,vlBv)R?\ ne 03RS-NN2RgN,vlBvACE;[*01999t^02gNhttp://www.ncbi.nlm.nih.gov/pubmed/10030325,11723089?report=DocSum&format=html CAPRICORN:Carvedilol Post-infarct Survival Control in LV Dysfunctionr%`'`_K{h^X_n0][_j NhQ`k0J0D0f0 necarvediloln0TuOuzvuJ00s0{kNsk0[Y00wgRg0i0hQ{kN _@{u`k000eQbo0carvedilolR"00000hQ{kNb6RRgcarvedilol000002005t^02gWhttp://www.ncbi.nlm.nih.gov/pubmed/11356434,15708698,14707020?report=DocSum&format=htmlHCarvedilol Post-Infarct Survival Control in Left Ventricular DysfunctionCAPRIEBClopidogrel versus Aspirin in Patients at Risk of Ischaemic Events\b@\gclopidogrelh0aspirinn0RlxS'`u`zvub6Rn0pK00]0n0v[ gR'`0UO3h^X0_K{h^X0@{|{kNn0b6RRgclopidogrelaspirin*01996t^11gVhttp://www.ncbi.nlm.nih.gov/pubmed/8918275,24239662,10874265?report=DocSum&format=htmlCAPSCardiac Arrhythmia Pilot Studyo_['` Nte0b Ntek000wgvk0b6RY00S0h0g0uX[sL09eUU000h0D0F0Nn0i<0vvh0W0_0'Y!jfCASTn000000000000flecainide encainide moricizineL0000000 gR01988t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/2894169?report=DocSum&format=htmlCAPTIMUComparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction|primary angioplastyL0eQbMR@hnBvl00*Q0f0D00K00i030evk0J0Q00{kN ^{k'`Qh^X Nwn0_j03RS-Nn0b6Ro0@hnBvl8.2% primary angioplasty6.2% g0B0c0_0p0.29 0Whttp://www.ncbi.nlm.nih.gov/pubmed/12243916,19429632,15708697?report=DocSum&format=html CAPTIVATEbCarotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment EffectsACAT;[pactimiben000000'`RlxSn02U\N2Rgh0[hQ'`0i012K0g_n0g'Y8RQ--NSpactimibeR"00000&NLW0f0L00_0ACTIVATEfL000000'`RlxS2U\b6RRg0:y[0j0K0c0_0S0h00SQ0f0fo0e0k0B}NW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/19293413?report=DocSum&format=htmlCAPTURE;c7E3 Fab Antiplatelet Therapy in Unstable Refractory AnginaaPTCAeLOk0J0D0f0 @\gGPIIb/IIIaS[SObbabciximabn0 gR'`0i0PTCAeL_30eNQn0hQ{kN0_K{h^X0}%`@LQ^Sb6RRgabciximab000002004t^01ghttp://www.ncbi.nlm.nih.gov/pubmed/9164316,14747500,12952835,12668510,12646667,12566361,12559939,10807457?report=DocSum&format=html CAPTURE 2500Carotid RX ACCULINKR/RX ACCUNET? Post-Approval Trial to Uncover Unanticipated or Rare Events s(W0{v2 o0}}-Ng0 ,gzvho0{v2 ፒ0B}NW0_02500Og0n0P}g0)00000`k0J0D0f0 8R0000k00030e_n0_@{0000so0ؚO0j0D00CARDIA7Coronary Artery Disease Risk Development in Young Adultu;mca{0K0n0VP[n0QRu`2U\x0n0[Nk0Y00wgxvz0khttp://www.ncbi.nlm.nih.gov/pubmed/29735485,26791067,27028434,26503880,26112189,24496536,23160723,24041951,23428218,22871870,21346180,19139385,19109114,18492970,17283263,17512357,16728422,16603565,16567569,16622141,15639678,15210592,14732757,14679272,14570949,12651040,11966382,10815118,9669612,9672072,8727231,7797754,8196117,j0W0,3204420?report=DocSum&format=htmlCARDia-Coronary Artery Revascularization in DiabetesU0000 i0k000PCIn0[hQ'` gR'`0CABGh0kY0001t^_n0hQ{kN _K{h^X 3RS-Nn0T0000000b6RRgPCIn0CABGk0[Y00^R'`o0000Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20117456?report=DocSum&format=html7|?\u`k0J0Q001t^_n0{kN ^{kv_K{h^X03RS-Nb6RRgk0J0D0f0PCIh0CABGk0 ga]o0000Z00CARDINALDComplement and Reduction of Infarct Size<  after Angioplasty or Lytics܈SOC5k0[Y000000000bSOpexelizumabL0h^X0000n\U0[00K0 0^09eUY00K00 puj00QLpAmBvl2fg0i1) COMPLY@hnBvl ܈SO;m'`0;[Y00L0 h^X0000 g[j0聊^0^o0b6R[0Z0 2) COMMAprimary PCI h^X000k0o0Rg0S|0U0j0K0c0_0L0 {kNs0 gak0NO N0Whttp://www.ncbi.nlm.nih.gov/pubmed/12925455,12925454,16611669?report=DocSum&format=html Cardio-Sis_Studio Italiano Sugli Effetti Cardiovascolari del Controllo della Pressione Arteriosa Sistolica\SBPn0Se'`ranolazinen0br_uRgJ00s0bZ@Rg0i0000Bfk0J0Q00000000KRBf^wranolazine0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/14734593?report=DocSum&format=htmlCARISMAGCardiac Arrhythmias and Risk Stratification After Myocardial Infarctionl000_ i0W_0(uD0 EFL0NO NW0_0AMI`k0J0Q00 Nten0zvusJ00s0N_h0n0#0UO0͑^n0_'` NteJ00s0;'` Nten0zvusL0ؚO0 zv\O'`ؚ^?b[0000o0_Ӂ{kn00c0h007_D0N,nVP[g0B0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20837897?report=DocSum&format=htmlCARMEN:Carvedilol ACE Inhibitor Remodelling Mild CHF Evaluation .Carotid Stenosis Trialists CollaborationCSTC70skN Nn0uP'`8Rrz`g0o0 8RQeRSCEA n08R0000YunSCAS k0[Y00f0K0j0*Q'`L0000_00S00o0 CASg0S0n0t^bd\n0hTSg000L0ؚK0c0_0Ne CEAg0o0t^bk000]L0j0K0c0_0_00g0B0c0_00t^bo0!Nh00k0wg000k0o0q_0S|0U0j0K0c0_00CARP-Coronary Artery Revascularization Prophylaxis,__jv@{SMRn0QR@LQ^Sn0 gR'`0i02.7t^_n0{kNb6ReLR"^eL0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15625331?report=DocSum&format=html__jv@{SeLMRn0@LQ^o0N_09eU[0Z00 CARPORTNCoronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism StudyaQrzsk0[Y000000000A2S[SObbGR32191Bn0 gR'`0i0g\@{_9eU0QrzN2Rgj0W00{kN ^{k'`_K{h^X 0000S QP< TCAeLGR32191BR"000001991t^10gDhttp://www.ncbi.nlm.nih.gov/pubmed/1833088?report=DocSum&format=html CARRESS-HF=Cardiorenal Rescue Study in Acute Decompensated Heart Failurek000)R?\bN Ng0N_jn0`Sh0c}vj0F0c0@000%`'`^NQ'`_ NhQk0J0D0f0 000)R?\n0Ylk0O00y0SOmϑ0n\U0[00PY0Nk00096Bf_n0N_jL0`SW0 F0c0@0c}0SO͑n\0irlBvh0]o0j0D00CARS#Coumadin Aspirin Reinfarction StudyHb@\gaspirinn0XSrbNh0 aspirin bQVwarfarinn0NO(uϑuO(ubNn0 gR'`h0[hQ'`0k0k0 ga]j0O0fB}N01997t^08gVhttp://www.ncbi.nlm.nih.gov/pubmed/9259652,11524065,11451256?report=DocSum&format=htmlCART-1%Canadian Antioxidant Restenosis Trial{ؚ@u(uprobucoln0[[Nirg0B00AGI-1067L0Qrz0b6RY00K00i0AGI-1067h0probucolo0PCI_n0Qrz0b6R0probucolh0puj00 AGI-1067o0QTc0^wU0[0Z0 jvu Yn0QT_0b'YW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12566365?report=DocSum&format=htmlCARTERNCilnidipine versus Amlodipine Randomized Trial for Evaluation in Renal Disease^L NWCabbcilnidipineh0LWCabbamlodipinen0bˆ}v?\Rg0k0?\ˆ}v/000000Cr kn0NO N:cilnidipineamlodipine*02007t^12gEhttp://www.ncbi.nlm.nih.gov/pubmed/17943080?report=DocSum&format=htmlCASCADEICardiac Arrest in Seattle: Conventional versus Amiodarone Drug EvaluationNb Nteamiodaronen0L}vbNh0 lutigB00D0o00000_Vg0 gRh0U00_0Ih0n0k0uX[s9eURgamiodaroneI01993t^08gLhttp://www.ncbi.nlm.nih.gov/pubmed/8342505,2000790?report=DocSum&format=html5Clopidogrel After Surgery for Coronary Artery Disease>CABGeLOk0J0D0f0 aspirink0clopidogrel0uO(uW0f000000Qn0Nb_b X['`k0 gR'`o0000Z00CASE-J9Candesartan Antihypertensive Survival Evaluation in Japanrwgn0_@{0000b6RRg0AIIS[SObbcandesartanh0Cabbamlodipineh0g0kY000z6q{k 3@{0000 _0000 N0000 @{0000candesartanR"amlodipine0ihttp://www.ncbi.nlm.nih.gov/pubmed/18172059,14717341,19347033,21833000,18971535?report=DocSum&format=htmlnؚ000ؚ@'W`k0J0D0f0 AIIS[SObbcandesartanh0Cabbamlodipinen0wgn0_@{0000b6RRgk0 ga]o0000Z00]['Y e|?\uzvuo0candesartang0 gak0NOK0c0_00Dؚ000ؚ@'W`k0J0D0f0 AIIS[SObbcandesartann0_@{0000b6RRg0Cabbamlodipineh0kY000CASHCardiac Arrest Study Hamburglb Nteamiodarone propafenone metoprolol h0 i0Wd0}RhVICD k000lBv0k0propafenoneL0ؚ{kNsg0f-Nbk0{kN0z6q{kN2RgICDb Nte*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10942742?report=DocSum&format=htmlCASIS5Canadian Amlodipine/Atenolol in Silent Ischemia Studyr000000000J00s048Bf0000_V-Nn0Z@k0[Y00Cabbamlodipine neatenolol J00s0!Nn0uO(un0Rg0k0KR[9eU0Z@b6RRguO(uamlodipineatenolol*01995t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/7860905?report=DocSum&format=htmlCASSCoronary Artery Surgery Study5QR0000SCABG n0Rg0irlBvh0k0{kNsJ00s0;Nj0_K{h^XzvusCABGR"000001984t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/6608052?report=DocSum&format=htmlCassese S, et al.everolimusnQuSO8TS'`00000000o0everolimusnQё^\0000k0O00y0100g_n0`g d1Y_L0'YM0K0c0_00n0n0 1t^_n0Q@LQ^So0 TI{g0B0c0_00_0`0W0 00000000g0lBvW0_0`o0h0O0k0N%`'`gn00000@hu000L0ؚK0c0_00 CASSIOPEAKwBf\O(uWn0Svcv;m'`S,{XaVP[;[idrabiotaparinuxo0warfarinn0 ggj0Nfh0j00S'`L0B00 Q@0000NOD00Ehttp://www.ncbi.nlm.nih.gov/pubmed/22130488?report=DocSum&format=htmlCASTChinese Acute Stroke TrialNegaspirinlBvn0eg{kNJ00s0;Nj0TuOuzvuk0[Y00Rg0i0{kN ^{k'`3RS-Nb6RRgaspirin0000*0Q@'`3RS-N000001997t^06gDhttp://www.ncbi.nlm.nih.gov/pubmed/9186381?report=DocSum&format=html$Cardiac Arrhythmia Suppression TrialCb NtelBvk000 Nte0b6RL0 Nte{k0NO NU0[00K00i0 Nte{k0]0n0Nn0SVk000_Ӂ{kb6RRg0000b Nte*01991t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/1900101?report=DocSum&format=htmlCAST II'Cardiac Arrhythmia Suppression Trial IIb NtemoricizinebNk000 Nteb6RL0 Nte{k0NO NU0[00K00i0wgfg0n0{kNb6RRg0000moricizine*0wgfg0n0{kNb6RRgmoricizineR"00000^{k'`oR\O(ub6RRg0000moricizine*0f-Nbk01992t^07gDhttp://www.ncbi.nlm.nih.gov/pubmed/1377359?report=DocSum&format=htmlCastellucci LA, et al.L}SbQV4dRh0b@\gn0aspirino0 D0Z0000000/[k0O00y0Y@h^XhuVTE n0Qzv0b6RW0_00jn(uϑn00000Kbbo0g0 gRg0B0c0_0Ne ͑'Yj0Q@n00000g0ؚK0c0_00VTEQzvN2RgL0g0\U0K0c0_0n0o0aspirin0CASTLENComparison of Candesartan and Amlodipine for Safety, Tolerability and EfficasyhA IIS[SObbcandesartanh0Cabbamlodipinen0 gR'`h0_['`0k0M'WRgcandesartanR"amlodipine _['`candesartanamlodipine0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11249891?report=DocSum&format=html CASTLE-AF|Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial FibrillationChQ{kN N[Yn0eQb0Y00_ NhQ`Sn0T0000000000NO N000000000000irlBv<sup>*</sup>02018t^02gEhttp://www.ncbi.nlm.nih.gov/pubmed/29385358?report=Do< cSum&format=htmlCATCardiomyopathy TrialICDn0{kNN!kN2Rg0i{kNN2Rgo0000Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11914254?report=DocSum&format=htmlThe Cardiomyopathy Pilot TrialCATCH2Combination of Antihypertensive Treatment in ChibaD000000000000TuOؚ@'W`k0[Y00AIIS[SObbARB /NO(uϑ)R?\TdR h0ARB Cabbn0uO(uBvln0ki CATHARSISUCilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery StenosisuP'`-˄Q@{rz`k0J0Q00gon0lBvln0i0CATIS5China Antihypertensive Trial in Acute Ischemic StrokeV24BfNQk0SBPn010^25%n0NO N0vcY0M'WlBvn0 gR'`0 M'WlBv0L0j0D04XTh0kY00014eNQn0{kN 14eNQ/bBfn0[M'WlBvR"M'W^lBv0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24240777?report=DocSum&format=htmlzvuK0048BfNQg0SBPg"140mmHgn0%`'`Z@'`3RS-N`k0J0D0f0 MzuivM'WlBv24BfNQk0SBP 10-25%M'W!7eNQk0140/90mmHgk0M'W o0 [gq^M'WlBv k0O00y0 gak0M'WW0_00n0n0 14e_~0_0o0bBfh030g_n0{kN [k0o0]L0j0K0c0_00CATS#Canadian American Ticlopidine StudyCb@\gticlopidinebNn0[hQ'`J00s0 gR'`0i0Qh^X0_K{h^X0@{{kb6RRgticlopidine0000*0 3_t Z@'`_u`1989t^06gDhttp://www.ncbi.nlm.nih.gov/pubmed/2566778?report=DocSum&format=htmlCATS (Captopril) Captopril and Thrombolysis StudyWegkk0J0Q00ACE;[captoprilbNn0Rg0i0][[MzXRRgcaptoprilR"00000][b5_b6R0_ NhQb6RRgcaptopril0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8752803?report=DocSum&format=htmlCAVALIER at HOMEhCandesartan-Based Treatment for Variability Lowering of Individual Blood Pressure and Heart Rate at HomeM'WMTdRL0@'W YR0_b YRk0NH00q_0CAVATAS;Carotid and Vertebral Artery Transluminal Angioplasty Study\8Rn0rzlBvh0W0f0n0 gR'`h0[hQ'`0@{QlBvL}vv@{b_bS h0YylBvQdSS h0g0k0lBv_3t^n0@{QlBvn03RS-NN2000J00s0 gR'`o08RQdSSh0 TI{0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11403808?report=DocSum&format=htmlCAVEAT8Coronary Angioplasty versus Excisional Atherectomy Trialdirectional atherectomyh0balloon angioplastyn0Rg0Qrz TuOu ;SBvn0bK00k0@{_XRRgatherectomyangioplasty*0Qrzb6RRgatherectomyangioplasty0TuOuzvu0eQbb6RRgangioplastyatherectomy*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8316266?report=DocSum&format=html CAVEAT-II;Coronary Angioplasty versus Excisional Atherectomy Trial IIkDCAdirectional coronary atherectomy h0PTCA0k0QT_XRRgDCAPTCA*0+gh^Xhu0^Qlh^Xb6RRgPTCADCA0Qrzs {kNsPTCAR"DCA01995t^04gDhttp://www.ncbi.nlm.nih.gov/pubmed/7895354?report=DocSum&format=html CAVEFT-Kokura/Cardiovascular Events Follow-up Trial in Kokura(PCIeL_n0`k0J0D0f0 Cabbamlodipineo0ifgQT d1Y0b6R0CAVI-J$Cardio-Ankle Vascular Index in Japan5Rn0lxU0n0cjg0B00cardio-ankle vascular index (CAVI)n0 g(u'`n0i0ؚ@'W |?\u N_j[ 3_tCCAIT4Canadian Coronary Atherosclerosis Intervention TrialhHMG-CoA reductase;[lovastatinn0Rg0i0rz2U\b6RRg0000lovastatin*0.~04O0j0D02U\b6R0eQRu Yb6RRglovastatin0000*01994t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/8124836?report=DocSum&format=htmlCDPCoronary Drug Project4.z^estrogen dextrothyroxine clofibrate niacin n0NO Nn0wglBvn0 gR'`h0[hQ'`0i0estrogen dextrothyroxineo0oR\O(un0_00-Nbk0clofibrateo0 gR'`00Z00niacino0^{k'`_K{h^Xo0i^k0NO NW0_00n0n0 {kNpeo0n\[0Z001986t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/3782631?report=DocSum&format=html CE-MARC 2MClinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease 2_ӁMRigCMR k0We0O000o0 NICE000000~0_0o0_K{000igMPS k0We0O000k0O00y0 Nj0QR q_0n\U0[00h0D0F0N0i<012K0gNQn0 Nj0QR q_n\CMR MPSNICE0000000CMRR"MPS0Ehttp://www.ncbi.nlm.nih.gov/pubmed/27570866?report=DocSum&format=htmlCHAMPNCandesartan Cilexetil in Hypertension Ambulatory Measurement of Blood Pressure00000000IIS[SObbcandesartan cilexetiln0 gR'`;'WPP x0n0RgJ00s0bNϑk000Rg @'Wh0'Wx0n0=0losartanh0k0ARB!NdRo0PPNO N Rgn0c}k0]L0B00 candesartann0eL0losartan00NO NsL0'YM0O0 c}Bf0wK0c0_00Xϑk00c0f0SBP DBP PPx0n0Rgk0UD0L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11081784?report=DocSum&format=html0Combination Hemotherapy and Mortality Prevention]b@\gaspirin bQVwarfarinuO(uBvlL0aspirinXSrBvl00 gRK00i0{kN _K{h^Xn0Qzv 3RS-Nb6RRguO(uR"XSr0͑'Yj0Q@zvu000uO(uXSr*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11827919?report=DocSum&format=html CHAMPION PCIZCangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PCI^0000000|n0eb@\gcangrelorn0MRbN(Yl)n0 gR'`00000000|b@\gclopidogrelh0kY00048BfNQn0hQ{kN _K{h^X Z@k000@LQ^SQeLn0Tk0[Y00cangrelorn0clopidogrelk0[Y00*Q'`o0000Z00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19915221,19915223?report=DocSum&format=htmlNPCIeLOk0J0Q00{kN Z@'`0000b6Rk0J0D0f0 eb@\gcangrelor*n0KbbMR^Kbb_Yln0clopidogre< lk0[Y00*Q'`0:y[0Z00CHAMPION PHOENIXVCangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition^0000000|n0b@\gg0B00ADPS[SOP2Y<sub>12</sub>;[cangrelorMRbNYl n0Z@'`TuOub6RRg0i<048Bf_n0{kN _K{h^X Z@k000Q@LQ^S 0000@hun0T0000000b6RRgcangrelorclopidogrel*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23473369,23473370?report=DocSum&format=htmlb^0000000|n0b@\gg0B00ADPS[SOP2Y12;[cangrelorYlo0PCIeLOg0'YQ@0000X'YY00S0h0j0O0 hTSgn00000@hu0+T0Z@'`0000 {kN0 gak0b6R0CHAMPION PLATFORM_Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PlatformHeb@\gcangrelorYln048Bf_n0{kN _K{h^X Z@k000@LQ^SQeLn0Tk0[Y000000h0kW0_0*Q'`o0000Z00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19915222,19915223?report=DocSum&format=htmlCHANCEPClopidogrel in High-risk Patients with Acute Nondisabling Cerebrovascular Eventspclopidogrelh0aspirinuO(ubN21e k00090e_n0N!kN2Rg0aspirinXSdRh0kY00090en03RS-Nb6Rclopidogrel aspirinaspirin<sup>*</sup>0Whttp://www.ncbi.nlm.nih.gov/pubmed/23803136,23803138,27348249?report=DocSum&format=htmlCHANMPION PLATFORM8PCIeLOk0J0D0f0 hTSgn0eb@\gcangrelor*Yln0{kN Z@'`0000b6RRgo0000Z00CHAOS!Cambridge Heart Antioxidant Study]ؚ(uϑ0000En0bNL0_K{h^XMI J00s0_@{{kn00000NO NY00K0i0000NO N0MIb6RRg0000E0000*0_@{{k0hQ{kNb6RRg00000000E0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8622332?report=DocSum&format=htmlCHARISMA`Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidancedclopidogrel aspirinn0uO(ubNh0aspirinXSrbNn0_@{0000b6RRgn0k0_K{h^X 3RS-N _@{{kb6RRgclopidogrel aspirinR"aspirin02010t^06grhttp://www.ncbi.nlm.nih.gov/pubmed/16531616,20516378,19933933,17673448,17659194,17498584?report=DocSum&format=htmlY00000'`@hu00000k0J0Q00_K{h^X 3RS-N _@{{kn0Rzvb6RRgk0J0D0f0 b@\gclopidogrel aspirinh0aspirink0 ga]o0000Z00CHARMOCandesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity00000000IIS[SObbcandesartann0 gR'`0i0CHARM-AddedEFf"40%O CHARM-AlternativeEFf"40%n0ACE;[ N_[O _@{{k CHF`Sk000eQbb6Rcandesartan0000* CHARM-PreservedEF40% _@{{k CHF`Sk000eQbb6Rcandesartan00000 http://www.ncbi.nlm.nih.gov/pubmed/13678868,13678869,13678870,13678871,28426886,25406306,23850914,19683640,19055992,17996561,17638930,17562950,17601544,17291934,16697316,16476847,16461840,16330684,16219883,15983242,15466644,15492298,15522471?report=DocSum&format=htmlOCandesartan in Heart Failure Assessment of Reduction in Mortality and MorbidityGEFf"40%n0ba'`_ NhQ`k0J0D0f0 sL_ NhQlBv AIIS[SObbcandesartano0_@{{kJ00s0_ NhQk000eQb0 gak0b6R0CHART>Chronic Heart Failure Analysis and Registry in Tohoku RegistryOqSzVP[0 gY00e,gNn0ba'`_ NhQOk0J0Q00N_o0j0J0 Nog0B00 uX[sJ00s0QOL09eUY00_00k0o0qSzVP[g0d\%RSW0_000000L0_g0B00h0H00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/15118283,15671603?report=DocSum&format=htmlCHART-2DChronic Heart Failure Analysis and Registry in the Tohoku District 2_ NhQk0Y00ub000n0'Y!j0000xvz0_ NhQ ]0n0NChatterjee S, et al.V^Xhu` yrk0@LRKao0[[W0f0D00L0S[_j[0 gY00-NI{^000`k0J0D0f0 @hnBvlo0bQVBvl000{kNsL0NOO0 'YQ@ -˄QQ@n0000L0ؚK0c0_02014t^06g CHECKMATEFChest Pain Evaluation by Creatine Kinase-MB, Myogloblin and Troponin Ipen0_K{X{k0000000000 CK-MB 00000 ) 0000000g0,n[Y00multimarker strategyn0a0i0ŏj0pen00000n0,n[o0 0WWige-g0n01d0n00000n0,n[000}'`O0eO0X%RW0 00oD0000d\%RL0g0M000Ehttp://www.ncbi.nlm.nih.gov/pubmed/11294799?report=DocSum&format=htmlChen Y, et al.Nqg000Ng0o0BMIh0_@{u`CVD {kn0Oo0UW[W WS000Ng0o0BMIo0CVD{kn01_D0000VP[Asia Cohort Consortium 0Cheng YJ, et al;000000|b̃n0bNo0_Ӂz6q{k0_[;b'` Nte _@{{kn0000XRh0#W0_0L0 hQ{kNh0o0#W0j0K0c0_00CHEST-1ZChronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1HSn'`0000x00000:Roriociguatn0 gR'` [hQ'`0iY000161_n06RikLݍ^wriociguat0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23883377?report=DocSum&format=htmlCHF STATBCongestive Heart Failure: Survival Trial of Antiarrhythmic Therapy8b NteamiodaronebNn0}{kNN2Rg0i0{kNs z6q{kzvusamiodaroneR"00000 Nte _ NhQ1995t^07gDhttp://www.ncbi.nlm.nih.gov/pubmed/7539890?report=DocSum&format=htmlCHICAGODCarotid Intima-Media Thickness in Atherosclerosis Using Pioglitazoner}8RQ--NSIMT n02U\b6RRg000000bb'`9eUpioglitazoneh0SUdRglimepirideh0g0kY000]S}8Rn0_XIMTb6RRgpioglitazoneglimepiride*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/17101640,18413496?report=DocSum&format=htmli@'W000000L0o}Yg00000bNsL050%N N s^GWLDL-CL0113mg/dLn02W< |?\u`k0J0D0f0 pioglitazone180gbNo0glimepiridek0ky0 8RQ--NSn02U\0b6RCHILL-MItEfficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction=QtSutߘiX4ln0leQh0000000(uD0_0@{QQtSn0uO(uk000NOSO)n\n0_OwRg0i<0h^X000NOSO)nR"[gq02014t^05gEhttp://www.ncbi.nlm.nih.gov/pubmed/24509284?report=DocSum&format=htmlCHOICEi0000b5_W'YR_SAPIEN XT 0O(uW0_0TAVRh0]b5_W'YR_CoreValve TAVR0kY00030e_n00000bR0000b5_W_]b5_W'YR_<sup>*</sup>02014t^04gWhttp://www.ncbi.nlm.nih.gov/pubmed/24682026,24682010,26271061?report=DocSum&format=htmlaؚ000n0uP'`͑u'YR_rzu`k0J0D0f0 L}00000v'YR_ncSTAVR k0O(uY000000n0bRsbSvvn0T o0 0000b5_W_n0{0F0L0]b5_W_00 gak0ؚK0c0_00CHOIR<Correction of Hemoglobin and Outcomes in Renal InsufficiencyKzOP[D}0cH0000000000000000 k0000000009eUk000_@{{kN _K{h^X F0c0@'`_ NhQk000eQb 3RS-N 000L0 Nf0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17108343?report=DocSum&format=htmlACholesterol Treatment Trialists' Collaboration: CTT Collaboration(@{0000ؚ000n0|?\u`k0o00000|dRk000lBv0naY0y0M0g0B000Chowdhury R, et al.m_@{lBvn00000000 NoOo0YD040% 0EUn0OOlk0S_f0o000h0 hQCVDn0}9%L00000000 Nok0000n0h0c[U00_000000000o}YOo0 NoOk0O00y0CVD000 hQ{kN000L0 gak0NOK0c0_00 CHRISTMASDCarvedilol Hibernating Reversible Ischaemia Trial: Marker of Success1necarvedilolo000000000_K{0Z@_K{ B00D0o0Sek0NW0EF09eUY000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12853194?report=DocSum&format=html+Chronic Kidney Disease Prognosis ConsortiumMN,OOlk0J0D0f0 eGFR60mL/R/1.73m<sup>2</sup>J00s0?\-N00000/000000kg"10mg/go0 {kNn0rzW0_0N,nVP[0N|?\u`o0^|?\uk0O00y0{kNh0+ggN NhQn0000L0ؚK0c0_00n0n0 ]000n0000n0eGFR ACRn0 YSk04OF0v[v YSo0|?\un0q_0SQ0j0K0c0_00CHSCardiovascular Health Study5QR_u`J00s03RS-Nn0zvuh0L}Nn0#VP[0 T[W0 ؚbk0J0D0f0N2Sj0000VP[0 T[Y00uf[02018t^04ghttp://www.ncbi.nlm.nih.gov/pubmed/29352072,26940919,28254175,26538580,25124495,25104519,24799513,23250801,23487436,23391194,22871870,22703926,22282329,21078811,19841297,19761940,19064831,18678768,18285566,18268154,17996566,17631213,17576871,17452608,17336721,16818809,16936145,16843180,16651468,15793190,16432070,15983251,15901858,15827312,15262826,14736436,15193681,15193686,11824854,12243634,11348601,11448406,11343441,11723018,11263606,11023931,11067785,10636269,10807470,10466662,9878640,10403851,1669507?report=DocSum&format=htmlCIAO.Coronary Interventions Antiplatelet-based Onlyr*gR;uheparinj0i0n0bQVBvl0[e[0Z0b@\gBvln00n0uO(ulBvg0eLY00__jvPCIn0[hQ'`J00s0 gR'`0UOY00^R'`f030eNQn0{kN %`'`_K{h^X }%`@LQ^Sb6RRgheparin^bNjnlBv02008t^10gNhttp://www.ncbi.nlm.nih.gov/pubmed/18929239,18929240?report=DocSum&format=htmlCIBIS&Cardiac Insufficiency Bisoprolol StudyfnebisoprololbNk000N_n09eU0i0{kN z6q{k Nte#{kbisoprololR"00000_ NhQk000eQbb6RRg NYHA__jR^9eURgbisoprolol0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7923660?report=DocSum&format=htmlCIBIS II)Cardiac Insufficiency Bisoprolol Study II>nebisoprololbNn0Rg0i0{kNN2Rg eQb000b6RRgbisoprolol0000*0f-Nbk01999t^01gihttp://www.ncbi.nlm.nih.gov/pubmed/10023943,12643888,11428837,11245648,11157688?report=DocSum&format=html CIBIS III*Cardiac Insufficiency Bisoprolol Study IIInebisoprololh0ACE;[enalapriln0D0Z000HQLbNY00K0hQ{kN hQeQbn0RVzvub6Rk0J0D0f0bisoprololk000lBvYn0enalaprilk000lBvYk0[Y00^R'`o0per-protocol㉐gg0o0<fU00j0K0c0_0L0 !Nn0[hQ'` gR'`o0 Tig0B00h0`0000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16143696?report=DocSum&format=html6Cardiac Insufficiency Bisoprolol Study III z6q{kSCD n0㉐g\u^-NI{un0ba'`_ NhQ`k0J0D0f0 1t^_n0z6q{k0nebisoprololHQLlBvL0ACE;[enalaprilHQLk0ky0 gak0b6R0W0K0W0_ NhQ`Sk000eQbL0XRW0_00 Oba'`_ NhQ`k0J0D0f0 nebisoprololg0lBv0YW0_04XTn0 gR'`J00s0[hQ'`o0ACE;[enalaprilg0lBv0YW0_04XTh0 Tig0B000CIBIS-JZThe Cardiac Insufficiency BIsoprolol Study in Japanese Patients with Chronic Heart Failure+ba'`_ NhQ`k0J0Q00nelBvbisoprolol vs carvedilol CIDS(Canadian Implantable Defibrillator StudyZ i0Wd0}RhVICD h0b Nteamiodaronen0{kNb6RRg0k0ICDn0amiodaronek0[Y00hQ{kNn0v[000n\o020% Nte{ko033% ga]j0W0 0`http://www.ncbi.nlm.nih.gov/pubmed/10725290,15238454,11245646,10758047?report=DocSum&format=htmlCILON-TxInfluence of Cilostazol-based Triple Antiplatelet Therapy on Ischemic Complication after Drug-eluting Stent Implantationa2dRuO(ub@\gBvlDAT k00000000000;[n0cilostazol0RW0_03dRuO(uBvlTAT n0 gR'`0iuSQT[X[L000003RS-N NN'`3Z@zv\O`k0J0D0f0 _?b-N k d0000n0N!kN2Rgo0iirBvl0 NV0Z00CLOTBUSTbCombined Lysis of Thrombus in Brain Ischemia Using Transcranial Ultrasound and Systemic t-PA Trial7-˄Ql0000lk000T-PAk000QLpAmL0X'YW0 0000k0ky03RS-NK00n0V_sL0ؚD0PT0:yW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15548777?report=DocSum&format=htmlCMCS%Chinese Multi-provincial Cohort Study\Framinghamn0Q000n0{[_0-NVN0000k0i(uY00h0 CHD000s0[00ؚO0N,nW0f0W0~0F0L0 -NVn00000RsTW0_00n0k0Y00h0N,no09eUW0-NVNg00 g(ug0B0002004t^06gEhttp://www.ncbi.nlm.nih.gov/pubmed/15173150?report=DocSum&format=htmlCOACT)Coronary Angiography after Cardiac Arrest=bY_\Pbk_k0uk0bRW0_0ST NfL0j0D0uOk0[Y00}%`CAGn0[eo0 E^CAGk0O00y0 90e_uX[s09eUW0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/30883057?report=DocSum&format=htmlCOAG9Clarification of Optimal Anticoagulation through Geneticsxwarfarinn0bN0e_0k0YY00`k0J0D0f0 RgbNϑ0zOP[`1X 聊^`1Xk0We0O0000000k000zl[W0_04XTh0zOP[`1Xn00n0000000k000zl[W0_04XTh0g0o0 lBvY_41n0INR000000k0]o0000j0K0c0_00 COAST0Heparin-Coated Stents in Small Coronary Arteries0000 yrk0heparin0W0_00000n0@{ q_@bk0[Y00Rgh0聊^vRg0i0f[vj00000 iH0004OF0PTCAh0ky0 heparinj0W00000J00s0heparin-coated0000n0g\@{_o0^j0L00 gak0'YM0O0 聊^0000o0 gag0o0j0< D00n0n024%NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12628946?report=DocSum&format=htmlCOBRA?Comparison of Balloon-Angioplasty versus Rotational Atherectomy;PTCAh0000000000RA n0wg wgRg0kY000Kbbn0bRs TuOuzvus QrzsPTCAR"RA0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11052840?report=DocSum&format=htmlCOGENTAClopidogrel and the Optimization of Gastrointestinal Events Trial]PPIomeprazole uO(un0 gR'`h0[hQ'`0iY000g106e-N.Y$P g0njёT Nk000egk0-NbkmS{0000b6RRgomeprazoleuO(u0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20925534?report=DocSum&format=htmlCOLMhCombination of Olmesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients StudyDؚbn0ؚ000ؚ@'W`k0J0Q00 AIIAT<sub>1</sub> S[SObbolmesartanh0Cabb )R?\n0uO(uf0COMET'Carvedilol or Metoprolol European Trialhnecarvedilolh0metoprololn0{kNsJ00s0TuOub6RRg0k0hQ{kNb6Rcarvedilolmetoprolol* hQ{kN hQeQbb6RcarvedilolR"metoprolol0rhttp://www.ncbi.nlm.nih.gov/pubmed/12853193,17237130,17336720,16630997,16040619,15767288?report=DocSum&format=htmlCOMETSGComparative Study with Rosuvastatin in Subjects with Metabolic SyndromedHMG-CoA reductase;[rosuvastationRSV n0 gR'` [hQ'`0atorvastatinATV) 0000h0k061_n0LDL-CNO NRSVATV*0 pu8^u ؚ@'WEhttp://www.ncbi.nlm.nih.gov/pubmed/16143705?report=DocSum&format=htmlCOMFORTmCombination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial2ؚ@'W`k0J0Q00ARBh0000000|M'W)R?\h0n0MTdRk000dR00000000n09eUn0i0COMFORTABLE AMIComparison of Biolimus Eluted from an Erodible Stent Coating with Bare Metal Stents in Acute ST-Elevation Myocardial InfarctionbuR'`000000sNx n0biolimusnQ0000h0000000000BMS n0 gR'`J00s0[hQ'`0k01t^_n0;N g[_0000b6RRgbiolimusnQ0000BMS*Ehttp://www.ncbi.nlm.nih.gov/pubmed/22910755?report=DocSum&format=html COMMANDER HFA Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureK%`'`X`W0_0CADTuOn0^AF][ƙQsNO Nn0ba'`_ NhQ`k0J0Q00NO(uϑrivaroxabanRo0 hQ{kN MI 3RS-Nn00000NOnW0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/30146935?report=DocSum&format=htmlCOMMIT9Clopidogrel and Metoprolol in Myocardial Infarction Trial(1)b@\gclopidogreln0aspirinx0n0 NWN[0Rgn0i0{kN Qh^X 3RS-N hQ{kNb6RRgclopidogrel aspirin0000* (2)nemetoprololn0egbNk000jnlBvx0n0 NWN[0Rgn0i0{kN Qh^X _\Pbk hQ{kNb6RRgmetoprololR"00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/16271642,16271643?report=DocSum&format=htmlCOMMIT/CCS-2 (aspirin)ClOpidogrel and Metoprolol in Myocardial Infarction Trial/ Second Chinese Cardiac Study Randomized, Placebo-controlled Trial of Adding Clopidogrel to Aspirin in 46,000 Acute Myocardial Infarction PatientsR-NVn0%`'`_K{h^X`k0J0D0f0 b@\gaspirin clopidogrelbNk000;Nj0_@{0000L0 gak0NO N1000Og010_@{00000N2 0COMMIT/CCS-2 (metoprolol)ClOpidogrel and Metoprolol in Myocardial Infarction Trial/ Second Chinese Cardiac Study Placebo-controlled Trial of Early Metoprolol in 46,000 Acute Myocardial Infarction PatientsA-NVn0_K{h^X`k0J0D0f0 metoprololo0{kN0b6RW0j0K0c0_00Qh^Xh0_[0}R0b6RW0_00n0n0_S'`0000L0XRW0_00COMPACTTCarvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial.@LQ^S_n0_?b0}ހN20necarvedilolh0metoprololh00kY000Comparison of the Effectiveness of Carvedilol Versus Metoprolol for Atrial Fibrillation Appearing After Off-Pump Coronary Bypass Surgery in the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial<00000CABGOPCAB _n0_?b0}RAF b6RRg0necarvedilolh0metoprololh0g0k COMPANIONJComparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure~0000000k000_ӁQ TglBvCRT iirBvl 00000000d0}RhVk000CRT iirBvl iirXSrBvlh00k00000000k000CRTo0hQ{kNJ00s0hQeQbn00000NO N i0Wd0}RhV0uO(uW0_04XTo0{kNs0 gak0NO N0rhttp://www.ncbi.nlm.nih.gov/pubmed/15152059,19204305,17190867,17159063,16360064,16360067?report=DocSum&format=htmlWComparison of Medical, Resynchronization, and Defibrillation Therapies in Heart Failure/-NI{uK00͑un0_ NhQ`k0J0D0f0 irBvl _ӁQ TglBvCRT o0{kNJ00s0eQb0b6R0COMPAREeverolimusnQ0000n0[hQ'`J00s0 gR'`0,{NNNpaclitaxelnQ0000h0kY00012K0gn0hQ{kN ^{kv_K{h^X jv@{@LQ^SQeLn0T0000000b6RRgeverolimusnQ0000paclitaxelnQ0000*0`http://www.ncbi.nlm.nih.gov/pubmed/20060578,2010990< 0,21824922,21514083?report=DocSum&format=htmlkRole of Coumadin in Preventing Thromboembolism in Atrial Fibrillation Patients Undergoing Catheter Ablations0000000eLBfk0warfarinn0bN0}}W0_04XTn0hTSgn0@h^XheQ@0000N2Rg0 warfarin0-NeW0_04XTh0k048Bfn0@h^Xh0000000warfarin-Ne}}<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24744272?report=DocSum&format=html4COzaar in Marfan PAtients Reduces aortic EnlargementlbN00000uP`k0J0D0f0 jnlBvx0n0losartanRk000 3t^_n0'YRWb5_sL0NO N0Y0g0k0N2vj0'YRWncS0SQ0f0D0_0`g00 losartanRk000'YR_b5_sn0NO NL0000_00 Compare-AcutewQ@AmNPϑkFFR 000 Ng0^h^XN@{lBv0LF0[hQ@LQ^L0N@{n00n0@LQ^000*Q0f0D00S0h00i*</sup>0Nhttp://www.ncbi.nlm.nih.gov/pubmed/28317428,28317460?report=DocSum&format=html COMPARE-HF8Comparative Effectiveness of Therapies for Heart Failurez[0W聊^g0n00000000bbn0 gR'`0UOY000bBfn00000000bbn0bNYk0003t^_n0{kN _@{u`k000QeQbn09eUo0000j0K0c0_0L0 _ NhQk000QeQbo09eUW0_00Ne ؚ0000@uk000QeQbn0000o0 gak0XR0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23188026,23188032?report=DocSum&format=html COMPARE IIuSO8TS'`00000biolimusnQ0000n0 gR'`J00s0[hQ'`0 EN'`00000everolimusnQ0000h0[0W聊^g0kY00^R'`f012K0g_n0_Ӂ{k _K{h^X TVRn0T0000000biolimusnQ0000R"everolimusnQ00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/23374650?report=DocSum&format=htmlCOMPASSCCardiovascular Outcomes for People Using Anticoagulation Strategiesrivaroxabanaspirinh0aspirinXSrn0[hQ'` gR'`n0k0CV{k 3RS-N MIn0T0000000b6Rrivaroxaban-aspirinuO(uaspirinXSr<sup>*</sup> 'YQ@000rivaroxaban-aspirinuO(uaspirinXSr<sup>*</sup>0rivaroxabanXSrn0aspirinXSrh0O00y0_0o}Yj0CV0^o0:yU00Z0'YQ@000L0ؚK0c0_002019t^05grhttp://www.ncbi.nlm.nih.gov/pubmed/28844192,28844176,31072566,29540326,29132880,29132879?report=DocSum&format=htmlREASONiRandomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in DiabetesHQRu`CAD 0TuOW0_02W|?\u`n0LDL-Ck0S|0Y0q_0DPP-4;[anagliptinh0sitagliptinh0g0kY000 |?\u pu8^u COMPASS-HFYChronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure3͑u_ NhQk0J0Q00 i0W@LRKa0000000000Chronicle &reg; o0[hQg0 gR0COMPERAYComparative, Prospective Registry of Newly Initiated Therapies for Pulmonary HypertensionHbQVo0yrzv'`R'`ؚ@'W`n0uX[s09eUY00S'`L0:yU00_00n0n0 Nn0000n0R'`ؚ@'W`k0d0D0f0o0fxj000000o0_00Z00ؚ@'W uf[2014t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/24081973?report=DocSum&format=htmlComplior StudyYwgM'WBvln0'YRlOd^PWV UOk000RstiffnesslxU0 n09eURg0iY000PWV00000000h0W0_0'Y!jNeQfn0eLn0S'`0:yY0gRn0f0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11330885?report=DocSum&format=htmlCOMPLY & COMMAComplement Inhibition in Myocardial Infarction Treated with Thrombolytics & Complement Inhibition in Myocardial Infarction Treated with Percutaneous Transluminal Coronary Angioplasty0 CONDIfprimary PCIpPCI MRn0`Z@00000000000RIC n0wg聊^0^x0n0q_0iY0003.8t^-N.Y$P _n0;N g[_03@{0000b6RRgRIC pPCIpPCI*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24031025?report=DocSum&format=htmlCONFIRMmCAC000L000n0uP'``k0J0D0f0 ^X'`CADo0_@{0000n0XRk0#0QRCTk0CAC0RW0f000000N,no09eU[0Z0ACC/AHAn0000000c(un0CADn0igMRxso0 CAD gus0N'YUO0Whttp://www.ncbi.nlm.nih.gov/pubmed/22079127,22025600,25205531?report=DocSum&format=html CONSENSUS7Cooperative North Scandinavian Enalapril Survival StudyV_egn0_ NhQlBvk0ACE;[enalapril0RH0hQ{kNL09eUY00K00i0{kNN2Rgenalapril0000*0z6q{kb6RRgenalaprilR"00000Dhttp://www.ncbi.nlm.nih.gov/pubmed/2883575?report=DocSum&format=html CONSENSUS II8Cooperative New Scandinavian Enalapril Survival Study IIdACE;[enalapril0egbNY00S0h0k0006K0g{kNs09eUg0M00K0i0{kNb6RRgenalaprilR"00000_ NhQ2Lk000{kNb6RRgenalapril00000f-Nbk0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1495520?report=DocSum&format=html CONTAK CDCONVERT_?b0}RN20vvh0W0_0b NteamiodaronelBvln0i0amiodarone#0Wy_u`#n0;Nj0 g[Nan0T0000000o0 QzvBfbNh0}}bNk0]o0j0K0c0_0L0 QzvBfbNg0o0_?b0}Rn0Qzv hQ{kNJ00s0_@{u`k000eQbL0 gak0XR0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18854540?report=DocSum&format=htmlCONVINCEEControlled Onset Verapamil Investigation of Cardiovascular End PointsCabbCOERcontrolled-onset extended-release verapamil0,{Nxbh0W0_04XTn0_@{u`n0N2Rgo0 neatenolol~0_0o0000000|)R?\hydrochlorothiazideg0lBv0YW0_04XTh0 TI{h0o0H0Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12709465?report=DocSum&format=html COOPERATE:<Font Size="3" Color="#ff0000"><b>%S0n0֊eo0dVU00~0W0_0</b></Font>֊edV2009t^10gNhttp://www.ncbi.nlm.nih.gov/pubme< d/19819378,12531578?report=DocSum&format=htmlCOPEDCombination Therapy of Hypertension to Prevent Cardiovascular Events{ARB neBB ~0_0o0000000|)R?\TD n0uO(uk000M'WRgh0_@{0000N2Rg0kY000_@{0000h0M'WvjTbM'WvjTbk0]o0j0W00_@{0000o0TDuO(ug0NOD0PTL0000_0L0lBvk0 ga]o0j0W00Ehttp://www.ncbi.nlm.nih.gov/pubmed/21610513?report=DocSum&format=htmlICombination Therapy of Hypertension to Prevent Cardiovascular Event TrialQe,gNn0ؚ@'W`k0J0D0f0 Cabbbenidipine0Wyh0W0f0AIIS[SObb ne 000000|)R?\n0D0Z00n0D}T0[0L0*Q0f0D00K00k0Copenhagen AFASAK6Copenhagen Atrie Flimmer Aspirin Antikoagulation Studywarfarink000bQVBvl b@\gNO(uϑaspirinBvl 0000k000@h^Xh'`TuOuk0[Y00Rg0k0@h^XhuJ00s0@{'`{kNn0b6Rwarfarinaspirin 0000*0Q@k000-Nbkb6R0000aspirinwarfarin01989t^01gDhttp://www.ncbi.nlm.nih.gov/pubmed/2563096?report=DocSum&format=htmlCopenhagen City Heart Study&0000000000000k0J0D0f0_@{u`n0000VP[0iW0f0D00uf[02014t^09ghttp://www.ncbi.nlm.nih.gov/pubmed/25169175,19001625,18955664,18971492,18971498,17635890,16157768,15210602,14662715,12932598,12798568,11056092,10821816,9341693,8044059,2040311?report=DocSum&format=html COPERNICUS5Carvedilol Prospective Randomized Cumulative SurvivalEnecarvediloln0uX[sx0n0Rg0i0carvediloln0{kNJ00s0TuOun0zvuN2RgL0 ͑u_ NhQ`g00000_00`http://www.ncbi.nlm.nih.gov/pubmed/11386263,15381643,12585949,12390947?report=DocSum&format=html;Carvedilol Prospective Randomized Cumulative Survival Trial"͑u_ NhQ`k0J0D0f0 necarvediloln0 gR'`0i0 COPPS POAFSColchicine for Post-Pericardiotomy Syndrome and Post-Operative Atrial Fibrillation NulBvL}S00000L0_ӁKbS_n0_?b0}R0N20 000000g0B0000000n0_R_uPk0[Y00 gR'`0iW0f0D00COPPSfn000㉐g0CORAL8Cardiovascular Outcomes in Renal Atherosclerotic LesionsKRlxS'`NRrz0 gY00S.~gؚ@'WB00D0o0CKD`k0J0D0f0 irlBv 0000k000irlBv0 NV0;N_eN0000NO No0000j0K0c0_00CORE 64UCoronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiographyy64R0000000CTMDCT n0:en0|^0_egn0@{ q_h0kY000MDCTk000^X'`CADn0X[(W ͑u^ @LQ^Sn0_0iQW0__0L0 }'`J00s0p'`v-NsK00f0sBfpg0o0MDCTo0_egn0Q@{ q_k0N000n0h0o0j00j0D00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19038879,19038877?report=DocSum&format=htmlCORE320vCombined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320-row Detector Computed Tomographyl320RCTk000QR q_ _K{LpAm000000o0 ؚD0|^g0QRu`0iQg0M0 30eNQn0@LQ^Sn0N,n0 _egn0OrvQR q_ 8h;Sf[igk000_K{LpAm000000h0 TI{e,g0+T080VqQ Txvz 0CORE64K64R0000000CTh0QR q_0kW0_0Rn0MRTM0 Ye-qQ Tf0QRu Yn0:ek0J0D0f0 64R0000000CTn0ؚD0:eL0000_00 COREA-TAXUSOEffect of Celecoxib on Restenosis after Coronary Angioplasty with a Taxus StentNCOX-2xbv;[celecoxibn00000QeuQXkb6RRg0iY0006K0g_n00000Q@{_ d1Yb6RRgcelecoxib[gq*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17707751?report=DocSum&format=htmlCoreValve US Pivotal Trial<Yyv'YR_ncSSAVR ؚ000n0͑uuP'`'YR_rz`k0J0Q00]b5_WTAVRh0SAVRn0 gR'`0k0gYyv_ncSk000{kN000L0ؚD0͑uuP'`'YR_rz`k0J0D0f0 1t^_n0{kNso0 ]b5_Wn0Medtronic CoreValve&reg; SystemL0Yyv'YR_ncS00 gak0NOK0c0_00CORONA<Controlled Rosuvastatin Multinational Trial in Heart FailurelsLlBvx0HMG-CoA reductase;[rosuvastatin0RW0_04XTn0_@{0000b6RRg0iY000_@{{k ^{kv_K{h^X ^{kv3RS-Nb6RRgrosuvastatinR"00000{http://www.ncbi.nlm.nih.gov/pubmed/17984166,25810334,25406306,22513778,20883926,19917888,19892235?report=DocSum&format=html[ؚbn0Z@'`_ NhQ`k0J0D0f0 iirlBvx0n0HMG-CoA reductase;[rosuvastatinRbNk000{kNb6RRgo0000j0K0c0_0L0 _@{0000o0NO N0CORONARY+CABG Off or On Pump Revascularization Study=30e_ 5t^_n0{kN _K{h^X 3RS-N g0Y00N NhQk0J0D0f0 00000CABGh000000CABGo0 TI{g0B000ihttp://www.ncbi.nlm.nih.gov/pubmed/22449296,22449294,27771985,24886787,23477676?report=DocSum&format=html,1t^_n0_N0^ Q@LQ^S QOL w_jk000000h000000h0k0]o0j0K0c0_0RThe Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study>00000QR0000SCABG n0wg30e n00^o000000CABGh0 TI{ CABGg'Y!jn00000SkfCORP%Colchicine for Recurrent PericarditisD000000sLlBvx0RW0_04XTn0Qzv'`_pn0N!kN2n0[hQ'`h0 gR'`0iY00018K0g_n0Qzvb6R000000000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21873705?report=DocSum&format=html>Qzv'`_pRzv`k0J0D0f0 000000n0colchicine00000 n0Ro0 180g_n0Qzvn0b6Rk0 gRg0B000CORP-2'Colchicine for Recurrent Pericarditis-2HQzv0p~0ԏY0_p`k0J0D0f0 sLbpulBvx0n0ulBv00000colchicine NWN[0k000 180g_n0QzvL0 gak0n\W0_00COSMOS0Copeptin in Osmoregulation and Stress AssessmentQMR-proANPo03h^X_90en0{kNJ00s0_jv0^0rzW0f0N,nY00N_0000g0 NIHSSk0MR-proANP$P0RH00S0h0k000N_N,no0T NY000Ehttp://www.ncbi.nlm.nih.gov/pubmed/20846604?report=< DocSum&format=htmlCosta F, et al.l5vt^b 000000000000 000000 }v@tpe 6qzvu'`Q@e_ g0Q@0000UOY00PRECISE-DAPT000o0 PCIeL_n0DAPTg-Nn0bYQ@0000N,nY00jn000h0j00_00COSTAMI.Cost of Strategies after Myocardial Infarctioncegirw_000eL_k0_K{Z@L0<fU00j0K0c0_04XTo024BfNQk0bU0[00000000o0 聊^igJ00s0KRw_V0b_k0[eY00000000h0ky0f0 NO000g01t^_n00^o0 Ti0Ehttp://www.ncbi.nlm.nih.gov/pubmed/14499225?report=DocSum&format=htmlCostanzo P, et al.._thVlBvk0008RIMTn0.~B00D0o02U\b6Ro0_@{0000n0b6Rh0#W0j0K0c0_00 COSTAR II>Cobalt Chromium Stent with Antiproliferative for Restenosis IIXeW0D0paclitaxeldRnQ000000000Tё0000g0B00CoStarn0 gR'`h0[hQ'`0paclitaxelnQ0000Taxus DES h0kY00^R'`f0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18420096?report=DocSum&format=html Couma-GenZzOtf[zOP[W k0We0O0warfarinn0}c(uϑ-[PG-guided therapy n0 gR'`h0[hQ'`0iY000INRvj{VYx0n081b6Rk0J0D0f0jnlBv0QR0Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17989110?report=DocSum&format=htmlA Double-Blind, Randomized Trial of Genotype-guided versus Standard Warfarin Dosing in Patients Initiated on Oral Anticoagulation.QwarfarinbNk0J0Q00INRn0vj{VYx0n081b6Rk0J0D0f0 zOP[Wk000bNY(uϑ-[bNPG-guided therapy o0jnvbN0QR0Z00COURAGELClinical Outcomes Utilizing Revascularization and Aggressive Drug EvaluationJRglBvh0W0f0 iirlBvk0PCI0uO(uW0_04XTn0QR0000b6RRg0i0hQ{kN ^{kv_K{h^Xb6RRgPCI irlBvR"irlBv0http://www.ncbi.nlm.nih.gov/pubmed/17387127,27585501,26559572,23973693,23500281,20338496,18703470,18268144?report=DocSum&format=htmlZClinical Outcome Utilizing Revascularization  Aggressive Guideline-Driven Drug Evaluation1iirlBvx0n0PCIRk000_K{Z@L0 gak0n\0Z@kX[so0{kN _K{h^Xzvu000h0v0<[[QRu``k0J0D0f0 iirlBvk0PCI0uO(uW0_04XTn0wg{kN ^{kv_K{h^Xn0b6RRgo0000j0K0c0_00COURT,Contrast Media Utilization in High-risk PTCAX g[_0000zvun0pg0 q_dR I{5_^000dRn0iodixanolh0NO5_000dRn0ioxaglate0k0eQb-Nn0 g[Nab6RRgiodixanolioxaglate*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10801758?report=DocSum&format=htmlCoutinho T, et al.GCAD`k0J0Q00{kNsn0 Nfk0o0-N_'`nL0vc#Y00Ne BMIo0#[0Z0 -N_'`nn0{kNsk0[Y00q_o0BMIck8^k0000000COX-2;[celecoxibn0pooled㉐g(COX-2;[celecoxibn0000o0(uϑJ00s0_@{000^h0#Y000CPORT-E=Cardiovascular Patient Outcomes Research Team Non-Primary PCIR61_n0{kN 9K0g_n0;N g[_0000k0J0Q00 _Ӂ@{YyKbSn0g0M0j0D0e-g0n0PCIeLn0_Ӂ@{YyKbSn0g0M00e-g0n0eLk0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/22443460?report=DocSum&format=html7Atlantic Cardiovasclar Patient Outcomes Research Team-E@90g_n00^k0J0D0f0 ꁽe-k0_Ӂ@{Yy0 gU0j0D0e-g0n0__jvPCIn0_Ӂ@{Yy0 gY00e-k0[Y00^R'`L0000_00-Cardiovascular Patient Outcomes Research Team@PCIL}L0J[g0_ӁKbSn0g0M0j0D0e-g0n0__jvPCIo0 _ӁKbSL0Sj0e-g0n0[eh0 Y00Z0[hQg0 g[Nak00]o0j0D00 CQI in CABGBContinuous Quality Improvement in Coronary Artery Bypass Grafting0CREATEICardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Betaj@n0[hQck8^Sk000_@{0^z6q{k _K{h^X %`'`_ NhQ 3RS-N NN'`3Z@zv\O 24BfN Nn0eQb0Y00 B00D0o0eQbL0w_O0r_u +ghRu` 24BfN Nn0eQb0Y00 Nte n09eUo0000Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17108342?report=DocSum&format=htmlhClinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluationx8^lBvk0NORP[ϑheparin reviparin0eg7eRbNW0_04XT 3RS-N0XRU0[00S0h0j0O0{kNJ00s0Qh^X0b6R0u}T0K0Y0Q@o0reviparinbNk00000XRW0_00n0n0 ]0n00000 NV0000000L0_00_002005t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/15671427?report=DocSum&format=htmlhClinical trial of Reviparin and mEtabolic modulation in Acute myocardial infarction Treatment EvaluationE%`'`_K{h^XJ00s0ST NfW_K{h^Xk0J0D0f0 8^lBv NORP[ϑ0000reviparino03RS-N0XRU0[0Z0k0{kN Qh^X0 gak0b6R0 CREATE-ECLAClinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation- Estudios Cardiologicas Latin America<8^lBv ؚ(uϑ0000000000000000Bvlk00030e_n0{kN _\Pbk _S'`0000b6RRgo0000j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15671428?report=DocSum&format=htmlInternational Trial Clinical trial of Reviparin and mEtabolic modulation in Acute myocardial infarction Treatment Evaluation-Estudios Cardiologicos Latinoamerica international3ST NfWn0%`'`_K{h^X`k0J0D0f0 GIKBvlo030e_n0{kN _\Pbk _n'`00000b6R[0Z00CREATE Pivotal;Carotid Revascularization ev3 Arterial Technology Evolution,+gh@hN20000O(un08R0000o0 0000000k0f00_0@LQ^Sg0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16781363?report=DocSum&format=html Japanese CTO PCI Expert RegistryUJapanese Chronic Total Occlusion Percutaneous Coronary Intervention Expert Registry)*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24963567?report=DocSum&format=htmlCSPPT%China Stroke Primary Prevention TrialS;egB}N=IxuO(uk0003RS-NN!kN2Rg0i*</sup>0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25771069,25770867?report=DocSum&format=htmlCSPS.com?Cilostazol Stroke Prevention Study for Antiplatelet Combination;ؚ000Z@'`3RS-N`k0J0Q00b@\gcilostazol0+T02dRuO(ub@\gBvlDAPT n0 gR'`h0[hQ'`0CSRS and PCIRSXCardiac Surgery Reporting System and Percutaneous Coronary Intervention Reporting System-{kN {kN _K{h^Xo02gu Y 3gu YD0Z00k0J0D0f00CABGL0DES00NOK0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/18216353,26361150?report=DocSum&format=htmlCSSSChina Salt Substitute Study"-NVn0ؚ@'Wؚ000Ok0J0D0f0 N(uiXk000S.~g@'WL0 gak0NO N0/CSTC: Carotid Stenting Trialists CollaborationJ70skN Nn0uP'`8Rrz`k0o08R0000 i0o0eLY0y0M0g0o0j0D0L0 70sk*gnn0`g0o08RQRdSh0[hQ'`o0 TI{g0B00h0`0000CTAF3Canadian Trial of Atrial Fibrillation Investigators_?b0}Rn0QzvN2k0J0D0f0 b Nteamiodaronen0NO(uϑbNo0sotalolB00D0o0propafenone00 gRK0i0QzvN2Rgamiodaronesotalol propafenone*0oR\O(ub6RRgsotalol propafenoneamiodarone*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10738049?report=DocSum&format=htmlCTOPP$Canadian Trial of Physiologic Pacing0utv00000h0_[00000n0 gR'`0k0!Nk03RS-NB00D0o0_@{{kN2Rgk0]o0j0W00`http://www.ncbi.nlm.nih.gov/pubmed/10805823,147070< 22,11425772,11451268?report=DocSum&format=html+Celecoxib Cross Trial Safety Analysis: CTSA(celecoxibk000_@{000o0(uϑ 000000Bfn0000k000puj000CTSN&Cardiothoracic Surgical Trials NetworkCP=^_O_SP=^_b_bS h0P=^_ncSn0 gR'`h0[hQ'`0kY00012K0g_n0][000000P=^_b_bSR"P=^_ncS0Nhttp://www.ncbi.nlm.nih.gov/pubmed/24245543,26550689?report=DocSum&format=htmlIMVSeLN[n0c}'`0wgc}'`AF`k0J0Q000000000Rn0 gR'`n0ih0 0000000jvMOh0W0f0n0Yh0!N?b000n0k0-NI{^n0Z@'`P=^_Am`CABG P=^_O_S64sk CABG65sk k0J0Q001t^_n0][000000o0 CABG P=^_O_Sh0CABGg0 TI{0{kN MACCE QeQb QOLk00]o0j0K0c0_0L0 -NI{^-͑^n0P=^_Amo0CABGg0YK0c0_00CTSN SMRKCardiothoracic Surgical Trials Network Severe Ischemic Mitral Regurgitation,͑uZ@'`P=^_Amk0J0Q00120g_n0][000000o0 _O_Sh0_ncSo0 TI{04CTT (Cholesterol Treatment Trialists ) Collaboration/LDL-C 38.7mg/dL1.0mmol/L NO NB0_00;N@{0000o0}28%n\0 CULPRIT-SHOCKCCulprit Lesion Only PCI versus Multivessel PCI in Cardiogenic ShockNu Yn00n0PCI^Nu Yk0o0staged@LQ^S o0 Ygu Yk0[Y00immediate PCI0000^L0o}Yg0B00h0D0F0N0i<030eNQn0hQ{kN NNfBvlL0_k0j00͑uN NhQn0T0000000000NO NNu Yn00n0PCIYgu Yk0[Y00immediate PCI<sup>*</sup>02018t^11gNhttp://www.ncbi.nlm.nih.gov/pubmed/29083953,30145971?report=DocSum&format=htmlCURE:Clopidogrel in Unstable Angina to Prevent Recurrent Eventsab@\gaspirin clopidogrelbNn0wgbNh0wgbNn0 gR'`J00s0[hQ'`0k0clopidogrelo0_@{{k ^{k'`_K{h^X 3RS-N0b6RY00L0 'YQ@n0000L0 Nf0http://www.ncbi.nlm.nih.gov/pubmed/11519503,20979470,16286169,15766816,15313956,14504182,12600908,12419297,12270853,11520521?report=DocSum&format=htmlCClopidogrel in Unstable Angina to Prevent Recurrent Ischemic EventsCURRENT AS RegistryjContemporary Outcomes after Surgery and Medical Treatment in Patients with Severe Aortic Stenosis RegistryS!qurn0`k0J0D0f0 'YR_ncSAVR RglBvh0OX[vlBvn0wg0^0k0hQ{kNh0_ NhQk000eQbb6RRgAVROX[vlBv<sup>*</sup>0Whttp://www.ncbi.nlm.nih.gov/pubmed/26477634,26718671,26718670?report=DocSum&format=html͑u'YR_rzu`k0[Y00lBvlxbJ00s0N_n0iCURRENT-OASIS 7Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events  Seventh Organization to Assess Strategies in Ischemic Syndromesclopidogreln0000000000J00s0Rg}c(uϑn02 P(uϑo08^(uϑk0ky0f0 B00D0o0aspirinn0ؚ(uϑo0NO(uϑk0ky0f0 gR'`J00s0[hQ'`k0*Q00K030e_n0_@{{k _K{h^X 3RS-Nn0T0000000clopidogrel aspirinn0D0Z000(uϑk000 ga]o0000j0D00Nhttp://www.ncbi.nlm.nih.gov/pubmed/20818903,20817281?report=DocSum&format=htmlCURRENT OASIS 7qClopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for InterventionsRؚ(uϑclopidogreln0_@{0000N2Rgo08^(uϑclopidogrel0 NV0Z0 'YQ@o00Z0K0k0XR0PCIeLOg0o0ؚ(uϑg0n0 gR'`L000000CVD-REAL2 StudyE000*Ys^ m0WW -Nqg Ss|n0E^^D02W|?\u`k0J0D0f0 SGLT-2;[lBvYo0 U0~0V0~0j0_@{0000000n0NO Nh0OW0_002018t^06gCvLPRIT-Complete versus Lesion-only Primary PCI Trialc@{ q_ N gaj0rz00_0^h^X#RIRA 0+T0_0DESk000[hQ@LQ^h0IRAn00n0@LQ^0k012K0g_n0MACEb6RRg[hQ@LQ^IRAn00<sup>*</sup>0Whttp://www.ncbi.nlm.nih.gov/pubmed/25766941,25766942,26700834?report=DocSum&format=htmlCYRANO00000000000L0ؚhTl000000000000RFCA h0 TI{n0wg0wgn0 gR'`0 gW0 8l}'`?b[AV 0000n00000NO NU0[00K00iY0000000000 NbR 8l}'`AV0000 ?b[P}{000000'`;bQzvb6RRgRFCA00000000000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21098435?report=DocSum&format=html8d,l-Sotalol Implantable Cardioverter-Defibrillator StudyRICDn0;zvY000000n0b6Rk0J0D0f0III\O(uh0ne\O(u0T0[0cd0sotaloln0 gR'`h0[hQ'`0i0{kN00000b6RRgsotalol0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10369848?report=DocSum&format=htmlDaemen J, et al.BYgu Yk0J0D0f0 5t^_n0[hQ'`o00000h0CABGo0 TI{g0B00L0 @LQ^SQeL ;N g[_030000o0CABGL0 gak0b6R0DAIS+Diabetes Atherosclerosis Intervention StudyQؚ@u(ufenofibratek00000ˆ}vpu8^n0/fckL0 QRlxSk0S|0Y0Rg0i0QRu Yn02U\00000b6RRgfenofibrate00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/11289345?report=DocSum&format=html dal-OUTCOMES_;egB}N=CETP;[dalcetrapibn0_@{u`000k0[Y00 gR'`0UOY000dalcetrapibg0000000HDL-Co0 NfW0_0L0 _@{u`Qzvo0b6RU00j0K0c0_002015t^06gNhttp://www.ncbi.nlm.nih.gov/pubmed/23126252,26022813?report=DocSum&format=htmlwEffects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndromehse'`n0%`'`QuP`k0J0D0f0 sLlBvx0n0CETP;[0000000dalcetrapib Rk000HDL-Co0J00]030% LDL-Co00Z0K0k00W0K0W0 _@{u`b6Rn0 NWN[0Rgo0000Z00 dal-VESSELXEfficacy and safety of dalcetrapib in patients with or at risk of coronary heart diseasetQRu` ]0n0ؚ000`k0J0D0f0 CETP;[0000000dalsetrapib o0LDL-C ApoB100k0q_Y00S0h0j0O0ApoA1 HDL-C0 NfU0[0 @{Qv_j0[[0Z0 @'W0 NfU0[0Z0,{< IIbvf 0DANAMI-2the Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Coronary Angioplasty in Acute Myocardial Infarctionprimary angioplastyo0`00WWubK00@LQ^SL0Sj0OrlBv0000x0yW0f00j0J0 0WWubg0n0@hnBvl00 gRg0B00K00i030eNQn0hQ{kN 聊^ Nn0Qh^X Nw0Y003RS-Nb6RRg@LQ^S@hnBvl*0Whttp://www.ncbi.nlm.nih.gov/pubmed/12930925,19874989,16186438?report=DocSum&format=htmlxDanish Multicenter Randomized Trial on Thrombolytic Therapy vs Acute Coronary Angioplasty in Acute Myocardial InfarctionDANAMI 3-DEFERh^XN@{n0@AmL0[[W0 +gh^Xhn0000L0nX00~0g00000Yun0E0[00deferred0000o0 jnvj0primary PCIk0O00y0_K{@Amn0NO N0b6RW0 聊^0^09eUY00K00i*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/26347918?report=DocSum&format=htmlDANAMI3-PRIMULTIThe Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: PRImary PCI in MULTIvessel Disease-DANAMI3-PRIMULTIPzvuK0012BfNQn0STEMIk0[W0h^XN@{IRA x0n0pPCIL0bRW0_0Ygu``k0J0Q00 bMRk0^IRAx0n0@LQ^0LF0[hQ@LQ^n0 gR'`0DANISHmDanish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality6_ӁQ TglBvn0_'`0OU0Z0 ICD i0n0 gR'`h0[hQ'`08^00h0k0hQ{kNICDR"8^000Whttp://www.ncbi.nlm.nih.gov/pubmed/27571011,27571386,28877914?report=DocSum&format=htmlDanish Nationwide Cohort Study#(1)[[QRu`TuO_?b0}R`k0J0Q00b@hBvl (2)@{u`0TuOW0_0_ NhQ`k0J0Q00b@hBvl (3)_ NhQn0͑u^h0|?\uzvu000 (4)M'WXSdRlBvh0AFzvu000 (5) ba'`NӁuCKD TuO_?b0}RAF `k0J0Q00b@hBvl (6) |?\u`k0J0Q000000h00}\@{u000 (7)AF`k0J0Q00-˄QQ@_n0bQVBvlQ (8)AF^TuO_ NhQ`k0J0Q00CHA<sub>2</sub>DS<sub>2</sub>-VASC000 (9) bQVtkn0j0D0AF`k0J0Q00NOAC 3dR (10) HQ)Y'`_u`CHD `n0wu000uf[ Z@'`_u` _ NhQ Ntehttp://www.ncbi.nlm.nih.gov/pubmed/29440121,24470482,24794118,24849568,24347316,25500231,25217178,26059010,26318604,27312796?report=DocSum&format=htmlDANPACEoThe Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndromeCm NhQuP`k0J0D0f0o0 _b_T{W_?b00000g0o0j0O0 _?b0}RJ00s0QKbSn0000L0NOD0_b_T{WNT000000O(uY0y0M00DAPC1Diabetic Atherosclerosis Prevention by Cilostazolm00000'`RlxSn02U\b6RRg02.z^n0b@\gaspirinh00000000000;[g0B00cilostazolh0g0k0}8Rn0g'YQ--NS2U\b6RRgcilostazolaspirin*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20516379?report=DocSum&format=htmlDAPPAF6Dual-Site Atrial Pacing to Prevent Atrial FibrillationؚMOS?bRA 0000000000000 S?bQ2p00000J00s0DDI~0_0o0VDI000000000SP n0 gR'`0k0dual-site RA00000o0[hQg0 high RA00000J00s0SP000_['`L0o}Yg0 _?b0}Rn0b6RRgk0*Q0f0D000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12354441?report=DocSum&format=htmlDDual-Site Atrial Pacing for Prevention of Atrial Fibrillation Trial DAPTDual Antiplatelet Therapy0000000|dRclopidogrel0prasugrel aspirink0002dRuO(ub@\gBvlDAPT 01t^N N}}W0_04XTn0 gR'`J00s0[hQ'`0UO0;N g[_03@{0000DAPT 0000@hub6RDAPT 30K0g12K0g<sup>*</sup>0-NI{^^͑^n0Q@00030K0g12K0g<sup>*</sup>0{http://www.ncbi.nlm.nih.gov/pubmed/25399658,28228427,27046159,26994121,27576774,27022822,25787199?report=DocSum&format=htmlDESXience 47% Taxus 27% Endeavor 13% i0_n0`k0J0D0f0 DAPT0000000|dR;clopidogrel 65% prasugrel 35%= aspirin 300go0 120g0012-300g_n0MACCE STL0\j0K0c0_00 DAPT-STEMI`Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMIIPCI_n00000zvun0j0D0STEMI`k0J0D0f0 6K0gn0wgDAPT_n0aspirinXSdRBvlo0 12K0gn0DAPTk0[W0^R'`0:yW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/30279197?report=DocSum&format=htmlDARTDiet and Reinfarction TrialjN!kN2k0[Y00ߘNn0q_0i0c\NO N {kNk0#j0W00Zc\hQ{kNL0c\j0W000NO N*0J~}c\{kNsk0 ga]j0W00ߘNc\k0 Qh^XzvuJ00s0Z@'`_u`{kNn0 gaj0b6RRgo0j0W001989t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/2571009?report=DocSum&format=html'Dispatcher-Assisted Resuscitation TrialnE\T0[0_0Qe%`1XL0OcNTn0qg0n0c:yk0_c0f0'WXSrn0_uCPR 0Lc0_04XT 'W SF0d0W0clk000CPRk0ky0f0uX[sL0 NfY00n0K0uX[bs'WXSrR"'W SF0d0W0cl0Nhttp://www.ncbi.nlm.nih.gov/pubmed/20818863,20818869?report=DocSum&format=htmlDASH'Dietary Approaches to Stop HypertensionUߘNn00000h L0@'Wk0S|0Y0q_0i0DASHߘ0000 Α܃ < NOsNT0Y0k0BdSW0 T  0000000n0BdS0cH00 o0Rgvk0M'WW0_00hhttp://www.ncbi.nlm.nih.gov/pubmed/9099655,12847067,11509468,11136953,10981543?report=DocSum&format=htmlDAVID@Drug Evaluation in Atherosclerotic Vascular Disease in Diabeticsthromboxane A2/ prostaglandin endoperoxide H2TXA2/PGH2 S[SObbg0B00picotamiden0{kNJ00s0_@{0000N2Rg0aspirinh0k0{kNb6RRgpicotamideaspirin*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15474700?report=DocSum&format=html4Dual Chamber and VVI Implantable Defibrillator TrialNT00000DDDR n0 gR'`0backup_[00000VVI h0k0{kNB00D0o0F0c0@'`_ NhQk000RVn0eQb^zvusVVI 83.9% DDDR 73.3%pf"0.03 {kNs6.5% vs 10.1% eQb13.3% vs 22.6%0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12495391?report=DocSum&format=htmlDAVID II1Dual Chamber and VVI Implantable Defibrillator IIG_?b00000AAI n0 gR'`0backup_[00000VVI h0kY00^R'`f0{kN _ NhQk000eQb~0g0n0BfAAIR"VVI0Nhttp://www.ncbi.nlm.nih.gov/pubmed/19264245,19264246?report=DocSum&format=htmlDavis MI, et al.DlBvbb'`ؚ@'W`k0J0D0f0 Nd^yL}o060g_k0Wfj0M'WRg00_00W0_00S00o0 xvz0000000000n0.z^k000Z0000_00DAVIT I#Danish Verapamil Infarction Trial IQCabbverapamilbNk000 }{kNh0Qh^Xzvuk0[Y00Rg0i0{kNpeverapamilR"00000Qh^Xb6RRgvarapamil000001984t^07gDhttp://www.ncbi.nlm.nih.gov/pubmed/6383832?report=DocSum&format=htmlDAVIT II$Danish Verapamil Infarction Trial III{kNh0Qh^Xj0i0n0;Nj00000zvuk0[Y00 Cabbverapamiln0Rg0i0{kNJ00s00000b6RRgverapamil000001990t^10gDhttp://www.ncbi.nlm.nih.gov/pubmed/2220572?report=DocSum&format=htmlDAYLIGHTCVitamin D Therapy in Individuals at High Risk of Hypertension Trial+0000DL}SbNn0M'WRg0i024BfS.~g@'W0000Dؚ(uϑR"NO(uϑ0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25359163?report=DocSum&format=htmlDe Berardis G, et al.N|?\u`k0J0D0f0 aspirinn0fxj0;N_@{0000N!kN2Rgo0:yU00j0K0c0_00_K{h^Xn0N2k0W0f0o0'`]L0͑j0q_0S|0Y0S'`L0:yU00_00De Caterina R, et al.rNO NlBvn0j0K0g00000|dRo0{kv0^{kv3RS-Nn0000NO Nk00c0h00 gR`0L0 ]0n0 gR'`o0}0000000J00s0LDL-Cn0NO Nsk0kOY000W0K0W0 {kv3RS-Nn0000k0d0D0f0o0i0n0NO NlBvg00NO NW0j0K0c0_00 DEBATE II5Doppler Endpoints Balloon Angioplasty Trial Europe IIfprimary0000h0Doppler@Am^n0000k0000000n0(u[Rg0k0Doppler@Am^n0000k0000000o01t^_k0J0D0f00000000000L0K0K00L0 gR'`o0000j0K0c0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/11113042,11927525,11985916?report=DocSum&format=htmlDEBUTaDrug-Eluting Balloon in stable and Unstable angina: a randomized controlled non-inferiority Trial3Q@ؚ000uOk0[Y00DCBlBvo0 90g_n0;N g[_0000zvuk0J0D0f0 BMSlBv00*Q0002019t^07gEhttp://www.ncbi.nlm.nih.gov/pubmed/31204115?report=DocSum&format=htmlDECAAF\Delayed Enhancement - MRI determinant of successful Catheter Ablation of Atrial Fibrillationv_?b0}RAF `k0J0D0f0 0000000MR30ek0[eW0_0E^ q_DE -MRIg0UOW0_0_?b}}Sn0 z^o0 0000000_90en0AFQzvn0 gaj0N,nVP[090e_k0kX[Y00}}SW^*</sup>02015t^05gNhttp://www.ncbi.nlm.nih.gov/pubmed/25631070,25631071?report=DocSum&format=html DES-DIABETES5Drug-Eluting Stent in Patients with Diabetes MellitusNsirolimusnQ0000SES h0paclitaxelnQ0000PES 0kY0006K0g_n000000QQrzb6RRgSESPES*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18718419?report=DocSum&format=html DESCARTES<Durable Effect of PCSK9 Antibody Compared with Placebo StudyI[hQ00bPCSK90000000bSOdRevolocumab 41k01Vn0RbNk000 521_n0LDL-Co00000k0O00y0 gak0NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24678979?report=DocSum&format=htmlDEScover Registry0s|Vk0J0D0f00000lBvh0W0f0dRnQ'`00000xbU00_0uOn0yr_ 0^0iY00{v2xvz0Nhttp://www.ncbi.nlm.nih.gov/pubmed/17488964,17060386?report=DocSum&format=htmlDESTINI5Doppler Endpoint Stenting International Investigationt__jv0000?ceQOelective stent h0 PTCA_k0@{ q_[ϑvQR q_ online QC J00s0QRQl0000lg0 NASRh0$ReU00_0uOn0000000 i0guided PTCAn0wg0^0kEhttp://www.ncbi.nlm.nih.gov/pubmed/11113043?report=DocSum&format=htmlDETAIL.Diabetics Exposed to Telmisartan and EnalaprilPAII S[SObbtelmisartanh0ACE;[enalapriln0|tSOoNsn09eURg0k0telmisartano0enalaprilk0R0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15516696?report=DocSum&format=html DETO2X AMILDetermination of the Role of Oxygen in Suspected Acute Myocardial Infarction#0000n0x }Bv< lk000 gR'`0UO01t^n0{kNx }BvlR"[gq0Ehttp://www.ncbi.nlm.nih.gov/pubmed/28844200?report=DocSum&format=htmlDHCCP8Department of Health Hypertension Care Computing ProjectmgouX[s0\O0i@'W$P0i0S.~gk0W0f0o0hQ{kN 3RS-N{k Z@'`_u`{kIHD h0n0k0v}OL0000_0L0 b5_g@'Wk0W0f0o0 IHDk0W0f084^89mmHg0nadirh0Y00JWOL0000_00Dhttp://www.ncbi.nlm.nih.gov/pubmed/8026001?report=DocSum&format=htmlDi Angelantonio E, et al.nE^^D0rl Ng0BNP NT-proBNPo^h0CVD000o07_O0vY000 BNP NT-proBNPn00^N,nn0 g(u'`0f0K0k0W0 QHr00000Q00_00k0 'Y!jj0N,^lk0J0Q00xvzg0n0U00j00iL0Bl00000DIABETES$Diabetes and Sirolimus-Eluting StentQQrzN2Rg0sirolimusnQ0000h0jn0000h0g0k09K0g_n000000Qifg d1Yb6RRgsirolimusnQ0000jn0000*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/16203930,16750681?report=DocSum&format=htmlDIAL?Randomized Trial of Phone Intervention in Chronic Heart Failure`Yeh000000000n09eU0vvh0Y00 ww+^k000qNeQL0 1 3t^_n0{kNJ00s0_ NhQk000eQbk0S|0Y0q_0UO0`n0LRJ00s0cak0'YM0j0q_0NH0 {kN _ NhQk000eQbn0T00000000 gak0b6R0NeQg-Nk0000_0 gR'`o01t^ 3t^_0c}W0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/20650358,20650359?report=DocSum&format=htmlDRandomized Trial of Telephonic Intervention in Chronic Heart Failure-ba'`_ NhQ`k0J0D0f0 ww+^k000qg0n0c\k000_ NhQk000eQbL0 gak0NO NW0_00 DIAMOND?Danish Investigations of Arrhythmia and Mortality on DofetilidexbvK0000nedofetiliden0Rg0i0{kNsdofetilideR"00000dofetilidek0_?b0}R0m_k0;bY0Rg00 m_n0}cRgo0000000 ga0_K{h^X_n0͑u_ NhQn04XTn0{kNb6RRgo0dofetilideR"00000http://www.ncbi.nlm.nih.gov/pubmed/10486417,11145491,17101637,15451149,14998615,14720529,12727154,11457747,11245647,11171791,11152835?report=DocSum&format=htmlDIANA0DIAbetes and diffuse coronary Narrowing Analysis%u|?\uk0[Y00irNeQk000QRu Yn02U\N2Rgk0Y00聊^xvz0DIGDigitalis Investigation GroupM00000dRdigoxinn0{kNs eQbk0[Y00Rg0i0{kNsdigoxinR"00000_ NhQ`Sk000eQbb6RRgdigoxin0000*01997t^02ghttp://www.ncbi.nlm.nih.gov/pubmed/9036306,16864724,15337214,12932612,12588271,12409542,12354436,11527638?report=DocSum&format=html?ACE;[h0)R?\0bNU00f0D00EFL0NO NW0_0ؚbn0ba'`_ NhQ`k0J0D0f0 digoxino030e_n0hQeQb0 gak0b6R0DIGAMIDDiabetes and Insulin-Glucose Infusion in Acute Myocardial InfarctionYN_VP[n0 T[h0|N9eUn0Rg0i0{kNN2Rg000007_S0000n0|?\ulBv*0ؚb _ NhQe_ yug eQbBfn0@|$P HbA1co0{kNn0rzW0_0N,nVP[0Nhttp://www.ncbi.nlm.nih.gov/pubmed/10338454,10739728?report=DocSum&format=htmlDIME5Diuretics In the Management of Essential Hypertensionؚ@'W`k0J0Q00000000|)R?\n0 g(u'`0iY000DIMT!Dutch Ibopamine Multicenter Trial}L}S;m'`W0000S[SO:Roibopaminen0wgbNlBvn0 gR'`h0[hQ'`0i0digoxinh000000k0KR9eUdigoxin0000*0@?o00000000J00s00009eURgibopamine digoxin0000*01993t^11gDhttp://www.ncbi.nlm.nih.gov/pubmed/7901256?report=DocSum&format=htmlDINAMIT2Defibrillator in Acute Myocardial Infarction Trial i0Wd0}RhVICD n0N2vj0 i0o0hQ{kN0b6R[0Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15590950?report=DocSum&format=html,Defibrillator in Acute Myocardial Infarction&_K{h^X_egn0ؚ000Ok0J0D0f0 ICD iH00o0hQ{kN0b6RW0j0K0c0_00DIPOM4DIabetic POstoperative Mortality and Morbidity Trial=^_ӁSeLn0|?\u`k0J0D0f0 hTSgn0nemetoprololn0{kNs _TuOu g[Nax0n0 gR'`o0000Z00DIRECT0Dietary Intervention Randomized Controlled Triall3.z^n0ߘNBvlNOߘ 0W-Nwmߘ NOp4lSirߘ n0[hQ'` gR'`0k0nϑRgNOp4lSirߘ 0W-Nwmߘ*NOߘ0 0W-Nwmߘ@|L0o}Y h0NOp4lSirߘL0o}Y o0NOߘn0Nfߘk0j00S'`L0:yU00_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/18635428,20194883?report=DocSum&format=html4DMR in Regeneration of Endomyocardial Channels Trial"DIRECT-Prevent 1, DIRECT-Protect 1<Diabetic Retinopathy Candesartan Trials Prevent 1, Protect 1ARB candesartann0|?\u'`}un0N!kN2DIRCET-Prevent 1 2U\b6RRgDIRCET-Protect 1 0i0candesartang0}uN!kN2o0000_0L0 }u2U\N2o0000j0K0c0_0vs 0000 0Whttp://www.ncbi.nlm.nih.gov/pubmed/18823656,18823657,19451554?report=DocSum&format=htmlDIRECT-Protect 20ARB candesartann0}u2U\b6RRg0icandesartanR"00000Whttp://www.ncbi.nlm.nih.gov/pubmed/18823658,18823657,19451554?report=DocSum&format=htmlDISTDutch Iliac Stent Trial; k'`ۍLlBvk0J0Q00L}vvBvln0QOLk0[Y00Rg0i0QOL9eURg0000R"L}v@{b_bS xbv00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/10377079?report=DocSum&format=html DKCRUSH-IIIjDK Crush versus Culotte Stenting for the Treatment of Unprotected Distal Left Main Bifurcation Lesions-III DNETT-Japan&|?\u'`Nun0[㉒0vcW0_0000;SBvk000Ɩ}vlBvk0Y00'Y!j聊^xvzDOCTORS>Does Optical Coherence Tomography Optimize Results of StentingxPCIhTSgn0IQr^ ned\lOCT [ek000QR q_00 gvj0聊^`1X0_000K0 ]0n0`1Xk0We0D0_0lBv&beun0 Yfg0_jv0^L0 YSY00K00i0KbbB}NBfn0Q@AmNPϑkOCT000QR q_00< 0<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/27573032?report=DocSum&format=htmlDOSE+Diuretic Optimization Strategies Evaluationl)R?\furosemide n0bN&beu0000Yl c}pn ؚ(uϑ NO(uϑ 0kY0000000YlK0c}pnK0 ؚ(uϑK0NO(uϑK0k0K0K000Z0 `ꁫL0UOW0_0ur N_jn0NO Nk0 gaj0]o0000j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/21366472,21366480?report=DocSum&format=htmlDouxfils J, et al. dabigatrano0_K{h^XMI 000n0 gaj0XRh0#0DPPOS*Diabetes Prevention Program Outcomes Study,MR|?\un0ck8^@|Tbo0MR|?\urKan0c}k0O00y0f0|?\uzvu0000NO NU0[00K0 DREAMHDiabetes Reduction Assessment with Ramipril and Rosiglitazone MedicationO|?\un0ezvu {kNN2Rgo01) ACE;[ramiprilR"0000 (2) 00000bb'`9eUrosiglitazone0000*0`http://www.ncbi.nlm.nih.gov/pubmed/16980380,16997664,21515846,19477351?report=DocSum&format=html-Dutch Randomized Endovascular Aneurysm Repairw@{QlBvo0hTSgn0uX[sg0yKbS00*Q0f0D00S0h0L0:yU00f0D00L0 S0n0 gR'`o02t^N Nc}W0j0D0h0D000f0D000]0S0g0@{QlBvn0wgn0 gR'`0i<06t^n0uX[so0yKbSh0 T z^g0j0L00 QNeQso0@{QlBvn0{0F0L0 gak0ؚD00Nhttp://www.ncbi.nlm.nih.gov/pubmed/20484396,20484400?report=DocSum&format=htmlDRSDiltiazem Reinfarction StudyJCabbdiltiazemL0Qh^X0n\U0[00K00i0Qh^Xb6RRgdiltiazem00000{kNb6RRg0000diltiazem01986t^08gDhttp://www.ncbi.nlm.nih.gov/pubmed/3526151?report=DocSum&format=htmlDUAAL*Double-blind Atorvastatin Amlodipine trialHMG-CoA reductase;[atorvastatinL0XSdR ~0_0o0Cabbamlodipineh0n0uO(ubNk000 LDL-CNO Nh0o0rzW0_0\O(uk000NN'`_K{Z@0nY00K00i0261vn0:d/^W_Vig48Bf-Nk0zvuW0_0Z@00000peamlodipineR"atorvastatinR"amlodipine atorvastatinuO(u0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20494902?report=DocSum&format=htmlDUCCS 1+Duke University Clinical Cardiology Study 1[@hn㉬anistreplaseAPSAC Bvl_n0bQVheparinYln0Rg0i0{kN Qh^X Qzv'`Z@ h^XNRn0^Xb6RRgheparinbNR"^bN0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8277068?report=DocSum&format=html Dutch BOA2Dutch Bypass Oral Anticoagulation or Aspirin Study}!_N Nn00000S_n00000^XJ00s00000zvub6Rk0d0D0f0 L}SbQVh0b@\gaspirin0k0^Xb6RRgbQVR"aspirin0bQVg0o0Y0000Og0RgL0 aspiring0o0^Y0000Og0RgL0000_002000t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/10665553?report=DocSum&format=htmlDUTCH PEERS (TWNETE II)Durable Polymer-Based Stent Challenge of Promus Element versus Resolute Integrity: Randomized Multicenter Trial in All Comers Population Treated Within Eastern Netherlands-II,{ NNNdRnQ'`0000 0000000zotarolimusnQ0000ZES h00000000everolimusnQ0000EES n0[hQ'`J00s0 gR'`00000000g0kY00all-comerf01t^_n0jv@{ NhQk0J0Q00ZESn0EESk0[Y00^R'`L00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/24183564?report=DocSum&format=htmlDutch Stent Thrombosis Registryclopidogreln0bN-Nbk 0000000n00000 `'`k v Nu YяMOn0-NI{^rzu Yo00000@hun0N,nVP[definite 0000@huRzv_o0{kNsJ00s0QzvsL0ؚO00^ No0|?\u EF45% wD00000w іu Y PCI_n0TIMI grade3 0000lBvn0_00n0}%`PCIBfn0R0000o00^ Noh0#0Nhttp://www.ncbi.nlm.nih.gov/pubmed/19371823,19188507?report=DocSum&format=htmle-MUSTXEvaluation en Mdecine d Urgence des Stratgies Thrapeutiques des infarctus du myocardefub0R@wMR_\PbkSCA n0#VP[0 T[W0 0000k0UOU00f0D005VP[t^b ^|?\u ^n o`R0 uK00EMS000~0g0n0Bf 0(uD0f0\ObW0_0000N,n000g0 SCA0000c[g0M000Ehttp://www.ncbi.nlm.nih.gov/pubmed/27793995?report=DocSum&format=htmlE-SEARCHUEhime Study -Effect of Anti hypertensive therapy on Regression of Cardiac Hypertrophy;_'YTuOؚ@'W`k0[Y00AIIS[SObbARB /NO(uϑ)R?\TdR h0ARB Cabbn0uO(uBvln0kiE-SIRIUSEuropean Multicenter, Randomized, Double-Blind Study of the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Coronary Artery Lesions>sirolimusnQ0000n08K0g_n00000Qg\@{_ Qrzb6RRgsirolimusnQ0000[gq*0`http://www.ncbi.nlm.nih.gov/pubmed/14550694,18036446,15655127,15629365?report=DocSum&format=html E2F DecoyX0000SOk0J0Q0000001YWeJ00s0euQXk0b6RY00_00n0Y0000x0n0E2F000GT003 bNo0 [hQg0_['`0o}Y01t^_n00000Qrz0 gak0b6RW0_00EAFT"European Atrial Fibrillation Trial\bQVBvlJ00s0aspirinn0@h'`^XhNEeN2Rg0i0bQVBvln0@{0000;Nk03RS-N b6RRgo090O/1000Net^0aspirinn0N2Rgo040O/1000N0t^0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7901582?report=DocSum&format=htmlEARLYZEndothelin Antagonist Trial in Mildly Symptomatic Pulmonary Arterial Hypertension Patients86K0g_n0[YBfn0@{bb 6RikLݍn09eURgR'`ؚ@'WulBvbosentan00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/18572079,18572063?report=DocSum&format=html EARLY ACSZEarly Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary SyndromeyGP IIb/IIIaS[SObbeptifibatide< n0ibNY000000iY00096Bf_n0hQ{kN _K{h^X }%`@LQ^0Y00Z@n0Qzv PCIBfn0@h'`TuOuegbNCAGn012BfN NMR R"__jbNCAG_ 0Whttp://www.ncbi.nlm.nih.gov/pubmed/19332455,19458369,23684676?report=DocSum&format=html[Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes^ؚ000n0^ST NfWACSk0J0D0f0 GP IIb/IIIaS[SObbeptifibatideegbNn0__jvbN0QP096Bf_n0 gaj00000b6RRgo0000Z0 Q@000L0X'Y0 Early ACTIDEarly Activity in Diabetesb7_SߘNBvlk0SO;mRNeQ0RH00S0h0k000 @| @'W  J00s000000bb'`L0009eUY00K00iA</sub> Receptor Antagonist Trial in Heart FailureIjnlBvk0puj00(uϑn0000000AS[SObbdarusentann0RL}SbNk000][000000 聊^ur N_k0Rgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15276394?report=DocSum&format=htmlEASEEEarly Surgery versus Conventional Treatment in Infective EndocarditisIag'`_Qp`k0J0D0f0 48BfNQn0KbSagD}T~Rd P=^_b_bS o0{kN ^Xh'`0000b6Rg0 jnlBvbuirYlj0i0 00*Q00 EASIEKEvaluation of Insulin Glargine versus Sitagliptin in Insulin-naive Patients000000000000metformin g0@|000000 NASRj000000bNL}n0j0D02W|?\u`k0J0D0f0 HbA1cNO NL0'YM0D0n0o0 cRW00000dRn000000000000glargine vs DPP-4;[0000000sitagliptin EAST&Emory Angioplasty versus Surgery TrialeRV@LQ^Sh0W0f0PTCAh0CABG0k0{kN Qlh^X Z@ YSzvusPTCAR"CABG0Q0000S0@{b_bSb6RRgCABGPTCA*0QRg r_ub6RRgCABGPTCA0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8090163?report=DocSum&format=htmlAEdaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke-%`'`3h^Xk0J0Q003OwdRedaravoneh0b00000argatrobanh00k0EASY?Early Discharge After Transradial Stenting of Coronary ArteriesM@\gGP IIb/IIIaS[SObbabciximab0000bNn00g0n0S_ebo0 0000bN 12BfYl_n0ebh0ky0f0聊^vk0R0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17145988?report=DocSum&format=htmlHHjRK00n00000eL_n0abciximab0000bNS_eb n0 gR'`o0abciximab0000bN 12BfYlk0ky0f0R0j0D00 EBBINGHAUSdEvaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk SubjectsTFOURIERfn0000000k0J0D0f0MRTM0k0w_j0UO0w_jk0J0D0f0evolocumabn00000k0[Y00^R'`L0000_0L0 *Q'`o0:yU00j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/28813214?report=DocSum&format=html ECASS III+European Cooperative Acute Stroke Study IIIezvuK003BfN NL}N_3^4.5Bf_ n0@hn㉬Yln0 gR'`J00s0[hQ'`0i090e_n00^o}YOalteplase0000*0-˄QQ@b6RRg0000alteplase*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/18815396,18815401?report=DocSum&format=htmlEchoCRT9Echocardiography Guided Cardiac Resynchronization TherapyL;egB}N=_[Q TglBvCRT n0 gR'`h0[hQ'`0iY000hQ{kN _ NhQX`k000RVeQbn0T0000000CRT-onR"CRT-off0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23998714,23998715?report=DocSum&format=htmld_000g0 Tg NhQL0xU00_0QRSE^n0rD0130msec uP'`_ NhQEFf"35% `k0J0D0f0 _ӁQ TgBvlCRT n019.60g_n0hQ{kN _ NhQ`Sk000eQbg0n0 g(u'`o0000Z00ECOSTDEffectiveness and Cost Of ICD Follow-up Schedule with TelecardiologyCICD i0`g0n0;N g[0000k0J0D0f0 ken0`000000000n0_egn0Yeg[k0[Y00^R'`L00000^R'`f 0 ECRIS&EndoCoronary-Rhenium-Irradiation-StudyP}ng0B00mSO00001880EQkXW0_0000000000k000>e\}Bvln0 gR'`0i06K0g_n0jv@{n0Qrzb6RRg000022.5Gy[gq*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12796137?report=DocSum&format=htmlECSG European Cooperative Study Groupr@hn㉬rt-PAJ00s0rt-PA }%`PTCAn0 g(u'`05t^uX[sg0i0eQb-Nn0{kNsb6RRgtr-PA0000 rt-PArt-PA PTCA0b_n0{kNsrt-PAR"0000 r-PAR"rt-PA PTCA0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7648654?report=DocSum&format=htmlECSG 2REuropean Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator1h^XNQRn0X['`k0[Y00@hn㉬rt-PAn0Rg0i0X[Rgrt-PA0000*01985t^11gDhttp://www.ncbi.nlm.nih.gov/pubmed/2865502?report=DocSum&format=htmlECSG 5[h^X000 ][_j uX[sk0[Y00@hn㉬rt-PAaspirin heparinuO(u n0Rg0i0{kNN2Rg h^X000.~\Rg ][_j9eURgrt-PA000001988t^11gDhttp://www.ncbi.nlm.nih.gov/pubmed/3146370?report=DocSum&format=htmlEFFECT7Enhanced Feedback for Effective Cardiac Treatment Studyuf[vyr_J00s0N_0UOW0 ƙQsL0NO NW0f0D00_ NhQ`h0kY000_ NhQk000eQb_n0hQ{kN__jOcR"__jNO N0Rzvn0_ NhQk000eQb`n0F0a0ƙQsL050%0H00__jL0OcU00f0D00uOo0YO0 S0n0ƙ< QsL0OcU00f0D00uOn0uX[so0NO NuOh0 Ti02006t^07gEhttp://www.ncbi.nlm.nih.gov/pubmed/16855266?report=DocSum&format=htmltEffectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysisWbN|?\uYegk0J0D0f0 00n09eUquality improvementQI &beu*o0HbA1cNO N @{000{t 0}\@{TuOun0000000 J00s0yYqk0 gRK0Effects of 12 Weeks of Treatment with RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects on High and Maximal Dose Statinsmؚ(uϑ~0_0o0g'Y(uϑn00000g0lBv-Nn0ؚ0000000@u`k0J0D0f0 41T0h0n0bPCSK9000000000bSOdRRN316;PF-04950615= Yln0Rk000LDL-CL0 gak0NO N,{2vf 0EINSTEINEINSTEIN programo0L}Svc\O(uW,{XaVP[;[rivaroxabann0 gR'`0mY@h^Xhu`g0i %`'`^Xhu`g0i lBv}}n0in03d0n0fK00b00Y@h^XhuQzvb6RRgAcute PEfrivaroxaban0000* Acute PEfrivaroxabann0jnlBvk0[Y00^R'`L0000_0 Extensionfrivaroxaban}}0000*0Whttp://www.ncbi.nlm.nih.gov/pubmed/22449293,21128814,21175319?report=DocSum&format=htmlEINSTEIN CHOICEeReduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolismnrivaroxaban 2(uϑ aspirinn01t^bNn0[hQ'` gR'`0kW0_00lBv(uϑ20mg  N2(uϑ10mg o0aspirinh0O00y0 Q@000L0 gak0 NfY00S0h0j0O0Qzv000L0 gak0NOK0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/28316279,28316277?report=DocSum&format=html EINSTEIN DVTOral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolismGuP'`mY@hu`k0J0D0f0 L}Svc\O(uW,{XaVP[;[0000000rivaroxaban n0jnlBvk0[Y00^R'`L000000 EINSTEIN PE9Oral Rivaroxaban Alone for Symptomatic Pulmonary EmbolismQ%`'`uP'`^Xhu`n0QzvN2k0J0D0f0 L}S,{XaVP[;[rivaroxabano0enoxaparin 0000Kbbk0[W0f0^R'`g0 'YQ@o0 gak0b6R0EISEuropean Infarction Study\u}TN_ _Ӂ{k ^{k'`_NEek0[Y00neoxprenolol_>edRn0Rg0i0{kNb6RRgoxprenololR"00000{kNso0bN-NbkJ00s065^69skg0ؚK0c0_00Dhttp://www.ncbi.nlm.nih.gov/pubmed/6373264?report=DocSum&format=htmlLEkelund U et al for the Lancet Physical Activity Series 2 executive committe_-NI{^n07_^n0SO;mR}60-75R/e k000wBfn0^MOk000{kN000n0XRo0m1YY00S'`L0:yU00_00Ne wBfn0000tk000{kN000n0XRo01_~000n0n0 m1YW0j0K0c0_00ELATE;Extended Low-Intensity Anticoagulation for Thrombo-EmbolismfwarfarinlBvk0J0D0f0 NO7_^INR 1.5^1.9 h08^INR 2.0^3.0 n04XTn0 gR'`h0[hQ'`0k0mY@h^Xhun0Qzvub6RRg8^NO7_^*0Q@8^R"NO7_^0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12917299?report=DocSum&format=htmlELEVATE-TIMI 56aEscalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis in Myocardial Infarction 56LclopidogrelNOS_CYP2C19n0zOP[YWO gO n0[[QRu``k0J0D0f0 3 Pn0}c(uϑk000@\gS_'`L0^O gOh0 TI{~0g0NO N0ELISA-23Early or Late Intervention in Unstable Angina Trialiaspirin clopidogrel tirofibann03dRk000b@\gMRlBvk000 ^ gaj0L00h^X000L0.~\W0 *glBv@{n0RgLpAmL0 gak09eU _K{h^Xzvu04O0j0D0uX[sn09eUPTL0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16682384?report=DocSum&format=htmlELISA IIA randomised comparison of dual versus triple antiplatelet therapy in patients with non-ST segment elevation acute coronary syndromes.QPCIeLn0^ST NfW%`'`QuPk0J0D0f0 aspirin0clopidogrel0tirofibann0MRbNo0QLpAm0 gak09eU N_9eUn07_D0PT0:yW0_00ELITE+Evaluation of Losartan in the Elderly Studyk00000000IIS[SObblosartann0[hQ'`h0 gR'`0ACE;[captoprilh0ki0{kNB00D0o0_ NhQk000eQbb6RRg oR\O(uk000lBv-Neb6RRglosartancaptopril0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9074572?report=DocSum&format=htmlELITE II.Evaluation of Losartan in the Elderly Study II]00000000IIS[SObblosartano0uX[s9eUJ00s0_['`n0pg0 ACE;[captopril00*Q0f0D00K0i0hQ{kNb6RRglosartanR"captopril0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10821361?report=DocSum&format=htmlELIXA5Evaluation of Lixisenatide in Acute Coronary Syndrome00000i0000-1GLP-1 S[SO\OR0000000lixisenatide n0_@{0^k0[Y00q_0UOY000_@{{k ^{kv_K{h^X ^{kv3RS-N N[[r_uk000eQbn0T0000000k0J0D0f0 lixisenatiden00000k0[Y00^R'`L0:yU00_0L0 *Q'`o0:yU00j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/26630143?report=DocSum&format=htmlElliott WJ, et al.?|?\uezvuh0n0#L0g0NOD0n0o0AIIS[SObbARB ACE;[ !kD0g0Cabb 0000 ne )R?\0Elmariah S, et al.S2dRuO(ub@\gBvlDAPT g^wk000 aspirinXSdR~0_0o0wg60g DAPTh0kW0_0hQ{kN _@{{k ^_@{{k000n0XRo0000j0K0c0_00ELSA,European Lacidipine Study on AtherosclerosisCabblacidipinek000wgM'WlBvL08Rn0g'YQ -NSIMT k0S|0Y0q_0neatenololh0k0lacidipinek000M'Wo0atenolol00\U0K0c0_0L0 IMTn02U\J00s00000pek0[Y00b6RRgL0'YM0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/12417537,11677363?report=DocSum< &format=htmlELUTES/European Evaluation of Paclitaxel Eluting Stentvbk vpaclitaxelnQ0000k0J0Q00puj00paclitaxel(uϑg0n0 gR'`h0[hQ'`0i0paclitaxel 2.7g/mm20000000k0vcWX^W0_00000o0 0000Qrz0 g[Na0zvuY00S0h0j0O0b6RW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/14744971?report=DocSum&format=htmlELVERA`Effects of Amlodipine and Lisinopril on Left Ventricular Mass and Diastolic Function (E/A Ratio)gCabbamlodipineh0ACE;[lisinoprilwgbNn0][K{͑ϑJ00s0b5__jk0[Y00 gR'`0k0][K{͑ϑn\RgJ00s0b5__j9eURgamlodipineR"lisinopril0Nhttp://www.ncbi.nlm.nih.gov/pubmed/11212974,15201546?report=DocSum&format=htmlEMBRACEc30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event^Orv000000000k00030en01uLR NECG000000n0AFiQ0 jnvj024Bf0000ECGn0R2h0kW0 AFiQk000lBvn0 YS0i<090eNQn030yN Nc}Y00AF/_?b|Rn0eiQ0000000000000ECG<sup>*</sup>0bQVn0O(uL0XR0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24963566?report=DocSum&format=html EMBRACE STEMIsEvaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients with Acute Coronary EventsUPCIeLN[n0RzvMRXSTEMI`k0J0Q000000000jv0000bendavia&trade; 0.05mg/kg/Bfn01BfYlh0h^X000,{IIavf 0Emdin CA, et al.A2W|?\u`k0J0D0f0 M'Wo0{kN0Nn0聊^0^n09eUh0#W0 000000S.~g@'Wg"140mmHgO{0i0000n0NO NL0'YM0D00>VgO0xzY00k0o0s0}j0iL0_g0B00L0 _?b0}Ro0sY'`k0J0D0f07u'`0007_Rj0_@{u`J00s0{kNn0qSzVP[g0B000EMERALDQEnhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris Triald}%`PCIeLOn0'YJSg0`MO0000^XJ00s08T_0000o0^Xhdebrisn0dSk0 gRj0L00 _\@{n09eU QLpAmbRsn09eU h^X000n0.~\ 000004O0j0D0uX[sn0 Nfo00_00U0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15741528?report=DocSum&format=htmlEMERASCEstudio Multicentrico Estreptoquinasa Republicas de America del Sur]zvu_n0Bfh0@hnBvln0 gR'`n0O0i0eQb-Nn0{kNsstreptokinaseSK R"00000SKg0zvu_7^12Bfn0{kNsL0NO NY00PTL0000_00n0n0 ga]j0W001993t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/8103875?report=DocSum&format=htmlEMIAT,European Myocardial Infarct Amiodarone TrialNb NteamiodaroneL0u}TN_09eUY00K0i0hQ{kNN2RgamiodaraneR"00000 Nte{kN2Rgamiodarone000002000t^04gVhttp://www.ncbi.nlm.nih.gov/pubmed/9078197,10758969,10226092?report=DocSum&format=htmlEMIP&European Myocardial Infarction ProjectS@hnBvlk0d0D0f0eQbMRlBvh0eQb-NlBv0kW0 ]0n0 g(u'`h0[hQ'`0i030e_n0{kNseQbMRlBvR"eQb-NlBv0_u`{kNb6RRgeQbMRlBveQb-NlBv*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8326971?report=DocSum&format=htmlEMIP-FR4European Myocardial Infarction Project-Free RadicalsDbr_utrimetazidinen0{kNsk0[Y00Rg0i0@hnBvleLOg0o0Rgo0j0K0c0_0L0 ^eLOg0o0 gR'`L0000_002000t^09gEhttp://www.ncbi.nlm.nih.gov/pubmed/10973768?report=DocSum&format=html EMPA-REG BP00000000000qQ8SOSGLT 2;[empagliflozin 121bNn0@'W0@|000000 [hQ'` _['`0i<0121_n0HbA1c 1uLR N@'W,n[ABPM g0n024BfSBPempagliflozinn0_['`o0o}Yg0 0000k0O00y0@'W HbA1cL0 gak0NO NW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/25271206?report=DocSum&format=htmlEMPA-REG OUTCOME00000000000qQ8SOSGLT 2;[empagliflozinRn0CVTuOu {kNx0n0q_0iؚ000Ok0J0D0f00 xbv0000000bb000000eplerenone n0RlBvn0 gR'`h0[hQ'`L0:yU00_00 _jnvlBv0SQ0f0D00uS.~ NhQ`k0J0D0f0 xbv0000000bb000000eplerenone n0Rk000{kNJ00s0_ NhQk000eQb000L0 gak0NO N (vs 0000 )0ENABLE 1 AND 2KEndothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure ENCHANTED>Enhanced Control of Hypertension and Thrombolysis Stroke Study[;eg7_SM'W vs jnM'Wfo02L-N= alteplaseNO(uϑ vs jn(uϑ^R'`f 90e_n0{kN SOn0[k0J0Q00NO(uϑn0jn(uϑk0[Y00^R'`o0:yU00Z00Nhttp://www.ncbi.nlm.nih.gov/pubmed/27161018,27160775?report=DocSum&format=htmlENCORcEffects of Enrasentan, a Nonselective Endothelin Receptor Angagonist, in Class II-III Heart Failu< re)ba'`_ NhQ`k0J0D0f0000000S[SObbenrasentann0 gR'`0i0ENCORECardiovascular benefits associated with the DASH diet alone and in combination with exercise and weight reduction in men and women with high blood pressure5@'WL0ؚ0n0NSO͑0n`k0J0D0f0 DASHߘ*h0KRk000nϑc\k000DASHߘn0000@'WL0NO N0ENCORE IMEvaluation of Nifedipine and Cerivastatin on Recovery of Endothelial FunctionCabbnifedipine GITS B00D0o0HMG-CoA reductase;[cerivastatinn0XSrbN uO(ubNk000QRQv_jL09eUY00K00i0nifedipineo00000000k000@{S.~S_L0g'YMOk0J0D0f0QRQv_j09eU0,nW0_0hQQRMO0Y0y0f0}Tvk0UOY00h0 nifedipineh0cerivastatinn0uO(uk0J0D0f0n00 gak09eUW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12551866?report=DocSum&format=html ENDEAVOR IIB9K0g_n0jv@{[b6RRg000000000000Endeavor zotarolimusnQ000000000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16908773?report=DocSum&format=htmlrandomized trial to Evaluate the safety and efficacy of medtroNic ave abt-578 eluting Driver coronary stEnt in de novo nAtiVe corOnary aRtery lesion II0Endeavorsirolimus|n0ABT-578nQ #0000o0[hQg0 000000k0ky0jv@{ NhQ Qrz0 gak0b6R0 ENDEAVOR III@8K0g_n000000QQ_ d1Yb6RRgsirolimusnQ0000eXkb6RzotarolimusnQ0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17174180?report=DocSum&format=html ENDEAVOR0IVsRandomized Comparison of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients with Coronary Artery DiseasezotarolimusnQ0000ZES n0[hQ'`J00s0 gR'`0paclitaxelnQ0000PES h0kY00^R'`f09K0g_n0jv@{ NhQ_Ӂ{k _K{h^X jv@{@LQ^SQeLn0T b6Rg0 ZESn0PESk0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20152559?report=DocSum&format=htmlENGAGE AF-TIMI 48xEffective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48L}Svc,{XaVP[;[edoxabann0 gR'`h0[hQ'`0warfarinh0kY000Rzvn03RS-N hQ'`^Xhun0T0000000edoxabano0warfarink0[W0^R'`<sup>*</sup> 'YQ@000NO Nedoxabanwarfarin<sup>*</sup>0{http://www.ncbi.nlm.nih.gov/pubmed/24251359,28302288,27609678,25769361,25769357,25104527,24302269?report=DocSum&format=htmlyEffective aNnticoaGulation with factor xA Next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 483RS-N000L0-NI{^^ؚ^n0_?b0}R`g0n03RS-N~0_0o0hQ'`^Xhun0N2k0J0D0f0 eL}S,{XaVP[;[000000edoxaban o060mg/ebN 30mg/ebNn0D0Z000warfarink0[W0f0^R'`g0B00 Q@h0_@{{kn0000L0 gak0NOK0c0_00ENHANCEUEzetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis0Regressions000000000000000;[ezetimibe simvastatinuO(uo0simvastatinXSr000LDL-C CRP0 gak0NO NW0_0k00K0K000Z0 Q-NSn0 YSk0J0D0f0!Nk0 ga]o0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/18376000?report=DocSum&format=htmlENOS"Efficacy of Nitric Oxide in Stroke00000000000dR7ebNn0[hQ'`h0 gR'`0iW0 U00k0M'WlBvOk0J0D0f0M'WlBv}}h03RS-Nzvu_11n0lBv-Nbkn00^0k000000000L}vbNo0[hQ`0L0 90e_n0_jv0^o09eU[0Z00~0_0 3RS-NzvuMR g(un0M'W}}0/ecU00Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/25465108?report=DocSum&format=htmlENRICHD,Enhancing Recovery in Coronary Heart DiseaseEF0d0n0lBvJ00s0>yOv/ecL0uX[s Qh^X00009eUY00K00i0_tf[vNeQk000000004O0j0D0n0uX[x0n0Rgo0000j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/12813116,11673340?report=DocSum&format=html5Enhancing Recovery in Coronary Heart Disease PatientsENTIRE-TIMI 23/ENTIRE-Thrombolysis in Myocardial Infarction 23b00000RlBvh0W0f0n0 gR'`0 NORP[ϑheparin enoxaparinh0full-dosen0tenecteplaseTNK ~0_0o0half-dosen0TNK abciximabBvl ^R;uheparinUFH k000uO(uBvlh00k0eg[hQQLpAms 'YQ@000enoxaparinR"UFH {kN0MIn0Qzvb6RRgenoxaparinUFH*0`http://www.ncbi.nlm.nih.gov/pubmed/11940541,15824203,15673542,15261928?report=DocSum&format=htmlEPESE@Established Populations for Epidemiologic Studies of the ElderlyV{kN ba'`rKa [ e-S[n0`1X0eQKbW0 communitiesg0u;mY00t^n0xQW00000:yY00u`0[0eQb0e-S[J00s0{kNsn0000VP[0 T[Y00uf[0ghttp://www.ncbi.nlm.nih.gov/pubmed/11308433,10076478,10029125,9827785,8481423?report=DocSum&format=htmlEPHESUSUEplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study2gij0QylBvk0xb'`0000000bbeplerenone0RY00h0 {kNJ00s0TuOuL0NO N0rhttp://www.ncbi.nlm.nih.gov/pubmed/12668699,22032706,18824643,17420346,16053953,15723981?report=DocSum&format=html4%`'`_K{h^X_n0][_j NhQ`k0J0D0f0 xb'`0000000bbeplerenoneo0hQ{kN0b6R0EPIC]Evaluation of IIb/IIIa Platelet Receptor Antagonist c7E3 in Preventing Ischemic Complicationsc0000000bSOFab000000c7E3 L0Qrzb6Rk0S|0Y0Rg0i0{kN MI }%`@LQ^Sb6RRgc7E3 0.25mg/kg0000bN_ 10g/R12BfYl0000*01994t^04gMhttp://www.ncbi.nlm.nih.gov/pubmed/7908357,11447080?r< eport=DocSum&format=htmlVEuropean Prospective Investigation into Cancer and Nutrition|Norfolk Population StudyLvh0ߘNVP[J00s0]0n0Nn0zl[VP[h0n0#0iW0f0D009K0VqQ TxvzEPIC n0V0Norfolk000000000000000ˆ}vCETP ˆ}vϑh0CADzvuo0#'`o0B00L0 CETPn0 Nfo00000000$PL0ؚD04XTk0J0D0f0n00CAD000n0 Nfk0#02019t^06ghttp://www.ncbi.nlm.nih.gov/pubmed/15337694,31006335,29844013,19005195,18261682,18040028,18071080,17923573,17616301?report=DocSum&format=htmlEPICA@Elderly Patients Followed by Italian Centres for AnticoagulationKQ@000h0bQVn0ꌒ0MRTM0k0i165</sub>0000W0_000000DNAn0L}vvyeQk000@{euBvln0 gR'`0i03K0g_n0_K{LpAm9eU@{euBvlR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/15808751?report=DocSum&format=htmlEUROMAX6European Ambulance Acute Coronary Syndrome AngiographyuQe%`,d-Nn0bivalirudinbNYo0heparin GP IIb/IIIa;[n0xbvbN[gq k0O00y0{kNh0Q@0b6RY00K00i2</sub>S[SObbtolvaptan0RW0_04XT ͑{j0 g[Na04OF0S0h0j0O0.z0n0urJ00s0_P09eUW0_0L0 wgn0{kN _ NhQ#TuOun0b6RRgo0000j0K0c0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/17384437,17384438,18544725?report=DocSum&format=htmlREfficacy of Vasopressin Antagonism in Heart Fasilure: Outcome Study eith TolvaptanC%`'`^NQ'`_ NhQ`k0J0D0f0 0000000V2S[SObbtolvaptanbNk000wg9eUo0000_0L0 wgN_o09eU[0Z00 EVEREST II/Endovascular Valve Edge-to-Edge Repair Study IIcMitraClip&#174;<sup>*</sup>k000L}vv_O_Sh0_egn0KbSn01t^_n00^0k0Am9eURgo0NOK0c0_0L0 L}vv_O_So0KbS000[hQg0聊^0^o0 TI{g0B0c0_00ihttp://www.ncbi.nlm.nih.gov/pubmed/21463154,21463152,26718672,25011722,22222076?report=DocSum&format=htmlEVOLVEA Prospective Randomized Multicenter Single-Blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System [Evolution Stent System] for the Treatment of a De Novo Atherosclerotic Lesionoen0uSO8TS'`0000everolimusnQ0000EES SYNERGY*n02(uϑn0[hQ'`h0 gR'`0 _egn0EN'`0000EESPROMUS h0kY00030e_n0jvu Y NhQb6RSYNERGYR"PROMUS0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22341736?report=DocSum&format=html EVOLVE IIPCIeL120g_n0TLF_Ӂ{k jv@{#MIB00D0o0Z@k000jvu YQ@LQ^S k0J0D0f0 uSO8TS'`0000EESSYNERGY&#8482; n0EN'`0000EESPROMUS Element&#8482; Plus k0[Y00^R'`L0000_00EWOLUTION registryq i0K0030e_~0g0n0hTSg0^YunbRs98.5% n0bRo099.3%0hTSg000o0NOD07eNQn0͑{j0 g[Nao04.1%g0 Kbbe0000#o02.8%g0HQLn0聊^f00NOD0030e_o07.9%g0 3.6%0uf[ NteEhttp://www.ncbi.nlm.nih.gov/pubmed/26822918?report=DocSum&format=htmlEWPHEBEuropean Working Party on High Blood Pressure in the Elderly TrialAM'WlBvn0_@{TuOuk0[Y00N2Rg0i0{kNN2Rg[R"00000_@{{kN0_@{TuOub6RRg[0000*01985t^06gThttp://www.ncbi.nlm.nih.gov/pubmed/2861311,2503114,2875317?report=DocSum&format=html EWTOPIA75NEzetimibe lipid lowering trial on prevention of atherosclerosis in 75 or olderQؚLDL0000000@u0 gY0075skN Nn0ؚ000ؚb`k0J0Q00 \x000000000000000;[ezetimiben0_@{0000b6RRgn0i Ex JAPAN-ACSUExtended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome`PCIeLK0072BfNQn0%`'`QuPk0J0D0f0QR0000[Mz0pitavastatinh0atorvastatino0 TI{k0.~W0_0h02009t^k0zvhW0_0JAPAN-ACSn0g^wxvzEXACT-HFDXanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients00000000000XO ;[allopurinoln0L}SbNk0000^L09eUY00K00iY000241_n0{kN _ NhQ`Sk000eQb0Qe%`S: _ NhQ`Sk000irlBvn0 Yf Patient Global Assessmentg0UOW0_0T聊^0000000allopurinolR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/25986447?report=DocSum&format=html EXAMINATIONNClinical Evaluation of the Xience-V Stent in Acute Myocardial Infarction Trialh,{NNNdRnQ0000g0B00everolimusnQ0000EES n0000000000BMS k0[Y00*Q'`f01t^n0}{kN _K{h^XMI Qzv Q@LQ^ST0000000EESR"BMSWhttp://www.ncbi.nlm.nih.gov/pubmed/22951305,22951304,26520230?report=DocSum&format=htmlA Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients with ST-segment Elevation Myocardial Infarction n0000000g0n0ؚ000ST NfW_K{h^X`k0J0D0f0 ,{2N0000everolimusnQ0000o01t^_n0hQ{kN _K{h^X Q@LQ^S0 gak0b6R[0Z000000@hun0zvuso0NOD0all-comerf 0 EXAMINENExamination of Cardiovascular Outcomes with Alogliptin versus Standard of Care.DPP-4;[alogliptino00000k0ky0f0;N_@{00000XRU0[0j0K0c0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/23992602,23992603,25765696?report=DocSum&format=htmlNEXamination of cArdiovascular outcoMes with alogliptIN versus standard of carEs%`'`QuPACS 0zvu_15-90en0lBv Nn02W|?\u`k0J0D0f0 180g_n0;N g[_0000g0n0000000000000DPP -4;[0000000alogliptin n00000k0[Y00^< R'`L000000EXCEL0Expanded Clinical Evaluation of Lovastatin StudySHMG-CoA reductase;[lovastatinn02t^bNn0 gR'` _['` [hQ'`0i0lovastatino09eURgL0B00 _['` [hQ'`0o}Y0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7942524?report=DocSum&format=htmlkEvaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main RevascularizationI3t^_n0hQ{kN 3RS-N _K{h^Xn0T0000000k0J0D0f0 everolimusnQ0000O(un0PCIn0CABGk0[Y00^R'`L0:yU00_00Whttp://www.ncbi.nlm.nih.gov/pubmed/27797291,29447735,29097293?report=DocSum&format=html EXCELLENTPEfficacy of Xience/Promus versus Cypher to Reduce Late Loss after Stenting TrialReverolimusnQ0000n0sirolimusnQ0000k0[Y00`gn0@{ q_0^9K0g_n000000Q`gQ_ d1Yb6R k0J0Q00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/22018294?report=DocSum&format=htmlEXCITE?Evaluation of Oral Xemilofiban in Controlling Thrombotic EventsV@\gGP IIb/IIIaS[SObbxemilofibann0wgL}SbNL0{kN _K{h^X }%`@LQ^S0b6RY00K00i0b6RRgxemilofibanR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/10793164?report=DocSum&format=html EXPEDITIONhEffects of Na+/H+ Exchange Inhibition0(NHE-1) by Cariporide on Death and Non-Fatal Myocardial Infarction5CABGeLn0ؚ000Ok0J0D0f0NHE-1;[cariporideo0_K{h^X0b6RW0_00n0n0{kNo0XR0EXPIRAmThrombectomy with Export Catheter in Infarct-Related Artery during Primary Percutaneous Coronary Interventiongprimary PCIn0܈RBvlh0W0f0n0@h8T_L0_K{LpAmJ00s0h^X000k0NH00q_0UOY000_K{og0000g"2J00s090R_n070%n0STV_@h8T_000000uO(uW0_0PCIjnvPCI*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/19161878?report=DocSum&format=htmlEXPRESS)Existing Preventive Strategies for Stroke0TIA~0_0o0u3RS-N_egk0_eglBv0YY00S0h0k000 3RS-Nn0egQzv000L080%n\0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17928046?report=DocSum&format=htmlExTRACT-TIMI 25zEnoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction 25p@hnBvln0܈EQBvlh0W0f0n0 gR'`0NORP[ϑheparinLMWH enoxaparinh0*gR;uheparinh0g0k030en0hQ{kN ^{kv_K{h^XQzvb6RRgenoxaparin*gR;uheparin*0rhttp://www.ncbi.nlm.nih.gov/pubmed/16537665,17515461,17560290,17560289,17560287,17600039?report=DocSum&format=html=30e_k0xU00_0ST NfW_K{h^X`k0J0Q00enoxaparin n0 gaj0{kN _K{h^Xb6RRgo01t^_0}}W0_00EXTRACT-TIMI 25|Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis In Myocardial Infarction 25IST NfW_K{h^X`k0J0D0f0 enoxaparinNORP[ϑheparin o0^R;uheparink0ky030e_n0{kN Qh^X0 gak0b6RW0_00FACETCFosinopril versus Amlodipine Cardiovascular Events Randomized TrialJ00s0|?\u000000n0pg0ACE;[fosinoprilh0Cabbamlodipine0k0M'W00000009eURgfosinoprilR"amlodipine0%`'`_K{h^X 3RS-N eQb0Y00r_un0zvub6RRgfosinoprilamlodipine*01998t^04gDhttp://www.ncbi.nlm.nih.gov/pubmed/9571349?report=DocSum&format=html FACTOR-64v!quPn0|?\u`1W12%2W88%yugCCTA12.3t^ [gq13.5t^ k0J0D0f0 CT@{ q_g0n0CAD0000000k0We0O0lBv7_Sk0004t^_n0CVDhQ{kN ^{kvMI UAk000eQb n0n\o0000Z00 FAILSFailure in Left Main StudySdRnQ'`0000DES i0_n0Qrzn0zvuh0{t0UOY000Qrzo0{0h00i0n0uOg0g\Pn0Orv00000k000{tL0Sg0B00 eg ifgh00P}go0o}Y0Ehttp://www.ncbi.nlm.nih.gov/pubmed/19761932?report=DocSum&format=htmlFAIR-Randomized Femoral Artery In-Stent RestenosisdRpaclitaxel 0000000000@{b_bSDCBA n0 gR'`h0[hQ'`0jnv0000@{b_bSPOBA h0k06K0g_n00000000lk000/}Mz0000QQrzQzvb6RDCBAPOBA<sup>*</sup>0{kNj0i0n0[hQ'`k0!N]o0j0W00Ehttp://www.ncbi.nlm.nih.gov/pubmed/26446728?report=DocSum&format=htmlFAIR-HFOFerinject Assessment in Patients with Iron Deficiency and Chronic Heart FailurepD kON'`@lBvferric carboxymaltose0000000000D n0YlL0ur09eUY00K00i<0@n0 g!qk0K0K000Z0 241_n0eP^rKa SO_j QOL0 gak09eUW0_00oR\O(uo01[{VQg0B0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19920054,19920053?report=DocSum&format=htmlsFerric Carboxymaltose Assessment in Patients with Iron Deficiency and Chronic Heart Failure with and without Anemia^D kONrKan0uP'`ba'`_ NhQ`k0J0D0f0 D kON'`@lBvferric carboxymaltose*n0Ylo0 @n0 g!qk0K0K000Z0 241_n0eP^rKa SO_j QOL0 gak09eU0FAMEEFractional Flow Reserve versus Angiography for Multivessel EvaluationU_jv[hQ@LQ^L0VRf[v[hQ@LQ^0QP0S0h0L0:yU00_00 1t^_n0;N g[_0000b6RRg@AmNPkn00000,n[ @{ q_@{ q_<sup>*</sup>0{http://www.ncbi.nlm.nih.gov/pubmed/19144937,19144945,27056776,26333474,21903052,20537493,20579537?report=DocSum&format=html6dR+^k000`Ye [gv0000k000ؚbn0irlBvn0u[sL0 gak0 NfW0 @'W$P LDL-CL09eU0FAME 2GFractional Flow Reserve versus Angiography for Multivessel Evaluation 2;egB}N=N[02t^W0_0P}gQR q_Bfk0Q@AmNPϑk0,n[W0 utf[vj0Z@0 gY00uOn00k0PCIh0iirl< Bv0Lc0_04XT iirlBvn00k0O00y0;N g[_0000b6Rk0*Q00K00iY000_@{0000b6RRgPCI irlBvirlBv<sup>*</sup>02018t^07grhttp://www.ncbi.nlm.nih.gov/pubmed/25176289,25176288,22924638,22924622,29785878,27884241?report=DocSum&format=htmlHFractional Flow Reserve versus Angiography for Multivessel Evaluation IIcdRnQ'`0000k000PCI0eLN[n0[[Ygu Y`k0J0D0f0 Q@AmNPϑk0cjh0W0_0PCI iirlBvo0iirlBvn00k0O00y0 g[_0000 yrk0}%`Q@LQ^Sn00000 gak0b6R0 FAMOUS-NSTEMIElBvln0zl[k0J0D0f0 Q@AmNPϑkFFR 000h0QR q_000h00k0irlBv`n0rRTFFR000QR q_000*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25179764,25179765?report=DocSum&format=htmlFANTASY=Fatty Liver Protection Trial by Telmisartan or Losartan Study8ؚ@'W04OF0^00000'`'`[`k0J0Q00ARB telmisartan losartann0 g(u'`n0iFASTHAtrial Fibrillation Catheter Ablation versus Surgical Ablation Treatmentgؚ@'WL0B00]?bL0b5_W0_0O 000000000000L0 NbRuOk0J0D0f0 Yyv0000000o0000000000000k0ky0hTSgn0 g[0000000L0ؚK0c0_00n0n0 12K0g_n0]?bwn Nte0b6R0 Nte ؚ@'WEhttp://www.ncbi.nlm.nih.gov/pubmed/22082673?report=DocSum&format=html/Factor Seven for Acute Hemorrhagic Stroke TrialUzOP[D}cH0;m'`WVIIVP[rFVIIa 20g/kg 80g/kgn0 gR'`0UOY00090e_n0͑^n0[ {kN20g/kgR"80g/kgR"00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/18480205,18480212?report=DocSum&format=htmlFukuoka Atherosclerosis Trialؚ@u(uprobucol~0_0o0HMG-CoA reductase;[pravastatink000NO NL0 00000'`8RlxSn02L0E^ .~0O2U0[00K00i0probucolo000000000NO N 00000[[U0[0_0000n0zvu0b6R0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11849859?report=DocSum&format=html<irlBvbb'`_?b0}R`k0[Y00NOOrYy0000000o0 ]?bn0 NteN2g000000000000000*Q0f0D000FAST-MAG0Field Administration of Stroke Therapy-MagnesiumZQe%`Tk000zvu_2BfNQn0kxx000000bNk000wgn0_jv0^L09eUY00K00i090e_n0modified Rankin Scaleg0UOW0_0_jv9eUo0000Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/25651247?report=DocSum&format=htmlFAST-MI;French Registry on Acute ST-Elevation Myocardial InfarctionPprimary PCIPPCI h0@hnBvl_n00000@{ q_ PCIn00^0kY000eg 1t^_n0uX[sPPCIR"@hn㉌_n0@{ q_ PCI0rhttp://www.ncbi.nlm.nih.gov/pubmed/18591434,18625904,24657993,24258072,19106083,19164193?report=DocSum&format=htmlFAST-MI programmePFrench registry of Acute ST-elevation and non ST-elevation Myocardial InfarctionUST NfW_K{h^X`n030e_{kNso015t^g068%NO N0S00o0`̀ofn0 YS0,dBfn0w.~ lBvln09eUk0000000n01995-2010t^n04{v2xvzK00 0FATS(Familial Atherosclerosis Treatment Study]uP'`QR_u``g0L00f0D007_R@nNO NBvlL0 g(ug0B00K00i0яMOu Y2Lb6R0.~Rg7_RlBv_eglBv0_@{0000b6RRguP'`O 7_RlBv_eglBv*01993t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/8252687?report=DocSum&format=htmlFeASTIron and Atherosclerosis Study* p@k000SOQD5n0dSL0N_k0q_Y00K00i0{kNb6RRgDdSR"[gq02007t^02gEhttp://www.ncbi.nlm.nih.gov/pubmed/17299195?report=DocSum&format=htmlFEVER Felodipine EVEnt Reduction studyb-NVNؚ@'W`k0J0D0f0 )R?\hydrochlorothiazideHCTZ CabbfelodipineuO(uBvlo0 UYq |?\u ]['Y t^bk0K0K000Z0 gak0_@{00000b6R0 Felodipine Event ReductionG-NVNؚ@'W`k0J0D0f0 hydrochlorothiazidek0Cabbfelodipinen0RbNk0003_@{0000L0 gak0NO N0FIELD=Fenofibrate Intervention and Event Lowering in Diabetes Study_ؚ@u(ufenofibrateo0N!k0000000g0B00QR0000n00000 gak0NO NW0j0K0c0_0L0 ;Nk0^{kv_K{h^XJ00s0@LQ^Sn0b6Rk000hQ_@{0000L0 gak0n\W0_00http://www.ncbi.nlm.nih.gov/pubmed/16310551,25149070,22210576,21052978,20668832,19465233,19095138,17988728?report=DocSum&format=html7Fenofibrate Intervention and Event Lowering in DiabetesK2W|?\u`k0J0D0f0 ؚ@u(ufenofibrateo0_K{h^X PCIeL0b6RY00S'`0:yW0_0L0 ;Nj0QR0000n0 gaj0b6Ro0:y[0Z00FinCVFinnish Cardio Version`@h^Xh'`TuOun0zvush0000VP[0iY000d0}R_30eNQn0x[j0@h^Xh'`0000000o0^8^k0NOK0c0_00_ NhQ |?\u 60skj0i0n0SxQv0000peO gY00`g0o0000 Nf0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23850908,23850931?report=DocSum&format=htmlFINE%Finland, Italy, Netherlands , Elderly#'k]n0ؚbk0J0Q00hQ{kNsh0_@{000VP[h0n0O0iY00uf[0Mhttp://www.ncbi.nlm.nih.gov/pubmed/11259144,8781010?report=DocSum&format=htmlFINESSEGFacilitated Intervention with Enhanced Reperfusion Speed to Stop Eventsv@\gGP IIb/IIIaS[SObbabciximab JSϑreteplaseuO(ubN abciximabXSrbNk000facilitated PCIn0D0Z000 primary PCIh0ky0_0 gaj00^n09eURgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/18499565?report=DocSum&format=htmlFinnmark Study'wL03RS-NJ00s0_@{'`n0000VP[h0#Y00K00iY0000000n0uf[0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8941116?report=DocSum&format=htmlFIPS#Frankfurt Isoptin Progression StudydQR0000S_n0QR00000lxSn02Lk0S|0Y0Cabbverapamiln0q_0i00000s _K{h^X0_Ӂ{k0_ӁKbSJ00s0PTCA0Y00rKazvuverapamilR"000001990t^Dhttp://www.ncbi.nlm.nih.go< v/pubmed/2261941?report=DocSum&format=htmlFIR CollaborationB0000n0egOrlBvo0__jvOrlBv000wg_@{{k _K{h^Xn00000NO NW0_00 gR'`L0g0'YM0K0c0_0n0o0ؚ000Og0B0c0_00FIRE#FilterWire EX Randomized Evaluation~00000NM000000k000+gh^XhN2FilterWire EX n0[hQ'`h0 gR'`0GuardWire0000g0+gh0W0 ^XhP[08T_Y000000 h0k030e_n0;Nj0 g[_0000FilterWire EXR"GuardWire0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12874191?report=DocSum&format=html FIRE AND ICE000000000000000h0ؚhTl00000000kY00^R'`f 0 gR'`90e_NMn0Rzvn0聊^v NbR [hQ'`hQ{kN 3RS-N0NN'`3Z@zv\O ͑{j0lBv# g[Nan0T 000000000000000R"ؚhTl00000000Ehttp://www.ncbi.nlm.nih.gov/pubmed/27042964?report=DocSum&format=htmlFIRST&FGF Initiating RevaScularization TrialZD}cH0W}}0}ހXkVP[-2rFGF2 n0QRQXSV0000bNn0 gR'`h0[hQ'`0irFGF2o0KR[ _K{LpAmo09eUW0j0K0c0_0L0 90e_k0ur9eUn0PT0:yW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11854116?report=DocSum&format=html.Flolan International Randomized Survival Trial]000000000dRepoprostenoln0Rg0i0epoprostenolg0n0{kNsL0ؚO03K0g_30% vs jnlBv24% 6K0g_48% vs 37% fo0-Nbk01997t^07gMhttp://www.ncbi.nlm.nih.gov/pubmed/9266782,11376303?report=DocSum&format=htmlFISH(Finnish Isradipine Study in Hypertension|Cabbisradipine nemetoprololXSrbN J00s0!NdRuO(uk000M'WRg _['` @nx0n0q_0i0M'WRgisradipineR"metoprolol09eURgmetoprololisradipine*01992t^08gDhttp://www.ncbi.nlm.nih.gov/pubmed/1381022?report=DocSum&format=htmlFish Oil for AFEfficacy and Safety of Prescription Omega-3-Acid Ethyl Esters (P-OM3) for the Prevention of Recurrent Symptomatic Atrial Fibrillation (AF)>b Nte^bNn0uP'`_?b0}R`k0J0D0f0 000-3x0000000P-OM3 k000N!kN2Rgo0000Z00 FIT Heart?A Novel Family-based Intervention Trial to Improve Heart HealthC_@{u``n0[e0[ah0W0_0Mzuivj0NeQk000LDL-CNOnRgo0_00j0K0c0_0L0 HDL-Ch0ߘcak0d0D0f0o09eUL0000_00Flather M, et al.BYgu`k0[W0f0CABGh0PCIn0i0a00L0v[vk0 gRK0o0 t^bk000puj000ؚbk0o0CABG t^k0o0PCIn0{0F0L0}Y~0W0D00Flec-SLFlecainide Short-Long trial`b Nteflecainide n0bNg0w.~W0_04XT QzvN2Rgo0wgbNh0 Y00j0D0K00ihttp://www.ncbi.nlm.nih.gov/pubmed/29699974,28500036,28559398,28428346,28159800,26863354,26172893,25743624,25960110,25769640,25416177,25361552,25274000,24713533,23340887,23690532,23553971,23483176,22507977,22907935,23172839,22939561,22948697,22871870,21346180,21774709,21076174,20876437,20679552,20660804,20212282,20100973,20083680,19948972,19933936,19581493,19506113,19506114,19307472,19265054,19211484,19245965,16461820,19118251,19103986,19029465,18955667,18574071,18591432,18499567,18212285,18212276,18180395,18195335,18206734,16186276,17709632,17709633,17698726,17699011,17602937,17576866,17620505,17646581,17652652,17533184,17502528,17533210,17485578,17353490,17242302,17224472,17312290,17190894,17182988,16837677,16785337,16636175,16476848,16401818,16380547,16087792,15956133,15738353,15734611,15569842,15562129,15451778,15262842,15262834,15229305,15199036,15148273,15138242,14993133,14988289,14769683,14747241,14970063,14960742,14600184,12874190,12882936,12941677,12460872,12351489,11897450,11560851,11447076,11356398,11152833,11015340,10645922,10594797?report=DocSum&format=htmlFRANCE 2,French Aortic National CoreValve and Edwards<;go05t^1t^_n0P}g=͑u'YR_rzn0ؚ000ؚb`k0J0D0f0 TAVIL0YS_j0xbg0B00S0h0L0:yU00_00`http://www.ncbi.nlm.nih.gov/pubmed/22551129,30571260,27712776,24566199?report=DocSum&format=htmlFranklin SS, et al.L}vcRgn0000k0o0t^bL0OY00L0 CVD000h0o0#W0j0D00'YJSn0}vcؚ@'WOk0J0Q00CVD000o0 t^b 000te_n0ck8^@'WOh0 TI{g0B000 FRAX.I.S.!Fraxiparine in Ischaemic SyndromedNORP[ϑheparin nadroparinh0^R;uheparinn06e 14ebNn0Rg0k0_{kN _K{h^X N[[r_uQzvN2Rgnardarin 6e 14ebNR"^R;uheparin0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10529323?report=DocSum&format=htmlFREEDOMqFuture Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel DiseaseSMzuivirlBv dRnQ'`0000DES L0CABGk0N00@LQ^Sh0j00_0K00i<0hQ{kN ^{kv_K{h^X ^{kv3RS-Nb6RRgCABGDES*0{http://www.ncbi.nlm.nih.gov/pubmed/23121323,23121324,28081820,27585501,25236509,24129463,23500281?report=DocSum&format=htmlqFuture Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Diseaser|?\uTuOYgu``3gu Y83%|?\uyug-N.Y$P10.2t^ k0J0D0f0 CABGo03RS-N0000 NfU0[0_0L0 {kN _K{h^Xb6Rg0dRnQ'`0000paclitaxel0sirolimusnQ0000 000*Q000FreezeAFO6K0g_ 12K0g_n0_?b'` Nten0VK0d0c}'`TuOun0Vk0J0Q0000000000000000000000n0ؚhTl0000000k0[Y00^R'`L0:yU00_002015t^10gEhttp://www.ncbi.nlm.nih.gov/pubmed/26283655?report=DocSum&format=html< French-UK-Sweden CRT Network__ӁQ TglBvCRT ICDk0000^0_K{un0uV%Rk0i*</sup> W0K0W03K0g_o0dalteparinR"00000 (2)egOrBvlh0^OrBvl0k0{kN0_K{h^XMI b6RRgOr^Or0MIb6RRgOr^Or<sup>*</sup>0http://www.ncbi.nlm.nih.gov/pubmed/10475180,10475181,27585757,17909103,17848615,16980115,15708700,12651033,11741360,11741361,12020486,12106927,11451294,11583868,10892758?report=DocSum&format=htmlZFragmin and Fast Revascularization during Instability in Coronary Artery Disease II 5t^_n0P}g--N z^^ؚ000n0^ST NfW%`'`QuPk0J0D0f0 egOrBvlo0{kN _K{h^X0b6R0 FUJIYAMAAؚ@'Wn`k0J0Q00[^@'W @| Nx0n0q_0AIIS[SObbcandesartanh0telmisartanh0g0k0Fulcher J, et al.T000000Bfn0_@{000L0 TI{n07usYk0J0D0f0 0000n0;N@{0000b6RRgo0 TI{Cholesterol Treatment Trialists'CTT 0Fushimi AF Registry[聊^k0J0Q00L}SbQVn0L}Bfvj0O(usln0 YS J00s0warfarinh0O00y0_0vc\O(uWL}SbQVDOAC n0聊^0^0UOW0_000000000n0e8^聊^k0J0D0f0 3RS-N/hQ'`^Xhu 'YQ@k0W0f0warfarinh0DOACn0 gR'`k0 ga]o0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/28428449?report=DocSum&format=html FUSION IIZFollow-Up Serial Infusions of Nesiritide for the Management of Patients with Heart Failure=0000Dn0ba'`^NQ'`_ NhQYeg`k0J0Q00nesiritide#}leQk000{kN _@{J00s0Nu`o00000h0 Ti0FUTURA/OASIS-8bFondaparinux Trial with Unfractionated Heparin during Revascularization in Acute Coronary SyndromeVPCIeLBfn0*gR;uheparinUFH RbNi(uϑ0i0hTSgn0'YQ@ \Q@ @{0000MOk0#W0_0;Nj0TuOun0T0000000ؚ(uϑR"NO(uϑ0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20805623?report=DocSum&format=htmlFUTURA OASIS 8VFondaparinUx Trial with UFH During Revascularization in Acute Coronay Syndrome OASIS 8FbQV000000000fondapalinux 0bNW0_0PCIeL`k0o0 *gR;uheparinn0NO(uϑ000jn(uϑ0O(uY0y0M00FUTUREbFollow-Up of Transient Ischemic Attack and Stroke Patients and Unelucidated Risk Factor Evaluation@]0n0_n0{kNsh0{kNSV0gW0 N,OOln0c[{kNsh0kY000]0n0_20t^n0{kNsL0NSq} Nn0c[{kNs000ؚK0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/23512060,23512064?report=DocSum&format=htmlG-FORCE%Guidewire for Chronic Total Occlusionba'`[hQ^Xu Yk0[Y00PCIk0J0Q000000000n0iGABI<German Angioplasty versus Bypass Surgery Investigation TrialXCABGh0PTCAn0Rg0k0S_n0eQbg9eURg Qlh^Xb6RRgPTCACABG0{kNsCABGR"PTCA0}%`000000000b6RRgCABGPTCA*01996t^08gLhttp://www.ncbi.nlm.nih.gov/pubmed/8090162,8869860?report=DocSum&format=htmlGAIN,German Atorvastatin Intravascular Ultrasoundn00000'`RlxSn02U\b6RRgh00000n0000^n0 YS0 HMG-CoA reductase;[atorvastatink0007_SNO NBvlh08^n0NO NBvlh0g0k07_SBvlo0^n0rzu Yn0bw0b6R0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11468198?report=DocSum&format=htmlGamma 1_0000QQrzlBvh0W0f0QRQ}lBviridium-192 n0 gR'`0i0Qrzb6RRg}lBv0000*0}lBvg0o0E^'`@hun0ؚzvuk0#W0 MIn0000L0 Nf0Nhttp://www.ncbi.nlm.nih.gov/pubmed/11172151,12163429?report=DocSum&format=htmlGarcia S, et al.9CABGB00D0o0PCIk000@LQ^S0eLY00Ygu``k0J0D0f0 [hQ@LQ^o0TuOu {kNn0NO Nh0#Y000 GARFIELD-AF>Global Anticoagulant Registry in the FIELD-Atrial Fibrillation:eK002t^_n0hQ{kN 3RS-N/hQ'`^XhuSE 'YQ@n0zvush0 zvuVh0j0c0_0`̀ofJ00s0lBvn01XJT0g0;^L0ؚK0c0_0 g[0^o0{kN0{kN 3RS-N/SE 'YQ@n0zvusL0ؚK0c0_0n0o0gRn04K0gg0 ]0n0_8on03RS-N#{ko010%g0gYg0o0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27357359?report=DocSum&format=htmlGargiulo G, et al.V|?\uo0DESYun_n0MACEn0rzW0_0N,nVP[g0o0B00L0 |?\un0 g!q0OU0Z0DAPTwgeLn0wgeLk0O00y0_0MACEn0000NO No0000Z0 Q@000L0 NfW0_00GARYGerman Aortic Valve RegistryYyv'YR_ncS_n0eQb-Nn00^o0o}Yg0B00 ~0_0TAVRo0KbSؚ000 ؚb`k0J0Q00NflBvlg0B00/ Yyv'YR_nSo0 NO000`k0J0D0f01t^_n00^L0o}Y0KbSؚ000 ؚbn0`g0o000000lBvL0 gRj0NflBvlg0B00/ TAVRn00^o0o}Yg0 TuOuo0t^0n\W0f0D000Whttp://www.ncbi.nlm.nih.gov/pubmed/24022003,25079769,25787198?report=DocSum&format=htmlGerman Aortic Valve RegistrYe'YR_u`k0[Y00OrvlBvn0}28%L0L}00000v'YR_ncSTAVI 0ؚbg0TuOun0< B00uOL0YO0 eQb-Nn0{kNso0L}'Y00000L0}5% L}_\00000L0}8%000n0{v2xvz 0GAUS German Activator Urokinase StudyOh^XNQRn0X[h0egQ^Xk0J0Q00@hn㉬rt-PAh0urokinaseUK 0k0X[Rgrt-PAR"UK0Qh^Xb6RRgrt-PAUK01988t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/3042835?report=DocSum&format=htmlGAUSSGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS): Interim Results from a Randomized, Double-blind, Placebo-controlled Study|K{#n0oR\O(un0_00 gRϑn00000k0 N_[n0ؚ0000000@u`k0J0D0f0 bPCSK9000000000bSOdRAMG-145 n041T0h0n0v Nlk000121_n0LDL-CL0ezetimibeXSrbNk0O00y0 gak0NO N,{2vf 0GAUSS-2XGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2webPCSK9[hQ000000000bSO000000evolocumab *v NbNn0LDL-CNO NRgh0[hQ'`0 ezetimiben0L}SbNh0kY000121_n0LDL-CNO NRgevolocumabezetimibe*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24694531?report=DocSum&format=htmlXGoal Achievement after Utilizing an anti-PCSK9 antibody in Statin intolerant Subjects -22dRN Nn00000k0_[g0M0j0D0ؚ0000000@u`k0J0D0f0 bPCSK9[hQ00S0000000bSO000000evolocumab 140 mg 1V/21~0_0o0420 mg 1V/gv NbNo0 D0Z000ezetimibeL}SbNk0O00y0121_n0LDL-C$P0 gak0NO NW0 _['`0o}Yg0B0c0_0,{IIIvf 0GAUSS-3WGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3K{#n0 g[Nak0000000 N_[O0yr[_ LDL-CNO N0PCSK9;[n0evolocumabh0ezetimibe0kY000LDL-C$Pn0000000K00,{221h0,{241n0s^GW$P~0g0n0s^GWNO Nsh0 ,{241~0g0n0s^GWNO Nsn0D0Z000evolocumabn0{0F0L0'YM0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27039291?report=DocSum&format=htmlGEANE1Gene Evaluation for Antihypertensive Drug EffectsM'WaS'`zOP[0 T[Y00_00n0MRTM0Ye-f0GEMICALGrupo de Estudio Multicentrico de la Insuficiencia Coronaria en la Argentinavb Nteamiodaronen0Ylk0}O0L}SbNL0TuOun0zvusJ00s0{kNsk0S|0Y0Rg0i0{kNN2Rg0000ؚ(uϑamiodarone NO(uϑamiodarone00000oR\O(ub6RRg0000amiodarone02000t^02gEhttp://www.ncbi.nlm.nih.gov/pubmed/10639301?report=DocSum&format=htmlGEMINIXGlycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensivesqnecarvedilolh0metoprololn0@|000000Rg0kY000carvedilolo0HbA1co0 YS[0Z0 metoprololo0 Nf0carvedilolo000000aS'` _ϑ00000?\n02U\09eU0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15536109?report=DocSum&format=htmlHGlycemic Effects of Carvedilol vs Metoprolol in Hypertensives with NIDDMF2W|?\u0uOzvW0f0D00ؚ@'W`k0J0D0f0 necarvedilol o0metoprolol000@|$P 00000aS'`0 gak09eU0 GEMINI-AALAdؚ@'W Npu8^n0`k0J0D0f0 pen0qSzVP[0000000Y00single pill (amlodipine/ atorvastatin)n0_['`o0o}Yg0 @'W NO Nn0vjTbk0 gRg0B000GEMT German Eminase Multicentre TrialN@hn㉬anistreplaseAPSAC n0[hQ'`h0 gR'`0bQVheparinh0k0eQb28eNQn0{kNN2RgAPSACheparin*aDhttp://www.ncbi.nlm.nih.gov/pubmed/3046283?report=DocSum&format=html GENERATIONMGlobal Evaluation of New Events and Restenosis After Stent Implantation Studywؚo^C-reactive proteinCRP lipoprotein(a)[LP(a)] }0000000tHCY L0 wgN_k0S|0Y0q_0i0CRP Lp(a)o0`gn0 g[Nan0zvus Nfh0#Y00L0 tHCYo0W0j0D002002t^10gEhttp://www.ncbi.nlm.nih.gov/pubmed/12392824?report=DocSum&format=htmlGENESISA Randomized, Multi-center Study of the Pimecrolimus-Eluting and Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arterieste1gu Yg0n0Qrzb6Rk0J0Q00000000;[pimecrolimus0000000 nQ0000n0paclitaxelnQ0000k0[Y00^R'`o0:y[0j0K0c0_0L0 00000_jk0002dRnQn0[hQ'` [sS'`L0:yU00_00 GENESIS-PRAXYmGender and Sex Determinants of Cardiovascular Disease: from Bench to beyond-Premature Acute Coronary Syndromeo00000ve'`vyr_h0b_12K0gn0Rzvn0ACSQzv ;N g[_0000 hQ{kNh0n0#0c[W0 ]0n0#L}0c"}Y00000000n0sY'`vyr_o0 uirf[vj0sY'`h0o0rzW0f012K0g_n0ACSQzv000n0XRh0#0`http://www.ncbi.nlm.nih.gov/pubmed/26791057,26791058,24638026,25074696?report=DocSum&format=htmlGerman PreSCD II RegistryW_K{h^X_n0][ƙQsNO NOEFf"30% o0\j0O02.5% 40gNQn0ICD i0so0NOD025% 0ICDn0{kNb6RRgL0'YM0D0n0o0zvu_110gn0 i0O0 GESIC7Grupo Espanol para el Seguimiento del Injerto Coronario}O(WY0000n0eg^Xn0N2k0d0D0f0 b@\gNO(uϑaspirinXSrbNn0 gR'`0i0`MO;TTn0^Xb6RRgaspirin000000000^Xb6RRgaspirin dipyridamole0000* aspirin000001990t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/2203555?report=DocSum&format=htmlGESICAJGrupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina[NO(uϑamiodaronen0{kNsk0[Y00Rg0i0{kNN2 {kN~0_0o0_ NhQ`Sk000eQbb6RRgamiodarone[gq)R?\ digitalis ACE;[ *0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7914611?report=DocSum&format=htmlgetABI4German Epidemiological Trial on Ankle Brachi< al Indexv+gh@{u`PAD k0Y00000n0[xvz00000000k0J0Q008^n00000000g0:eU000!quP'`PAD`n0{kN0@{0000n0000o0ؚO0 {kNn0000o0uP'`J00s0!quP'`PADg0 TI{g0 ^PAD`k0ky0 gak0ؚD00Ehttp://www.ncbi.nlm.nih.gov/pubmed/19901192?report=DocSum&format=html=00000000k0J0D0f0ABIo0+ghRu`PAD n0zvk0 g(u0 PADo0uP'``0Q0g0j0O0!quP'`0{kN000L0 Nf0GIFA5Gruppo Italiano di Farmaco-epidemiologia nell'Anziano>ACE;[g0lBv0YW0_04XT w_jL0 gak09eU0Rgo0@'Wh0o0rzW0 bNϑn0YD0O bNgn0wD0Og0'YM0K0c0_00_ NhQ uf[Ehttp://www.ncbi.nlm.nih.gov/pubmed/15618043?report=DocSum&format=htmlGIPSGlucose-Insulin-Potassium StudyTPTCAeLk0uO(uY000000000000000000GIK leQBvlo0 _ NhQ_Pn0j0D0On0{kN0 gak0b6RW0_0L0 %`'`_K{h^XOhQSOn0{kNo0 gak0b6RW0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12957421?report=DocSum&format=htmlFKillipR^Class In0%`'`_K{h^X`k0J0D0f0 GIK0000000000000000 Bvl0uO(uW0_0@{b_bSo0uX[s09eU0GIPS II&Limbs International Medical Buflomedil&QLpAmOk0J0D0f0 0000000000000000leQlBvo0{kN0b6R[0Z00GIPS-IIIGlycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Trial?000000|@|M NmetforminL0][_j0OcY00K00iY0004K0g_n0EFmetforminR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/24687169?report=DocSum&format=htmlfGlycometabolic Intervention in Patients presenting with St-segment elevation Myocardial infarction-III[%`'`ST NfW_K{h^Xk0[W0primary PCI0eLY00^|?\u`k0J0D0f0 000000|@|M Nmetforminn0PCI_bNk00040g_n0][ƙQsn09eUo0000Z00GISSI 1JGruppo Italiano per lo Studio della Streptochinasi nell'Infarto MiocardicoF@hn㉬ؚ(uϑstreptokinaseSK Yln0wgJ00s0wgn0 gR'`0i021eJ00s012K0gNQn0{kNN2RgSK[gq*01987t^10gUhttp://www.ncbi.nlm.nih.gov/pubmed/2868337,2889079,12020485?report=DocSum&format=htmlGISSI 2IGruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardicoq@hn㉬streptokinaseSK h0t-PAn0 gR'`h00000k heparinn0 g(u'`0i0{kN ͑{j0][ NhQn0zvuSKR"t-PA heparinuO(uR"^uO(u0'YQ@b6RRgheparin^uO(uuO(u*01990t^07gDhttp://www.ncbi.nlm.nih.gov/pubmed/1975321?report=DocSum&format=htmlGISSI 3VACE;[lisinoprilJ00s0]xxn0XSr ~0_0o0uO(ubNn0Rg0k0{kN0{kN __j[zvulisinopril uO(ug0 gak0NO N0]xxo0Rgj0W00Vhttp://www.ncbi.nlm.nih.gov/pubmed/7910229,15120826,10636270?report=DocSum&format=htmlGISSI-AF]Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial FibrillationA8^lBvk0ARB valsartan0RbNW0_04XTn0_?b0}Rn0QzvN2Rg0i0Qzvb6RvalsartanR"00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/19369667,19369674?report=DocSum&format=htmlGISSI-HFWGruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Heart FailureqHMG-CoA reductase;[rosuvastatin n-3YO NTxPUFA n0 gR'`0i0hQ{kN hQ{kNJ00s0_@{u`k000eQbb6RrosuvastatinR"0000 PUFA00000`http://www.ncbi.nlm.nih.gov/pubmed/18757089,18757090,25810334,19717850?report=DocSum&format=htmlFZ@'`0^Z@'`n0uP'`ba'`_ NhQ`k0J0D0f0 n-3YO NTxn0e8^vO(uk000 {kN _@{u`k000eQb00Z0K0`0L0b6Rg0M000CZ@'`0^Z@'`n0uP'`ba'`_ NhQ`k0J0Q000000|dRrosuvastatin n0bNo0[hQ`0L0 0^x0n0 gR'`o0000Z00GISSI-PrevenzioneWGruppo Italiano per lo Studio della Sopravvivenza nell' Infarto miocardico|Prevenzioned0000Eh0n-3YO NTxPUFA n0܈EQk000TuOuzvuJ00s0{kNb6RRg0i0PUFAo0{kN ^{k'`_K{h^X ^{k'`3RS-N0 gak0b6RW0_0L0 0000Ek0 gR'`o0000j0K0c0_00ihttp://www.ncbi.nlm.nih.gov/pubmed/10465168,18056527,17720018,16022955,11997274?report=DocSum&format=htmlGISSOCBGruppo Italiano di Studio sullo Stent nelle Occlusioni CoronaricheEPTCAk0*Q00000n0 gR'`L0 wgc}Y00K00i06t^_n0 g[_0000zvub6RRg0000PTCAp0.0555 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12742287?report=DocSum&format=htmlRoush GC, et al.Yvckk000 indapamideo0chlorthalidoneh0 Tik0N,vj0Qeϑg0HCTZ00M'WRgL0ؚD0S0h0L0:yU00 N00000x0n0 g[j0\O(uo0000j0K0c0_00Giustino G, et al.DESYun_n0iDAPTg0kW0_000㉐gg0 S-DAPTDAPTg8.50g o0L-DAPT23.20g k0O00y0Q@000L0NOD00n0n0 0000@hu000L0ؚO0 hQ{kN000o0NOD0PTL0:yU00_00S-DAPTn00000@hu000o0,{NNNDESg0UWg0 ,{NNNDESg0o0n1_W0_00 ㉐gk0(uD0_0fn0UD0L0'YM0O0 P}gn0ȑk0la0Y000GLAGOVdGlobal Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular UltrasoundrPCSK9;[evolocumabn000000'`RlxSun02U\k0[Y00 gR'`0iY000 IVUSg0UOW0_0,{781n000000[MzsPAV n0000000K00n0 YSevolocumabg0NO N 0000g0o0 YSj0W00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27846344?report=DocSum&format=htmlGLANT1Study Group on Long-Term Antihypertensive Therapy\ACE;[delaprilh0Cabbn03_@{u`b6RRgh0 oR\O(uk0d0D0f0ki0M'WRgCabbdelapril*03_@{u`b6RRgCabbR"delapril0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7584934?report=DocSum&format=htmlGlasgow Blood Pressure Clinic ؚ@'W`J00s0lBvn0jn`1X< 02Y00_00k01968t^k0-z0http://www.ncbi.nlm.nih.gov/pubmed/10423081,9533425,9683206,8461810,8450527,2170517,3236316,3606286,3711657,2878954?report=DocSum&format=htmlGlobal SYMPLICITY Registry0K[0W聊^g0Nd^yL}0eLW0_0`k0J0D0f0 hTSgJ00s060g_n0[hQ'`o0o}Yg0 :[[S.~g@'WSBP 24Bf1uLR NSBP0 gak0NO NW0_00GMTGoteborg Metoprolol Trial5nemetoprololn03K0g{kNsNO NRg0i0{kNN2Rgmetoprolol0000*01983t^06gDhttp://www.ncbi.nlm.nih.gov/pubmed/6342837?report=DocSum&format=htmlGOALS!Group Oriented Arterial Leg StudyC k'`ۍLn0 g!q0OU0Z0 (W[g0n0ikLKRBvlk000 ikLݍ SO;mRϑ `ꁫn0UOk000ikLcENRJ00s00000L0 gak09eU0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23821089?report=DocSum&format=htmlGOLDAU-Assessing Ultegrap@h'`TuOu0g\Pk0J0U0H00_00k0ij0@\gGP IIb/IIIaS[SObbk000@\gQƖb6R0000i0@\gQƖ;[k0`g0p00d0M0B000L}Nn0TBfpg0,n[W0_0@\gQƖ;[o0_Ӂ g[Nazvun0N,nVP[0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11382726?report=DocSum&format=htmlGmez-Outes A, et al.[яt^n0_?b0}R`k0J0Q00聊^fg0o0 {kNn0'YJSL0_Ӂ{kg0 3RS-N0Q@k000{kNo0{kVn0T0O0N萒0`S00k0NN0j0D00U00j00{kNsNO Nn0_00k0o0bQVBvlNYn0NeQL0_g0B000GOPCABECGerman Off-Pump Coronary Artery Bypass Grafting in Elderly Patientsc00000h000000n0 gR'`0kY00030e_ 12K0g_n0{kN 3RS-N _K{h^XMI Q@LQ^S eNNfBvln0T000000030e_ 12K0g_D0Z00000000R"000000Ehttp://www.ncbi.nlm.nih.gov/pubmed/23477657?report=DocSum&format=html:German Off-Pump Coronary Artery Bypass in Elderly Patients___jvCABG0R0f0eLY0075skN Nn0ؚbk0J0D0f0 30e_ 120g_n0{kN 3RS-N _K{h^X Q@LQ^S eNNfBvln0T0000000o0 00000h000000g0 Y00Z00GR-II Randomized Clinical Trial[GR-II0000h0Palmaz-SchatzPS 0000n0wgQR q_J00s0聊^0^0k0jvu Y@LQ^Sj0W0n0uX[s 0000@h0Qrzb6RRgPSGR-II*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10993853?report=DocSum&format=htmlGRACE(Global Registry of Acute Coronary Events%`'`QuPk0Y00g'Y!jn0{v2xvz0 ,g1Xo01999t^7^12g vs 2005t^7^12geQb-Nn0`{trln09eUk04OD0 eQb-Nn0{kN F0c0@'`_ NhQ/4lk MIQzv/:[K0024Bf_n0zvu _S'`0000 J00s0b_6K0gn0 g[_0000L0NO N0ihttp://www.ncbi.nlm.nih.gov/pubmed/17473299,18725494,18025530,17846396,17562671?report=DocSum&format=htmlK];Ny^u Yk0[Y00@LQ^So0 ؚ000`k0o0PCI NO000`k0o0CABGL0L00f0D00PT  CABGeLn0b60g_n0uX[so0o}Y0GRACIA-15Grupo de Analisis de la Cardiopatia Isquemica Aguda-1U@hnBvl_n0eg_00000L0 _egn0Z@On00x0n0OrlBvk0ky0f0*Q0f0D00K00i01t^_n0{kN ^{kvQh^X @LQ^Sb6RRgOrlBvOX[vlBv*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15380963?report=DocSum&format=htmlGRAVITASMGauging Responsiveness with a VerifyNow Assay Impact on Thrombosis and Safetyeclopidogrelؚ(uϑbNo0jn(uϑbNk0ky0f0_@{0000b6RRgk0*Q00K00iA</sub> Receptor Blockade TrialujnlBvk0ETAS[SObbdarusentan0RW0_04XTn0 (uϑT0h0n0@LRKaJ00s0^yL}SOmk0S|0Y0q_0i031_n0_Ope9eURgdarusentan0000* k0}{TieQ'WdarusentanR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12438291?report=DocSum&format=htmlHEAT-2-Hypertension: Endothelin Antagonist Treatment HEAT-PPCIeST NfW_K{h^Xk0[Y00primary PCIeL`k0J0Q00MACEb6Ro0 *gR;uheparinL0bivalirudinD0Z000 bailout GPIuO(u 0 gak0 NV00Q@o0!N TI{0HEBE IIIFA single dose of erythropoietin in ST-elevation myocardial infarction 4ST NfW_K{h^XRzv`k0J0D0f0 PCI_n000000000XSV0000Ylk000__j9eUo0j00Z00HELP-VTHeart Centre of Leipzig VT^wgbRso0^Z@'`b5_W_K{uNIDCM `h0Z@'`_K{u`g0 TI{g0B0c0_0L0 wg0^o0NIDCM`n0{0F0L0 No00000000_n0_[;bzvn0[hQm1Yo0o}Yj0wg0^h0#0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24211823?report=DocSum&format=html=Heneghan C, et al. and Self-monitoring trialist collaborationUL}SbQVBvln0]000000k000@h^Xh0000o0 gak0n\W0_0L0 {kNJ00s0'YQ@o0n\[0Z00]000000o0 t^b0OU0Z0i_`k0h0c0f0[hQj0xbg0B000HERCULES`Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis79K0g_n0binaryQrzso010.5%0S.~g@'Wo0 i0v_K00 gak0NO NW0 ]0n0_3t^NO NL0}cW0_0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24909590?report=DocSum&format=htmlVHERMESHighly Effective Reperfusion Evaluation in Multiple Endovascular Stroke Trials e'Y@{^Xk000%`'`Z@'`3RS-N`k0J0D0f0 egn0@{Q@hdSS irlBv o0irlBvn00k0O00y030g_n0[^L0NOK0c0_00 gaj0 gR'`L0000_0n0o0zvuK007.3Bf_~0g0n0eLOg0B0c0_00HERO#Hirulog Early Reperfusion/OcclusionPh^X#Rn0egn0[hQj0QLpTbn0_00n0b00000hirulog 2(uϑn0[hQ'`h0 gR'`0heparinh0k0X[Rghirulogheparin*Vhttp://www.ncbi.nlm.nih.gov/pubmed/9337184,12208225,10801752?report=DocSum&format=htmlHERO-2,Hirulog and Early Reperfusion or Occlusion-2streptokinasek000@hnBvl0SQ00`k0J0D0f0 b00000bivalirudinhirulog n0 gR'`0heparinh0k030eNQn0{kNb6RRgbivalirudinR"heparin Qh^Xb6RRgbivalirudinheparin*0ihttp://www.ncbi.nlm.nih.gov/pubmed/11741625,16908761,16798389,15992631,12648970?report=DocSum&format=htmlHERS.Heart and Estrogen/Progestin Replacement Study30000܈EQBvlHRT n0CHDN!kN2RgJ00s0[hQ'`0i0HRTk0QR0000b6RRgj0W00http://www.ncbi.nlm.nih.gov/pubmed/9683309,9718051,21788534,18391103,15353499,15489091,12513038,12529088,12939228,12081988,11804984,11864918,11829697,11919305,11156873,11527621,11680444,11056097,10770146?report=DocSum&format=htmlHERS IIw0000܈EQBvlHRT k000QR_u`n0N!kN2Rg00j0K0c0_0HERSB}N_n0f0HERSg0gB}t^k0000_0HRTn0CHD0000n0NOzvuso0 fB}N_o0c}[0Z0 HRTo06.8t^_k0_@{00000b6RW0j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/12090862,12090863?report=DocSum&format=html HF-ACTIONMHeart Failure: A Controlled Trial Investigating Outcomes of Exe< rcise Training1KRBvln0 gR'`h0[hQ'`0UO0hQ{kN hQeQbn0T0000000b6RRgKR8^lBv*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/19351941,19351942?report=DocSum&format=htmlTResults of A Randomized Controlled Trial Investigating Outcomes of Exercise Training,ba'`_ NhQ`k0J0Q00KRBvlo0[hQg0 {kN eQb0000NOnN_N,nVP[g0te_ 0HF-ACTION (00㉐g)0!ba'`_ NhQ`k0J0Q00KRBvlk000 eP^#QOLL0 gak09eU0HHPHonolulu Heart ProgramB000k0(WOOY00e|N7u'`k0J0D0f0 QR_u`J00s03RS-Nn02U\0i0e|NL0tXn0 YSg0uui 0'ks|SY00S0h00:yW0_0uf[0http://www.ncbi.nlm.nih.gov/pubmed/11779915,15383515,12681999,11502313,10480768,9508105,8790031,6720665?report=DocSum&format=htmlHHSHelsinki Heart Study`ؚ@u(ugemfibroziln0Rg0i09eURggemfibrozil00000_@{0000gemfibrozilg034%n\0{kNsgemfibrozilR"000001987t^11gMhttp://www.ncbi.nlm.nih.gov/pubmed/3313041,10645920?report=DocSum&format=html High-STEACSy@?o00000o^NO$Po0 ŏk0bL0g0M00_0000000L0^8^k0NOD0`n02/30 T[g0M000 ؚa^_K{00000Ik000_K{h^X _Ӂ{kNO000 T[Oo0ck8^Ok0O00y0f0\j0O0 ؚ000 T[Oo0YD0L0 0001n0_K{h^Xn0yrpu^o0NOD00 N_j[ Z@'`_u`2018t^01gNhttp://www.ncbi.nlm.nih.gov/pubmed/26454362,28978551?report=DocSum&format=html HIJ-CREATE_Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery DiseasenARB candesartann0wgbNo0ARBNYn0M'Wh0 TI{k0@'W000000Y00p0 ;N_@{0000n0b6RRgL000'YM0D0h0D0F0N0iƙQsL0OcU00f0D00_ NhQ`k0J0D0f0 irlBvo0KR[09eUW0_0L0 b5__j {kNk0[Y00 gR'`o0000j0K0c0_00HOMED-BP]Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure;P[@'W0(uD0_0[vj0ؚ@'WlBvk0Y00xvzO(uM'W< o0Cabb ACE;[ 00000000IIbb 0HOOPS2Heart Failure Optimal Outcomes from Pharmacy Study=00000000k0J0D0f0 _ NhQ`x0n0dR+^k000irlBvn0giSo00000000009eUW0_0L0 0000b6Ro0j00Z00HOPE$Heart Outcomes Prevention EvaluationMACE;[ramipriln0 g(u'`h00000En0 g(u'`0i0_K{h^X 3RS-N _@{{kb6RRgramipril0000*00000Ek0 gR'`j0W00http://www.ncbi.nlm.nih.gov/pubmed/10639539,10639540,16831981,11304102,16129815,15769967,15353497,15193680,12628949,12538424,12600907,11909785,11940542,12451002,12204499,11181464,11581138,11597291,11465962,11479247,11466120,10675071?report=DocSum&format=htmlHOPE 2&Heart Outcomes Prevention Evaluation 2AIx00000B6J00s012n0܈f}dR0000000NO NBvl k000_@{{k _K{h^X 3RS-Nn0 gaj0b6RRgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16531613?report=DocSum&format=htmlHOPE-2IHeart Outcomes Prevention Evaluation 2 N_jk000_NQ0㉐gHOPE-2 Renal analysis 4GFRNO NuOk0J0D0f00 0000000$Po0 gak0NO NW0_0L0_@{0000n0b6RRgo0000j0K0c0_00?Heart Outcomes Prevention Evaluation-2 Coronary Atheroma Burden-_@{u`J00s0|?\ue_`k0J0D0f0 0000000NO NBvlo0_@{00000b6R[0Z00HOPE 3&Heart Outcomes Prevention Evaluation-3CVD^zvun0000-NI{^`k0J0D0f0 1) M'WlBv 2) NO NlBv 3) M'Wh0NO Nn0uO(ulBvk0N!kN2Rg0i01) M'Wcandesartan 16mg/e+HCTZ 12.5mg/eMTdRn0;NCV0000n0NO No0000j0K0c0_002) NO Nrosuvastatin 10mg/eo0CV0000000L0 gak0NOK0c0_003) M'Wh0NO Nn0uO(urosuvastatin 10mg/eh0candesartan 16mg/e HCTZ 12.5mg/eMTdRn0uO(uo0000000CV0000000L0 gak0NOK0c0_0Y0y0f0vs 0000 0`http://www.ncbi.nlm.nih.gov/pubmed/27041480,27040132,27039666,27039945?report=DocSum&format=html HORIZONS-AMIUHarmonizing Outcomes with Revascularization and Stents in Acute Myocardial InfarctionXvc00000;[bivalirudinn0 gR'`J00s0[hQ'`0iY00030e_n0͑'Yj0Q@ ͑'Yj0Q@h0;Nj0 g[_0000n0Tb6R:bivalirudin>[gq*0http://www.ncbi.nlm.nih.gov/pubmed/18499566,24603308,24561145,21632496,21636031,21665265,21482968,20650362,20513595,19858413,19796737,19717185,19420364?report=DocSum&format=html1primary PCI On01t^n00000@huo03.3%0zvuBfgk000]0n0N,nVP[o0puj000HOS,Hypertension-Obesity-Sibutramine (HOS) Studybnsibutramine03.z^n0M'WlBvfelodipine ramipril verapamil trandolapril metoprolol hydrochlorothiazide k0uO(uW0_04XTn0 gR'`0kY000nϑRgsibutramine0000*0ACE;[ CabbuO(uM'WlBvo0ne )R?\uO(uk0ky0sibutraminen0nϑRgk000N9eURgk0*Q0f0D000Ehttp://www.ncbi.nlm.nih.gov/pubmed/17404163?report=DocSum&format=htmlHOSP4Hypertension Control Based on Home Systolic Pressureؚ@'W`k0J0D0f0 Oz0K0j0M'Wh0S0000000everolimusnQ0000PtCr-EES n00000000zotarolimusnQ0000CoCr-ZES k0[Y00^R'`0ie'`00000h0laropiprantn0MTdRn0Rk000;N@{0000N2Rg0iY000;N@{000000000R"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/25014686?report=DocSum&format=html|0000g0LDL-CL0o}Yk0000000U00f0D00CVDؚ000CADe_78% `k0J0D0f0 _>e'`00000/ laropiprant* MTdRn0 NWN[0k000HDL-C Nfo0\U0O0 gaj0;N@{0000b6RRgo0000Z0 g[NaL0XR0HPS3/ TIMI 55-REVEALHeart Protection Study3/<  Thrombolysis in Myocardial Infarction 55-Randomized Evaluation of the Effects of Anacetrapib through Lipid ModificationiCETP;[anacetrapib 100mg/en0wgbNk000 gR'`h0[hQ'`0'Y!j0000Skfg0UOY000;NQR0000b6RRganacetrapib0000<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/28847206?report=DocSum&format=htmlHSEHealth Survey for EnglandVg0t^1V[eU00f0D00_@{u` 000VP[k000000W0_0eP^gHealth Survey for Englandn00000(uD0f0 2011t^n0Vlk0J0Q00@'W000000n0[Ka0gW0 1994t^K00n0 YS0㉐g0@'W000000o02011t^~0g0n017t^g09eU0Nhttp://www.ncbi.nlm.nih.gov/pubmed/24881995,24881979?report=DocSum&format=htmlHy-CHydralazine Captopril Trials@{b5_hydralazineh0ACE;[captopriln0N_x0n0Rg0k01t^uX[s9eURgcaptoprilhydralazine*00000000so0captopril40% hydralazine22%01992t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/1545080?report=DocSum&format=html,Hybrid Revascularization Observational Study}000000QR@LQ^SHCR i_n0HCReL`h0YgPCIeL`k0J0D0f0 `n0yr_ 聊^0^ Te-g0n0[l0UOY00\egn00000Skfn00000h0[LS'`0c"}Y00_00n0[xvz012K0g_n0MACCEHCRR"PCINhttp://www.ncbi.nlm.nih.gov/pubmed/27443431,27443432?report=DocSum&format=htmlHYCAR"Hypertrophie Cardiaque et RamiprilPACE;[ramiprilbNn0][_K{͑ϑLVM h0@'Wk0[Y00Rg0i0.~Rgramipril0000* ,gRgo0lBvMRLVMOpeh0 gak0v01995t^01gDhttp://www.ncbi.nlm.nih.gov/pubmed/7843761?report=DocSum&format=htmlHyperGEN)Hypertension Genetic Epidemiology Network<_@{{kNJ00s0TuOuzvun0;Nj0000VP[g0B00ؚ@'Wk0J0Q00N_n0:el lBv N209eUY00_00n0zOP[uf[xvz0ihttp://www.ncbi.nlm.nih.gov/pubmed/11988194,12118910,11775131,11136693,10964005?report=DocSum&format=htmlHYVET&Hypertension in the Very Elderly TrialG)R?\indapamide_>edRk000M'WlBvo03RS-N {kN0b6RW0 ACE;[perindoprilh0n0uO(un0 g!qk0K0K000Z0 g(ug0B000rhttp://www.ncbi.nlm.nih.gov/pubmed/18378519,11302283,20573778,22218098,18614402,14654762?report=DocSum&format=htmlW80skN Nn0ؚbؚ@'W`k0J0D0f0 )R?\indapamide0000h0Y00_k000ACE;[perindpril0R lBvk000 3RS-NL000000030%NO N0$HPS (MRC/BHF Heart Protection Study)IMedical Research Council, British Heart Foundation Heart Protection StudynNO NBvlJ00s0bxS0000n0܈EQL0 {kNsJ00s0;Nj0TuOun0zvuk0S|0Y0Rg0i0simvastatin0sLlBvk0RW0_04XT {v2Bfn0$Pk0K0K000j0O0 gRg0B0c0_0L0 bxS0000n0 gR'`o0000Z00{http://www.ncbi.nlm.nih.gov/pubmed/12114036,12114037,22115874,21277016,17239712,15910950,12814710?report=DocSum&format=html I-PRESERVE<Irbesartan in Heart Failure with Preserved Ejection Fraction.ƙQsn0OcU00_0b5_'`_ NhQ`k0J0D0f0 ARB irbesartano0N_09eUW0j0D00rhttp://www.ncbi.nlm.nih.gov/pubmed/19001508,28426886,28052977,25406306,25212644,20231531?report=DocSum&format=html5S.~_jL0OcU00_0b5_'`_ NhQ`k0J0D0f0 ARB irbesartank000N_9eURgo0000Z00i-SEARCHoVT0h0n0_ϑ00000?\MAU n0y`s0UOW0 U00k0MAUh0_@{u`qSzVP[h0n0#'`0iY00NLu!jn0[xvz0NLuT0Wg0Yegؚ@'W`k0J0Q00MAUy`so0^8^k0ؚO0 yrk0_@{u`0000 gY00`g0UW0Nhttp://www.ncbi.nlm.nih.gov/pubmed/19383737,17921828?report=DocSum&format=html IABP-SHOCK II0Intraaortic Balloon Pump in Cardiogenic Shock IIGiQylBvx0n0'YRQ0000000000000000IABP n0Rk000{kNb6RRg0i*</sup>0ihttp://www.ncbi.nlm.nih.gov/pubmed/20189239,20304225,25453443,25677309,21998053?report=DocSum&format=htmlICTUSKInvasive versus Conservative Treatment in Unstable Coronary Syndromes Trial61t^n0{kN _K{h^XQzv r_uk000QeQbb6RRgiirBvl Ng0n0egOrvlBvR"xbvOrvlBv0Whttp://www.ncbi.nlm.nih.gov/pubmed/16162880,28408018,17350451?report=DocSum&format=html4International Citicoline Trial on Acute Stroke Trial>3_tN9eU00000citicoline n0V_x0n0Rg0i090e_n0V_citicolineR"00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/22691567,22691568?report=DocSum&format=htmlRInvasive versus Conservative Treatment in Unstable Coronary Syndromes Trial 3t^_n0P}g=_K{00000T$P Nf0 gY00^ST N< fW%`'`QuP`k0J0D0f0 egOrvlBvo0wgN_g00xbvOrvlBv0QR0Z00DInvasive versus Conservative Treatment in Unstable Coronary Syndrome&ؚ000n0 N[[r_u`k0J0D0f0 egn0OrlBvo0xbvOrlBv0QR0Z00IDEA9International Day for the Evaluation of Abdominal Obesity*000Nk0J0D0f0 yVo0BMIh0o0rzW0f0sY'`g0_@{u` 7usYg0|?\uh07_O0v0IDEALDIncremental Decrease in End Points Through Aggressive Lipid LoweringHMG-CoA reductase;[atorvastatink0007_Rj0LDL-CNO NBvlL0 simvastatink000-NI{^n0NO NBvlk0ky0U00j00 gR'`00_00Y0K00i0;Nj0QR0000QR{k ^{kv%`'`_K{h^Xk000eQb _\PbkK00n0u b6RRgatorvastatinsimvastatin0`http://www.ncbi.nlm.nih.gov/pubmed/16287954,20082922,18519851,18261682?report=DocSum&format=htmlDIncremental Decrease in End Points through Aggressive Lipid Lowering'_K{h^Xe_Ok0J0D0f07_Rj0LDL-CNO NBvlo0hQQR00000U00k0b6R0IDNT%Irbesartan Diabetic Nephropathy Trialg00000000IIS[SObbirbesartan~0_0o0CabbamlodipineL0 M'WRgh0o0rzW0f0Nun02U\0b6RY00K00i0irbesartano0M'WRgh0o0rzW0f0Nun02U\0N2Y000ؚ@'W pu8^u N_j[Whttp://www.ncbi.nlm.nih.gov/pubmed/11565517,16120823,12667024?report=DocSum&format=htmliFR-SWEDEHEARTInstantaneous Wave-Free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndromec;N g[_0000zvusg0 iFRwBf@AmNPϑk 000@LQ^So0FFR000k0[W0^R'`h0D0F0N0i<012K0g_n0;N g[_0000k0J0D0f0 iFRn0FFRk0[Y00^R'`L0:yU00_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/28317438,28972006?report=DocSum&format=html ILLUMENATE}!kNNNO(uϑdR0000000000n0PTAk0[Y00[hQ'`30e_n00000eKbb#{kn0V 12K0g_n0jv'YReJ00s0聊^t1uk000jvu YQ@LQ^Sn0Vk0T n0^R'` *Q'` gR'`12K0g_n0N!kX[s g0n0*Q'`L0:yU00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/28424223?report=DocSum&format=html ILLUMINATEZInvestigation of Lipid Level Management to Understand its Impact in Atherosclerotic EventsHDL-C0 NfU0[0000000000000ˆ}vCETP ;[torcetrapibn0_@{u`b6RRg000_00k0 HMG-CoA reductase;[atorvastatinXSrbNk0[W0f0atorvastatinh0torcetrapibuO(uk000iW0_0L0 torcetrapib atorvastating0n0{kN _0000n0000 Nf0SQ0N[00eO0B}N0Nhttp://www.ncbi.nlm.nih.gov/pubmed/17984165,21804130?report=DocSum&format=htmlZInvestigation of Lipid Level management to Understand its Impact IN Atherosclerotic Eventstorcetrapib atorvastatinuO(uHDL-C 72.1%! LDL-C 24.9%! S.~g@'W5.4mmHg! 0000L0 gak0! @n00000 ͑px 0000000L0 gak0! {kNn00000k1.58P=0.006 ;N_@{u`o01.25P=0.001 0 ILLUSTRATEInvestigators and Committees of the Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atheroscleosis by CETP Inhibition and HDL ElevationHMG-CoA reductase;[atorvastatink0[W0 HDL-C0 NfU0[0000000000000ˆ}vCETP ;[torcetrapibuO(uk000HDL-C NfRg 00000[Mzx0n0Rg0iHDL-C NfuO(uatorvastatinXSr* 00000[MzuO(uR"XSr0Nhttp://www.ncbi.nlm.nih.gov/pubmed/17387129,19029466?report=DocSum&format=htmlInvestigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL ElevationBQRu``k0J0D0f0 atorvastatin torcetrapibk000o0UWk09eUW0_0L0 bRlxSo0000j0K0c0_00IMAGES(Intravenous Magnesium Efficacy in Stroke/000000Yln0 gR'`0i090e_n0{kN Nw0Y00[000000R"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/14962524?report=DocSum&format=htmlIMAGINE[Ischemia Management with Accupril Post-bypass Graft via Inhibition of the Converting EnzymeYKbbK007eNQn0ACE;[quinaprilbNk000_@{0000b6RRg0i0S_egbNk0003t^n00^n09eUo0000Z0 yrk0Kbb_3K0gn0 g[0000L0XR0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18071079?report=DocSum&format=htmlcIschemia Management with Accupril post Bypass Graft via Inhibition of Angiotensin Converting Enzyme1CABGeLOk0J0D0f0 ACE;[;[quinapriln0hTSgbNk000 gR'`o0000Z00 IMMEDIATEdImmediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care_Qe%`;SBv0000wT0000000 k00000000-00000-0000GIK bYYlk000 gR'`0iY00024BfNQn0ACSK00_K{h^Xx0n02U\b6RRgGIKR"00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/22452807,22570466?report=DocSum&format=html&Qe%`0R@wMRn00000000k000GIKBvln0_K{h^Xb6RRgo0000Z00tImmediate Reduction in Acute Myocardial Infarctions after the Implementation of a Comprehensive Smoke-free OrdinancelQqQn04Xg0n0yYqagOk000_Ӂzv\Ok000eQbL0 gak0NO N0IMPACTBInternational Mexiletine and Placebo Antiarrhythmic Coronary Trialwb Ntemexiletine_>edRn0b NteRg0i0_[gYS.~n0zvuJ00s0#zvb6RRg1K0gh04K0gvo0mexiletine0000* 12K0gvo0mexiletine00000{kNN2Rgmexiletine000001984t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/6209318?report=DocSum&format=html IMPACT-HFaInitiation Management<  Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure>bMRn0carvedilolbNYo0oR\O(un0XR0eQbgn0^w00_00Y0S0h0o0j0O0 60e_n0neO(us09eUW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15120808?report=DocSum&format=html IMPACT-IIFIntegrilin to Minimise Platelet Aggregation and Coronary Thrombosis-IIl@\gGP IIb/IIIaS[SObbeptifibatideL0Z@'`TuOu0b6RY00K0i030eNQn0{kN _K{h^X }%`YyKbS PTCAn0QeL 0000 i0b6RRgeptifibatide00000Thttp://www.ncbi.nlm.nih.gov/pubmed/9164315,9935014,9626829?report=DocSum&format=htmlIMPRESSvasopeptidase;[omapatrilatL0ACE;[lisinopril000 KR[J00s0聊^v0^g0*Q0f0D00K00i0KR[omapatrilatR"lisinopril00^9eURgomapatrilatlisinopril*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10968433?report=DocSum&format=htmlcImmunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent ImplantationFL}Sprednisonek000bpuMQub6RBvlo00000{kN _K{h^X Q@LQ^SL0_j0urn0Qzv J00s0Qrzs0Wfk0NO NY000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12475452?report=DocSum&format=htmlbIntramural Infusion of Low Molecular Weight Heparin to Prevent Restenosis after Stent ImplantationjNORP[ϑheparin nadroparinn0XQbNL00000Qrz0b6RY00K00i0nadroparin@{XQbNo0Sg0[hQg0B00L0 6K0gn0QrzJ00s0 g[0000zvun0b6RRgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11052841?report=DocSum&format=html IMPROVE-CHF=Improved Management of Patients with Congestive Heart Failure3N+gz00BW00000)R?\0000NT-proBNP igo0:e09eU 0000JRnW0 g(ug0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/17548729?report=DocSum&format=htmlFQe%`Qe}T[g0n0|T8TV ^NQ'`%`'`_ NhQL0u000`k0J0Q00N+gz00BW00000)R?\0000NT-proBNP igo0 g(ug0B000 IMPROVE-ITDImproved Reduction of Outcomes: Vytorin Efficacy International Trialzezetimiben0simvastatinx0n0Rk000_@{0000b6RRgh0[hQ'`0iY000_@{{k ;NQ0000 ^{kv3RS-Nb6RRgsimvastatin ezetimibesimvastatin<sup>*</sup>0http://www.ncbi.nlm.nih.gov/pubmed/26039521,26039520,29263150,28972004,28231942,27569841,26821621,26330412?report=DocSum&format=htmlDIMProved Reduction of Outcomes: Vytorin Efficacy International TrialvACSzvu_5eg0LDL-C 95mg/dLn0`k0J0D0f0 simvastatin ezetimiben06t^_n0CVD o0simvastatin000 gak0\j0K0c0_01t^_n0LDL-C  53.2 vs 69.9mg/dL 0 IMS III'Interventional Management of Stroke IIIY@hn㉬n0D}T~0000000000000t-PA Yl @{QlBvn0 gR'`0jnvj0t-PAYlh0kY00090e_n0_jvzt-PAYl @{QlBvR"t-PAYl0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23390923,23394477?report=DocSum&format=htmlIN-TIMETS.~_j[0 gY00ba'`_ NhQ`k0J0D0f0 00000000_jNM0ICD/CRT-Do0jn00k0O00y01t^_n0{kNsL0NOO0 _ NhQ`SOL0\j0K0c0_0,{IVvf 0 IN.PACT-DEEPhRandomized Amphirion DEEP DEB vs Standard PTA for the Treatment of below the Knee Critical Limb IschemiapaclitaxelnQIN.PACT Amphirion0000IA-DEB k000zR NR@LQ^n0 gR'`h0[hQ'`0 L}vv@{b_bSPTA h0k0IA-DEBn012K0g_n0 gR'`jvu YQ@LQ^S;CD-TLR= `g d1Y_ o0PTAh0 TI{g0B00 6K0g_n0[hQ'`hQ{kN 'YRe CT-TLR k0J0D0f0IA-DEBn0^R'`L0:yU00_0L0 12K0g_n0'YReL0XRPT0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25301459?report=DocSum&format=html IN.PACT SFAIN.PACT Admiral Drug Eluting Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease I (INPACT SFA I) & IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of SFA and Proximal Popliteal Artery (INPACT SFA II)pdR0000000000DCB n0[hQ'`h0 gR'`0 L}vv@{b_bSPTA h0kY00'k]g0n0INPACT.SFA Ih0s|Vg0n0IN.PACT SFA IIn02kK00b0012K0g_n0N!kX[RgDCBPTA0uf[ ]0n0NNhttp://www.ncbi.nlm.nih.gov/pubmed/25472980,26476467?report=DocSum&format=html/Incidence of Infective Endocarditis in England Vk0J0D0f0 2008t^n0NICE000000g0okyj0i0n0OrvQng0n0ag'`_QpN2n0_00n0b̃bNL0chYK00dYU00_0S0h0k000 ]0n0_5t^n0amoxicillin 3g/clindamycin 600mgn0N2vQeo0'YM0O0n\0Sb ag'`_Qpo0 gak0XRW0_00 INCLUSIVEQlBvL0Vj0ؚ@'W`k0J0D0f0 AIIS[SObbirbesartan/)R?\hydrochlorothiaziden0TdRV[(uϑ o0@'W0o}Yk00000000FInduction of Mild Hypothermia Following Out-of-Hospital Cardiac Arrest[bY_\PbkK00n0]_bQOk0J0D0f0 ub0R@wMRn04!utߘiX4l2LleQo0 mSO)n0 NR0 8^00k0O00y0f034!0RTL0eK0c0_0L0 uX[h0bBfn0_jvrKao09eUW0j0K0c0_00 INFINITYInvestigation of Relationship Between Cholesteryl Ester Transfer Protein Deficiency and Carotid/Coronary Atherosclerosis in Patients with Hyperalphalipoproteinemia%ؚ000000ˆ}v@u`k0J0Q00CETP k dh000000'`RlxSn0Ouf[ pu8^u INFUSE-AMIYbQVBvl0Lc0_0%`'`MRXST NfW_K{h^Xk0J0D0f0 primary PCIMRn0L}00000vabciximabQRQ0000leQo0h^X0000.~\W0_0L0 @h8T_o0.~\[0Z00INHERITINHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy - a Randomized Inte< rvention Trial with losartanj'YW_K{u`losartan51sk 000052sk 'YJSL0NYHA I-II^ k0J0D0f0 ARB losartank0001t^_n0][͑ϑn\Rgo0000Z00000h0n0]o01g/m&#178; 0 INHIBIT6Intimal Hyperplasia Inhibition with Beta Instent TrialTQRQ}lBvn0 gR'`0i00000000000g0automatic afterloaderk000-emitter32Pяcgq\Bvlo0 @LQ^Sn0eL0n0Y00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11867107?report=DocSum&format=html INNOVATE PCIA Phase II Safety and Efficacy Study of PRT060128 (Elinogrel), a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI.W__jvPCIeL`k0J0D0f0 eb@\gelinogrelo0clopidogrelk0ky0f07_Rj0@\g;[\O(u0:yW0_0Ne Q@000k0o0 ga]00Z0,{IIvf 0 INNOVATIONnIncipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 diabetic NephropathyEARB telmisartano0U'`Nux0n02U\0000000 gak0b6RW0_00,g gR'`o0(uϑOX[g0M'WRgk0o0OX[W0j0D0S0h0L0:yUU00_00Whttp://www.ncbi.nlm.nih.gov/pubmed/17389334,16372586,18633177?report=DocSum&format=html INNOVATION0H_ϑ00000?\04OF0ؚ@'WJ00s0ck8^@'Wn02W|?\u`k0J0D0f0 AIIS[SObbARB telmisartann0NOwRgL000000 INOVATE-HF'Increase of Vagal Tone in Heart Failure~;egB}Nf=p^yL}:RoVNS n0 gR'`hQ{kN RVn0_ NhQ`Sk0wVY000000n0T0000000 [hQ'`0000 i0_90en0Kbbe0000#TuOuVs75% 1t^NQn0{kNB00D0o0Rzvn0hQTuOu VNSR"QyvlBv0Nhttp://www.ncbi.nlm.nih.gov/pubmed/27058909,27386768?report=DocSum&format=htmlINSIGHTUInternational Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment\_@{u`TuOuzvuJ00s0{kNb6RRg0 Cabbnifedipine GITSh0MT)R?\h0g0k0_@{{k0_K{h^X0_ NhQB00D0o03RS-Nb6RRgnifedipineR")R?\0Nhttp://www.ncbi.nlm.nih.gov/pubmed/10972368,11413085?report=DocSum&format=htmlINSPIRE.Adenosine Sestamibi Post-Infarction Evaluationh_V Tg00000wTc-99m sestamibi_K{@AmXSIQP[>e\W0000000ed\dq_lADSPECT n0eg[ek000 1t^_n0{kNJ00s0Qh^XzvusL02%*gnn0NO0000ckxk0 T[g0M000Nhttp://www.ncbi.nlm.nih.gov/pubmed/17174181,17174182?report=DocSum&format=htmlF%`'`_K{h^X_egOk0J0D0f0 00000J00s0Tc-99m sestamibiMIBI 0(uD0_0_K{@Am000000o00000ckxk0UO0INSURE-Incidence Free Survival after ICD ReplacementNcMRk0iRj0ICDlBvL0L00_0`h0N^0L00j0K0c0_0`h0g0ICDNc_n0ICD\ORs0kW0 U00k0NO\ORs0N,nY00VP[0c"}Y000ICDn0[}TL0R00~0g0k0iRj0ICDlBvL0L00j0K0c0_0`n0YO0L0 Nc_k0iRj0ICDlBv0SQ0f0D0_00ICDn0NO\ORs0N,nY00VP[o0yr[U00Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/22771679?report=DocSum&format=htmlInSync ICD Clinical TrialINTACT=International Nifedipine Trial on Antiatherosclerotic TherapyiCabbnifedipinek0QRu`n02U\J00s0eW0D0u Yn0N2RgL0B00K0i0u Y2U\b6R0.~RgnifedipineR"000001`S__00n0eu Yb6RRgnifedipine0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1971861?report=DocSum&format=html INTEGRITI:Integrilin and Tenecteplase in Acute Myocardial Infarction@\gGP IIb/IIIaS[SObbeptifibatide NO(uϑ@hn㉬tenecteplaseTNK n0Rg0i0eptifibatide0000000bN JSϑTNKo0 TNKXSrbNh0ky0f0QR q_ Nn0LpAm09eUW0ST YS0m1YU0[0_0L0 8@h0^3'`Q@04Oc0_00`http://www.ncbi.nlm.nih.gov/pubmed/12706917,15824203,15262838,14975462?report=DocSum&format=html INTER-HEART/_K{h^Xn0'YJSL0聊^s4Xg0!|XSk0,ng0M00000VP[k000N,ng0M0 ]000n0VP[o0 YfW0F000INTERACTTIntegrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment@\gGPIIb/IIIaS[SObbeptifibatideh0NORP[ϑheparing0B00enoxaparinn0uO(uBvln0 gR'`h0[hQ'`0i096Bf_n0CABGk0wVW0j0D0͑'Yj0Q@b6RRgenoxaparin eptifibatide^R;uheparin eptifibatide*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12538422?report=DocSum&format=html INTERACT2LSecond Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage TrialRMzuivj0M'Wn0[hQ'` gR'`0 sL000000L0chYW0f0D00vjSBPL000ؚD0jnlBvh0kY00090e_n0{kN ͑'Yj0[b6RRgMzuivM'WjnM'W0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23713578,23713579?report=DocSum&format=html InterASIA;International Collaborative Study of Cardiovascular in ASIA6-NVk0J0Q00_@{u`n0qSzVP[0iY00[xvz0000000000000MS J00s0NSO͑y`n01XJT0Nhttp://www.ncbi.nlm.nih.gov/pubmed/16043645,15836888?report=DocSum&format=html INTERCEPTqIncomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (Diltiazem)vCabbdiltiazemL0_K{h^X_gRk0@hn㉬lBv0SQ0_0uOk0J0D0f0 _00000NO NU0[00K0i0_{kN0^{kvh^X0lBvbb'`Z@b6RdiltiazemR"00000@LQ^Sb6RRgdiltiazem0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10832825?report=DocSum&format=html INTERHEART`NLu-Nk0J0Q00QRu`n0000VP[n0͑'`0UOY00_00n0'Y!jjnSuO[gqxvz0i0j0000VP[h0%`'`_K{h^Xh0n0#^n0zl[NQ0 ]0n0#^L00WW le '` t^bk000puj00K00i02011t^02ghttp://www.ncbi.nlm.nih.gov/pubmed/21272754,20488312,19147041,18936332,18640459,18334475,17339564,17227980,16920470,16330696,15364185,15364186?report=DocSum&format=html INTERSTROKE(1)NO^-N< @b_V0+T0_0NLu22K0Vk0J0D0f0 SxQv0eqSzVP[h03RS-NuW%Rh0n0O qSzVP[n03RS-Nx0n0[Ns0UOY00uO[gqxvz010n0qSzVP[L03RS-Nn090%k0#W0 M'WlBv yYq SO;mRn0O2 eP^vj0ߘu;mk0003RS-N0b6RW0F000 (2) 32K0Vk0b'YW0f00 0WW N.z '`%R t^b0OU0Z0 OckSj010n0qSzVP[o0hQ3RS-Nn0ƖV[NqSz^n0}90%0`S0f0D0_00_0`0W0 TVP[n0v[v͑'`k0o00WW]L0B00 S0n0]L03RS-Nzvush0case-mixn0NLuvj0p00d0M0n0NVg0B00S'`L0:yU00_00Whttp://www.ncbi.nlm.nih.gov/pubmed/20561675,20561674,27431356?report=DocSum&format=htmlInTIME<Intravenous nPA for Treatment of Infarcting Myocardium Early@hn㉬lanoteplaseSO͑teXSV0000bNn0(uϑS_Oh0[hQ'`0i0(uϑOX[vk060R_ 90R_n0X['`09eU090R_n0[hQQLpAmslanoteplase 120kU/kgalteplase0[hQ'`lanoteplaseR"alteplase01998t^11gDhttp://www.ncbi.nlm.nih.gov/pubmed/9815865?report=DocSum&format=html InTIME-II?Intravenous nPA for Treatment of Infarcting Myocardium Early II\@hn㉬lanoteplasen0XSV0000bNn0 gR'`h0[hQ'`0alteplaseh0k0SO͑telanoteplasen0XSV0000bNn0uX[Rgo0alteplasek09SueY000rhttp://www.ncbi.nlm.nih.gov/pubmed/11102251,14607434,12849652,11686667,11705559,11716882?report=DocSum&format=html INTRINSIC RV;Inhibition of Unnecessary RV Pacing with AVSH in ICDs StudyG_bpe_T{Wn0?b[O\000_jNM0NT00000n0hQ{kN _ NhQk000eQbb6RRgb6RRgk0J0D0f0 XST00000h0ky0^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17179021?report=DocSum&format=html INTRO AMIGIntegrin and Low-Dose Thrombolysis in Acute Myocardial Infarction Trial60R_n0h^X@{n0X[Rg0@\gGP IIb/IIIabbeptifibatideh0@hn㉬NO(uϑt-PAh0g0i0t-PAk0ky0 eptifibatiden0double0000bN t-PA 1/2(uϑ48BfYlo0 TIMI gradeh0000009eU [hQ'`o0Nn0lBvlh0 Ti0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11823073?report=DocSum&format=htmlINVEST*International Verapamil-Trandolapril StudyWCabb0000h0Y00lBvCAS h0^CabbNCASne 0000h0Y00lBvn0hQ{kN ^{kv_K{h^X ^{kv3RS-Nb6RRg0k0CASR"NCAS0`http://www.ncbi.nlm.nih.gov/pubmed/14657064,25145522,20606150,16458134?report=DocSum&format=html-International Verapamil SR-Trandolapril Study+M'WlBvk000b5_gNO@'Wg0_K{h^XL0XRY00J000sao0 QRLpAmn0[k0000PQRu`0 gY00ؚ@'W`k0J0D0f0 {kN ^{kv_K{h^XB00D0o03RS-Nn0b6RRgo0Cabbverapamil h0neatenolol g0 TI{0IONAImpact of Nicorandil in AnginaPbr_unicorandilL0Q00000b6RY00K00i0QR_u`{k ^{k'`_K{h^X uk000}%`eQbn0b6RRgnicorandil0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11965271?report=DocSum&format=htmlCR\O'`r_u`k0J0D0f0 K0000Snicorandilo0QR_u` ^{k'`_K{h^X uk000z6qn0eQb0 gak0b6RW0_00IPPPSHBInternational Prospective Primary Prevention Study in Hypertensionneoxprenololn03_@{TuOuk0[Y00Rg @'W000000 _['`0i0z6q{kN2RgoxprenololR"00000M'WRgoxprenolol0000*0_Vck8^SBfw.~Rg NO0000@ub6RRg _['`o}Y^oxprenolol000001985t^08gDhttp://www.ncbi.nlm.nih.gov/pubmed/2864374?report=DocSum&format=htmlIPSYS)Italian Project on Stroke in Young AdultsH0000n00000xvzwgn0@h^Xh0000Qzv000o0 OckSj0 t^byrpuvj0qSzVP[h0#0Qzv0000c[Y00IPSYS0000\Ob0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24508827?report=DocSum&format=htmlIRAD1International Registry of Acute Aortic Dissectionj2013t^~0g0n017t^g0;Nurk0Wfj0 YSo0000j0K0c0_00AWg0o0CTn0O(uh0KbSL0XRW0 KbS{kNsJ00s0bQ{kNsL0NO NW0_0Neg0 BWg0o0@{QlBvL0XRW0_0L0bQ{kNsk0o0 YSL0j0K0c0_00`http://www.ncbi.nlm.nih.gov/pubmed/26205591,26205592,29598863,27587434?report=DocSum&format=htmlIRIS/Immediate Risk Stratification Improves Survival?d0}RhV i0ICD L0iirlBvn00n04XTk0ky0uX[s09eUY00K00iY000hQ{kNb6RRgICDR"iirlBv0Nhttp://www.ncbi.nlm.nih.gov/pubmed/19812399,19812407?report=DocSum&format=html,Insulin Resistance Intervention after Stroke|00000bb'`9eUg0B00000000pioglitazoneL03RS-NQzv _K{h^XMI 0N2Y00h0D0F0N0i<0Rzvn0{kve^{kv3RS-N~0_0o0{kve^{kvMIb6Rpioglitazone0000<sup>*</sup>0Whttp://www.ncbi.nlm.nih.gov/pubmed/26886418,26886417,28246237?report=DocSum&format=htmlIRIS-FFR RegistryZInterventional Cardiology Research In-cooperation Society Fractional Flow Reserve Registry,{NNNDESBfNk0J0Q00FFRn0$P0i<0FFRo0deferredu Yk0J0Q00MACEn0000h0v}vk0#0NO$Pf"0.75 n04XTo0 @LQ^SeLu Yn0{0F0L0deferredu Y000^L0o}Yg0B00Ne ؚ$Pg"0.76 n04XTo0 irlBvL0YS_K0d0[hQj0lBv&beug0B0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/28356440?report=DocSum&format=html Irish StudykCabbnifedipinen0egbNn0Rg0UO0%`'`_K{h^XzvuJ00s02U\b6RRgnifedipineR"00000CK-MB;m'` Nfnifedipine00000{kNsnifedipine000001986t^10gDhttp://www.ncbi.nlm.nih.gov/pubmed/3792347?report=DocSum&format=htmlIRMA-2FIrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study:00000000IIS[SObbirbesartann0NOwRg0i0M'WRgh0o0rzW0f0NOwRgL0000_00`http://www.ncbi.nlm.nih.gov/pubmed/11565519,21788629,17130503,14633817?report=DocSum&format=htmlIRMA 2IIrbesartan Microalbumin type 2 Diabete< s Mellitus in Hypertensive PatientsIRS IIInvasive Reperfusion Study IIc@hn㉬anistreplaseAPSAC h0streptokinaseSK egbNn0Rg0ki0X[RgAPSACSK*0egn0Q^XJ00s0Q@'`TuOub6RRgAPSACSK01991t^02gDhttp://www.ncbi.nlm.nih.gov/pubmed/2044551?report=DocSum&format=htmlISAM8Intravenous Streptokinase in Acute Myocardial Infarction[@hn㉬streptokinaseSK Yln0wgJ00s0wgn0Rg0i0{kNsSKR"00000h^X0009eURgSK0000*07K0g_n0Qh^Xb6Rs0000SK*01987t^01gLhttp://www.ncbi.nlm.nih.gov/pubmed/2871492,3540072?report=DocSum&format=htmlISAR2hntracoronary Stenting and Antithrombotic Regimenk i0K0030e_n00^0b@\gBvlticlopidine aspirin h0bQVBvlphenprocoumon h0g0kY000_0000 Q@'`J00s0@{|TuOun0zvub6RRgb@\gBvlbQVBvl0]http://www.ncbi.nlm.nih.gov/pubmed/8598866,11179521,9133509,9244213?report=DocSum&format=htmlISAR-3/Intracoronary-Stenting-and-Antibiotic-Regimen 30000_n0Qrzk0[Y00000000|buirg0B00roxithromycinn0 gR'`0i0roxithromycinn0^xbvO(uo0Qrzn0N2k0o0 NASRj0L00 pW00000bSOOk00c0f0o0puj0c0_0RgL0_000CWpbSOOn0ؚD0Ok0J0D0f0roxithromycino0Qrzs0NO N 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11445102?report=DocSum&format=html ISAR-CABG[Is Drug-eluting-stenting Associated with Improved Results in Coronary Artery Bypass Grafts?JdRnQ'`0000DES n000000000BMS k0[Y00*Q'`f01t^_n0{kN _K{h^X jvu YQ@LQ^Sb6RRgDESBMS*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21872918?report=DocSum&format=htmlgRandomized, Superiority Trial of Drug-Eluting-Stent and Bare Metal Stent in Safenous Vein Graft LesionsWeO(WY0000u Yk0J0D0f0 1t^_n0;N g[_0000b6RRgo0dRnQ'`0000DES L0000000000000*Q00DESg0o0Q@LQ^SL0J00]050%NO N0 ISAR-CHOICEtIntracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effectab@\gclopidogreln0puj00bNYϑn0b@\gQƖRg0i300mgk0ky0600mgg0bN0YW0_04XTn0@\gQƖn0b6RRgo0 gag0B0c0_0L0 900mgo0600mgh0 Ti0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16260639?report=DocSum&format=html ISAR-COOL>Intracoronary Stenting with Antithrombotic Regimen Cooling-Offl00000000000000MRk0LF03^5en0b@hBvln0 gR'`0eg000000000h0k030en0^{kv large _K{h^X hQ{kNb6RRgeg000000000prolongedb@hBvl*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/14506118?report=DocSum&format=htmlAssesment of the Value of the Cooling off Strategy (Extended Antithrombotic Pretreatment) in Patients with Unstable Coronary Syndromes Treated Invasively. The Intracoronary Stenting with Antithrombotic Regimen ISAR-DESIRE\Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosism2.z^n0dRsirolimusJ00s0paclitaxel nQ0000h00000h00k0Qrzb6RRgsirolimus0000*p0.001 paclitaxel0000*p0.001 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15644543?report=DocSum&format=html ISAR-DESIRE 2^Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis 2V TX0dRnQ'`0000DES 0 i0&beuhomo-DES h0puj00DES0 i0&beuhetero-DES n0 gR'`0k00000Qifg d1Y_SESR"PES0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20226618?report=DocSum&format=html ISAR-DESIRE 3oIntracoronary Stenting and Angiographic Results: Drug Eluting Stent In-Stent Restenosis: 3 Treatment ApproachespaclitaxelnQ0000PEB n0paclitaxelnQ0000PES k0[Y00^R'` PEBh0PESn00000@{b_bSk0[Y00*Q'`0i*</sup>0`http://www.ncbi.nlm.nih.gov/pubmed/16139655,12414200,25465111,19329361?report=DocSum&format=htmlISCHEMIA\International Study of Comparative Health Effectiveness with Medical and Invasive Approaches&ؚ000n0[[Z@'`_u``k0J0Q00gon0lBvle,gSRn0NLuqQ Txvz ISIS-1-First International Study of Infarct SurvivalYneatenololegbNn0Rg0i0@{{kN2RJ00s07__O(ub6RRgatenolol[gq*0^{k'`_\PbkJ00s0Qh^Xb6RRgatenolol[gq01986t^07gDhttp://www.ncbi.nlm.nih.gov/pubmed/2873379?report=DocSum&format=htmlISIS-2.Second International Study of Infarct Survival_@hn㉬streptokinaseSK h0b@\gaspirinn0XSrBvl ~0_0o0S0n02dRn0uO(uBvl0k0@{'`{kNN2RgSK aspirin0000* uO(uBvlo0U00k0 gR0Dhttp://www.ncbi.nlm.nih.gov/pubmed/2899772?report=DocSum&format=htmlISIS-3-Third International Study of Infarct SurvivalstreptokinaseSK t-PA anistreplaseAPSAC n0Rg0k U00k0heparin aspirinn0uO(uRg0aspirinXSrh0k03NYg0n0Q@NEeb6RSKAPSAC* SKrt-PA* aspirinaspirin heparin0Qh^X {kNsSKR"APSAC03RS-Nb6RSKt-PA*0aspirinR"aspirin heparin0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1347801?report=DocSum&format=htmlISIS-4.Fourth International Study of Infarct Survival}L}S]xxn0_>e'`isosorbide mononitrate ACE;[L}Scaptopril ~0_0o0Ylmagnesium0sLn0jnlBvk0RW0 51_n0Rg0k0{kNN2Rgcaptopril0000 magnesiumk0Rgj0W00Dhttp://www.ncbi.nlm.nih.gov/pubmed/7661937?report=DocSum&format=htmlISSUE-36International Study on Syncope of Uncertain Etiology-3,͑u^S.~g'`^yL}{'`1Y^y`k0J0D0f0 0000000o01Y^yQzv0b6R,{4vf 0ISTInternational Stroke TrialZb@\gaspirinJ00s0bQVheparinv NbNn0[hQ'`h0 gR'`0i0heparink0Rgo00Z00aspirinn0{kN Nw[b6Ro0\U0D00n0n0xK0j09eURg0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9174558?report=DocSum&format=htmlIST-3 Third International Stroke Trial>zvu_6BfNQn0rt-PAk000YQ@hnBvln0 gR'`0UOY0006K0g_n0z_jv9eU rt-PAR"[gq0Nhttp://www.ncbi.nlm.nih.gov/pubmed/22632908,22632906?report=DocSum&format=htmlItalian AT500 RegistryGR^Xhuo0Z@'`_u` ؚ@'W |?\u 3RS-Nn0qSzVP[0 gY00Ok0YO0 1eN Nc}Y00_?b0}Ro0^Xh'`0000n0rzW0_0qSzVP[g0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16286180?report=DocSum&format=htmlITALIC<Is There A LIfe for DES after discontinuation of ClopidogrelXience V0 i0`0aspirinaS'`On01t^_n00^{kN MI 3RS-N TVR 'YQ@ k0J0D0f0 DAPT clopidogrel ;prasugrel2% ticagrelor 0.1%= aspirin 60gn0240gk0[Y00^R'`L0000_0{v2n0OULk000egB}N 0ITALICShInvestigation by the Thoraxcenter of Antisense DNA Using Local Delivery and IVUS after Coronary Stenting{proto-oncogene c-myck0[Y000000000000000000000AS-ODN n0@\@bvcbNL0 0000Qrz0b6Rg0M00K00i00000QeuQ`S gs ifgloss index QrzsAS-ODNR"000002002t^01gEhttp://www.ncbi.nlm.nih.gov/pubmed/11788220?report=DocSum&format=htmlIVUS-XPL^Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long LesionsmIVUS000 Nn0everolimusnQ0000Yuno0QR q_000 Ng0n0Yunk0O00y0wgn0聊^0^L0o}YK00i01< t^_n0;N g[_0000b6RRgIVUS000>QR q_000<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/26556051?report=DocSum&format=htmlIWHSIowa Women's Health StudyZSOR^h0u`zvusn0O0UOY00'Y!j0000xvz00000000ko0BMI0yV000ؚbsY'`n0N_N,nL0ؚD0/Nn0000000n0 g(uo0ؚbsY'`n0{kN000XRh0#0Nhttp://www.ncbi.nlm.nih.gov/pubmed/10904454,21987192?report=DocSum&format=htmlJ-ACT II!Japan Alteplase Clinical Trial IInzOP[D}cH0Wrt-PA alteplase 0.6mg/kgYln0 gR'`0UOY00e,gn0phase IVf0egQk000o}Yj00^L0g_g0M000Qs o}Yj00^so0Y0g0k01XJTU00f0D000.9mg/kgh0 TI{0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20075341?report=DocSum&format=htmlJ-CARP)Japan Central Aortic Pressure Prospective -N_@'Wn0[xvz0J-CHEARS!00iRj0ؚ@'Wn0{teݑn0xz0vcY0ؚbؚ@'W0000xvz0J-CHFJapanese Chronic Heart Failure4e,gN_ NhQ`k0J0D0f0 necarvedilol 3(uϑn0{kN eQbb6RRgk0]o0000Z00TAssessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failureba'`_ NhQ`k0J0Q00nek000lBvxzn0_00n0fJ-COREzJapan-Combined Treatment with Olmesartan and a Calcium Channel Blocker versus Olmesartan and Diuretics Randomized Efficacyؚ@'W`k0J0D0f0 ARB olmesartank0Cabbazelnidipineh0)R?\HCTZ0uO(uW0_04XTn0 gR'`0iY000-N_SBP 'YRlOd^NO Nolmesartan azelnidipineolmesartan HCTZ*0Whttp://www.ncbi.nlm.nih.gov/pubmed/19667251,19667254,22547439?report=DocSum&format=html~Japan-Combined Treatment with Olmesartan and Calcium Channel Blocker versus Olmesartan and Diuretics Randomized Efficacy StudyARBolmesartan n0 g(uj0uO(ulBvn0ij-Cypher Registryxb@\gBvln00000@hux0n0q_0i<0aspirinJ00s00000000|dRn0bN-Nbko00000@hun00000X'YW0_0L0 0000000|n00n0-Nbko0X'YW0j0K0c0_00 i0_6K0gNMn00000000|dRn0 gR'`o0:y[0j0K0c0_00`http://www.ncbi.nlm.nih.gov/pubmed/19204304,22203694,20566954,19858414?report=DocSum&format=htmlJ-DEFINEgJapan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing EffectQRrzu Yn0_jvUOln0i J-DESsERT8Japan-Drug Eluting Stents Evaluation; a Randomized TrialPCIi(uOg0n0TAXUS0000 vs Cypher0000J-DHF&Japanese Diastolic Heart Failure Studyb5_g_ NhQlBvlxzn0_00n0f0 J-DISCOVERODISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan(2dRvn0|?\ulBvn0bN0YW0_02W|?\u`k0J0Q00lBvn0srh0wgN_0J-DOIT3ZJapan Diabetes Optimal Treatment Study for 3 Major Risk Factors of Cardiovascular DiseasesA3VP[@'W @|  k0[Y00q}Tv7_SlBvn0jnlBvk0O00y0_0T_@{000NO N0[hQk0/ecY00P}go0_00j0K0c0_00 |?\u ؚ@'W pu8^uEhttp://www.ncbi.nlm.nih.gov/pubmed/29079252?report=DocSum&format=htmleJapan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases42W|?\uk0J0D0f0 @| @'W NlBvn0F0a0|?\uTuOuN2n0pg0*Q0_0lBvlo0UOg0B00K00i0J-ELAN"ؚ@'W'`]['Y_k0J0D0f0 M'WL0][b5__jk0NH00q_n0i0J-HEALTH Study8Japan Hypertension Evaluation with AIIA Losartan Therapyؚ@'W`k0J0D0f0AIIS[SObblosartann0wgbNo0_@{00000b6RW0oR\O(u0\j0D00^|?\u`g0o0140/85mmHg*gn |?\u`g0o0130/85mmHg*gnk0@'W0 NR00y0M0g0B00085skN Nn0ؚbg00@'W{to0_@{000b6Rk0 gR0J-HOME>Japan Home versus Office Blood Pressure Measurement Evaluationj,gk0J0Q00M'WlBv0SQ0f0D00,gKa'`ؚ@'W`k0J0Q00[^@'Wk0We0O0@'W000000rl0iY00xvz0[^@'WJ00s0YegBf@'Wk0We0O0@'W000000n0yr_0 T[W0 lBvOk0J0Q00;S+^n0UOh0n0#n01XJT0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15785011?report=DocSum&format=html J-HOME AIGThe Japan Home vs. Office blood pressure Measurement Evaluation with AIGARBXSdRBvlg0Rg NASRj0ؚ@'WuOk0J0Q00ARB/)R?\TdRh0ARBؚ(uϑn0[^@'W Yeg NU@'W AI0-N_@'Wk0S|0Y0\O(uk0Y00f J-HOMECARELJapanese Heart Failure Outpatients Disease Management and Cardiac Evaluation,_ NhQ`k0J0Q00(W[000n0u`{t00000k000000009eU,{IIIvf 0 J-LANCELOTBJapanese Lessons from Antagonizing the Cellular Effect of ThrombinUe,gN%`'`QuPJ00s0ؚ000QRu``k0J0D0f0 eb@\gatopaxarn0Q@XR04O0j0D0;N g[_@{0000b6Rn0S'`L0:yUU000,{IIvf 0J-LESSON~Japan Unprotected Left main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy on New Generation Stents1^Ow];Ny^u YULMCA k0[Y00eNN0000everolimusnQ0000 {v2xvzJ-LITJapan Lipid Intervention Trial$Ph0QRu`zvun0#0i0HMG-CoA reductase;[simvastatinNO(uϑk000Q0000N!kN2&beuo0 TC240mg/dL LDL-C160mg/dL TG300mg/dL HDL-C40mg/dL0N!kN2o0LDL-C120mg/dL HDL-C40mg/dL0Nhttp://www.ncbi.nlm.nih.gov/pubmed/12499611,12499612?report=DocSum&format=html J-MELODICbJapanese Multicenter Evaluation of LOng-versus short-acting Diuretics In Congestive heart failure -)R?\n0000Rgk0We0D0_0ba'`_ NhQk0[Y00RgvirBvln0xzk0Y00Ye-qQ Txvz0J-MIND_Japan Multicenter Investigation of Antihypertensive Treatment for Nephropathy in Diabetes < StudyOCabbnifedipinen0Nun08OU\b6RRgJ00s0[hQ'`0ACE;[enalaprilh0k0Nub6RRgnifedipineR"enalapril0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11689274?report=DocSum&format=htmlJ-MUBA3Japanese Multicenter Study on Barnidipine with ABPMCabbbarnidipinen0M'WRg0:d/^WR@'Wk0001uLR N24Bf@'W,n[ABPM k00c0f0UOY000YegBf ABPg0 gaj0M'WRg0inverted-dipper non-dipperg0%S0n0֊eo0dVU00~0W0_0</span>P֊edV<!--sLlBvk0ARB valsartan0RW0_04XTn0 NWN[0Rg0i0_@{{k _@{TuOuN2RgvalsartanR[gq*0-->ؚ@'W _ NhQ Z@'`_u`Nhttp://www.ncbi.nlm.nih.gov/pubmed/24012258,17467513?report=DocSum&format=htmlJIKEI HEART Study=sLM'WlBvk0AIIS[SObbARB) valsartan0RW0_0o0^ARBk0ky0 _@{u`0 gak0b6RW0_00JIKEI Heart StudyJؚ@'W QRu` _ NhQ`k0J0D0f0 sLM'WlBvk0AIIS[SObbvalsartan0RW0_04XTn0 gaj0_@{0000b6RRgL000000JLIGHT[Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patientst00000000IIS[SObblosartanh0Cabbamlodipinen0M'WRgJ00s0NOwRg0kY000M'WRglosartanR"amlodipine024Bf?\-Nˆ}vclϑo0losartann00g0 gak0NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15055252?report=DocSum&format=htmlJMIC-B<Japan Multicenter Investigation for Cardiovascular Disease-BuwBf\O(uWCabbnifedipineh0ACE;[n0_0000b6RRgk0_Ӂ{kB00D0o0z6q{k _K{h^XMI r_uB00D0o0_ NhQk000eQb ͑{j0 Nte QR000000000nifedipineR"ACE;[0rhttp://www.ncbi.nlm.nih.gov/pubmed/15080377,23458588,19927011,17885543,15851624,15302980?report=DocSum&format=htmlJMIC-MCJapan Multicenter Investigation for Cardiovascular Diseases-Mochida%Qb5_trapidilwgbNk000T_@{0000L0 gak0NO NW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/14516877?report=DocSum&format=html JMS 0000xvzJapan Morning Surge2ؚ@'W000000n0@'WR^k000{kN000o0 7u'`g0o0-NI{uN N sY'`g0o0͑uؚ@'Wg0 gak0 Nf0JMS-1%[^@'Wk0J0Q00egؚ@'Wo0@'W000h0o0rzW0f0ؚ@'W'`ӁhV[h0#0-[^@'Wk0J0D0f0wz'`ؚ@'W0UOY004XT 1\[MR00w^Bfn0eL0ؚ@'W'`ӁhV[h0#0JMS-TOP9Japan Morning Surge-Total Organ Protection: JMS-TOP Study,lBv-Nn0egؚ@'W`k0J0Q00ARB0O(uW0_0eg@'W{tk000ӁhV[b6Rk0Y00xvz Jobs A, et alDOrvlBvegYn0__jvYk0O00y0_0{kNsNO No0000j0K0c0_00W0K0W0 ؚ000`g0o0egYk000{kNb6Rn0S'`L0:yU00_00JOCR< I:Japanese Off-Pump Coronary Revascularization InvestigationwN]_0O(uW0j0D0_bR NQR0000Soff-pump CABG: OPCAB h08^n0CABGn00^0kY000-N1XJT%`'`gn00^ OPCABn0[hQ'` [hQ@LQ^s eg0000X[so0sLn000000n0CABGh0 Ti0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16159843?report=DocSum&format=html)JOETSU Diabetes Prevention Trial N00000) JOETSU Diabetes Prevention Trial.|pu8^|?\uXLuWIGT `k0J0Q001l2ewgYeeQbn0|?\u2U\N2Rgn0iJohns Hopkins StudyWkvؚ(uϑn0Cabbnifedipinen0egbNn0Rg0i0][_jnifedipineR"00000h^X000J00s0R'W9eURgnifedipine000001988t^04gDhttp://www.ncbi.nlm.nih.gov/pubmed/3285878?report=DocSum&format=htmlJolly SS, et alST NfW_K{h^X`k0J0D0f0 PCI-Nn00000n0@h8T_k000聊^0^n09eUo0000j0K0c0_00@hϑL0YD0`g0o0@h8T_k000_@{{kn0000L0NO NY00L0 3RS-Nh0NN'`3Z@zv\On0000o0XRY00S'`L0:yU00_0Thrombectomy Trialists Collaboration 0JOMS(Japan Obesity & Metabolic Syndrome StudyDe,gk0J0Q00nu0000000000000k0Y00Ye-qQ TxvzVzub_ji ?eV{;SBvQRlN'`u` 000000聊^qQ Txvz 0JPADHJapanese Primary Prevention of Atherosclerosis with Aspirin for DiabetesBe,gN2W|?\u`k0J0Q00b@\glBvNO(uϑaspirin o0[hQg0B00L0 gaj0RlxS'`0000n0N!kN2Rgo0000Z002017t^02gihttp://www.ncbi.nlm.nih.gov/pubmed/18997198,18997199,27881565,21270185,21515838?report=DocSum&format=htmlNJapanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial\e,gN2W|?\u`k0J0Q00b@\glBvNO(uϑaspirin o0[hQg0B00L0 RlxS'`0000n0 gaj0N!kN2Rgo0000Z00 {kv0000 65skN Ng0n0 gR'`L0:yUU00_00(2W|?\u`k0J0D0f0 aspirinn0_@{u`N!kN2n0S'`L0:yUU0000JPHC/Japan Public Health Center-Based Study Cohort I+OeP@b0bph0W0f0Lv _@{u` ]0n0Nn0u;mca#u`0iY00wg0000xvz0http://www.ncbi.nlm.nih.gov/pubmed/28324761,28445513,27087361,27005903,26732562,25941187,23493733,23404536,18658036,18635855,18025534,17092383,15717882,15017008,15118170,16401768?report=DocSum&format=htmlJPPP#Japanese Primary Prevention ProjectL;egB}N=aspirinNO(uϑ100mg/e n0CVDN!kN2Rg0iY000CVD{k ^{kv3RS-N0_K{h^XaspirinbNR"^bN0 ؚ@'W pu8^u |?\uEhttp://www.ncbi.nlm.nih.gov/pubmed/25401325?report=DocSum&format=htmlhCVDqSzVP[0 gY00ؚb71 sk e,gNk0J0D0f0 aspirin 100mg/ek000CVDCVD{k ^{kv3RS-NeMI N!kN2o0000Z00000peL0\j0O0g-N.Y$P5.02t^g0egB}N 0pJapanese Primary Prevention Project with aspirin in the elderly with one or more risk factors of vascular eventsؚbk0J0Q00aspirinn0_@{u`N!kN2n0i0JSAPJapanese Stable Angina PectorisNwgN_0irlBvRglBvh0W0f0irlBv0[e h0PCIHQL irlBv h0g0k0hQ{kN ACS 3@{u` }%`eQbb6RRgPCIHQLirBvl*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/19463347?report=DocSum&format=htmlJSSRS(Japan Standard Stroke Registration Study 3RS-N0000000 JUMBO-TIMI 26fJoint Utilization of Medications to Block Platelets Optimally-Thrombolysis in Myocardial Infarction 26en0b@\gprasugreln0[hQ'`0clopidogrelh0kphase 2f 0Q@so0!Ng0NOO0 CABGk0#W0j0D0TIMI'YQ@J00s0\Q@n0zvuo0prasugrel1.7% clopidogrel1.2%0000k1.42 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15967851?report=DocSum&format=htmlEJoint Utilization of Medications to Block Platelets Optimally-TIMI 260%`'`QuPg0PCIeLOk0J0Q00b@\gCS-747n0[hQ'`o0clopidogrelh0 TI{0 Jun M, et al..000000|dRo0 ;Nk0QR0000n0b6Rk000;Nj0_@{0000n00000NO NY000'000000|dRo0ba'`NӁu`n0$P09eUW0 _@{00000N2Y000JUPITERaJustification for the Use of Statins in Prevention: an Intervention Trial Evaluating RosuvastatinELDL-Cck8^$P hs-CRPؚ$POk0J0D0f0 0000|dR rosuvastatinn0 gaj0;N_@{0000N!kN2RgL0000_00http://www.ncbi.nlm.nih.gov/pubmed/18997196,18997195,26408274,24243886,22883507,22516441,22187510,21968126,21492764,21310313,20655105,20176986,20206456,20026779,19329177,19329822?report=DocSum&format=html"rosuvastatink0uP'`Y@h^Xhub6RRgL0000008LDL-C CRP!N$Pn0NO Nk000 0000|dRrosuvastatinn0_@{u`N!kN2RgL0'YM0O0j000eJustification for Use of Statins in Primary Prevention: an Intervention Trial Evaluating RosuvastaitnOLDL-Cck8^$P hs-CRPؚ$POk0J0D0f0 0000|dR rosuvastatinn0 gaj0;N_@{0000N!kN2RgL0000_0vs. 0000 0 JUPITER IInDouble blind randomised comparison of JANUS tacrolimus-eluting stent with the tecnic carbostent JANUS tacrolim:JANUS tacrolimusnQ0000000o0TECNIC0000000000jvu Y@LQ^S046%NO N0|pu8^`g0n0pitavastatink000|?\uzvun0E^B00D0o0N2 Pitavastatin for the Delay or Prevention of Diabetes Development in Individuals with Impaired Glucose Tolerance.K-CAT/Kanagawa Combination Anti-Hypertensive Therapy )ARBXSdRg0o0000000g0M0j0D0ؚ@'W`k0J0Q00uO(ubNn0 gR'`h0[hQ'`n0iKAMIR+Korean Acute myocardial Infarction RegistryST NfW%`'`_K{h^Xg0primary PCI0eLY00`k0J0D0f0 2.z^n0b@\gBvlaspirin clopidogrel k0cilostazol0RH0_03.z^n0b@\gBvln0 gR'`J00s0< [hQ'`0i03.z^n0b@\gBvlo02.z^n0b@\gBvl000 g[_00000b6RW0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19528339,19528332?report=DocSum&format=htmlKAMIT*Kentucky Acute Myocardial Infarction Trial|1/2(uϑn0@hn㉬t-PA streptokinaseSK n0uO(uBvl0 t-PA8^ϑn0lBvlh0k090RBfX[J00s00000000n\Rgt-PA SKt-PA*0Q^X0Qh^X0}%`0000Sn0b6RRgt-PA SKt-PA0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1907228?report=DocSum&format=htmlKang SH, et al.?1t^NQn00000@huo0 PESh0ZES-E0dO0DESL0BMS000\j0D0L0 00[hQ'`k0*Q0f0D00n0o0CoCr-EES0Kangbuk Samsung Health Study:ӗVn0*jexvz0N|qSzVP[0 gW0f0D0j0D0no0ck8^SO͑k0O00y0f0!quP'`RlxS'`QRu`n0 gusL0ؚD00Whttp://www.ncbi.nlm.nih.gov/pubmed/24794119,24794116,24870949?report=DocSum&format=htmlKAPS'Kuopio Atherosclerosis Prevention StudybHMG-CoA reductase;[pravastatinn08Rn0RXJ00s0'YRk0[Y00Rg0i08RlxS2U\b6RRgpravastatin0000*0'YRg0o0 ga]j0W001995t^10gDhttp://www.ncbi.nlm.nih.gov/pubmed/7671358?report=DocSum&format=htmlKaptoge S, et al.fSxQv000VP[0(uD0_0_@{000UO000k0CS_'`ˆ}vCRP ~0_0o0000000000RY00h0ؚ000On0X%RL09eU c[g0o010t^g0400^500NB0_001Nn0_@{00000N2g0M000Kastrati A, et al.wguX[s _K{h^X^TuOuX[sk0J0D0f0 000000000BMS h0kW0_0sirolimusnQ'`0000SES n0 gaj0 gR'`o0000j0K0c0_00 SESn0Kbb_n0@LQ^SQeLn0b6RRgo0c}W0 0000@hun0000o0BMSh0 Tig0B0c0_00Kavousi M, et al.c00000RlxS'`_@{u`ASCVD NO000sY'`n036%k0QRwppSCAC L0000 ASCVDzvu000 Nfh0#W0_00CACo0SxQvqSzVP[h0O00y0N_N,n|^00Z0K0k09eUW0_00KCHF$Kyoto Congestive Heart Failure StudyF0c0@'`_ NhQeQb`{v2xvz0KCPS?ؚ000n0_@{u``k0J0D0f0 Z@'`_@{0000n0b6RRg0telmisartanh0candesartanh0g0kY000Keene D, et al.[HDL-C0 NfU0[0000000 000000|dR CETP;[n0D0Z00k0d0D0f00 0000uO(uOk0J0Q00hQ{kN QR_u`{k _K{h^X 3RS-Nn0 gaj0n\o0000j0K0c0_00KIHD*Kuopio Ischaemic Heart Disease Risk FactorHZ@'`_u`n0SV0c0_00 000000n0Kuopiog0u~00_07u'`k0J0D0f0_tvJ00s0LR#000VP[n0uirf[v000000iY00uf[0http://www.ncbi.nlm.nih.gov/pubmed/19933935,15451789,12460094,11390336,11094031,10993858,10066846,9403606,9301625,9146441,9102170,7629402,8452137,3408213?report=DocSum&format=htmlKINGKitanagoya Genome study_@{u`aS'`zOP[YWn0 T[n0_00n0[xvz0KLISKyushu Lipid Intervention StudyHMG-CoA reductase;[pravastatink000wgn00000000NO NBvln0QR0000;_K{h^X QRYySJ00s0@{Q^S _Ӂ{k z6q{k= 3h^XN!kN2Rg0i0pravastatin vs _eglBvn0v[000o0QR0000o00.86 3h^Xo00.78 QR0000 3h^Xo00.8102000t^Ehttp://www.ncbi.nlm.nih.gov/pubmed/11426582?report=DocSum&format=htmlKMIC#Korea Medical Insurance Corporationbkv}0000000TC n0NOD0ӗVk0J0D0f0 NOTCL0Q@'`3RS-N3QQ@ O00 NQ@ n0rzW0_0000VP[g0B00K0&TK00i0NOTCo03QQ@ O00 NQ@n0rzW0_0000VP[g0o0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11289349?report=DocSum&format=htmlKodama S, et al.C|?\u`k0J0D0f0 SO;mRϑn0YU0o0hQ{kN CVD000n0'YM0j0NO Nh0#0_0`0W0\j0D0;mRϑg00;mRW0j0D000o0000o0NO NY000Kostis WJ, et al."0000n0_@{0000J00s0hQ{kNn0 gaj0b6RRgo0 7usYg0 TI{0Kotecha D, et al.ynen0hQ{kNNO No0m_n0_ NhQ`g0o0000_0L0 _?b0}RAF TuO_ NhQ`g0o0000j0K0c0_00AFTuOOk0J0D0f0o0ne0Nn0000000000k0*QHQW0f0O(uY009hbo0j0O0 N_09eUY00jnlBvh0W0f0H00y0M0g0o0j0D00Kotecha D et alDm_n0EFL0NO NW0_0_ NhQ`g0o0 t^b0'`%R0OU0Z0 nek000{kNJ00s0eQb000n0NO NL0000_0BB-meta-HF 0Kotecha D, et alTm_n0S.~'`_ NhQ`k0J0D0f0 fSRMRn0_bpek0[Y00lBvtk0OU0Z0nek000{kNsL0NO NW0_00~0_0nek000_bpeL0n\W0_00n0o0{kN000L0NOK0c0_00KPAFKansai Plus Atrial Fibrillation<!--2L-N-->00000 N00xATP 000 NYPVI  vs jnvPVIUNDER-ATPf h00000000_90en0b NtebN vs [gqEAST-AFf n02fK00j000 UNDER-ATPf_?b'`;'` NteQzvATP000 NPVIR"jnvPVI0Ehttp://www.ncbi.nlm.nih.gov/pubmed/26321237?report=DocSum&format=html&_?b0}Rk0[Y000000000n0wg0^9eUn0_00n0tf[v00000n0iKPNC cohort study2Kaiser Permanente Northern California cohort studyW0000 g0000000o}YOg0n0Qzv000NO No0 _?b0}RAF n0TuOk0K0K000Z0000_00AF03h^XN!kN2h0W0f0n00000lBvK00dYY00t1uh0Y00y0M0g0o0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/28596457?report=DocSum&format=htmlKronish IM, et al.J[聊^k0J0Q00M'Wn00000000o0dR000k000UD0L0B000 v[vk0)R?\h0neL0NOO0 ARBh0ACE;[L0ؚK0c0_0L0 }X0f0 NASR0Kunz R, et al.XARBo0ˆ}v?\n0^TD0 Wyu`h0o0rzW0f0ˆ}v?\0b6RY000ARBh0ACE;[k0bˆ}v?\Rgk0]o0000j0D0L0 !NdRn0uO(ubNk000 gR'`o0D0Z00n0XSrbN000'YM0D00KVTKanagawa Valsartan StudyNba'`Nu`TuOؚ@'W`k0J0D0f0 sLn0M'WlBvk0AIIS[SObbvalsartan0RY00S0h0k000 NJ00s0_@{u`000N2g0M00K00iY000 KYOTO HEART(ؚ000ؚ@'W`k0J0Q00ARB(valsartan)n0 NWN[0Rg0iY00. KYOTO HEART Studya֊edV<!-- 201302040000000 sLlBvk0ARB valsartan0RW0_04XTn0 NWN[0Rg0i0_@{0000b6RRg: valsartanR^ARB*0-->Whttp://www.ncbi.nlm.nih.gov/pubmed/23376450,19723695,19723696?report=DocSum&format=htmlCAdd-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)#ؚ000ؚ@'W`k0J0Q00ARBRbNo0_@{00000 gak0b6R0LADIP%Loire-Ardeche-Drome-Isere-Puy-de-DomeIؚhTl000000000000o0wgvj0bRsL0o}Yg0B00 _?b0}Rzvun0000o0lvd0}R a< miodaronelBvh0 TI{g0 TuOuo0\j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17030680?report=DocSum&format=htmlLago RM, et al.p|?\uMRu~0_0o02W|?\u`k0J0D0f0 00000bb'`9eUg0B00000000|dRTZDrosiglitazone pioglitazone k000_ NhQn0000o0 NfW0_0L0 _@{{k000n0 Nfo0000j0K0c0_00Lansberg MG, et al.1%`'`3h^XzvuK003^4.5Bf_n0tPABvlo0{kN0000X'YY00S0h0j0O0o}Yj00^00_00Y00 LAPLACE-2WLDL-C Assessment w/ PCSK9 MonoclonaL Antibody Inhibition Combined With Statin ThErapy-2ؚ0000000@u`k0J0D0f0 bPCSK9[hQ00S0000000bSO000000evolocumab 140mg 1V/21~0_0o0420mg 1V/gv NbNn00000x0n0Ro0 D0Z00n0bNl0100121vn0s^GWLDL-C0 gak0NO N0~0_0atorvastatinx0n0 NWN[0Rgo0ezetimibe00 gak0'YM0K0c0_00LARS&Laser Angioplasty of Restenosed Stentsl0000 i0_n00000QQrzk0J0Q00 0000000J00s0RPTCA0000 k000QRb_bSn0[hQ'`J00s0 gR'`0i00000h00000000n0uO(uo0 0000Qrzk0[W0f0[hQg0 gRj0lBvlg0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/10399988?report=DocSum&format=htmlLATE.Late Assessment of Thrombolytic Efficacy StudyM@hn㉬alteplasen0 gR'`0i0{kNN2Rgalteplase0000 zvu_12BfNQk0lBvW0_04XTo0alteplase0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8103874?report=DocSum&format=htmlLCAS.Lipoprotein and Coronary Atherosclerosis Study[HMG-CoA reductase;[fluvastatinn0Rg0i0u Y2Lb6RRgfluvastatin0000*00000b6RRgfluvastatin00000Vhttp://www.ncbi.nlm.nih.gov/pubmed/9264419,10636265,11079660?report=DocSum&format=htmlLEADERWLiraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results00000i0000-1S[SO\ORliraglutiden0jnlBvx0n0RlBvn0wg_@{0^0i<0Rzvn0CV{k !quP'`0+T0^{kv_K{h^X ^{kv3RS-Nn0T0000000k0J0D0f0liraglutiden00000k0[Y00^R'`J00s0*Q'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27295427?report=DocSum&format=htmlLEADERS9Limus Eluted from a Durable versus Erodable Stent Coatingd9K0g_n0_Ӂ{k _K{h^X 聊^i_n0B00jv@{n0@LQ^Sk0J0D0f0 uSOR'`0000n0biolimusnQ0000n0EN'`0000n0sirolimusnQ0000k0[Y00^R'`L0000_00`http://www.ncbi.nlm.nih.gov/pubmed/18765162,18765163,22075451,20633818?report=DocSum&format=html LEADERS FREEProspective Randomized Comparison of the BioFreedom Biolimus A9 Drug-Coated Stent versus the Gazelle Bare-Metal Stent in Patients at High Bleeding Riskb@\g2dRuO(uBvl01K0gn00uO(uY000000000biolimusO(un0dR0000000000DCS n0 gR'` [hQ'`0BMSh0k0390e_n0[hQ'`_Ӂ{k _K{h^X definite0probable0000@hun0T0000000 gR'`jvu YQ@LQ^S b6RRgDCSBMS<sup>*</sup>0Nhttp://www.ncbi.nlm.nih.gov/pubmed/26466021,27806919?report=DocSum&format=html LEADLESS IIu;2L-N=00000_Ӂ0000000 i0n0聊^v gR'`h0[hQ'`0i*</sup>030eNQhTSg n0hQ{kN 12K0g_n0lBv#{k0Re0QlBvpaclitaxel DCBR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/26106946?report=DocSum&format=htmlLEVANT Japan Clinical TrialD'YzRlBvk0J0Q00MD02-LDCBpaclitaxel coated balloon00000 h0jn0000@{b_bSn0kLIDOLevosimendan versus Dobutamine[@LRKak0[Y00 gR'`0eCa000000levosimendanh07__dobutamineh0g0k0@LRKa9eU0{kNb6RRglevosimendandobutamine0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12133653?report=DocSum&format=htmlLIFE<Losartan Intervention for Endpoint Reduction in Hypertensionu00000000IIS[SObblosartanh0neatenololn0 gR'`0k0{kN _K{h^X 3RS-Nb6RRglosartanatenolol03RS-Nb6RRglosartanatenolol<sup>*</sup>0http://www.ncbi.nlm.nih.gov/pubmed/11937178,26056< 336,19332468,17893425,17664372,16968848,16567586,16116047,16534012,16505512,16365195,15655123,16139123,15837945,15583076,15734614,15734615,15326072,15028365,15547161,15547162,12885747,11835919,12022241,12160187,11877357,12105163,12243636,11937179,11305990,11564388,11775128,11497192,11497193,11499746,10642268,10642267?report=DocSum&format=htmlLIMB'+gh@{^Xu``k0J0D0f0 @{\ORbuflomedilo0N_09eUW0_00 LIMIT AMIYLimitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarctionk2000000c@wS[SOn0CD18000000k0[Y00 0000000n000SW0_0000000bSOrhuMAb CD18 n0h^X000.~\Rgh0[hQ'`0i0_['`o0o}Yj0L00_0000000n09eURgo0j0W00Nhttp://www.ncbi.nlm.nih.gov/pubmed/11733394,11804979?report=DocSum&format=htmlLINCLUCAS in Cardiac ArrestMbY_\Pbk`n0]_bQ_n04BfuX[sk0J0D0f0 LUCASR_Ӂ000000000k000_uLUCAS-CPR o0_egn0(uKbvCPRh0 TI{0LIPID<Long-Term Intervention with Pravastatin in Ischaemic DiseaseUHMG-CoA reductase;[pravastatink0000000000NO NL0CHD{k0N2Y00K00i0CHD{kb6RRgpravastatin0000*0http://www.ncbi.nlm.nih.gov/pubmed/9841303,14514569,15809366,15120888,11889008,11978335,11451296,11229669,11130382,10922421?report=DocSum&format=html'Lipid-Modulating Effects of EvacetrapibؚLDL-C@u NOHDL-C@u`k0J0D0f0 e00000000000ˆ}vCETP ;[0000000evacetrapib n0XSdRlBvk000(uϑOX[vk0HDL-CL0 Nf LDL-CL0NO N0Nl(uU00f0D000000h0n0uO(uBvlk000000000L0 gak09eUW0_0,{IIvf 0LIPS$Lescol Intervention Prevention StudyYHMG-CoA reductase;[fluvastatinL0;Nj0 g[_0000MACE 0b6RY00K00i0MACEn0000NO NRgfluvastatin0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12076217?report=DocSum&format=htmlLITLopressor Intervention Trial1nemetoprololn0hQ{kNk0[Y00q_0i01=OL0YO0{kNsn0NO N0iQg0M0Z0-Nbk0Dhttp://www.ncbi.nlm.nih.gov/pubmed/2890522?report=DocSum&format=htmlLIVEDLeft Ventricular Hypertrophy Regression, Indapamide versus EnalaprilU][͑ϑOpeLVMI .~Rg0c}W)R?\indapamideh0ACE;[enalaprilh0g0k0LVMI.~Rgindapamideenalapril*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11057435?report=DocSum&format=htmlLoDoCoLow-Dose Colchicine>sLn0N!kN2lBvx0n0colchicine 0.5mg/en0Rk000CVDb6RRgcolchicinesLlBv*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23265346?report=DocSum&format=html Long-DES IIVsirolimusnQ0000SES h0paclitaxelnQ0000PES n0k06K0g_n000000QbinaryQrz50% b6RRgSESPES*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17060388?report=DocSum&format=htmlSLong term impact of disease management in a large, diverse heart failure population3_ NhQ`k0J0D0f0 ww+^k000u`{tk000S.~_ NhQOg0uX[sL09eUW0_00n0n0 000o0JRng0M0Z00Long WRIST StudiesKWashington Radiation for In-stent Restenosis Trial for Long Lesions StudiesMQRQ>e\}Bvln0[hQ'`h0 gR'`0i06K0g_n0QrzJ00s012K0g_n0 g[_0000b6RRg18Gy00000192015Gy0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12665490?report=DocSum&format=html Look AHEAD"Look Action for Health in DiabetesA;egB}N=nϑ0vjh0W0_0wgn0u;mca7_SNeQk000_@{0000L0n\Y00K00iY000CVDu;mca7_SNeQR"[gq0ihttp://www.ncbi.nlm.nih.gov/pubmed/23796131,23796132,22455415,23288372,21593294?report=DocSum&format=htmlLpez-Lpez JA, et al.DOACo0INR 2.0-3.0n0warfarink0O00y0 3RS-N hQ{kN 'Y0-˄QQ@n0000L0NOK0c0_00~0_0 000o0ؚD00n0n0(u[Rgg0warfarin000}Y~0W0D0DOAC0B00 XR}OvL0g0'YM0K0c0_0n0o0apixaban 5mg2V/e !kD0g0dabigatran 150mg2V/e rivaroxaban 20mg/e edoxaban 60mg/e0+Los Angeles Barbershop Blood Pressure study0t+^k000eP^O2h0}0SQ0_0\dR+^k000ؚ@'WlBv{tk00c0f0'YM0j0M'WL0_00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/29527973?report=DocSum&format=htmlLoWASALow-dose Warfarin and AspirinkV[NO(uϑwarfarinh0aspirinn0wguO(ubNL0N_09eUY00K00aspirinXSrbNh0k0_@{0000_@{{k Qh^X 3RS-N _@{{kaspirin warfarinR"aspirin0Ehttp://www.ncbi.nlm.nih.gov/pubmed/14972424?report=DocSum&format=html(Lp-PLA<sub>2</sub> studies collaboration~Lp-PLA<sub>2</sub>n0;m'`J00s0o^o0 non-HDL-C S.~g@'Wh0 T z^k0QRu`CAD n0000h0v0 Lp-PLA<sub>2</sub>n0;m'`h0o^n0#n00L0@{0^k0#Y00n0g0o0j0O0 $Pk0OX[Y00R0B000LRC-CPPT8Lipid Research Clinics Coronary Primary Prevention Trial\ؚ@u(ucholestyraminek0000000000NO NL0QR_u`(CHD)n0b6Rk0 gRK0i0CHD{k ^{k'`_K{h^Xb6RRgcholestyramine000001984t^01gLhttp://www.ncbi.nlm.nih.gov/pubmed/6361299,6361300?report=DocSum&format=htmlLRTLovastatin Restenosis TrialWHMG-CoA reductase;[lovastatinbNk000NO NL0PTCA_n0Qrz0N2 E^g0M00K00i0S_6K0gn0Qrz0N2 0W0O0o0E^W0j0D00Dhttp://www.ncbi.nlm.nih.gov/pubmed/7935702?report=DocSum&format=htmlLSS-HC/Life Style support for the Hypercholesterolemia%ؚ0000000@u`k0[Y00u;mca9eUc\00000n0 gR'`n0i<0 Lu Y, < et al.>BMIؚ$Pk04OF0QRu`000n0}1/2 3RS-N000n0}3/4o0@'W 0000000$P @|$Px0n0NeQk000[QW0F000pLong-term follow-up of MRC hypertension trial in older adults and lack of impact of glycaemic change on outcomes<MRC hypertension trial in older adultsfn0wgfB}N_U00k020t^ P}gM-HEART0Multi-Hospital Eastern Atlantic Restenosis TrialWPTCAbR_ corticosteroidsL0Qrzn0zvuk0q_0NH00K00i0Qrz {kN QZ@ QR0000Sb6RRgcorticosteroidsR"000001990t^06gDhttp://www.ncbi.nlm.nih.gov/pubmed/2188753?report=DocSum&format=html M-HEART II3Multi-Hospital Eastern Atlantic Restenosis Trial II\PTCA_Qrzk0[Y00aspirin0000000A2Tbn0^xbv;[ h0sulotroban0000000A2S[SObb n0Rg0i0Qrzb6RRglBv00000Dhttp://www.ncbi.nlm.nih.gov/pubmed/7586303?report=DocSum&format=htmlMAASMulticentre Anti-Atheroma StudycHMG-CoA reductase;[simvastatink000NO Nn0s0+o'`J00s0@\@bvQR00000b6RRg0i0rzb6RJ00s0rz0009eURgsimvastatin0000*01994t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/7864934?report=DocSum&format=htmlMaastricht Aging StudyRbk04OF0w_jn0zl[VP[0iY00xvz0_@{u`CVD n0 guh0zvun012t^k00_00w_jn0cy0i<0-Nt^k0J0D0f0 CVD guh0zvuo0w_jNO N0N,n0_jNO NL0CVDzvuBfh0000W0f0D0_0S0h0K00 iBfj0CVD{tk000w_jNO Nn0Y~000E^g0M00S'`L0:yU00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/29020327?report=DocSum&format=htmlMACH-16Mortality Assessment in Congestive Heart Failure Trial]8^n0lBvk0TWCabbmibefradil0RW0_04XTn0q_0i0{kNN2Rgmibefradil00000_@{0000zvusJ00s0{kNsmibefradil00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/10683349?report=DocSum&format=htmlMADIT6Multicenter Automatic Defibrillator Implantation TrialA[k0VT0VFL0zvU000se'`MIOg0o0ICDn0 gR'`L0xU00_00FDAo0S0n0P}g00h0k0W0f0ICD i0n0i_0b'YW0_00Dhttp://www.ncbi.nlm.nih.gov/pubmed/8960472?report=DocSum&format=html MADIT-CRT]Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy_N2v_[Q TgBvlCRT -d0}RhVICD L0{kN _ NhQ0000NOnY00K0ICDXSrlBvh0kY000hQ{kNB00D0o0^{kv_ NhQCRT-ICDICD<sup>*</sup>0http://www.ncbi.nlm.nih.gov/pubmed/19723701,19723700,28494974,24179073,24678999,23770172,23500269,23449428,23040580,23062542,21982313,21357819,21310317,20733097?report=DocSum&format=html]Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization TherapyA7t^_n0uX[so0 ]0000Og0o0CRT-ICDL0ICDk0O00y0o}Yg0B0c0_0L0 ^]0000Og0o0 Tn0 gR'`o0:yU00Z00]Multicentre Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy(_[Q TgBvlo0urL0Oz0K0j0_K{u`k0J0D0f00d0}RhV iH00XSr00 gR0MADIT II9Multicenter Automatic Defibrillator Implantation Trial II. i0Wd0}RhVICD n0u}TN_9eURg0i0uX[s9eURgICDirBvl*0http://www.ncbi.nlm.nih.gov/pubmed/11907286,22651863,20837894,18387436,18206738,17397670,16814657,16769917,16750701,16682305,16487843,16386671,16256874,15583079,15464332,15093884,14993128?report=DocSum&format=htmlImproved Survival with Prophylactic ICD Therapy in Patients with Prior Myocardial Infarction and Reduced Left Ventricular Ejection Fraction MADIT-RITUMulticenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy800000g"200bpm g"170bpmg0n000000000000o0wgn0 NiRj0ICD\OR hQ{kN0b6R0Whttp://www.ncbi.nlm.nih.gov/pubmed/23131066,23131065,23881862?report=DocSum&format=htmleiirlBvg0[[W0f0D00m_n0N!kN2h0W0f0ICD/CRT-DL0 i~00_0`k0J0D0f0 0000000000 0000000h00k0jn0000000k0O00y0RV NiR\OR0}75%N2 {kN0b6R0MAGELLANqRivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients~%`'`Qyu`k000eQb`k0J0D0f0 L}Svc\O(uW,{XaVP[;[0000000rivaroxaban n0Y@h^XhuN2Rgo0NORP[ϑ0000enoxaparin h0 TI{0Q@zvuso0!Nh00NOK0c0_0L0 rivaroxabang0000L0X'Y0Multicenter, rAndomized, Parallel Group Efficacy Superiority Study in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin1Y@h^Xhuؚ000`k0J0Q00,{XaVP[;[rivaroxabann0 gR'`0[hQ'`n0i0 Z@'`_u` _ NhQ 3_t;MAGGICMeta-analysis Global Group in Chronic Heart Failure >EFL0OcU00_0b5_'`_ NhQ`o0 t^b '`%R _ NhQn0SV0OU0Z0 EFL0NO NW0_0S.~'`_ NhQ`000{kN000L0NOD00MAGIC7Myoblast Autologous Grafting in Ischemic Cardiomyopathy1]~n0B00e-g0n0^}%`PCIn0[hQ'` gR'`o0 _Ӂ@{Yyn0B00e-g0n0PCIk0[W0f0^R'`0 Mass-DAC?dRnQ'`0000DES h0000000000BMS n0wg0^0kY0002t^_n0hQ{kNb6RRgDESBMS*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/18852368,18852362?report=DocSum&format=htmlMass-DAC Registry:Drug-Eluting and Bare Metal Stenting for Diabetes Mellitus7|?\u`k0J0Q00DESn0wgN_o0 egn0 gR'`L0c}W0BMSh0ky0_@{n00000X'YU0[00S0h0j0O0o}Y0MASS II'Medicine, Angioplasty, or Surgery StudyUirBvl PCI CABGn00000b6RRg0kY0005t^_n0hQ{kN Qlh^X @LQ^S0Y00㖻l'`r_ub6RRgCABGirBvl*0PCIR"irBvl0rhttp://www.ncbi.nlm.nih.gov/pubmed/17339566,23828828,20733102,16949484,16820611,15145093?report=DocSum&format=html+The Medicine, Angioplasty, or Surgery StudyMASS III+Medicine, Angioplasty, or Surgery Study III=00000h0000000kY000hQ{kN 3RS-N _K{h^X Q@LQ^Sn0T000000000000R"000000Ehttp://www.ncbi.nlm.nih.gov/pubmed/20837925?report=DocSum&format=htmlMAST-E%Multicenter Acute Stroke Trial-EuropeUstreptokinaseSK @hnBvln0 gR'`h0[hQ'`0i010e_n0{kN ͑^[SKR"0000010e_J00s06K0gNQn0{kNN2Rg0000SK*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8657211?report=DocSum&format=htmlMAST-I$Multicenter Acute Stroke Trial-ItalystreptokinaseSK < @hnBvl aspirinb@\gBvln0XSrJ00s0uO(uBvln0000/000000kn0i0SKg010eNQn0{kNsL0 gak0XR0eg{kNN2RgSKaspirinSK aspirin06K0gNQn0{kN ͑^[SKR"aspirin0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7491044?report=DocSum&format=htmlMASTERgMicrovolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients Trial"TlNNo0ICD i0_n0_['`;'` Nte00000N,nW0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/18992649?report=DocSum&format=htmlMASTER IRThe0Microvolt T-Wave AlternanS TEsting for Risk Stratification of post MI patients6_K{h^Xe_n0B00ICD i0Ok0J0D0f0 voltTlNNigo0_[;b00000000S fW0j0K0c0_00MATCHEManagement of Atherothrombosis with Clopidogrel in high-risk PatientsV3h^X _K{h^X @{{k[Q@{k0+T0] %`'`Z@'`0000k000QeQbb6RRgaspirin clopidogrelR"clopidogrelXSrp0.244 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15276392?report=DocSum&format=html Matisse StudyhRglBvh0W0f0n0Tbb00000fondaparinuxn0[ϑ1e1Vv NbNn0 gR'`J00s0[hQ'`0*gR;uheparinh0k0Y@h^XhuQzvb6RRg Q@sfondaparinuxR"heparin0Ehttp://www.ncbi.nlm.nih.gov/pubmed/14585937?report=DocSum&format=htmlMATRIXfMinimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox3d0n0lBvln0 gR'`h0[hQ'`0i6</sub>Nir MC-1n0KbbvMRJ00s0Kbb_30ebNn0 gR'`0i030e_n0_@{{k ^{kv_K{h^Xb6RRgMC-1R"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/18381567?report=DocSum&format=htmlMENDEL-2Monoclonal Antibody against PCSK9 to Reduce Elevated LDL-C in Subjects Currently not Receiving Drug Therapy for Easing Lipid Levels-2evolocumabXSdRBvlQ2W~0_0o0QMv NbN n0 gR'`h0[hQ'`0ezetimibe~0_0o00000h0k0LDL-Cn0000000K00,{101h0,{121n0s^GW$P~0g0n0 YSs J00s0,{121~0g0n0 YSsD0Z000evolocumabg0 gak0NO N0 YSso0Q2WL0N00'YM0K0c0_00evolocumabn0_['`o0o}Y0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24691094?report=DocSum&format=htmlMente A, et al.pNO00000BdSo0ؚ@'Wn0 g!q0OU0Z0_@{00000hQ{kN000h0#W0_0L0 ؚ00000BdSh00000n0#o0ؚ@'W`n00g0000_00niX0LF0y0M0[ao000000BdSϑL0YD0ؚ@'W`n00g0B00S'`L0:yUU00_00MERCATORMulticenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and RestenosisIPTCA_n0QrzN2k0[Y00ACE;[cilazapriln0Rg0@{ q_g0i0@{_9eU 0000zvuscilazaprilR"00000Dhttp://www.ncbi.nlm.nih.gov/pubmed/1535568?report=DocSum&format=htmlMERIT-HFJMetoprolol CR/XL Randomised Intervention Trial in Congestive Heart FailureJ1e1V g(uWnemetoprolol CR/XLn0Rg0i0hQ{kN0z6q{kN2J00s0{kN hQeQbb6RRgmetoprolol0000*0http://www.ncbi.nlm.nih.gov/pubmed/10376614,10714728,17397675,11927527,12142116,11231439,11583861,11127443?report=DocSum&format=htmlMERLIN?Middlesbrough Early Revascularization to Limit Infarction Trial'30e_n0hQ{kNb6RRgrescue@{b_bSR"OX[vlBvirBvl 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15261920?report=DocSum&format=htmlMERLIN-TIMI 36hbr_uranolazinewgbNn0 gR'`h0[hQ'`0iY000 gR'`_@{{k _K{h^X Z@n0Qzvo0ranolazineR"0000 [hQ'`hQ{kN uP'` Nteo0ranolazineR"00000Whttp://www.ncbi.nlm.nih.gov/pubmed/17456819,20644019,20298924?report=DocSum&format=htmlThe effect of ranolazine, a novel anti-anginal agent with electrophysiologic properties, on the incidence of tachyarrhythmias: results from the MERLIN-TIMI 36 randomised controlled trial./^ST NfWACSk0J0D0f0 br_uranolazinek0_['`0_?b'` Nteb6Rn0S'`0lMetabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes -TIMI 36D^ST NfWACSk0J0D0f0 br_uranolazinewgbNk000_@{{k _K{h^X Z@Qzvn0 gaj0b6RRgo0000j0K0c0_00MESA%Multi-Ethnic Study of AtherosclerosisT!qurn0_@{u`n0yush0h00k0 qSzVP[h0n0v0iY000wppSn0rl1XJTQRwppSy`J00s0ϑk0J0D0f0le]L0000_0L0 S00o0qSzVP[g0o0fg0M0j0D00http://www.ncbi.nlm.nih.gov/pubmed/29352072,28159799,28320601,28254175,27233746,26801055,26449135,26224808,25457400,26547466,25404190,24657688,24480627,24412444,24141324,24247483,23500236,23033247,22932258,22910756,22871870,21844289,22051329,21867837,21718910,21527159,21511109,20846602,20424251,20117440,19139385,18452784,18367736,17698721,17646582,17601545,17502571,17276184,17161261,16979004,16949496,16636166,16781369,16545644,16461837,16458137,16847154,16365194,16286174,15769774?report=DocSum&format=htmlMesserli FH, et al.^24Bf1uLR N@'Wk000UOW0_0)R?\HCTZ 12.5^50mg/en0M'WRgo0 Nn0000n0M'W000R0S0h0L0f0K0k0j0c0_00HCTZo0ؚ@'Wn0,{Nxbh0W0f0o0 NiRg0B000METEORJMeasuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin|HMG-CoA reductase;[rosuvastatink0008RQ--NSCIMT n02U\b6R .~RgL0B00K0&TK00xY000g'YCIMTn0t^ YSs0000k0ky0rosuvastatink0 gaj02U\b6RRgL0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17384434?report=DocSum&format=htmlJMeasuring Effects on Intima-media Thickness: an Evaluation of Rosuvastatin:!quP'`n0_@{u`NO000`k0J0D0f0 rosuvastatink0008RQ--NSn02U\b6RL0000_00 METOCARD-CNICTEffect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction TrialQQLpAmMRn0nemetoprololn0egYlk000h^X000L0.~\Y00K00iY000zvu_5^7en0h^X000b6RRgmetoprololYl[gq*0Whttp://www.ncbi.nlm.nih.gov/pubmed/24002794,27052688,24694530?report=DocSum&format=htmlMEXIS)Metoprolol and Xamoterol Infarction StudyWKRRk0d0D0f0 S[SOn0partial agonistg0B00xamoterolh0metoprololn0Rg0k0KRBf^wxamoterolR"metoprolol01995t^08gDhttp://www.< ncbi.nlm.nih.gov/pubmed/7546992?report=DocSum&format=htmlMHFTMunich Mild Heart Failure TrialmACE;[captopriln0N_Rg0i0_ NhQ2Lk000{kNN2Rgcaptopril00000z6q{kcaptoprilR"00000NYHA IV^x0n0_ NhQ`Sb6RRgcaptopril0000*01992t^04gDhttp://www.ncbi.nlm.nih.gov/pubmed/1389702?report=DocSum&format=htmlMI FREEE@Post-Myocardial Infarction Free Rx Event and Economic EvaluationbW0_0_K{h^X`k0J0D0f0 gR'`L0xzW0f0D000000 ne ACE;[/ARBn0]bё0j0O0Y0S0h0g0 N!k0000000;N@{0000 @LQ^S o0b6RU00j0K0c0_0L0 ;N@{0000n00j00b6R 0000000o09eUW0 ;SBvo0bH000_00MIAMI/Metoprolol in Acute Myocardial Infarction Trial[zvu_wg15e {kNsJ00s0y`sk0[Y00nemetoprololn0Rg0i0{kNN2Rgmetoprolol0000 ؚ000g0o0metoprolol0000*01985t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/2863148?report=DocSum&format=htmlMICAT6Coronary Slow-flow and Microvascular Diseases Registry00000000@hun0zvus 聊^vyr_0UOW0 N,nVP[0c"}0U00k0rn0BVSYun00000g0n0ScTn\Rg0i012K0g_k03%k0TW0_0L0 iYunl0O(uY00S0h0g0 gak0NO NY00S'`L0:yU00_00N,nVP[o0eQSu Y NOEF Sgq@{_ Kbb_n0g\@{_0Nhttp://www.ncbi.nlm.nih.gov/pubmed/26916481,26916482?report=DocSum&format=html MICRO-HOPE HOPEn000000004Microclinic Social Network Behavioral Health Program;SBvnjnL0P0000We(WOOn0NSO͑~0_0o0NqSzVP[O gk0J0D0f0 000000000000000000000)R(uW0_0nϑ0N00000000000 n0SRo0 jnvj0OeP@\n000000)R(uW0_0Nk0O00y0 160g_n0SO͑ yV @'W HbA1cL0 gak0NOK0c0_00 MIDAS5Multicenter Isradipine Diuretic Atherosclerosis StudyCabbisradipineh0)R?\hydrochlorothiaziden0M'WlBvk0J0Q008Rn0g'Ys^GWQ-NSIMT 2U\b6RRg0k0g'YIMTisradipineR"hydrochlorothiazide0_@{0000b6RRghydrochlorothiazideisradipine*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8769587?report=DocSum&format=htmlMihaylova B, et al.Oc[5t^;N@{0000000L0NOD010% `g0o0 LDL-C 38.7mg/dLNO NB0_00n0;N@{0000n0v}[NO No05t^g0}11/1,000N0MILIS<Multicenter Investigation for the Limitation of Infarct Size200000dRdigoxink000lBvn0[hQ'`0i0{kNN2RgdigoxinbN^bN01986t^01gDhttp://www.ncbi.nlm.nih.gov/pubmed/3510391?report=DocSum&format=htmlMills EJ, et al.#0000|dRk0_@{{kJ00s0;N0000n0N!kN2RgL000000MINAP+Myocardial Ischaemia National Audit Project^ST NfW_K{h^X`n0000J00s0lBvn0L}Bfv2003^ 04t^! 12^ 13t^ j0 YSh00^9eUh0n0#0i<0b_180en0hQ{kNhQ{kNsL0NO N0S0n0NO No0S0n0n0QROrvlBv&beuh0#W0 `000n0NO N0irlBvXRk0000n0g0o0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27574717?report=DocSum&format=htmlMINERVARMINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failurek_?b'`;'` Nten0e_0 gY00_`k0J0D0f0 Nj0S[000000g\SY00MVP000 N2e_?bb;b00000o0 jnNT00000k0O00y0 2t^_n0{kN CVDk000eQb 8l}'`AF0 gak0b6RW0_00+Minneapolis Children's Blood Pressure Study<\PQgK00Rt^gk0K0Q0f0n0SOn0bwL0_@{000VP[zzyBf00000  S.~g@'W k0S|0Y0q_0iY00uf[01999t^03gEhttp://www.ncbi.nlm.nih.gov/pubmed/10086972?report=DocSum&format=htmlMIRACLBMyocardial Ischemia Reduction with Aggressive Cholesterol LoweringHMG-CoA reductase;[atorvastatink000egn07_RNO NBvln0{kN ^{k'`%`'`_K{h^X }%`QeQb0Y00uP'`_K{Z@n0Qzvb6RRg0i00000h0ky0_0atorvastatinn0v[000o00.84p0.048 0rhttp://www.ncbi.nlm.nih.gov/pubmed/11277825,26022813,16186288,15262833,12975259,12270864?report=DocSum&format=htmlAMyocardial Ischemia Reduction with Aggresive Cholesterol Lowering<egn0atorvastatink0007_Rj00000000NO NBvl N[[r_u ^Qlh^X`n0egZ@00000b6R0MIRACLE1Multicenter InSync Randomized Clinical Evaluatione_?b Tg!N[00000k000cardiac resynchronization_ӁQ Tg lBvCRT n0 gR'`0i0CRTk000 6K0g_n0NYHA__jR^ QOL 6RikLݍL0 gak09eU0Whttp://www.ncbi.nlm.nih.gov/pubmed/12063368,16401777,12668512?report=DocSum&format=html;]S_[n0 TgL01Y00_0_ NhQ`k0J0D0f0 !N_[00000k000_ӁQ TglBvCRT n0 gR'`J00s0[hQ'`0i0 MIRACLE ICD;Multicenter InSync ICD Randomized Clinical Evaluation Trial]_?b Tg!N[00000k000_ӁQ TglBvCRT h0 i0Wd0}RhVICD lBvuO(un0 gR'`h0[hQ'`0i0QOL __j9eURgCRTICD*06RikLݍCRTR"ICD0Nhttp://www.ncbi.nlm.nih.gov/pubmed/12771115,12771120?report=DocSum&format=htmlMIRACLE ICD II8Multicenter InSync ICD Randomized Clinical Evaluation IIZ_ӁQ TglBvCRT k0006K0g_n0RBfg'Yx }mϑpeak V<sub>O2</sub> o09eUW0_0L0[gqh0n0k0 ga]o0j0W00_Ӂn0i _j 聊^rlo0 gak09eU0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15505095?report=DocSum&format=htmlMIRSA=Multicenter International Randomized Study of Angina PectorisInebisoprololh0atenololn0 gR'`h0[hQ'`0k0r_uzv\Ob6R0KR[9eURgbisoprololR"atenolol01992t^06gDhttp://www.ncbi.nlm.nih.gov/pubmed/1376806?report=DocSum&format=html$Mission: Lifeline STEMI ACCELERATOR -Reginal Systems of Care Demonstration Project^s|V160WWn0484e-1,253n0EMS0)R(uW0_0STEMI`23,809Ok0J0D0f0 Qe%`ˊK00QLpAm~0g0n0Bf0< w.~Y00_00k0o0 EMSh0e-n0#:dL0͑g0B00S0h0L0xU00_00MISSION!SsirolimusnQ0000SES n0 gR'` [hQ'`0000000000BMS h0kY0009K0g_n000000Qifg@{_ d1Yb6RRgSESBMS*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18261680?report=DocSum&format=htmlMITI I?Myocardial Infarction Triage and Intervention Project - Phase I]0000000n0`xbn0q_0i0U00k0 Bfvj0{}0i0@hnBvl0YY00`0ub0R@wMRk00000000L0xbY00n0k0 0000000h0_Vn00(uD00n0L0YS_g0B001990t^04gDhttp://www.ncbi.nlm.nih.gov/pubmed/2312978?report=DocSum&format=htmlMITI II>Myocardial Infarction Triage and Intervention Project-Phase IIY@hnBvln0Yk0d0D0f0ub0R@wMRJ00s00R@w_g0k00R@wMRlBvg0o0zvuK00lBvY~0g0n0BfL0 gak0w.~ u0L0 gak0n\0{kN0EF0h^X0000R@wMRlBvR"0R@w_lBv0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8355383?report=DocSum&format=htmlMM-WES'Medco-Mayo Warfarin Effectiveness StudyN0000000k0J0D0f0 CYP2C9/VKORC1*n0zOP[YW0naW0_0warfarinbNϑzl[k000 eQbJ00s0Q@/@h^Xhun0000L030%NO N0MOCHA4Multicenter Oral Carvedilol Heart Failure Assessmente@{b5_Rg0 gY00,{3NNnecarvedilolk000ba'`_ NhQlBvn0 gR'`h0[hQ'`0i0KR[carvedilolR"00000EF9eU0{kNb6RRgcarvedilol0000*0Mhttp://www.ncbi.nlm.nih.gov/pubmed/8941106,11738299?report=DocSum&format=htmlMOLOYAMA8ؚ@'W0TuOY00U'`ˆ}v?\0 gY00|?\u'`Nu`k0[Y00telmisartanh0losartann0 g(u'`n0i N_j[ |?\u ؚ@'W MOMENTUM 3uMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 38`_Am000o0Am000k0O00y0 i0_n0000 NwQTk000QKbSn0eLsL0NOO0 6K0g_n00^L0o}Yg0B0c0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/27959709,30883052,29526139?report=DocSum&format=htmlMONICAMMultinational Monitoring of Trends and Determinants in Cardiovascular DiseaseaD0O0d0K0n0puj0c0_0ƖV010t^N Nk00_00W0 _@{u`n0PTh0zl[VP[ yrk0{k'`~0_0o0^{k'`QRzv\On0zvush0_@{u`n0000VP[@'W UYq 0000000 0kiY00uf[0http://www.ncbi.nlm.nih.gov/pubmed/20620719,18309149,16401673,16531419,12855832,16126719,15618061,15618045,15618037,15337690,15451783,12912821,12714025,12433511,11157701,11723022,11440492,10703799,10703800,8026046,3335877?report=DocSum&format=htmlMOPETT5Moderate Pulmonary Embolism Treated with Thrombolysis0-NI{^n0^Xhuk0J0D0f0 @hn㉬t-PAn0nϑo0[hQg0 ؚ@'Wh0^XhuQzvn0N2k0 gR0MORE*Multiple Outcomes of Raloxifene EvaluationMOSESdMorbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary PreventionM'W000L0 Tig0B00p0AIIS[SObbeprosartann03_@{TuOuJ00s0{kNb6RRgo0Cabbnitrendipine000'YM0D0h0D0F0N0i<0M'WRgeprosartanR"nitrendipine0hQ{kN hQ3_@{0000+T0hQQzv0000 b6RRgeprosartannitrendipine*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15879332?report=DocSum&format=htmlMOST.Mode Selection Trial in Sinus-Node DysfunctionzNT_?b_[ 00000L0_[00000000o}Yj00000VuX[sJ00s0QOL00_00Y0K00i0hQ{kN ^{k'`3RS-NNT00000R"_[000000NT00000o0_?b0}Rn0000 _ NhQn0uP0n\U0[0 0Z0K0j0L00QOL09eU0http://www.ncbi.nlm.nih.gov/pubmed/12063369,16636167,16750693,15867173,15630030,15172414,15120821,12668495?report=DocSum&format=htmlMOXSEMoxonidine Safety and Efficacy-Ng'`Na^yL}b6R_>e'`(SR) moxonidinen0wg0wgbNk000@n00000000o^n0(uϑ-S_h0n0vO0i0@n00000000o0moxonidine SRn0(uϑk0OX[W0Wfk0n\0n\o0000000000004Oc0_0L0 g[Na0XRW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11956122?report=DocSum&format=htmlMR CLEANlMulticenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands>8^00x0n0@{QlBvRn0 gR'`0i090e_n0modified Rankin000o}Y@{QlBvR8^000Whttp://www.ncbi.nlm.nih.gov/pubmed/25517348,25517349,28379802?report=DocSum&format=html MR-IMPACT_Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial3QRu`n0iwk0J0D0f0 xlqQlk000LpAmUOperfusion-CMR o0SPECT00o}Y0MRCMedical Research Council Studyj3RS-N ؚ@'Wk000{kN QRu`k0[Y00Rg0)R?\h0neg0k03RS-Nb6RRg)R?\ne0000*0QRu`zvu)R?\ neR"00000_@{u`b6RRg)R?\ ne000001985t^07gDhttp://www.ncbi.nlm.nih.gov/pubmed/2861880?report=DocSum&format=htmlMRC/BHF Heart Protection Study_@{0000ؚ000Ok0J0D0f0 HMG-CoA reductase;[simvastatink0bxS00000܈EQW0f00 {kNb6RRgo0j0K0c0_00simvastatino00000k0ky0hQ{kN MI{k 3RS-NJ00s0#@{{k0 gak0b6RW0_00,gRgo0fYBfn0LDL-C$Pk0Oj0O0000_00MRC ECST"MRC European Carotid Surgery Trialb3RS-NN2n0pg08R@{QdSSn0000J00s0 gR'`0i0rzs80%N Nn04XTeSo0 gRg0B0c0_003t^vn03RS-N0{kNb6RRgdSSeL^eL KbSn0v}[000000o011.6%0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9593407?report=DocSum&format=htmlMRC in older adultsKMedical Research Council Trial of Treatment of Hypertension in Older AdultsC3RS-N QRu`J00s0{kNn0b6RRg0)R?\h0neg0k0)R?\o03RS-N QRu`0 gak0N20neg0o0 gaj0NO Nj0W0019< 92t^02gDhttp://www.ncbi.nlm.nih.gov/pubmed/1445513?report=DocSum&format=htmlMRFIT'Multiple Risk Factor Intervention Trial7QR_u`CHD k0J0Q00YVP[NeQ00000n0 gR'`0i0}{kN CHD{kNyr%RNeQR"8^lBv01982t^09gphttp://www.ncbi.nlm.nih.gov/pubmed/7050440,21383313,14662707,12928465,12020303,2179590?report=DocSum&format=htmlMSC-HF;Mesenchymal Stromal Cells in chronic ischemic Heart FailureX͑uZ@'`_ NhQ`k0J0D0f0 ]Ě1uegn0I|0}ހMSC _K{Ql\k000__jL09eU0_K{͑ϑn0XR "vuD}T~n0n\ ur0QOLn09eU0000_0,{IIvf 0MT FUJIMulticenter Tolvaptan Study For Uncontrolled Volume Overload in Japanese Acute Decompensated Heart faIlure Patients: A Prospective Observational Multicenter Cohort Study6%`'`_ NhQ`k0J0Q000000000V<sub>2</sub>S[SObbtolvaptann0 gR'`h0[hQ'`MTOMoving to Opportunity Study*Vsn0ؚD00WWK00NOD00WWx0n0E\o0 ui^n0nJ00s0|?\un0 gusn0NO Nh0#0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22010917?report=DocSum&format=htmlMUCHA4Multicenter Carvedilol Heart Failure Dose Assessment|necarvediloln0i(uϑ0iY00_00 2(uϑ;5mg/eJ00s020mg/eR2 =n0 gR'`J00s0[hQ'`0k0ba'`_ NhQCHF n0hQ,v9eUs20mg0000*0carvedilolo0(uϑOX[vk0CHFJ00s0EF09eU0Ehttp://www.ncbi.nlm.nih.gov/pubmed/14760332?report=DocSum&format=htmlMulticentre International Study|zvu1^41_k0nepractololk000wgN2lBv0YW0 {kNJ00s0Qh^Xn0N @'W r_u Ntek0[Y00Rg0i0Qu`{k0{kN ^{kvh^Xb6RRgpractolol0000*0^{kvh^XpractololR"000001975t^09gChttp://www.ncbi.nlm.nih.gov/pubmed/240481?report=DocSum&format=html MULTISTRATEGYMulticentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab with Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction`abciximabk0[Y00tirofibann090R_n0STV_k0J0Q00^R'`L0:yU00 Neg0sirolimusnQ0000o00000000000008K0g_n0 g[_00000 gak0b6RW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/18375998?report=DocSum&format=html MUSASHI-AMIMulticenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients with Acute Myocardial Infarction2zvuK0096BfNQn00000k000NO NBvlo0@{0000n0Qzv yrk0F0c0@'`_ NhQ0b6RY000Nhttp://www.ncbi.nlm.nih.gov/pubmed/16616020,17721009?report=DocSum&format=htmlmMulticenter Study for Aggressive Lipid Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients with AMIFPCIeLn0%`'`_K{h^X`k0J0D0f0 egn00000k000NO NBvlo0_@{0000n0Qzv yrk0}%`eQb0Y00F0c0@'`_ NhQ0b6RW0_00Muscatine StudyH1\f[gK00W0_0t^bNk0J0D0f0 Q -NSIMT n0XRh0QRn0wppSL0OB00K0 _@{000VP[h08RIMTn0v0iY000Nhttp://www.ncbi.nlm.nih.gov/pubmed/11733400,10458720?report=DocSum&format=htmlMUSIC-Multicenter Ultrasound Stenting in Coronaries[IVUS@{Q000 000k00000000 i0 S_bQVBvl0L0j0D0lBvln0[hQ'`J00s0 g(u'`0i0bQV^O(ug00000 i0o0[hQk0eLU00 ij0b5_0_00_00Dhttp://www.ncbi.nlm.nih.gov/pubmed/9740343?report=DocSum&format=htmlMUSTIC)Multisite Stimulation in CardiomyopathiesHmultisite biventricular pacingn0 gR'`J00s0[hQ'`0i0_?b_[00000o0KR[ QOL0 gak09eUY000`http://www.ncbi.nlm.nih.gov/pubmed/11259720,12633545,12419298,12103264?report=DocSum&format=htmlMUSTT)Multicenter Unsustained Tachycardia TrialUlutigk000lBv0xbY00h0z6q{k0b6Rg0M00K0&TK00i0_\Pbk Nte{kN2Rglutigk000lBvlxb!qlBv* d0}RhV i0^ i0*0http://www.ncbi.nlm.nih.gov/pubmed/10601507,17868806,15364316,12821551,12105164,12417544,12438295,11468206,11583897,11499722,10874061?report=DocSum&format=htmlMultiple biomarkers and improvement in the prediction of CHD outcome: Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) nested case-control studyASCOTf0000QuO[gqxvzP}gNagata M, et al.%ˆ}v?\h0eGFRNO No0e,gNk0J0Q00_@{u`{kn0rzW0_0qSzVP[g0B000 NAGOYA-HEARTaNovel Antihypertensive Goal of Hypertension with Diabetes - Hypertensive Events and ARB Treatment.2W|?\u |pu8^ؚ@'W`k0J0D0f0valsartanh0amlodipine0kY000NAGOYA HEART StudyComparison between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients with Glucose IntoleranceI|?\u~0_0o0|pu8^TuOؚ@'W`k0J0D0f0 ARB valsartann0_@{0000N2Rgo0Cabbamlodipineh0 Y00j0K0c0_00NAMCS and NHAMCS\National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care SurveypirlBvh0u;mcan00000000RT0UOW0 NSRKa/聊^qSzVP[/;SBvOf}n0 YSn0q_ '`%R0N.zk000]pu0iStP8p^yL}:RoVNS n0Rk000_Ӂ000000L0b6RU00 __jL09eUW0 KR[L09eUY00K00iY00018K0gፈN[[hQ'` 06K0g_n0][S.~+gg_n0 YS gR'` VNSR"[gq0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25176942,25176941?report=DocSum&format=htmlNesiritide Study|300000)R?\0000nesiritiden0 gR'`J00s0[hQ'`0i0 gR'`fh0kfK00b00 gR'`f聊^rKan09eURgnesiritide0000*0kf聊^rKa |T8TV uRan09eURgnesiritideR"jnlBv0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10911006?report=DocSum&format=htmlNESTORZNatrilix SR versus Enalapril Study in Type 2 Diabetic Hypertensives with Microalbuminuria1_ϑ00000?\n02U\b6RRgACE;[enalaprilR")R?\indapamide SR0Nhttp://www.ncbi.nlm.nih.gov/pubmed/15257186,17198918?report=DocSum&format=htmlNEXT< LNOBORI Biolimus-Eluting versus XIENCE/ PROMUS Everolimus-eluting Stent Triale<!--2L-N--> gR'`1t^_n0jvu YQ@LQ^Sk0J0Q00@{Xn00k0uSO8TS'`00000000000W0_0biolimusnQ0000n0everolimusnQ0000k0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/23684673?report=DocSum&format=html1t^_k0:yU00_0jvu YQ@LQ^Sk0J0Q00uSO8TS'`00000000000W0_0000000biolimus nQ0000n0EN'`00000O(uW0_0everolimusnQ0000k0[Y00^R'`o0 2t^_0000_00~0_0[hQ'`{kN _K{h^X 0^R'`g0B0c0_00KNOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent TrialwPCIeL1t^_n0jvu YQ@LQ^Sh08-120g_n000000Q`g d1Y_k0J0D0f0 uSO8TS'`00000O(uW0_0000000biolimus nQ0000o0 EN'`00000O(uW0_0everolimusnQ0000k0[W0f0^R'`0NGKkAssessment of Genetic Risk of Metabolic Syndrome in Company Employee and Making New Health Guidance Program000000000000n0zOv000n0iuf[ |?\u ؚ@'W pu8^u ]0n0NNHANES0National Health and Nutrition Examination SurveyOs|Vln0eP^rKa h rKan0[gvj0gbck000NSRKaf[v000 >yOL}nf[vrl ߘN eP^rKan0^M0S0n0{0K0 ;Sf[vig SO,n[ n0㉐gP}g0http://www.ncbi.nlm.nih.gov/pubmed/29581125,29133599,28193605,28418481,28267855,26976914,26562046,26172894,25332288,24421370,25015340,23603918,23418368,24763487,24682242,24645848,24621268,23563124,23817481,23073951,23091084,22717317,22796254,22871871,22801930,22410814,22354940,22253363,22253364,22095826,21593298,21867837,21690489,21824920,21693741,21518989,21505207,21224291,21285387,20889854,21220734,21109116,20308607,20501926,20407058,20071471,19955525,19752328,19470881,18714061,18268146,17986697,17986696,17296856,16940191,12716754,16391156,15769771,15840860,15840861,14732743,14676144,12719276,11790693,11790215,11724207,11343443,11434794,11519501,7607734?report=DocSum&format=htmlNHEFSYNational Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up StudyNHANES ISRn0&~exvz0`http://www.ncbi.nlm.nih.gov/pubmed/18342687,10815083,10989403,10591385?report=DocSum&format=htmlNHLBI Family Heart Study<National Heart, Lung, and Blood Institute Family Heart StudyL'Y!jƖV,gNJ00s0[e k0J0D0f0 QR_u`CHD 00000'`RlxS _@{000VP[n0zOvJ00s0^zOvzl[VP[0iY00Ye-xvz0_http://www.ncbi.nlm.nih.gov/pubmed/8651220,15927976,12847072,10740155?report=DocSum&format=htmlNHSNurses' Health Study]sY'`k0J0Q00L}SY UYqh0;Nu`h0n0#n0g0vvh0W0f0YU00 n0a0k0ߘN KR 000000܈EQBvl0+T0i0j00000000n0can0eP^x0n0q_n0UOj0i00RH000_0uf[0chttp://www.ncbi.nlm.nih.gov/pubmed/28719691,28465308,27884868,27881409,27462052,27189229,27115377,26429077,26048094,25572509,24782515,25467028,25332277,24428469,23990623,23917291,23549584,21730242,21696306,20713902,19622819,19470888,18697819,18574045,18460664,18362231,18071069,17379619,17389261,17093250,16636169,16551711,16449729,16301356,16304074,16129796,15687137,15657325,15659724,15602020,15383516,12668520,12695299,12684356,12444862,11176840,11000647,10920059,10954760,10882764,10865274,10584044,10535433,10460816,10359388,9366580,7722205,1870648,2043016,2314422,3185634,3683458?report=DocSum&format=htmlNIAMI'Nitrites in Acute Myocardial InfarctionB%`'`STEMIRzv`k0J0D0f0 PCIvMR5Rn0N]xx00000Ylk0006-8e_n0h^X000.~\o0000Z0,{IIvf 0 NICE Combi&Nifedipine and Candesartan CombinationNO(uϑn0Cabbnifedipine AIIS[SObbcandesartanuO(uBvlh0candesartanXSrbNn0聊^Rg0k0nifedipine candesartanuO(ubNo0@'W000000J00s0NOwn0pg0candesartanXSrbN0QP00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15662234?report=DocSum&format=html NICE-StudyENippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study62W|?\u`k0J0Q00_@{0000b6RRg0RW000000000dRh0RW00000dRh0g0k0NICS-EH@National Intervention Cooperative Study in Elderly Hypertensivesp_@{0000n0b6Rk0[Y00Cabbnicardipineh0000000|)R?\trichlormethiaziden0Rg0k0M'W0_@{0000b6RRgnicardipineR"trichlormethiazide0Nhttp://www.ncbi.nlm.nih.gov/pubmed/10567194,11675939?report=DocSum&format=htmlNiigata Preventive Medicine@STpu8^h0ؚ;^n0gYS.~o0_?b0}RAF zvu000n0XRh0#Y000 000000000000o0AFn0000X'Yh0#Y000Whttp://www.ncbi.nlm.nih.gov/pubmed/16996849,18285562,18332275?report=DocSum&format=htmlNINDS rt-PA Stroke Study7National Institute of Neurological Disorders and Stroke]zvu3BfNQn0t-PAk000@hn㉬g000003K0g_n0[nRgL0U00k0wgc}Y00K00i01t^NQn0{kNN2Rgt-PAR"000000^n09eURgt-PA00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/10362821,11735758?report=DocSum&format=htmlNIPPON.Nippon ICD Plus Pharmacologic Option Necessity<_[0}RVF 0_[;bVT `k0J0Q00b Nteamiodaroneh0 i0Wd0}RhVICD uO(uRgn0i08Nobo< ri Dual Antiplatelet Therapy as Appropriate DurationGdRnQ'`0000biolimus A9nQ0000 i0Ok0J0Q002dRuO(ub@\gBvlDAPT n0i[egn0i,{IVvf 0 NIPPON DATAnNational Integrated Project for Prospective Observation of Non-communicable Disease And its Trends in the AgedCAD03RS-N0CVD{kn0000UO00000\Ob/ SBP Nfo0hQt^bd\n07u'`g0CVD{kn0rzW0_0qSzVP[`0L0 DBP Nfo0ؚbg0o0 gaj0vo0j0W0/ TCo0hQ{kNh0ckn0O/ _?b0}Ro03RS-N{k _@{{k hQ{kNk0q_/ Bf@|$P Nfo0 ck8^WQh0D0H0i0CVD{kn0N,nVP[/ 40skn0|?\uOo07usYh00^|?\uOk0O00y0YO}TL0wD0/ HDL-C$Ph0hQ{kNo0v/ CKDo0CVD{kn0rzW0_0qSzVP[/ |o0CVD{kk0͑j0y_rR0g_0W0f0D00S'`L0B000http://www.ncbi.nlm.nih.gov/pubmed/16998254,16467648,16529754,17526974,18197396,22296855,22308300,15913635,16864924,17363755,23877989?report=DocSum&format=html NIPPON DATA90 National Integrated Project for Prospective Observation of Non-communicable Disease And its Trends in the Aged90 Epidemiological Study on Glucose Intolerance (IGT)/ Diabetes (DM) and Cardiovascular Disease (CVD) Death in the General Population in Japan (NIPPON DATA90) e,gNg00000n0͑00XY0|?\u ؚ@| 0NIRVANA$NIR Vascular Advanced North Americanb,{NNN0000NIR0000L0RN0000Palmaz-SchatzPS 0000k0ky0\rL0j0D0K00i0kX[rzsb6RRgNIRPS*09K0g_n0 g[_0000b6RRgNIRPS0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11152830?report=DocSum&format=htmlNISNationwide Inpatient Samplec2000^ 10t^k0s|Vg0eLU00_0AF000000093,801Nk0J0D0f0 TuOuzvuso06.29%g0 g0YK0c0_0n0o0_ӁTuOu0SJ00s0ubn0t^0000000eLNpeo0TuOuh0 gak0#0Nhttp://www.ncbi.nlm.nih.gov/pubmed/27012780,24061087?report=DocSum&format=htmlNNECVDS1Northern New England Cardiovascular Disease Studys|Vn0Nothern New Englandk0J0D0f0 _@{u`lBvn0ꌒ09eUW0}Q00S0h00vvh0W0f0;Nvk0gW0f0D00Nothern New England Cardiovascular Disease Group;S+^ xvz ubwT k000 L}vvQR000000000PCIs n00^9eUn0i0rhttp://www.ncbi.nlm.nih.gov/pubmed/12505219,11263600,11157714,11113048,10483947,10483948?report=DocSum&format=htmlNOBLE7Nordic-Baltic-British Left Main Revascularisation StudyudRnQ0000DES k000PCIn0CABGk0[Y00^R'`0ie h0_egn0M'Wg0k0SBPn0M'W^o0_egL0 gak0'YM0D00n0n03RS-NL0diltiazemg0 gak0\j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/10972367?report=DocSum&format=html NORDISTEMIKNorwegian Study on District Treatment of ST-elevation Myocardial InfarctionPCIe-~0g0100^400kmn0ݍk0B0000000n00Wen0;SBve-g0@hnBvl0[eW0_0%`'`ST NfW_K{h^X`k0J0D0f0 PCIe-x0n0Qe%`,dh0_egn0ischemia-guided strategyh00k02K0g_n0{kN Qh^X 3RS-N en0_K{Z@b6RRgQe%`,d_eglBv0Ehttp://www.ncbi.nlm.nih.gov/pubmed/19747792?report=DocSum&format=html2,dݍL0100-400kmn0x0M00Wk0J0D0f00 ST NfW_K{h^X`n0Qe%`,dk000PCIo0 gR0NORSTENTNorwegian Coronary Stent TrialLsNn0DESh0BMSn0wg000-0000000'Y!jkfg0i05t^_n0hQ{kN 6qzvu^{kv_K{h^Xn0T0000000DESR"BMS0Nhttp://www.ncbi.nlm.nih.gov/pubmed/27572953,27573082?report=DocSum&format=htmlNORVITNorwegian VitaminE0000B0000000NO NBvl k000_K{h^Xn0Qzv 3RS-N QRu`z6q{kn00000h0kW0_0 gaj0b6RRgo0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16531614?report=DocSum&format=htmlNorwegian Vitamin Trial2_K{h^Xe_`k0J0D0f0 0000Bk0000000000o0NO NW0_0L0_@{u`N2Rgo0000Z00NRMI*National Registry of Myocardial Infarction_@{u`^e_Og0 eQb-Nn0{kNso0O g000VP[peh0v/ sY'`o07u'`k0ky0un0j0D04XTL0YO0bQ{kNsL0ؚD0L0 S0n0'`]o0Rbk04OD0.~\/ %`'`_K{h^X_n0{kNso0sY'`n0{0F0L0ؚD0L0 000000000n0 YSk00055skOg0o0'`]L0\U0O0j0c0f0D00/ PCISj0e-g0n0STEMIk0[Y00primary PCIo0t^0XRW0f0D000n0n0 @hnBvl0xbY00e-0B00 QLpAmln0i_o0e-k00c0f0puj00/ ^STEMIg0o0 TIMI risk index Nfk04OD0{kNsL0kvk0 Nf0ihttp://www.ncbi.nlm.nih.gov/pubmed/22089719,22357832,19858434,19948977,16630990?report=DocSum&format=htmlNTP6Nippon Medical School, Tohoku University, Pitavastatin'2W|?\uTuOؚ0000000@u`k0J0Q000000dRk000NeQf0 pu8^u |?\uNU-HITbNihon University Working Group Study of Low-dose Human ANP Infusion Therapy during Cardiac Surgery`00_?b'`00000)R?\0000hANP leQL0__jJ00s0N_jk0S|0Y0q_0i0hANPk000NJ00s0_Ow\O(uL0:yU00 S_n0TuOuzvuL0b6RU00 wgN_L09eUvs 0000 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20413036?report=DocSum&format=htmlNU-HIT Trial for CKDkNihon University Working Group Study of Low-Dose hANP Infusion Therapy during Cardiac Surgery Trial for CKDeCABGeLBfn000_?b'`00000)R?\0000hANPcarperitide NO(uϑn0 gR'`0i_'`000000lBv12K0g-Nbko0 @h_uPPTS N2k0J0D0f024K0g}}lBvk0[W0^R'`g0B00h0D0F0N0i<01t^lBvn02t^lBvk0[Y00^R'`o0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27245485?report=DocSum&format=htmlOctopusN00000QR0000KbSh000000KbSh0n01t^_n0_Ӂ0^J00s0(u[Rg0k01t^_n0_Ӂ0^o0]L0j0D0L0 00000Sn0{0F0L0(u[RgL0ؚD00Whttp://www.ncbi.nlm.nih.gov/pubmed/12556542,17312289,15381650?report=DocSum&format=html Octopus IIt00000_0000h0_\Pbk0W0j0D0 QR0000Sh0_egn000000KbSn00000X[sJ00s0聊^0^0k000000So000000S000_K{0000L0\U0O0 T z^k0[hQg0B0c0_0L0 3K0g_n00000X[so0NOK0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/14702424?report=DocSum&format=html Octopus Study,Long-term cardiac < and neurocognitive outcome.OPCAB*o0BMS**h0ky0[hQ'`o0 TI{ @LQ^Sn0000L0NO NW0wRL0o}Yg0B000O'Donoghue M, et al.T^ST NfWACSk0J0D0f0 7u'`J00s0ؚ000sY'`g0o0egOrvlBvo0 Tik0{kN _K{h^X ACSk000QeQb0b6RY000Ne NO000sY'`g0o0OX[vlBvL0 gRg0B000O'Donoghue ML, et al.f^ST NfWACS`k0J0D0f0 egn0OrvlBvo0|?\uTuOuOh0^TuOuOn0_@{00000 TI{k0b6RY000_0`0W0 OrvlBvk000^{kv_K{h^X000n0b6Ro0|?\uTuOuOn0{0F0L0'YM0D00F0g0B000ODYSSEY ALTERNATIVE2dRN Nn00000k0 N_[n0`LDL-C}190mg/dL k0J0D0f0 bPCSK9[hQ000000000bSO000000alirocumab 75/150mg 1V/21v NbNo0241_n0LDL-CL0ezetimibe00 gak0NOO096 vs 154 mg/dL *</sup> 0Nhttp://www.ncbi.nlm.nih.gov/pubmed/26330422,26330423?report=DocSum&format=htmlODYSSEY LONG TERMLong-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying TherapybPCSK90000000bSOn0alirocumabn0wgLDL-CNO NRgJ00s0[hQ'`0UOY00h0h00k0 post hoc㉐gg0CVDx0n0q_0㉐g0241_n0LDL-CNO Nalirocumab0000<sup>*</sup>0post hoc㉐gj0L00alirocumabg0CVDNO N0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25773378,25773740?report=DocSum&format=html ODYSSEY MONOPCSK9;[alirocumabXSdRBvl75mg 1V/21 n0 gR'`h0[hQ'`0ezetimibeh0k0,{241n0LDL-C$Pn0000000K00n0NO Nsg\NWNs^GW$P alirocumab 47.2% ezetimibe 15.6% <sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25037695?report=DocSum&format=htmlODYSSEY OPTIONS IPCSK9;[alirocumabn0Ro0 ezetimibeEZE n0R ATVn0Xϑ rosuvastatinRSV x0n0RfH0k0O00y0 gRK00i*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/26030325?report=DocSum&format=htmlODYSSEY OUTCOMESA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndromecؚ(uϑ~0_0o0g'Y(uϑn00000lBvk00c0f00j0J0ꌳ000000 Noj0ACSe_`k0J0D0f0 PCSK9;[alirocumabn0Ro0 0000k0O00y0Z@'`CV0000Qzv0000b6RW0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/30403574,31117810?report=DocSum&format=htmlOldgren J, et al.eN%`'`gn0%`'`QuP`k0J0D0f0 b@\gBvlx0n0eL}SbQVn0Rk000_@{0000o0B00 z^n\W0_0L0 Q@000o0'YM0O0XR0Q@000o02dRuO(ub@\gBvlx0n0Rk000Wfk0XRW0_00OLIVUSgImpact of Olmesarten on Progression of Coronary Atherosclerosis: Evaluation by Intravascular Ultrasound)ARB olmesartann0QR00000'`lxSu2U\b6Rn0S'`L0:yU00_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/20202514,20202515?report=DocSum&format=htmlOMEGAPsLn0000000k0We0D0_0lBvk0n-3YO NTx000-3x 0RW0_04XTn0N_9eURg0i0_Ӂz6q{k000-3xRR"sLlBv0Nhttp://www.ncbi.nlm.nih.gov/pubmed/21060071,21060074?report=DocSum&format=htmlbRandomized Trial of Omega-3 Fatty Acids on Top of Modern Therapy After Acute Myocardial Infarction2%`'`_K{h^XK001t^_n0_Ӂz6q{ko01.5%h0NOO0 0003xn0_Ӂz6q{kb6RRgo0000Z00 OMEGA-PCISOMEGA-3 Fatty Acids after PCI to Modify Responsiveness to Dual Antiplatelet Therapy2.z^n0b@\gBvlaspirin clopidogrel x0n0000-3 PUFAn0Rk000 b@\g\O(uL0X7_U000K00i<030e_n0P2Y<sub>12</sub> reactivity index000-3o00000k0ky022.2%NOO0 PCI_n0clopidogrelk000b@\g\O(uo0X7_U00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20394870?report=DocSum&format=html OmniHeart;Optimal Macronutrient Intake Trial to Prevent Heart DiseaseHp4lSirBdSϑn0N萒00000B00D0o0NO NTxk0NH00S0h0k000 00M'WW0 $PL09eUW0 c[_@{0000zvu000L0NO NW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16287956?report=DocSum&format=htmlOmniheart Feeding StudyaThe effects of carbohydrate, protein, and fat intake on cardiovascular risk factors: main results,p4lSir0ˆ}v NTk0NH00S0h0k000 00M'WW0L09eU _u`000L0NO N0On-TIME;Ongoing Tirofiban in Myocardial Infarction Evaluation Trial@\gGP IIb/IIIaS[SObbtirofibann0MRbNL0h^XN@{IRV n0QLpAmk0S|0Y0q_0 bNBfg0k0egn0tirofibanbNYo000000[0R@w_n0bNYk0ky0 PCIMRn0IRVn0TIMI grade 3n0LpAm0 gak09eUY00S0h0o0j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/15140531,15808754?report=DocSum&format=htmlOn-Time5Ongoing Tirofiban in Myocardial Infarction Evaluationq%`'`_K{h^X`k0J0D0f0 PCIeLMRn0@\gGP IIb/IIIaS[SObbtirofibann0egbNk000_K{n0QLpAmL0< 9eUW0 QRn0@hL0 gak0NO NW0_00n0n0 TIMI grade 3o00000h0 ga]o0j0K0c0_00 On-TIME 27Ongoing Tirofiban in Myocardial Infarction Evaluation 2pPCIe-0R@wMRn0@\gGP IIb/IIIaS[SObbtirofibann0ؚ(uϑ0000bNYL0聊^0^k0S|0Y0q_0iY00030e_n0;N g[_0000b6RRgtirofibantirofiban^bN*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20510211?report=DocSum&format=htmlfOne Year Follow-up of the Melody&trade; Transcatheter Pulmonary Valve Multicenter Post-Approval Study070000000k0J0Q00Melody&trade;L}00000R_n060g_n0@LRKaK000_0__jo0o}Y0ONEASTOngoing Evaluation of Depressor Effect and of Combination Therapy with Telmisartan and Low-dose Hydrochlorothiazide in Patients with Hypertension Uncontrolled on Amlodipine TreatmentXCabbamlodipineg0@'W0000000g0M0j0D0ؚ@'W`k0J0Q00ARB telmisartan )R?\hydrochlorothiazideuO(ubNn0 gR'`n0i0ONTARGETPOngoing Telmisartan Alone and in Combination with Ramipril Global Endpoint TrialbONTARGETfARB telmisartann0ACE;[ramiprilk0[Y00^R'`L0000_0L0 telmisartanh0ramipriln0uO(ubNn0 gR'`o0000Z0 g[NaL0XR0Z@'`_u` |?\u 3_thttp://www.ncbi.nlm.nih.gov/pubmed/18378520,15215792,28390695,23212996,22192672,22110105,21947289,21357827,19770395,18707986,17339550?report=DocSum&format=htmlPONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial_@{u` |?\u0 gY00ؚ000`k0J0D0f0 ARBtelmisartan n0ACE;[ramipril k0[Y00^R'`L000000N!k0000000o0_@{{k _K{h^X 3RS-N F0c0@'`_ NhQk000eQb0_['`o0telmisartann0eL000o}Y0OPALS)Ontario Prehospital Advanced Life SupportmuX[sk0[Y00egd0}RJ00s0eQbMRn0ؚ^Qe}TulALS 00000n0Rg YPJ00s0eQbMRn0͑{j0`k0[Y00ALSn0Rg0i0egd0}Rh0giSU00_0Qe%`;SBv0000k0ALS0RH0f00uX[so09eUW0j0K0c0_00ghttp://www.ncbi.nlm.nih.gov/pubmed/9701301,9867885,10199426,15306666,10424933?report=DocSum&format=htmlOPERAHOmega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation?hTSgn0n-3YO NTxPUFA n0bNL0S_n0_?b0}RAF 0b6RY00K00iY000AFPUFAR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/23128104?report=DocSum&format=htmlHOmega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation@_ӁKbSeL`k0J0D0f0 000-3xn-3 PUFA0000000 n0hTSgbNk000S__?b0}Rb6RRgo0000Z00vOptimal Duration of DAPT Following Treatment with Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese PatientsD0000000g0n0zotarolimusnQ'`0000eLOk0J0Q002dRuO(ub@\gBvlDAPT n0i[egphase IV OPINIONcOPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON PCIeLBfn0;uP:el @{QIQr^ ned\l vs @{QlOPTICFOptimal Pharmacological Therapy in Cardioverter Defibrillator Patients1ICD0000b6RRgamiodarone ne sotalolneXSrbN*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16403928?report=DocSum&format=htmlROptimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients4NTICD i0Ok0J0D0f0 nek0amiodaronen0RbNk0000000n0000L075%NO N0OPTICUS1Optimization with ICUS to Reduce Stent RestenosisR0000Qrzb6RRg0QRQlICUS 000k000 i0n04XTh0 QR q_000k000 i0n04XTh0g0k0Qrzs QlBvsICUSR"QR q_0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11560848?report=DocSum&format=htmlOPTIMAALROptimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan^00000000IIS[SObblosartann0{kNb6RRg0ACE;[captoprilh0k0captoprillosartan0_['`o0losartancaptopril*0rhttp://www.ncbi.nlm.nih.gov/pubmed/12241832,19383732,16891382,16325035,15618041,15542278?report=DocSum&format=html OPTIME-CHFcOutcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart FailureZjnlBvk0RH00000000000 III;[milrinonen0wgYlL00000009eUY00K00i060eNQn0_@{u`k000/}MzeQbepemilrinoneR"00000Whttp://www.ncbi.nlm.nih.gov/pubmed/11911756,15867182,12651048?report=DocSum&format=htmlOPTIMIZEOptimized Duration of Clopidogrel Therapy Following Treatment with the Zotarolimus-Eluting Stent in Real-World Clinical Practice@wg3K0g h0wg12K0g n02dRuO(ub@\gBvl0kY000}聊^e3 g[Nawgn0wgk0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/24177257?report=DocSum&format=html OPTIMIZE-HF^Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure00000k0We0O0lBv 000000chYlBvL0 lBvn0ꌒ09eUY00K00iY000S.~_jL0NO NW0_0uOB00D0o0kvO_00_0_ NhQk0J0D0f00 S.~g@'Wo0{kNJ00s0TuOun0rzW0_0N,nVP[g0B000SBP120mmHguOo0irlBvk0K0K000Z0N_L0 No0{http://www.ncbi.nlm.nih.gov/pubmed/19130987,18652942,18617067,17707182,17309900,17200476,17090768?report=DocSum&format=htmlOPUS-1(Optimal Angioplasty and Primary Stentingx00000000< h0PTCAJ00s0f[0000n0Rg (u0k06K0gNQn0{kN _K{h^X _ӁKbS jv@{n0@LQ^SN2Rg00000000PTCA*0RV00000000000n0eL0ؚMj0L00 6K0gn0s^GWub000o0 Ti0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10881893?report=DocSum&format=html OPUS-TIMI 16>Orbofiban in Patients with Unstable Coronary Syndromes-TIMI 16]@\gGP IIb/IIIaS[SObborbofibann0wgbNk000%`'`QuPn00000Qzvb6RRg0i030e_n0{kNsL0orbofibang0N`Yk0ؚK0c0_0_00fB}N0http://www.ncbi.nlm.nih.gov/pubmed/10889124,18565400,16880323,15936606,15824203,15541835,12912804,12578870,11586953,11079651?report=DocSum&format=htmlORBITBOral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit ThrombosisbL}S@\gGPIIb/IIIaS[SObbxemilofibann0wgbNk000 gR'` [hQ'`J00s00^0i000000 00000k0[Y00@\gQƖb6RRgxemilofibanR"000001998t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/9751674?report=DocSum&format=html>Outcome of Hospital Rectilinear Biphasic Investigational Trial+bY_\Pbkn0d0}Ri(uOk0J0D0f0 Nv'`n0d0}Ro0XSv'`n0d0}Rk0ky0*QMO'`0:y[0Z00ORBIT-AFFOutcomes Registry for Better Informed Treatment of Atrial Fibrillationb@\gBvlaspirin h0bQVOAC uO(un0[Ka CVD^TuO`k0J0Q00uO(ubNn0[e0gW0 uO(uh0#n0B00VP[ uO(uk000Q@000L0XRY00K00iOpen-Label Study of Long-Term Evaluation Against LDL-C 1 and 2;jnlBvx0n0bPCSK90000000bSOevolocumabRk000wg[hQ'`h0 gR'`,{IIe,{IIIvf 0 OSLER-1, -2EOpen-Label Study of Long-Term Evaluation against LDL-C Trial-1 and -2obPCSK90000000bSOevolocumabn01t^_n0[hQ'`h0LDL-CNO Nn0UOh0CV0^k0[Y00 gR'`0c"}vk0㉐g0 g[Nao069.2% bN-Nbko02.4%0LDL-C CVC0000o0jnlBv00 gak0NO N0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25773607,25773740?report=DocSum&format=htmlOslo Heart TrialTߘNn0 YSk000@n0000000$Pn0NO N yYqL0QR_u`zvus0NO NU0[00K0i0F0K00i0ꌹRgNeQ[gq0_K{h^X0z6q{kb6RRgNeQ0000*01981t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/6118715?report=DocSum&format=html Oslo StudyiS.~g@'Wh0b5_g@'WDBP n0i0a00L0{k'`3RS-Nn07_D0000VP[g0B00K0 ~0_0{k'`3RS-Nn0000k0#Y000000000 U00k0J000L0X[(WY00K0i0DBPn0eL0007_D0NwVP[0J000o00Z00Dhttp://www.ncbi.nlm.nih.gov/pubmed/8557969?report=DocSum&format=htmlOvA'Office versus Ambulatory Blood Pressureg1uLR N24Bf@'WL0YegBf@'Wg0te_0_@{0000J00s0{kNn0N,nVP[h0j00K00i024Bfn0SBPJ00s0DBPؚ$Po0 YegBf@'W,n[$PJ00s0000VP[g0te_0 _@{0000n0N,nVP[g0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12802026?report=DocSum&format=htmlPOffice versus Ambulatory Blood Pressure Yeg@'W 1uLR N@'W[ABP]n0_@{0000N,n0iY0000㉐g #Yeg@'W 1uLR N24Bf@'Wn0_@{0000N,nk0]o0000Z00OVATION|Olmesartan and Valsartan Anti-arteriosclerosis<  Trial in Patients with Mild-Hypertension: Using Three-dimensional Serial IVUS7uؚ@'Wu0TuOW0_0PCIeL`k0J0Q00AIIS[SObbARB n0egbNk000bRlxS\O(un0i0 ؚ@'W Z@'`_u`OVERTUREKOmapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events{vasopeptidase;[omapatrilath0ACE;[enalapriln0 gR'`0k0omapatrilato0hQ{kN YllBvL0_j0_ NhQk000eQbn00000NO NU0[0_0L0 enalaprilh0ky0f000 gRh0D0F0S0h0o0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12186794?report=DocSum&format=htmlOXVASCOxford Vascular Studyt^b0OU0Z0Y0y0f0n0%`'`PAD0000%`'`Z@ %`'`ӁhVZ@ ͑uZ@ 0yr[W0 zvus 0^ qSzVP[ zvuMRn0N2vlBv wgN_0i<0+ghR0000n0聊^vq_o0^8^k0'YM0D00`n0'YJSL0]0n0Nn0@{Wn0u`0TuOW0 lBvSj0qSzVP[0peO gW0f0D00k00K0K000Z0 zvuMRn0lBvso0NOD00Nhttp://www.ncbi.nlm.nih.gov/pubmed/28622955,26350058?report=DocSum&format=htmlPABA-CHFPulmonary Vein Antrum Isolation versus AV Node Ablation with Bi-Ventricular Pacing for Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure|YSh0?b[P}{0000000 i0Wd0}RhVk000!N[000000k06K0gn0EF 6RikLݍ Minnesota Living with Heart Failure000YS?b[P}{0000000 !N[00000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18946063?report=DocSum&format=htmlPABA CHFPulmonary Vein Antrum Isolation vs AV Node Ablation With Biventricular Pacing for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure[uP'`_?b0}RJ00s0_ NhQ`k0J0D0f0 0000000000000k000Y▢0000000o0?b[P}{0000000 !N[00000 000QOL __jJ00s0SO_j09eU0PACC'Prospective Army Coronary Calcium StudyKQRu`n00000000000h0W0f0 ~0_0000VP[9eUn0_00n0NeQh0W0f0n0 P[000000000ed\dq_k000QRn0wppSiQn0 g(u'`0i0Whttp://www.ncbi.nlm.nih.gov/pubmed/18387433,12570942,10220644?report=DocSum&format=html PACCOCATH0ISRKTreatment of In-Stent Restenosis with a Paclitaxel-Coated Balloon CatheterDpaclitaxel000000000n0 gR'`h0[hQ'`0i06K0g_n0ifg@{_ d1Yb6RRg0000^0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17101615?report=DocSum&format=htmlPACEIPrevention with Low Dose Aspirin of Cardiovascular Disease in the ElderlykNO(uϑaspirinbNk0J0Q0000000000 1=s _@{|u Yzvus0i000000000o0o}Y0S0n000000fn000000,gf15000O04t^ g0n0_@{{kNs50%NO Nn0iQRo020%0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8201151?report=DocSum&format=html#Pacing to Avoid Cardiac EnlargementLS[_\00000o0][0000000`SU0[0][_j0NO NU0[0_012K0g_n0EF ][S.~+gg[Mz L0 S000o0!N[00000k00c0f0b6Rg0M0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19915220,19915219?report=DocSum&format=htmlPACIFIC@Potential Angina Class Improvement from Intramyocardial Channels@0000(uD0_0L}vv_K{Q@LQ^SPTMR n0[hQ'`J00s0 gR'`0i0PTMRo0QOL09eUY00L0 u}TN_o09eUW0j0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11095257?report=DocSum&format=htmlMPrevention with a Combined Inhibitor and Folic Acid In Coronary Heart DiseaseTIx2kn0bNϑ L00000000o^k0S|0Y0q_0i0Ix2.0mg/e 0.2mg/en0D0Z0000000000o^0 NR0_0L0 NO Nso02.0mgn0eL0'YM0D00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12395803?report=DocSum&format=htmlPACK+Prevention of Atherosclerotic Complicationsu@\gQƖ0b6RY0000000S2S[SObbketanserinn0 gR'`0i0@{0000ketanserinR"00000{kNN2Rg0000ketanserin0ketanserino00000U1Y'`)R?\n0 g['`07_000Dhttp://www.ncbi.nlm.nih.gov/pubmed/9546928?report=DocSum&format=htmlPACT5Plasminogen-Activator Angioplasty Compatibility Trial_wBf\O(u0NO(uϑ@hn㉬BvlL0h^XNRIRA n0egX[s0 NfU0[00K0 gR'`h0[hQ'`0i0X[Rgrt-PA000003RS-N0'YQ@zvu ][_jrt-PAR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/10588209?report=DocSum&format=htmlPADPublic Access Defibrillation7_ulCPR n0}0SQ0_0N,^lL0RSOY_d0}RhVAED 0O(uW0_04XT uX[bpeL0XRW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15306665?report=DocSum&format=htmlPN,n0NL0RSOY_d0}RhVAED k000Qe}T0000000Lc0_0000000g0 _uSCRP 000000n00h0kW0f0ubY_\Pbkn0uX[sL02 Pk00PAIMS/Plasminogen Activator Italian Multicenter Study`@hnn0 gR'`k0d0D0f0@hn㉬rt-PAh0streptokinaseSK Yllg0k0QLpAms h^Xgn0X[srt-PAR"SK0EF9eURgrt-PA0000* SKR"00000Dhttp://www.ncbi.nlm.nih.gov/pubmed/2491867?report=DocSum&format=htmlPainFREE Rx IIAPacing Fast Ventricular Tachycardia Reduces Shock Therapies TrialND0_[;bFVT n0lBvh0W0f0n0b;b00000o0 l0000h0ky0FVT00000n0c}Bf 1Y^y FVTR z6q{kn0zvuk0]L0j0O0QOL09eU0Whttp://www.ncbi.nlm.nih.gov/pubmed/15492306,16022960,15927965?report=DocSum&format=htmlPALLASXPermanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy}jnlBvk0RW0_0IIIb Ntedronedaronen0;N@{0000b6RRg0iub0R@wMRk0Qe%`Qe}TXk000egn0@hnBvln0Rgn0i0ub0R@wMRk0@hnBvl0YY00S0h0L0lBvn0E00N2W0F000Dhttp://www.ncbi.nlm.nih.gov/pubmed/1947661?report=DocSum&format=htmlPatti G, et al.6PCIeLOk0J0D0f0 ؚ(uϑ0000|dRMRbNo0hTSgn0_K{h^X 30eNQn0 g[_00000 gak0b6R0PAVE!Post AV Nodal Ablation Evaluation@?b[P}{0000000lBv0W0_0ba'`_ NhQ`k0J0D0f0 !N_[00000o06RikLݍ g'Yx }BdSϑ KRBf0 gak09eU0PC-trial+the Physical Counterpressure Maneuver Trial< Nk0nYuW0_0@m0 -k00i0Y0Physical Counterpressure(PC)lk000 gak01Y^y0N20 PCI-CLARITY1Study set to change practice: PCI-CLARITY results/PCIeLMRn0bQVclopidogrelbNk000{kN _Ӂzv\OQzv 3RS-NL046%NO N0PCI-ExTRACT-TIMI 25 ExTRACT-TIMI25n0PCI0000000000 xExTRACT-TIMI 25f@hnBvl0SQ0_0%`'`ST NfW_K{h^X` g0bQVBvl0uO(uW0_0PCIeLuOk0J0D0f0 enoxaparino0Q@0000XRU0[00S0h0j0O0*gR;uheparin000{kN _K{h^XQzv0 gak0b6R0PCI in the OATPCI in the Occluded Artery Tria%s|Vk0J0Q000000PCIn02t^n0(u[Rgo0iirlBvk0ky0f0NOD00PCIRSBNew York State Percutaneous Coronary Intervention Reporting SystemedRnQ'`0000n0O(uL0Sk0j0c0_0BfNn0{0F0L0000000000W0K0j0K0c0_0BfN000{kN/_K{h^XMI ^{kvMI jv@{0u Y@LQ^Sn0eLso0NOK0c0_0L0 {kNsk0]o0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/18391112?report=DocSum&format=htmlPEACEBPrevention of Events with Angiotensin Converting Enzyme InhibitionNsLlBvx0n0ACE;[trandolapriln0 NWN[0Rg0i0_@{{k ^{kv_K{h^X @LQ^Sb6RRgtrandolaprilR"00000{http://www.ncbi.nlm.nih.gov/pubmed/15531767,23414791,19940289,18025537,17631211,17372173,16801465?report=DocSum&format=html5[[QRu`k0J0D0f0 sLlBvk0ACE;[0RbNW0f00 _@{{k _K{h^X @LQ^S0b6R[0Z00_Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy*HMG-CoA reductase;[pitavastatinn0bRlxSn0i0PEARLPitavastatin Heart Failure.HMG-CoA reductase;[pitavastatinn0ba'`_ NhQ9eURgn0i0PEARL HF/Parallel Evaluation of RLY5016 in Heart FailureNba'`NӁu0 gW0RAS;[0bNW0f0D00^--NI{^_ NhQ`k0J0D0f0 en000008T@w9jL00000$P0NO N ؚ0000@u0b6R,{IIbvf 0Pediatric Heart Network_\PQ^Rt^00000uP`losartan11.0sk atenolol11.5sk k0J0D0f0 3t^_n0'YRWb'Yso0neatenololh0ARB losartang0 TI{0PEGASUS-TIMI 54Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Thrombolysis in Myocardial Infarction 54NO(uϑaspirinh0ticagrelor 2(uϑ90mg, 60mg 2V/e n0wguO(un0;N_@{0000b6RRgJ00s0[hQ'`0UO033K0g_n0_@{{k MI 3RS-Nb6RRgJ00s0TIMI'YQ@000ticagrelor 2(uϑ aspirinaspirin<sup>*</sup>0{http://www.ncbi.nlm.nih.gov/pubmed/25773268,25773507,29406853,27576775,27046160,27046162,27334486?report=DocSum&format=htmlPrevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 541_K{h^Xzvu_1.7t^n0aspirin g(u`x0n0P2Y12S[SObbticagrelorR0PEITHOPulmonary Embolism ThrombolysisjnvbQVBvlheparin x0n0@hn㉬tenecteplaseXSV0000bNk000@hnBvlRn0 gR'`h0[hQ'`0iY0007eNQn0hQ{kN~0_0o0@LRKan0NQ NhQ~0_0o04x}b6RRg07eNQn03RS-N -˄Qn0͑'Yj0Q@J00s030eNQn0͑{j0 g[0000000tenecteplaseR0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24716681?report=DocSum&format=htmldck8^@'Wn0%`'`-NI{^000^XhuPE `k0J0D0f0 jnbQVlBv @hn㉬tenecteplasen0XSV0000bNk000 7eNQn0{kN @LRKan04x}L0 gak0b6RU0000 Q@000 Nf0PENTUA(Pentasaccharide in Unstable Angina Study;m'`SQV,{XVP[0xbvk0;[Y00TbN|^fondaparinuxn04(uϑh0enoxaparin0kY00(uϑ-[phase 2 f09e~0g0n0{kN %`'`_K{h^X uP'`/!quP'`_K{Z@n0Qzvb6RRgfondaparinux 2.5mgR"4mgR"8mgR"12mgR"enoxaparinITT㉐g 0Q@so0NOO0]o0j0W00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15193678?report=DocSum&format=html*Pentasacharide in Acute Coronary SyndromesPEP-CHF8Perindopri< l in Elderly People with Chronic Heart FailureAACE;[perindopriln0 gR'`n0i0hQ{kN _ NhQk000N[Yn0eQbb6RRgperindoprilR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16963472?report=DocSum&format=htmlNؚbb5_g_ NhQ`k0J0D0f0 ACE;[perindoprilk000 gaj0hQ{kN _ NhQk000eQbn0b6RRgo0000j0K0c0_0L0 urh0__j09eUW0_00 PEPCAD-DESePEPCAD DES-Treatment of DES-In-Stent Restenosis with SeQuent Please Paclitaxel Eluting PTCA CatheterDpaclitaxel0000k000@{b_bSo0_egn0^0000@{b_bS000`gQ_ d1Y Qrz _0000n0b6Rk0*Q000Ehttp://www.ncbi.nlm.nih.gov/pubmed/22386286?report=DocSum&format=html PEPCAD II ISRZPaclitaxel-Eluting PTCA-balloon catheter in Coronary Artery Disease II In Stent RestenosisA0000QQrzOk0J0D0f0 dR0000000000DEB n0paclitaxelnQ0000DES 0QP0 gR'`L0:yU00_00PERFECTw EUROPA;European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease= trialn000㉐g 4_ NhQ04O0j0D0[[CADk0J0D0f0 ACE;[perindoprilo0360g_n0Qv_j0009eU0PERFORMPrevention of Cerebrovascular and Cardiovascular Events of Ischaemic Origin with Terutroban in Patients with a History of Ischaemic Stroke or Transient Ischaemic AttackeL}Sb@\gg0B000000000-000000000S[SOxbvbbterutrobanL0aspirink0ky0f0N!kN2Rgk0*Q00K0i0F0K00i<0{kv0^{kv3h^X {kv0^{kv_K{h^X ]0n0Nn0@{{k1Y@{k0dO0 n0T0000000terutrobanR"aspirin0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21616527?report=DocSum&format=htmlPERIGEEPURSUITn00000000 PERISCOPEjPioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation0pioglitazoneo0glimepiridek0ky0 gak0QRn0RlxSn02U\0b6RW0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/18378631,21211686?report=DocSum&format=htmlVQRu`0uOzvW0_02W|?\u`k0J0D0f0 00000bb'`9eUpioglitazoneo0SU00000RlO2dR glimepiride000RlxSn02U\0b6R0PERSEUSProspective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System0000000Tё'` D000000n0eW0D0paclitaxelnQ0000PESTAXUS Element n0[hQ'`h0 gR'`0_egn0PESTAXUS Express 2 h0kY00^R'`f012K0g_n0jvu Y NhQTAXUS ElementR"TAXUS Express 2000000000k0O(uW0_0eW0D0Tё 00000000k0Y00[hQ'`n0OULo0000Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/20493653?report=DocSum&format=htmlPERSUADE<Perindopril Substudy in Coronary Artery Disease and Diabetes8|?\u`k0J0D0f00 ACE;[perindoprilo0_@{0000n0v[0000EUROPAh0 TI{k0NO N0Peters SA, et al.#sY'`n0|?\u`o0 QRu`zvu000L07u'``0040%N NؚD00sY'`n0|?\u`o0 3RS-Nzvu000L07u'``0027%ؚD00Peterzan MA, et al.M@'W 0000 ?\xiXn0(uϑS_On07_U0o0bendroflumethiazidechlorthalidonehydrochlorothiazide0 PHANTOM-SYPrehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke Studyg3RS-N\(uQe%`ʎSTEMO n0tPAlBvYBfk0S|0Y0q_h0[hQ'`0i*</sup> eQb000HFpEF<sup>*</sup>EF-RecoveredR"HF-pEF0Nhttp://www.ncbi.nlm.nih.gov/pubmed/24799515,24799514?report=DocSum&format=htmlPHYLLIS0Plaque Hypertension Lipid Lowering Italian Study08Rn000000'`RlxSo0)R?\(HCTZ)g02U\W0_0L0 ACE;[fosinoprilg0o0W0j0K0c0_002U\b6Ro0HCTZ pravastating00000_00 0ؚ@'WlBvk000M'Wg0M0f0D00`k0pravastatin0 NWN[0W0f00vRvM'WRgo0000j0K0c0_00Z@'`_u` ؚ@'W pu8^uWhttp://www.ncbi.nlm.nih.gov/pubmed/15514192,20339154,11204308?report=DocSum&format=htmlPhysicians Health Study II=50skN Nn07u'`k0J0D0f0 0000000k000_@{u`N2Rgo0000Z011.2t^16N4,000N0t^ 0Physicians' Health Studybb@\gNO(uϑaspirinL0_@{{k0n\U0[00K0 ~0_0-0000L0Lvn0zvu0n\U0[00K00i0_K{h^X000NO Naspirin0000*03RS-N0po vb6R0000aspirin01989t^07ghttp://www.ncbi.nlm.nih.gov/pubmed/2664509,19103991,18702962,17130341,16418466,12939216,12900344,12045163,11948270,11468199,11368701,11207350,11070099,10920060,10899094,10761956,10769275,10636266,10525492,10493207,10193737,8602179?report=DocSum&format=htmlPhysicians' Health Study II0000EeCf0000EJ00s00000CwgbNk000_@{u`000L0NO NY00K00i0;N_@{0000n0b6RRgo0000Z00 0000000f10t^N Nk00_00ken00000000 g(uk000;N_@{0000000NOno0000j0K0c0_00Whttp< ://www.ncbi.nlm.nih.gov/pubmed/18997197,23117775,21788538?report=DocSum&format=htmlPIAF3Pharmacological Intervention in Atrial Fibrillationv_bpe000000diltiazem h0m_000000amiodarone n0i0a00L0o}Yg0B00K00i0_ NhQ#urn09eURgdiltiazemR"amiodarone0KR[amiodaronediltiazem0Nhttp://www.ncbi.nlm.nih.gov/pubmed/11117910,12909072?report=DocSum&format=htmlPiccini JP, et al.wamiodraonebNk000_Ӂz6q{kSCD n0000 _@{u`{k000L0NO N0ICD Ni_OB00D0o0^ i0Og0o0SCDN2L0g_g0M00L0 amiodraonek0}{kNb6RRgo0j0O0 02urzx0n0k'`000L02^5 Pk0X'YY000dronedaroneo0amiodarone000m_}cg0R0L0 g[NaL0\j0D00 dronedarone01000Ok0bNY00S0h0k000amiodarone000AFQzvL0228OXRY00L0 {kNL09.6O bN-NbkL0_j0 g[0000L062Ob6Rg0M00h0c[U0000PICXELNBenefits of a low dose combination on left ventricular hypertrophy reduction Q]['Y0 gY00ؚ@'W`k0J0D0f0 ACE;[perindopril)R?\indapamideo0ACE;[enalaprilXSrbN000]['Y0b6RW0_00 PIGEON-MSYPioglitazone Intervention for Coronary Atherosclerois in Patients with Metabolic Syndrome<000000000000uOk0J0Q0000000bb'`9eUpioglitazonen000000'`RlxSb6RRgn0i0bPilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Hospital Cardiac ArrestpThe Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: The NHLBI and CCTRN TIME TrialRg000L0shockable_[0}R !q'`_[;b n0bY_\PbkK0060RNQk0u]_bQ W0_0`k0J0D0f0 vj)n^032!k0W0_0NOSO)nBvlo034!k0O00y0 60g_n0ؚ^j0Nw0_h0W0j0D0uX[sL0ؚK0c0_044.4% vs 11.1% P0.12 0PIMI9Psychophysiological Investigations of Myocardial Ischemia2SOv |^yv0000 Nk0B00QRu``k0d0D0f0 _K{h^Xn0urk0q_Y00 }0]0n0_j^0f0_http://www.ncbi.nlm.nih.gov/pubmed/8921780,11956119,10362185,10334411?report=DocSum&format=htmlPimobendan-Enalapril Studyg000000000000pimobendann0wgbNn0聊^ gR'` @LRKa\O(u [hQ'`k0d0D0f0ACE;[enalaprilh0k0bN-Nbk _ NhQ`S _Ӂ{kpimobendanR"enalapril0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7925517?report=DocSum&format=htmlPioglitazone and RosiglitazoneO2W|?\u ؚ@u`k0J0Q0000000bb'`9eUpioglitazoneh0rosiglitazonen0@|x0n0 gR'`o0 Tij0L00x0n0 gR'`o0puj000PIONEER AF-PCIOpen-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary InterventionNO(uϑrivaroxaban P2Y<sub>12</sub>;[012K0g NO(uϑrivaroxaban DAPT1e6e12K0g n0[hQ'`0 jnv3dRuO(uBvlwarfarin DAPT h0kY000聊^vk0͑'Yj0Q@b6RRgrivaroxaban 2(uϑjnlBv<sup>*</sup>0Whttp://www.ncbi.nlm.nih.gov/pubmed/27959713,27881555,27881554?report=DocSum&format=htmlPISAPersantin In Stable Angina;Qb5_dipyridamolen0[hQ'`h0 gR'`0i0dipyridamolen0L}SbNo0[hQg0_['`0o}Yg0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/11549300?report=DocSum&format=htmlPIUMA7Progetto Ipertensione Umbria Monitoraggio Ambulatorialeo1uLR N24Bf@'Wambulatory blood pressure: ABP n0N_k0S|0Y0q_0i0_@{u`zvub6RRg}vcؚ@'WR"@'Wck8^ }vcؚ@'Wc}'`ؚ@'Wdipper nondipper00zhttp://www.ncbi.nlm.nih.gov/pubmed/7995639,15037557,15145106,12084601,11869856,11673343,11382727?report=DocSum&format=htmlPLAC IBPravastatin Limitation of Atherosclerosis in the Coronary ArteriesUHMG-CoA reductase;[pravastatinL0QRlxS Z@0000n0b6RRg0i09eU0_K{h^Xb6RRgpravastatin0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7594023?report=DocSum&format=htmlPLAC IICPravastatin, Lipids, and Atherosclerosis in the Carotid Arteries IIHMG-CoA reductase;[pravastatinn0Rg0i0Q-NSIMT n\Rgpravastatin00000IMT2U\0hQ_K{h^XMI b6Rb6RRgpravastatin0000*0^{k'`MI {kN0{kv0000 ^{k'`MI00000Dhttp://www.ncbi.nlm.nih.gov/pubmed/7572688?report=DocSum&format=htmlpA Placebo-Controlled Safety and Pharmacology Study of ALT-711 in Older Patients With Stiffened CardiovasculaturePLATFORMQRCT@{ q_CTA 000K00@LRKa0000000W0f0Q@AmNPϑkFFR 0UOY00CTA/FFR<sub>CT</sub>o0 OrvQR q_k0N00igh0W0f0[LSg0 [hQg0B00 90eNQn0^^X'`CADiQsL08^0000 gak0NOK0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/26330417,27470449?report=DocSum&format=htmlPLATINUMA Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System PROMUS Element for the Treatment of up to Two De Novo Coronary Artery Lesionsae00000000000Tёeverolimus nQ0000PtCr-EES n01t^_n0[hQ'` gR'`o00000000Tёeverolimus nQ0000CoCr-EES h0 TI{0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21470815?report=DocSum&format=htmlgA Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coron< ary StentvV g@{eu Yk0J0Q00eeverolimusnQ'`00000000000TёPROMUS ElementPtCr-EES n00000000TёXIENCE V/PROMUS0000CoCr-EES k0[Y00^R'`L0000_00PLATO(Platelet Inhibition and Patient Outcomes9%`'`QuP`g0ticagrelorL0clopidogrel00_@{00000b6R 'YQ@000n0 Nfo0j0W00http://www.ncbi.nlm.nih.gov/pubmed/19717846,19717845,24682844,23900047,23277305,22261200,21545948,21685437,21194870,20802246,21060072,20801498,20805430,20079528?report=DocSum&format=htmlVPrimary PCIL0N[U00f0D00ST NfW_K{h^X`k0J0D0f0 eb@\gticagrelor*o01t^_n0_@{00000clopidogrel000 gak0b6R0=%`'`QuP`g0ticagrelorL0clopidogrel00_@{00000b6R 'YQ@000n0 Nfo00j0K0c0_00Plourde G, et al.z:evQR q_h0PCIk0J0D0f0 >e\}f}ϑo0L}HjR0000n0{0F0L0L}'YR0000000Z0K0j0L00 gak0YK0c0_00S0n0]o020t^g0.~\W0f0D00S0h0K00 ]0n0聊^vao0 NxK0g0B00 L}HjR0000n0 gv'`0 NV0S'`o0NOD00POISE'Perioperative Ischemic Evaluation Trial9^_ӁSOk0J0D0f0 nemetoprololk000_K{h^X0+T0_0000o0b6RU00_00n0n0{kN000L0 Nf0POISE-2 #PeriOperative ISchemic Evaluation-2>^_ӁKbSeLOk0J0D0f0 hTSgn0aspirinbNk000{kN _K{h^Xn0 gaj0NO No0000Z0 ͑'Yj0Q@000L0 NfW0_00POISE-20P^_ӁKbSeLOk0J0D0f0 hTSgn02S[SO:Ro00000clonidine bNk000{kN _K{h^Xn0 gaj0NO No0000Z0 聊^ N͑j0NO@'WL0XRW0_00POLONIA,Polish-American Local Lovenox NIR Assessment\eu Yk0[Y000000eLMRn0bQVNORP[ϑheparinenoxaparin n0XQbNL0Qrz0b6RY00K00i0ifgQT d1Yb6R0Qrzb6RRg@\@bbNhQbN*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11136681?report=DocSum&format=htmlPONTIACyNT-proBNP Selected Prevention of Cardiac Events in a Population of Diabetic Patients without a History of Cardiac DiseaseORAS;[~0_0o0nek0007_SlBvn0_u`N!kN2Rg0 8^n0|?\u00h0kY0002t^_n0_u`k000eQb {kNb6RRg7_SlBv8^lBv*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23810874?report=DocSum&format=htmlPOPE$Post- operative Pericardial Effusion=_ӁKbS_n0_000000ؚ000`k0J0D0f0 NSAID *diclofenack000_YnQmn\Rgo0000Z00POPPSEPrevention of In-stent Neointimal Proliferation by Pioglitazone Study12W|?\u`n0QrzN2k0[Y0000000bb'`9eUpioglitazonen0Rgk0Y00iPOPular~Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in clopidogrel pretreated patients undergoing elective PCIjclopidogrel0MRbNW0_0__jv0000Ok0J0Q001t^_n000000@h'`0000N,nL0ؚD0point-of-carePOC @\g_jigo0 00000N00xADP :Rok000@\gQƖig0POSCH6Program on the Surgical Control of the HyperlipidemiasuRvVx0000SPIB k0000000000NO Nk000 hQ{kNsJ00s0QR_u`(CHD)k000{kNsk0[Y00q_0i0hQ{kN0CHD{kN2RgPIB[gq0Nn09eUL0CHDn02U\b6Rk0 g(ug0B00S0h007_O0:yU0Dhttp://www.ncbi.nlm.nih.gov/pubmed/2205799?report=DocSum&format=htmlPOSEIDONqRandomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathyba'`Z@'`_K{un0][_j[`k0J0D0f0 T.z00I|y^0}ހMSC L}_QleQ][k0100@b o0[hQg0MQuS_o0000Z0 QOL __jn09eUo0]y^0}ހh0 T z^g0 T.zMSCL0]y^0}ހk0N00F00S'`L0:yU000,{1/2vf: 30Oe130g 0POSH+Prospective Outcomes Study in Heart FailureCN_jn0`So033%g0eQbgn0^w0bO00n0n0 eQb-Nn0;Nj0TuOuL0dYU00_04XTo0N_j^`SOh0{kNs QeQbso0 Tig0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16624834?report=DocSum&format=htmlPOSITIVEPrimary Prevention of Major Adverse Cardiac Events (MACE) with Standard and Intensive Statin Treatment in Patients with Diabetes: Survival and Cardiovascular Event Assessments62W|?\u ؚ@'W0TuOW0_0ؚ0000000@uk0J0Q000000lBvLDL-C7_SNO NlBvh0jnNO NlBv0POSTqEffects of Postconditioning on Myocardial Reperfusion in Patients with ST-segment Elevation Myocardial Infarctiondprimary PCIpPCI _n0Z@000000000000k000pPCI_n0_K{QLpAmL09eUY00K00iY00030R_n0ST Nf[hQm1Y000000000000 pPCIR"pPCIn000Ehttp://www.ncbi.nlm.nih.gov/pubmed/24068776?report=DocSum&format=html Post CABG!Post Coronary Artery Bypass GrafteMzuivk0LDL-C0NO NU0[0_04XTh0-NI{^k0NO NU0[0_04XT J00s0warfarin0bNW0_04XTn0O(WY0000k0J0Q00rzu Y0k0RlxSb6RMzui-NI{^*0{kNsNO NMzui-NI{^0qhttp://www.ncbi.nlm.nih.gov/pubmed/8992351,18702964,11723015,11092659,10889125,10385497?report=DocSum&format=html Pounds Lost9Preventing Overweight Using Novel Dietary Strategies LostZ ˆ}v p4lSirn0ϑL0puj00nϑߘn0nϑRg0kY0002t^g0SO͑L0n\W0_0n0o023%g0 NO0000ߘk000i0n0h }k0͑p0J0O0K00OU0Z0聊^vk0an0B00nϑL0g0M0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/19246357,19246365?report=DocSum&format=htmlPOWER1Practice-Based Opportunities for Weight Reduction)_@{u`n0qSzVP[0 gY00nOk0J0Q00`nϑc\o0[bnϑc\h0 TI{k0 gR0PPARkThe Japan Working Group for the Assessment that the Pioglitazone Protects DM Patients Against Re-Infarction6_K{h^Xe_n0|?\u`k0J0Q0000000bb'`9eUpioglitazonen0MIQzvN2Rg0iY000PPPPrimary Prevention ProjectRNO(uϑaspirinJ00s00000Ek000wglBvL0_@{00000b6RY00K00i0aspirink00000b6RRgL0000_0L0 0000Ek0o00< 00j0K0c0_00`http://www.ncbi.nlm.nih.gov/pubmed/11197445,14633812,16418466,10912743?report=DocSum&format=html'Prospective Pravastatin Pooling Project}HMG-CoA reductase;[pravastatink000NO NBvln0QRu`0000 {kNk0[Y00Rg0 CARE LIPID WOSCOPSn00000poolW0f0i0pravastatino0QR{k ^{k'`_K{h^X0 gak0b6R0qhttp://www.ncbi.nlm.nih.gov/pubmed/7484829,11034935,12021218,11914249,11792135,11157690?report=DocSum&format=htmlPQRST.Probucol Quantitative Regression Swedish TrialYprobucolk000bؚ@ulBvL0'YR00000RlxSuk0NH00q_0i0QT[Mz R~n0|U0n0 YS 'YR00000RlxSun0uKak0 ga]o0000j0K0c0_00Dhttp://www.ncbi.nlm.nih.gov/pubmed/7977117?report=DocSum&format=htmlPRAGUEPrimary Angioplasty in Patients Transferred from General Community Hospitals to Specialized PTCA Units with or without Emergency ThrombolysisZ00000-Pn0j0D0000n0ubg0@hnBvl @hnBvl PTCA PTCA0k030eNQn0{kN Qh^X 3RS-Nb6RRgPTCA@hnBvl PTCA@hnBvl*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10781354?report=DocSum&format=html PRAGUE-12<!--2L-N-->;5t^1t^_n0P}g=KbSh0 TBfk0]?b00000000LF0S0h0k000 hTSgTuOu0XRU0[00S0h0j0O0m_V_s0ؚ0 wgN_09eUY00h0D0F0N0i<0;N!k0000000= gR'`1t^_n024BfECG Nn0m_]?b0000000[gq* [hQ'`30e_n0CVD N NhQn0TR"]?b0000000[gq0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22930458?report=DocSum&format=htmlPrimary Angioplasty in Patients Transferred from General Community Hospitals to Specialized PTCA Units with or without Emergency Thrombolysis-12T_?b0}R`k0J0D0f0 _ӁKbSBfn0Yyv]?b0000000SMazeKbS o0hTSgTuOu0XRY00S0h0j0O01t^_n0m__0^s09eUW0_0L0 聊^0^o09eUW0j0K0c0_00 PRAGUE 14H_ӁNYn0KbS0eLN[n0_@{u`CVD e_Ok0J0D0f0 SMRn0b@hBvlOgo0hTSgn0Q@'`TuOuh00_@{TuOuh00 gak0#[0Z00 PRAGUE-181 prasugrelh0ticagrelorn0 gR'`J00s0[hQ'`0vckW0,{IVvf 2 %`'`g0NN0f0K00n0clopidogrelx0n0R0fH0n0;^h0]0n0t1u 0^0iCabbamlodipinen0 gR'`0i0hQ{kNh0;N_@{0000k000eQbb6RRgamlodipine00000Mhttp://www.ncbi.nlm.nih.gov/pubmed/8813041,12798560?report=DocSum&format=htmlPRAMI5Preventive Angioplasty in Acute Myocardial Infarction[;egB}N= garz0 gY00^N@{x0n0N2vPCIn0 gR'`0iY000^{kv_K{h^X 㖻l'`r_un0T0000000b6RRgN2vPCI>[gqN2vPCI^eL *0Nhttp://www.ncbi.nlm.nih.gov/pubmed/23991625,23991624?report=DocSum&format=html/Preventive Angioplasty in Myocardial Infarctionc%`'`ST NfW_K{h^XSTEMI `k0J0D0f0 h^XN@{NYn0 garzu Yk00PCI0eLY00N2vPCIo08^n0N@{< n00x0n0PCIk0O00y0 230g_n0{kN0+T0_00000 gak0b6R0 PRATO-ACSProtective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients with Acute Coronary SyndromeP4ln'`n00000|dRrosuvastatinn0%`'`gYbvRg0iY000 q_dRbN_72BfNQn0%`'` q_dRNub6Rrosuvastatin[gq*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24076283?report=DocSum&format=htmlProtective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary SyndromeE0000bNtkn0j0D0^ST NfW%`'`QuP`k0J0D0f0 QR q_MRn0ؚ(uϑrosuvastatinbNo0 %`'` q_dRNun0zvu0b6R0 Pre-RELAX-AHFRelaxin in Acute Heart Failure?00000relaxin o0|T8TV㖒0}TW0 ]0n0Nn00^09eUW0 [hQb01[g0M000n0g0B00phase IIbf 0Nhttp://www.ncbi.nlm.nih.gov/pubmed/19329178,19329180?report=DocSum&format=html>Relaxin for the Treatment of Patients with Acute Heart Failurebck8^0ؚ@'Wn0%`'`_ NhQ`k0J0D0f0 relaxin00000 *k000egk0urL09eU ]0n0Rgo0c}W0 0^L09eUW0_0phase IIf 0phase IIIn0(uϑo030g/kg/e0PREAMIFPerindopril and Remodeling in Elderly with Acute Myocardial InfarctioneACE;[perindopriln0 gR'`0i{kN _ NhQk000eQb ][000000b6RRgperindopril0000*0{0h00i0L0000000N2k0000n0g0 0^o09eUW0j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16567606?report=DocSum&format=htmlGPerindopril and Remodelling in Elderly with Acute Myocardial InfarctionIؚbn0_K{h^X_`k0J0D0f0 ACE;[perindoprilbNk000{kN _ NhQk000eQb _Ӂ000000n0v[000L038% gak0NO N0PRECISEHProspective Randomized Evaluation of Carvedilol on Symptoms and ExerciseLnecarvediloln0聊^Rg0i0uP9eURgcarvedilol 00000EF9eU0{kNb6RRgcarvedilol0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8941104?report=DocSum&format=html PRECISE-IVUSuPlaque Regression with Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasoound4PCI0eLY00ؚ0000000@u`k0J0Q0000000008TS0Tb;[k000QR0000.~0 PRECISION]Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or NaproxenxbvCOX-2;[celecoxib000000 n0CV0^j0i0n0[hQ'`0^xbv^00000'`bpun0ibuprofen0000000 naproxen000000 h0k0CV[hQ'`Q@{k0+T0CV{k ^{kv_K{h^Xe3RS-N k0J0D0f0celecoxibn0ibuprofen naproxenk0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/27959716?report=DocSum&format=html PRECOMBATPremier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery DiseaseaCABGh0sirolimusnQ0000k000PCIn0;N_@{03@{0000b6RRg0kY00^R'`f0;N_@{03@{0000b6RRgsirolimusnQ0000CABG*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/21463149,25787197?report=DocSum&format=html:^Ow];Ny^u Yk0[Y00PCIsirolimusnQ'`0000 L0CABGn0NflBvk0j00F00S'`L0:yU0000PRECORISs64R0000000CTUOk000h0 [n0k0j0D0^_S'`n03h^X~0_0o0TIA`n05Nk01NL0g"50%n0!quP'`CAD0_egn0000VP[k0RH0 g"50%n0rz0 gY003@{rzo0g"50%n0rz0 gY00!quP'`CADh07_O0#0Ehttp://www.ncbi.nlm.nih.gov/pubmed/20351236?report=DocSum&format=htmlPREDIMED]Prevencin con Dieta Mediterrnea <span style="font:1.1em;color:#ff0000">%S0n0֊eo0dVU00~0W0_0</span>֊edV <span style="color:#CCCCCC">;egB}N=0W-Nwmߘk00000000000000l~0_0o0000^0RY00ߘu;mn0N!kN2Rg0i*</sup>0</span>Whttp://www.ncbi.nlm.nih.gov/pubmed/23432189,23550674,24787471?report=DocSum&format=htmldPrevencin con Dieta Mediterrnea <span style="font:1.1em;color:#ff0000">%S0n0֊eo0dV_k0zvhU00_09eHrg0Y0</span>=_@{ؚ000k0J0D0f0, 0W-Nwmߘx0n00000000000000l~0_0o0000n0Ro0_@{00000000NO NU0[0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/29897866,23432189?report=DocSum&format=htmlpreDIVA1Prevention of Dementia by Intensive Vascular Care@qSzVP[k0[Y00 ww+^;N\n0YbvNeQn0wuN2Rg0i%`'`_K{h^X`k0J0D0f0 egn0HMG-CoA reductase;[cerivastatino0Z@0000n0Qzv0b6R0PRISM<Platelet Receptor Inhibition in Ischemic Syndrome ManagementV@\gGP IIb/IIIaS[SObbtirofibanL0N_09eUY00K00i048BfNQn0{kN _K{h^X 㖻l'`Z@b6RRgtirofibanheparin*0_http://www.ncbi.nlm.nih.gov/pubmed/9599104,15533869,11914253,10577636?report=DocSum&format=html)Patient Risk Information Services Managere P0n0`̀of00000S fW0_0 PNNin0PRISM* Tafo0 8^n00n0k0O00y0f0 TaS_00000Qnk0W0 u`0lBvk0Y00`n0t㉦^09eUW0 a`zl[x0n0SR0OW0 ;S+^h0`n0O07_000 PRISM-PLUSoPlatelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and SymptomsO@\gGPIIb/IIIaS[SObbtirofibann0Rg0i0tirofibanXSrk0J0Q007eNQn0{kNsL0ؚK0c0_0_00 ,gn0fo0-NbkU00_00qhttp://www.ncbi.nlm.nih.gov/pubmed/9599103,12021221,11792137,11179517,11076818,10517731?report=DocSum&format=html PRISON IIFPrimary Stenting of Totally Occluded Native Coronary Arteries II StudyQsirolimusnQ0000SES h0000000000BMS n0 gR'`0kY0006K0g_n0@{ q_ Nn0binaryQrzb6RRgSESBMS*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16908768?report=DocSum&format=htmlPro.V.A.Progetto Veneto Anzianim000000Bfk00000 [ CVD Lv wun0j0K0c0_0Nk0J0D0f0 0000MRkL0CVDzvuk0S|0Y0q_0i0CVDzvu000h0 gak0#000000mϑn0NO N uRa ikL^n0NO No0CVDzvuh0#W0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/25766943?report=DocSum&format=htmlPROACT:Prospective Randomized On-X Anticoagulation Clinical TrialmAVR_n0b@hBvlk0J0D0f0 warfarinjnlBvINR2.0^3.0 k0O00y0 NO000`g0o0DAPTg0@h^XhuJ00s0_^Xh000L0XRW0_00n0n0Q@0000k0UD0o0j0O0 ؚ000`g0o0warfarinNO(uϑINR1.5^2.0 g0'Y0\Q@0000o0'YE^k0n\W0_0L0@h0000J00s0hQ{kNk0]o0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/29903344?report=DocSum&format=html PROactive?PROspective pioglitAzone Clinical Trial In macroVascular Events00000bb'`9eUpioglitazonek000'Y@{TuOun0N!kN2RgJ00s0{kNn0b6RRg0i0hQ{kN ^{kv_K{h^X 3RS-N %`'`QuP QR~0_0o0 NRk0J0Q00@{Q~0_0o0Yyv000000000 00 Nn0 NReb6RRgpioglitazone00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/16214598,17466227?report=DocSum&format=htmlGPROspective pioglitAzone Clinical Trial In macroVascular Events 3RS-N00< ㉐g(2W|?\ug0pioglitazonebNk0003RS-Nn0N!kN2RgL000000?PROspective PioglitAzone Clinical Trial In MacroVascular EventsS2W|?\u`5238O k0J0D0f000000bb'`9eUpioglitazonen0'Y@{0000k0[Y00Rg0iW0f0D00PROactive studyn000㉐g0PROCAM(Prospective Cardiovascular Munster StudyR00000'`QRu`n0000h0@n0000000TG HDL-Ch0n0#k0d0D0f0i000000'`u`n0zvuh0HDL-C TGn0k0o0 gaj0vL0000_00pu8^u uf[_http://www.ncbi.nlm.nih.gov/pubmed/12714025,11804985,11216959,1519522?report=DocSum&format=htmlPRODIGY\Prolonging Dual Antiplatelet Treatment after Grading Stent-induced Intimal Hyperplasia Studyx3.z^n0DES, BMS00004&2dRuO(ub@\gBvlDAPT 24K0g vs 6K0g0 ;DAPTn0P}g=2t^_n0hQ{kN, _K{h^X 3@{u`n0T000000024K0gR"6K0g0BARCQ@b6R6K0g24K0g*0Xhttp://www.ncbi.nlm.nih.gov/pubmed/22438530,24161321,,23315904?report=DocSum&format=htmlProlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia study-0000 i0_n02dRuO(ub@\gBvlg60gh0240gn0 g[_0000b6RRgo0 TI{0PRoFESS:Prevention Regimen for Effectively Avoiding Second Strokes3h^X`n0QzvN2RgJ00s0[hQ'`0!kn02.z^n0lBvlg0iY000(1) M'WlBv3h^Xzvu_egn0ARB telmisartanbNY vs 0000 (2) b@\gBvlNO(uϑaspirin _>e'`dipyridamole vs clopidogrel (1)telmisartann0 gaj0Qh^X _@{0000 |?\ub6RRgo0000Z0 (2)aspirin _>e'`dipyridamolen0clopidogrelk0[Y00^R'`o0:y[0j0K0c0_0L0 3RS-NQzvo0!N Ti0Whttp://www.ncbi.nlm.nih.gov/pubmed/18753639,18753638,22089721?report=DocSum&format=htmlX3RS-NN!kN2Rg0 b@\gBvldipyridamole-aspirin vs clopidogrel M'WlBvk0ARB telmisartan0 NWN[0W0_04XTg0i0ProGEAR1Profile and Genetic Factors of Aspirin Resistance00000bb'`n0[Kaj00s0k0]0n0zOP[̀ofk0Y00xvz0PROGRESS5Perindopril Protection against Recurrent Stroke StudybACE;[XSrB00D0o0)R?\RL0 3RS-N0N2g0M00K00i03RS-NN2Rg[0000*0perindopril indapamiden03RS-NN2RgperindoprilXSr*0http://www.ncbi.nlm.nih.gov/pubmed/11589932,22535269,21700945,18272959,16145004,12958329,12742805,15080373,14671247,12633548?report=DocSum&format=htmlPROMISE4Prospective Randomized Milrinone Survival EvaluationuL}S0000000000PDE III;[g0B00milrinoneL0N_09eUY00K0i0hQ{kN0_@{'`{kNN2Rg0000milrinone*0NYHA IV^n0_ NhQ`g0milrinonebNk000N_L0 gak0`S01991t^11gMhttp://www.ncbi.nlm.nih.gov/pubmed/1944425,10618302?report=DocSum&format=htmlBProspective Multicenter Imaging Study for Evaluation of Chest Pain]QRCT q_CTA k000VRf[vigh0_jvig0k0{kN _K{h^X N[[r_uk000eQb ;Nj0KbbB00D0o0:eigTuOun0T00000002t^_ CTAR"_jvig0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25773919?report=DocSum&format=htmlBPROspective Multicenter Imaging Study for Evaluation of Chest Pain-NI{^000n0CADL0u000uYeg`n0Rg:e0<ezvu[[u`k0J0Q00_jvigKRwECG w8h;Sf[ig w_000 h0VRf[vigCTA n000008Promotion of Cardiovascular Health in Preschool Childrene00000n0|^zWPQ3-5sk h0]0n0k0J0D0f0 eP^vj0ߘu;mh0;mRvj0u;m0c\Y00000000n0[ek000 60g_k0000_0WPQJ00s0n0wX0YR0LRn0 gaj09eUo0 360g_0c}W0_00&Prospective Studies Collaboration: PSCW}0000000TC o0@'W t^bh0o0rzW0f0Z@'`_u`{kh0ckn0v0:yW0_00 60skN N @'Wؚ$Pg"145mmHg Og0o0TCh03RS-N{kh0k0ckn0#o0000j0K0c0_00PROSPER7Prospective Study of Pravastatin in the Elderly at RiskYHMG-CoA reductase;[pravastatinn0@{u`n0N2Rg0i0QR_u`{k ^{k'`_K{h^X hQ3RS-Nb6RRgpravastatin0000*0rhttp://www.ncbi.nlm.nih.gov/pubmed/12457784,28750699,27436880,23900315,18501419,16275871?report=DocSum&format=html8Prospective Study of Pravastatin in the Elderly at Risk Iؚ000ؚb`k0J0D0f0 HMG-CoA reductase;[pravastatino0QR_u`{k ^{k'`_K{h^X hQ3RS-N0b6RW0_000PROTECTPlacebo-Controlled Randomized Study of the Selective A<sub>1</sub> Adenosine Receptor Antagonist Rolofylline for Patients Hopsitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function00000A<sub>1</sub>S[SObbrolofyllineL0|T8TV㖒09eUW0 N_jn0`Sn00000NO NU0[0 00o}Yj0聊^L}Nk0d0j0L00K00i0uX[s _ NhQn0rKa N_jn0 YSk0We0O0lBvn0bR !qR N YrolofyllineR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/20925544?report=DocSum&format=htmlQUse of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient SettingoN+gz00BW00000)R?\0000NT-proBNP $P0cjh0Y00_ NhQlBvL0 000000k0_c0_0jnlBvk0O00y0f0_@{0000b6Rk0*Q00K00i0hQ_@{0000b6RRgNT-proBNPjnlBv*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22018299?report=DocSum&format=htmlCPatient Related Outcomes with Endeavor versus Cypher Stenting TrialMreal-worldg0n0QR^X`k0J0Q003t^_n00000@hun0zvuso0 zotarolimusnQ0000o0sirolimusnQ0000h0 TI{0PEffects of Rolofylline in Patients with Acute Heart Failur< e and Renal ImpairmentUN_j[0TuOW0_0%`'`_ NhQ`k0J0D0f0 xb'`00000A1S[SObbrolofyllinen000000fg0:yUU00f0D0_0N {kN QeQbx0n0 gR'`o0000Z00 PROTECT AFaWATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation<3RS-N _@{{k hQ'`^XhuT0000000b6Rk0J0D0f0 ]_3Sn0warfarink0[Y00^R'`L0000_00ihttp://www.ncbi.nlm.nih.gov/pubmed/23325525,29103847,25399274,23008509,19683639?report=DocSum&format=htmlRandomized Prospective Trial of Percutaneous Left Atrial Appendage Closure versus Warfarin for Stroke Prevention in Atrial Fibrillation7^_u'`_?b0}R`g0n0hQ{kN 3RS-Nb6Rk0J0D0f0]_3Sn0warfarink0[Y00^R'`L0:yU0000 PROTECT-CADProspective Randomized Trial of Direct Endomyocardial Implantation of Bone Marrow Cells for Therapeutic Angiogenesis in Coronary Artery Diseases1QRu``CAD k0J0D0f0 ĚXS8ht0}ހn0_K{Qy io0KRRJ00s0__j0 gak09eU0 PROTECT-CKDjProspective randomized study of tolerability and efficacy of combination therapy on chronic kidney disease!ba'`NӁu`n0ؚ@'Wk0[Y00uO(uBvln0_['`0 gR'`k0Y00xvz N_j[ ؚ@'WPROTECT-TIMI-30Randomized Trial to Evaluate the Relative Protection against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic Agents-Thrombolysis in Myocardial Infarction-30b00000bivalirudinn0Q@AmNPo0GP IIb/IIIaS[SObbeptifibatidek0ky0 gak0'YM0K0c0_00eptifibatideg0o0_K{LpAmn09eUJ00s0PCI_Z@gn0.~\L0_00_00n0n0\Q@J00s08@L0XRW0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/16781360,16781361?report=DocSum&format=htmlPROVE IT-TIMI 22ePravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22n{kNJ00s0;Nj0_@{0000b6RRgHMG-CoA reductase;[atorvastatink0007_Rj0NO NBvlLDL-C 62mg/dL pravastatink000jnvlBv95mg/dL *0http://www.ncbi.nlm.nih.gov/pubmed/15007110,21060068,20082923,19958964,18772061,18279736,17548728,16954134,16750703,16537575,16534008,16226162,16226163,16226164,15893181,15843667,15635109?report=DocSum&format=html$PROVE IT-TIMI 22 (Antibiotic Trial)vPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Antibiotic Trial,%`'`QuPk0J0D0f0 buirgatifloxacinn0wgbNo0_00000b6R[0Z00fPravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22gzvuK0010eNQn0%`'`QuPg0jnlBv0SQ0f0D00Ok0J0D0f0 HMG CoA-reductase;[atorvastatink0007_Rj0NO NBvlo0 {kN _K{h^X r_u @LQ^S0 gak0b6R0PROVEDOProspective Randomized Study of Ventricular Failure and the Efficacy of Digoxin;00000dRdigoxinbNn0 gR'`h0[hQ'`k0d0D0f0i0KR[`Sb6RRgdigoxin}}Obk*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8409069?report=DocSum&format=html PROVIDENCEProspective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other ENdpoints in Chlamydia SEropositive PatientsCrifalazilk000Chlamydiad̃L0+ghR'`u`n02U\0b6RY00h0n0N0i*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/28317415?report=DocSum&format=htmlRE-COVERieL}SbQVdabigatrann0 gR'`6K0g_n0uP'`Y@h^Xhun0QzvJ00s0#{k [hQ'`Q@'`0000 %`'`QuP ]0n0Nn0 g[0000 _j g0warfarink0[Y00^R'`L0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/19966341?report=DocSum&format=html RE-DUAL PCIRandomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary InterventionQ@000o02dRuO(uBvldabigatran P2Y<sub>12</sub>;[ n0{0F0L03dRuO(uBvlwarfarin DAPT;P2Y<sub>12</sub>;[ aspirin= 000NOK0c0_00@h^Xh0000000k0[W0f0o02dRuO(un03dRuO(uk0[Y00^R'`L0:yU00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/2884419< 3?report=DocSum&format=htmlRE-LY:Randomized Evaluation of Long-Term Anticoagulation Therapy/_?b0}R`k0J0D0f0dabigatrann0warfarink0[Y00^R'`h0[hQ'`L000000http://www.ncbi.nlm.nih.gov/pubmed/19717844,19717843,19376304,27496855,26065986,24323795,23743976,23770747,23271794,23027801,22374183,22215856,21606397,21576658,21436594,21200007,21059484,21147728,20801496?report=DocSum&format=html73RS-Nؚ000n0_?b0}R`k0J0D0f0dabigatrann0warfarink0[Y00^R'`h0[hQ'`L0000008Randomized Evaluation of Long Term Anticoagulant Therapy7^_u'`_?b0}R`k0J0Q00L}Svc00000;[dabigatran etexilaten0^R'`f0 RE-MEDY & RE-SONATE|RglBv`k0J0Q00bQVdabigatrann0^wbNk000N!kN2RgJ00s0[hQ'`0i*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25743173?report=DocSum&format=htmlOPreterax in Regression of Arterial Stiffness in a Controlled Double-Blind StudyNO(uϑn0ACE;[perindopril )R?\indapamideBvlL0 neatenolol00S.~g@'WSBP J00s0'WPP 0NO Ng0M00K00i0SBP PP R_jn0ck8^SRgperindopril indapamiden0NO(uϑbNatenolol*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/11641310,14715189?report=DocSum&fo< rmat=html?Recombinant Activated Factor VII Intracerebral Hemorrhage TrialhzOP[D}cH0;m'`W,{VIIVP[rFVIIa L0@kX'Yn0b6Rk0 gRK0 U00k00^09eUY00K00i024Bf_n03QQ@ϑJ00s03QQ@n0XRϑ 90e_n0{kNo0rFVIIag00000k0ky0 gak0NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15728810?report=DocSum&format=htmlRECORDTRosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesJ00000bb'`9eUrosiglitazoneRk000_@{u`k000eQb _@{{kk0[gqh0n0 ga]o0j0K0c0_00n0n0 _ NhQ000L0X'YW0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/19501900,19501899,17551159?report=DocSum&format=htmlRECORDAFQRegistry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillationr12K0gn0聊^0^k0 000000000 000000000n0lBv&beun0xbo0q_[0Z0 J00k0 Ntek000eQb ]0n0Nn0_@{VP[L0NY00S0h0L0:yU00_00000000000o0000000000k0ky08l}'`AFx0n02U\0b6R0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21777747?report=DocSum&format=htmlRECOVERRenal Toxicity Evaluation and Comparison between Visipaque and Hexabrix in Patients with Renal Insufficiency Undergoing Coronary AngiographyC q_dRn0Nk'`0iodixanolh0ioxaglateh0g0kY000 q_dRNub6RRgiodixanolioxaglate*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16949481?report=DocSum&format=htmlRECOVERSWRandomized Evaluation of Polytetrafluoroethylene-Covered Stent in Saphenous Vein GraftsQrzJ00s0;N g[NaMACE zvub6RRg0polytetrafluoroethylenePTFE g0W0_00000h0W0j0D00000SS h0g0k06K0g_n0QrzPTFER"SS 30e_n0MACEb6RRgSSPTFEg0B0c0_0L06K0g_o0PTFER"SS0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12821546?report=DocSum&format=html REDUCE-ITJReduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial80000lBv Nn0ؚ000`k0[Y00EPAdRn0RbNo0 ;NZ@0000n0zvu00000k0O00y0 gak0b6R02019t^01gNhttp://www.ncbi.nlm.nih.gov/pubmed/30415628,30898607?report=DocSum&format=htmlREFINE<Risk Estimation Following Infarction, Noninvasive EvaluationGzvuK0081_NM heart rate turbulence TlNN EF0.50 o0͑{j00000ؚ000`n0 T[k0 g(ug0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/18068035?report=DocSum&format=htmlREFLECT@Randomized Evaluation of Flosequinan on Exercise Tolerance Study6@{b5_flosequinann0Rg0i0KR[0ur9eURgflosequinan0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8509565?report=DocSum&format=htmlREGARDS7Reasons for Geographic and Racial Differences in Strokes|Vn03RS-NYzv0W/^h0D00000WWg0n0*je00000xvz0 N,OOlk0J0Q003RS-N0TIA*g:en03RS-Nurn0 guso0ؚD0/NCEP ATP-IIIk000MetSo0CVDs CADzvu000L0ؚD0L0 IDF[n00g00CVDs zvuN,nso0ؚD0CKDn0:ek000000C0000000h0ACRk0RY00h0 {kN +ggN NhQn0N,n|^L0T N0http://www.ncbi.nlm.nih.gov/pubmed/26659948,26260732,25628306,26151265,23743971,17030827,20211299,21482744,22699292?report=DocSum&format=htmlREGENT{Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction TrialqĚ1uegXS8ht0}ހQQleQ ꁶ[Ě0}ހ1uegn0MRƙ0}ހCD34}'`CXCR4}'`leQo0D0Z000EF [Mzn0 gaj09eU00_00U0j0K0c0_0L0 EFn0NO NL0UWg0 K0d0zvuK00@LQ^SL0E0_0`k0J0D0f0o0}Y~0W0D0PTL0000_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/19208649?report=DocSum&format=htmlREGRESS)Regression Growth Evaluation Statin StudylHMG-CoA reductase;[pravastatink000NO NL0QRlxSn02U\0.~k0NH00q_0i0QRQ_J00s0g\^X_n\b6R e_@{0000b6Rpravastatin0000*01995t^05gghttp://www.ncbi.nlm.nih.gov/pubmed/7743614,12742999,11015339,10190398,9626835?report=DocSum&format=html REGULATE-PCIgA Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI}PCIeLOk0J0Q00eb@h0000REG1PCIvMRk0,{IXaVP[;[n00000000;pegnivacogin=0YlW0 PCIB}NBfk0pegnivacoginn0-NTdRg0B000000000;anivamersen=0Yl n0 gR'`h0[hQ'`0 REHEARSE-AFmAssessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation:XSui\iECG0(uD0_012Vn0`000000o0 8^00k0O00y012K0gn0eAF:eL0XH00S0h0L0:yU00_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/28851729,28851730?report=DocSum&format=htmlREIN Ramipril Efficacy in NephropathyCACE;[ramipriln0NOwRg0i0^|?\uNuk0J0D0f0ACE;[o0^00000ˆ}v?\0 gY00Og00NOwRgL0B0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/10437863?report=DocSum&format=htmlREIN-2+ggNu`n02U\k0[Y00Rg0ACE;[ramiprilk0008^n0M'WBvlh0Cabbfelodipine0RW0_07_RM'WBvlh00k0+ggNu2U\8^M'Wramipril Nn0M'W R"7_RM'Wramipril Nn0M'W felodipine 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15766995?report=DocSum&format=htmlReinforcing EducationRELAXPhosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection FractionSPDE-5;[sildenafiln0L}SbNk000 KR[J00s0聊^rKaL09eUY00K00iY000< 241_n0g'Yx }BdSϑsildenafilR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/23478662?report=DocSum&format=htmlQb5_'`_ NhQ`k0J0D0f0 @{b5_\O(u00d00000000000-5;[0000000sildenafil 0bNW0f00241_n0KR[n09eUo0000Z00 RELAX-AHF~zOP[D}0cH0W0000000-2 serelaxin*n048BfYlo0|T8TVur09eUY00K00iY000|T8TVur9eURgserelaxin0000* |T8TVurn0-NI{^^Wfj09eU00_0`n0rRTserelaxinR"00000`http://www.ncbi.nlm.nih.gov/pubmed/23141816,23141815,23999454,23273292?report=DocSum&format=htmlGEfficacy and Safety of Relaxin for the Treatment of Acute Heart FailureS%`'`_ NhQ`k0J0D0f0 serelaxin*n048BfYlo0|T8TVur09eU0 180e_n0hQ{kN _@{{k0b6RY000 60e_n0QeQbo0b6R[0Z0,{3vf 0 RELAX-AMIvRandomized Early versus Late Abciximab in Acute Myocardial Infarction Treated with Primary Coronary Intervention TrialQe%`lBv[g0@\gGP IIb/IIIaS[SObbabciximab0bNW0_04XTegbN n0 gR'`000000[g0bNW0_04XT_gbN h0kY000KbbMRn0h^XNRn0TIMI grade ܈ckSTIMI frame count _K{og^n09eU^egbN_gbN*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17418289?report=DocSum&format=htmlREMATCH]Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failuref][܈RňnLVAD Left Ventricular Assist Device n0wgO(uL0uX[s QOL09eUY00K00ij0irBvlh0k0LVADo0uX[sJ00s0QOL0聊^ N gak09eUW0_00Whttp://www.ncbi.nlm.nih.gov/pubmed/11794191,15123534,15313942?report=DocSum&format=html\Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure REMEDIAL II@Renal Insufficiency After Contrast Media Administration Trial0II~furosemideYl0RW0_0ؚ?\ϑrKaRenalGuard0000?\ϑk0vS_Y00ϑn08m0leQY00S0h0g0 @mϑ0}cW0SOm Nn00000NOnY00000n0܈m0000 Ng0n0[eo0 px4l }00000 NACk000܈m00 q_dRNu0N20Ehttp://www.ncbi.nlm.nih.gov/pubmed/21844075?report=DocSum&format=html REMINDER0A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Early Treatment with Eplerenone in Patients with Acute Myocardial InfarctionA_ NhQn0j0D0%`'`STEMI`k0J0D0f0 jnlBvx0n0eplerenonen0zvu_24BfNQn0Ro0_@{00000 gak0b6R0 RENAALKReduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan?0000000IIS[SObblosartann0NOwRg0i0losartank0 gaj0NOwRgL0000 _['`0o}Y0 |?\u ؚ@'W N_j[http://www.ncbi.nlm.nih.gov/pubmed/11565518,21632472,20882268,17003295,15302780,15149345,12860578,12631367?report=DocSum&format=htmlRenda G, et al.7ؚ(uϑn0^0000KbbL}SbQVNOAC n0 gR'`J00s0[hQ'`k0 _Ӂ_uTuOn0 g!qk000UD0o0j0D00REPAIR/Reperfusion in Acute Infarction Rotterdam StudyYyrk}0SQ0_0Qe%`TL0[eY00alteplasert-PA k000ub0R@wMRn0@hnBvln0S'`h0[hQ'`0i0Qe%`Tk000ub0R@wMRn0@hnBvlo0`k0 gvg0B000Dhttp://www.ncbi.nlm.nih.gov/pubmed/1644083?report=DocSum&format=html REPAIR-AMI_Reperfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction;Ě1uegMRƙ0}ހn0QRleQL0][S.~_j09eUY00K00i04K0g_n0EFn0 NfĚ1uegMRƙ0}ހ0000*0Whttp://www.ncbi.nlm.nih.gov/pubmed/16990384,17620510,17098754?report=DocSum&format=html@_K{h^Xzvu_n0`k0J0D0f0 ꁶ[ĚMRƙ0}ހBMC n0QRx0n0y io0 0000k0kW0][ƙQsLVEF 02 PяO09eU0REPLACE@0000000Nck04OF0TuOu0MRTM0k0ieQY00eNNn0zotarolimusnQ0000o01t^_n0Qrzs0 {kN0_K{h^X 0000@huj0i0n00000zvus0NOK0c0_00RESOLUTE USR-US $Medtronic RESOLUTE US Clinical TrialMeW0D0zotarolimusnQ'`0000ZES n0[hQ'`h0 gR'`0_egn0ZESh0kY00012K0g_n0jvu Y NhQb6RRgeZEStkS[gq*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21470813?report=DocSum&format=htmlRESOLVDDRandomized Evaluation of Strategies for Left Ventricular DysfunctionAIIS[SObbcandesartanJ00s0ACE;[enalapriln0Rg0k0phase 2g0nemetoprolol CRn0Rg0i0candesartan enalaprilo0TdRXSrbN00][000000b6RRgL0'YM0D00_[_j9eUcandesartanR"enalapril metoprolol0000*0{kNsNO Nmetoprolol00000`http://www.ncbi.nlm.nih.gov/pubmed/10477530,10653828,14522567,10952826?report=DocSum&format=htmlRESPECTS2Recurrent Stroke Prevention Clinical Outcome Study#3RS-Ne_0 gY00ؚ@'W`k0J0Q00S*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25882510?report=DocSum&format=htmlREVEAL\Registry to Evaluate Early And Long-term Pulmonary Arterial Hypertension Disease ManagementJwg0wguX[N,nVP[0 T[W0 [ϑvj0uX[N,ncj0\Ob0vcY0{v2xvz01t^_n0uX[N,nVP[0 T[@{bb'` 60skn07u'` [etkj0i0 0Whttp://www.ncbi.nlm.nih.gov/pubmed/20585012,26510696,22086881?report=DocSum&format=htmlREVERSAL:Reversal of Atherosclerosis with Aggressive Lipid Loweringv00000'`RlxSn02U\b6RRgHMG-CoA reductase;[atorvastatink0007_Rj0NO NBvlLDL-C 79mg/dLk0NO N pravastatink0000000j0NO NBvl110mg/dLk0NO N 0ihttp://www.ncbi.nlm.nih.gov/pubmed/14996776,18582631,16769916,16524891,15635110?report=DocSum&format=html8Reversing Atherosclerosis with Aggressive Lipid LoweringREVERSETResynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction Trial#iirlBv Nn0_ӁQ TglBvk0001t^_n0][_j9eUL0000_00ihttp://www.ncbi.nlm.nih.gov/pubmed/19038680,19038681,23641006,19858419,19800193?report=DocSum&format=htmlNResynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction7u_ NhQ`k0J0D0f0 iirBvl Nn0_ӁQ TglBvCRT k0002t^_n0__j 0^n09eUL000000REVERT1Reversal of Ventricular Remodeling with Toprol-XLne_>e'`metoprololo0][00000009eU0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17576868?report=DocSum&format=html REVIVAL-2RRegenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells TrialcF|t0000:RoVP[granulocyte colony-stimulating factor: G-CSF bNk000y^0}ހRTn0 g(u'`0i0][h^X000n0.~\G-CSFR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/16507801?report=DocSum&format=html REVIVE IInMulticenter Placebo-Controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure0%`'`^NQ'`_ NhQ`k0J0D0f0 jnlBv Ca000000levosimendano00^09eU0Reykjavik Studyo'Y!jMRTM0xvz,gxvz h0gen000㉐gK00 CS_'`ˆ}vC-Reactive ProteinCRP J00s0]0n0Nn0pu0000L0QR_u`N,nn0iRj0N,nVP[g0B00K00UO0CRPo0kv-NI{^n0N,nVP[g0B000_http://www.ncbi.nlm.nih.gov/pubmed/20884698,15735197,8508850,15070788?report=DocSum&format=htmlRIBSDRestenosis Intra-Stent: Balloon Angioplasty versus Elective StentingSQ0000h00000@{b_bBA h00k0BAk0ky0Q0000n0{0F0L0Rgn0QR q_n0P}go0o}Yg0B0c0_0L0 QrzsJ00s0聊^00000n09eUo0000j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/12957423,16139121?report=DocSum&format=htmlBRestenosis Intra-Stent: Balloon Angioplasty vs. Elective Stenting.RIBS IIXRestenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting-II*9K0g_n000000QQ0rzb6RRgsirolimusnQ00000000*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/16750678,18992651?report=DocSum&format=htmlRIBS VdRestenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent@dRnQ'`0000DEB h0everolimusnQ0000EES 0kY0009K0g_n0g\@{_EESDEB*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/24412457?report=DocSum&format=html RIFLE-STEACSVRadial versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome=L}HjR0000h0L}'YR00000kY00030e_n0000 g[聊^0000b6RHjR0000'YR*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22858390?report=DocSum&format=htmlRIGHT1Cerivastatin Gemfibrozil Hyperlipidemia TreatmentHMG-CoA reductase;[cerivastatinh0gemfibroziln0NO NRg0k0cerivastatino0[hQg00000000J00s00000000$P0 gak0NO NY000Szv'`TWؚ@uk0J0D0f0cerivastatino0gemfibroziln0Nfk0iW0f0D000Dhttp://www.ncbi.nlm.nih.gov/pubmed/9737646?report=DocSum&format=htmlRIKS-HIARegister of Information and Knowledge about Swedish Heart Intensive Care Admissions (Swedish Register of Cardiac Intensive Care)00000n0egbNL0u}TN_k0NH00q_0i0eg0000lBvo01t^{kNsNO Nh0OW0f0D0_00rhttp://www.ncbi.nlm.nih.gov/pubmed/21521849,20338498,20332402,17032988,16624832,11242427?report=DocSum&format=html RiksSviktSwedish Heart Failure Registry7000000n0{v2xvz1t^_ 5t^_n0uX[sARB candesartanbNOlosartanbNO0`http://www.ncbi.nlm.nih.gov/pubmed/30351407,25399276,23188027,21224459?report=DocSum&format=html RIO-EuropeRimonabant in Obesity-Europe`xbv0000000-1CB<sub>1</sub> S[SObbrimonabantn0[hQ'`J00s0_@{qSzVP[9eURg0i01t^_n0SO͑NO NRgrimonabant0000*0Ehttp://www.nc< bi.nlm.nih.gov/pubmed/15836887?report=DocSum&format=htmlT1t^_k0000_0xbvcannabinoid type 1S[SO;[rimonabantn0 gR'`SO͑0Vn  000000000000n09eU o02t^_0c}0ENSO͑ nOg0xbvcannabinoid type 1CB1 S[SO;[rimonabanto0SO͑ V0n\W0 @|09eU0 RIO-LipidsRimonabant in Obesity-LipidsNrimonabantk000xbv0000000-1CB<sub>1</sub> S[SOneo0SO͑h0yV0 gak0NO NU0[0 D0O0d0K0n0NqSzVP[09eUW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16291982?report=DocSum&format=htmlRIO-NARIO-North AmericaYNO0000ߘk0xbv0000000-1CB1 S[SObbrimonabant0uO(uW0_04XT 2t^_n0SO͑J00s0yVn\o0i^j0L000c}W0f0NO NW0 _NqSzVP[o09eUW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/16478899?report=DocSum&format=html$Rimonabant in Obesity -North AmericaRNSO͑ nOg0xbvcannabinoid type 1CB1 S[SO;[rimonabant 20mgbNk000 SO͑ yV  00000aS'`L09eU0RISC8Research Group on Instability in Coronary Artery Disease]b@\gaspirinL0_K{h^XMI n0zvus0{kN @LQ^S0_h0Y00͑ur_un0zvuk0q_0S|0Y0K0i0F0K00i0MI0{kN0͑ur_uN2Rgaspirin0000*01991t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/1960301?report=DocSum&format=htmlRisk and Prevention StudyHn-3|YO NTxn0_@{0000N!kN2Rg0iY000_@{{k _@{u`k000eQbn0T0000000n-3xR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/23656645?report=DocSum&format=htmlRITA-1+Randomised Intervention Treatment of Angina7CABGh0PTCAn0Rg0k0{kN0_K{h^X0@LQ^S0QR q_0r_ub6RRgCABGPTCA*01998t^10gLhttp://www.ncbi.nlm.nih.gov/pubmed/8094826,9807988?report=DocSum&format=htmlRITA-22Second Randomized Intervention Treatment of Angina@PTCAh0irBvln0Rg0k0{kN0^{k'`_K{h^XN2RgirBvlPTCA0@LQ^S QR q_irBvlR"PTCA0Vhttp://www.ncbi.nlm.nih.gov/pubmed/14522473,10732887,9274581?report=DocSum&format=htmlRITA 32Randomized Intervention Trial of Unstable Angina 3Gegn0PCIL0_egBvl000*Q0f0D00K00i0PCIo0;Nk0͑ur_u0JSnU0[0 {kN MIn00000 NfU0[0j0D0_00 _egBvl00}Y~0W0D00Whttp://www.ncbi.nlm.nih.gov/pubmed/12241831,26227188,16154018?report=DocSum&format=htmlRITA-33-NI{^J00s0ؚ000n0^ST NfW%`'`QuPk0J0D0f0 PCIo05t^_n0{kN ^{kv_K{h^X0b6R0RITZ-2Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Tezosentan in Patients With Acute Decompensated Heart FailureRITZ-4)Randomized Intravenous Tezosentan Study-4P000000S[SObbtezosentann0 gR'`0i072BfNQn0{kN _ NhQn0`S Z@n0Qzv _K{h^Xb6RRgtezosentanR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/12742280?report=DocSum&format=htmlRIVAL2Radial vs Femoral Access for Coronary Interventiono@{ q_J00s0000000000k0J0D0f0 HjR0000o0'YR0000000*Q00K00iRandomized Olmesartan and Diabetes Microalbuminuria PreventionHARB olmesartann0_ϑ00000?\2U\b6R zvuN2Rg0i<0_ϑ00000?\zvub6RRgolmesartan0000*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/21388309,21388316?report=DocSum&format=htmlRobinson JG, et al.Fnon-HDL-Cn0NO Nsh0_@{000NO N^o0vY000 non-HDL-Co0QRu`CAD N2n0_00n0͑j0lBv00000g0B000ROC!Resuscitation Outcomes ConsortiumsbY_\Pbkn0zvu4X@bh0Rg000n0.z^L0uX[sk0q_Y00K0i0F0K00i*</sup>^R'`L00000 0http://www.ncbi.nlm.nih.gov/pubmed/21830957,21830960,25148838,26610874,25749644,24895454,24552831,24315894,24132190,24302273,23212720,21873708?report=DocSum&format=htmlRivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation`^_u'`_?b0}R`k0J0D0f0 ebQVg0B00L}Svc\O(uW,{XaVP[;[0000000rivaroxaban n03RS-NJ00s0^-Ng^yL}|hQ'`^XhuN2Rgo0warfarinh0 TI{0 ROMICAT IINRule Out Myocardial Ischemia/ Infarction Using Computer Assisted Tomography II$RgUOk0QRCT q_0\eQY00S0h0g0eQbgL0w.~W0 bsL0 Nf0Whttp://www.ncbi.nlm.nih.gov/pubmed/22830462,22830468,23685743?report=DocSum&format=htmlMACSL0u000uk000Qe%`ED Yeg`k0J0D0f0 egUOx0n0QRCT q_CCTA \eQk000 eQbBf :e~0g0n0BfL0 EDbs 0000ROOBYRandomized On/ Off BypassU00000CABGh000000CABGn0 gR'`0kY000wg30eNQ n00^00000R"00000 wg1t^ n00^ 0000X[o}Y00000000000Whttp://www.ncbi.nlm.nih.gov/pubmed/19890125,19890133,28813218?report=DocSum&format=htmlROSE AHF?Renal Optimization Strategies Evaluation in Acute Heart FailurelN_j[0TuOW0_0%`'`_ NhQAHF `k0J0D0f0 )R?\x0n000BW00000)R?\0000dRnesiritideNO(uϑYl~0_0o0NO(uϑdopaminen0Rk00072Bf_n0N[ F0c0@n09eUo0000Z00 Rothwell PM, et al<NN'`3Z@zv\O Z@'`3RS-N`k0J0Q00irlBvn0egQzvN2RgL0:yU00 aspirinn0egn0 gR'`o0'YM0K0c0_00Rotterdam StudyRbk04OF0u`n0zvuh0]0n0[VP[0wgk00_00W0f0D00000000n00000xvz055skBfn0umCVD000o07usYg0 TI{j0L00 Rzvn0CVDk0o0'YM0j0UD0L0B00 7u'`o0QRu` sY'`o03@{u` _ NhQ0zvuW00Y0D00D0Z00n0u`0YO0o0ؚbg0zvu0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25403476,30060115?report=DocSum&format=html6chlorthalidoneo0 hydrochlorothiazide000_@{0000b6RRgk0*Q000ROX CONTROL HTNrROX Coupler0(uD0_0}xRY;TTn0 gR'`h0[hQ'`08^00h0k06K0g_n0:[[S.~g@'WSBP J00s024Bf1uLR NSBPSBPNO No0D0Z000RY;TT irlBv8^00<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25620016?report=DocSum&format=htmlROXISBRandomised Trial of Roxithromycin in Non-Q-Wave Coronary SyndromesP000000|buirroxithromycinn0;Nj0Z@0000n0N2 b6RRg0i0jnlBvk0b00000buirꌒ0RH00lBvo0 gRg0B00S'`L0B000Dhttp://www.ncbi.nlm.nih.gov/pubmed/9259655?report=DocSum&format=htmlRRISCTReduction of Restenosis in Saphenous Vein Grafts with Cypher Sirolimus-Eluting Stent36K0g_n00000Q`gQ_ d1Yb6RRgsirolimusnQ0000000000000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17174178?report=DocSum&format=htmlRUBY-1fStudy Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects with Acute Coronary Syndromes b%`'`QuP`k0J0D0f0 jnb@\gBvlx0n0eL}Svc\O(uW,{XaVP[;[000000darexaban n0Ro0(uϑOX['`n0Q@000 NfL0000_0L0 k'`o0000Z0,{IIvf 0RUSSLANRandomised Study on Safety and Effectiveness of Levosimendan in Patients with Left Ventricular Failure due to an Acute Myocardial InfarctaCa000000levosimendann0 gR'`0i0levosimendann00.1^0.2g/kg/Rn0c}bNo0 NO@'WB00D0o0Z@0zvY00S0h0j0O0_ NhQn0`SJ00s0{kN0b6RW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/12208222?report=DocSum&format=htmlRUTHRaloxifene Use for the HeartYxbv000000S[SO0000000g0B00raloxifeneo0CHD0000 gak0b6RW0j0D00xmdo'`sNLvh0iSObo0b6RY00L0 Y@h^XhuJ00s0{kv3RS-N000o0XR0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16837676?report=DocSum&format=html RUTHERFORDReduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD): Interim Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial[[(uϑn00000\x000000000000000;[ezetimibek000lBv Ng00LDL-C100mg/dL0Tbg0M0j0D0000cTSO[e'`ؚ0000000@u`k0J0D0f0 bPCSK9000000000bSOdRAMG-145 n041T0h0n0v Nlk000 121_n0LDL-CL0NO N,{2vf RUTHERFORD-2PCSK9;[evolocumabn0LDL-CNO NRgh0[hQ'`0i0LDL-Cn0121_~0g0 J00s0101_h0121_n0s^GW$P~0g0n0 YSs121_n0LDL-CNO No0evolocumab140mg Q2W 61.3%;0000] 59.2%=, 420mg QM 55.7%; 61.3%=0101_h0121_n0s^GW$Po0 61.2%; 60.2%=, 63.3%; 65.6%= 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25282519?report=DocSum&format=htmlRxEACH:Alberta Vascular Risk Reduction Community Pharmacy Projecto0WWdR+^L0;N\W0f0 @{0000NO NY0y0M0uO0QW0 NeQY00000000zv0\eQW0 CVD000k0[Y00 gR'`0UO03K0g_n0c[CVD000n0 YS0000NO NdR+^NeQ8^00<sup>*</sup>0Nhttp:/< /www.ncbi.nlm.nih.gov/pubmed/27058907,27311524?report=DocSum&format=htmlvan Vark LC, et al.Aؚ@'W`k0J0D0f0 RAAS;[o04t^g0hQ{kN0000[gqlBvk0O00y0 gak0b6RW0_0L0 S00o0ACE;[k0000n0g0B0c0_00SACRAASmall Coronary Artery Treated by TAXUS Libert Registry in Japan\@{k0J0Q00paclitaxelnQ0000n0 gR'`SAFE,Saiseikai Acute Heart Failure in the ElderlyPhQVnuOYe-xvz 80skN Nn0%`'`_ NhQ`k0J0D0f0Su`h0W0f0n0QRu`n0zvuso0ؚO0o0j0D0L0 CADk0wVY00_ NhQ0zvuW0_04XTn0N_o0ui0f0 No0SAFE-ICD:Safety of Two Strategies of ICD Management at ImplantationX i0Bfk0d0}R000DT 0[eY004XTDT h0[eW0j0D04XTDT h0g0[hQ'`0k0 i0Bfn0͑uTuOuh0g-Nn00000n0Tb6RRgDT R"DT 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22858384?report=DocSum&format=htmlSAFE-T5Sotalol Amiodarone Atrial Fibrillation Efficacy TrialQm_n0V_h0}ck0d0D0f0b Nteamiodaroneh0sotalol0kY000_?b0}Rn0m_Sk0W0f0amiodaroneh0sotaloln0 gR'`o0 TI{0Nhttp://www.ncbi.nlm.nih.gov/pubmed/15872201,16904540?report=DocSum&format=html SAFEHEART2Spanish Familial Hypercholesterolemia Cohort StudyFH`n0N_VP[ lBv ASCVDzvu00000n0f0vvh0W0f0YU00_00000n0{v2xvzk0J0D0f0 vjLDL-CTbsh0NO NlBvh0n0#'` U00k0vjTbn0N,nVP[0i<07_Rj0NO NlBvk00K0K000Z0 YO0n0FH`g0LDL-C$Po0ؚD0~0~0g0 vjTbs0NOK0c0_00vjLDL-CTbn0N,nVP[o0 LDLS[SOn0 Ypun0.z^ ezetimiben0O(u |?\uTuO ASCVDn0e_0Nhttp://www.ncbi.nlm.nih.gov/pubmed/26988947,28275165?report=DocSum&format=htmlSAFER@Saphenous Vein Graft Angioplasty Free of Emboli Randomized TrialVGuardWire+gh^Xh0N2Y00device O(uBfh0_egn0000000O(uBfh0g0n00000n0 gR'`0k0;Nj0_ g[Nab6RRgGuardWire_eg*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/11901037,15519010?report=DocSum&format=htmlSAFETYFStandard versus Atrial Fibrillation-Specific Management Strategy Studyx_?b0}Rk0yrSW0_0 ww+^;N\n0b_{tNeQ k000jnv{tk0O00y0QeQbL0n\W0 uX[gL0^wY00K00i<0hQ{kNh0N[Yn0QeQbNeQR"jn{t0NeQk0000000VuX[epeo0^wW0j0K0c0_0L0 0000VuX[sL0ؚK0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/25467562?report=DocSum&format=htmlSAFIRE-DDSymptomatic Atrial Fibrillation Investigative Research on Dofetilide: Ntedofetiliden0m_V_0}cRgh0[hQ'`n0i0V_0}cRgdofetilide0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11067793?report=DocSum&format=htmlSAGE$Study Assessing Goals in the Elderly>12K0g_n0Z@Bfw.~Rg7_RNO NlBvatorvastatin R"-N z^n0NO NlBvpravastatin 0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17283260?report=DocSum&format=htmlSAKURASStudy of Assessment for Kidney Function by Urinary Microalbumin in Randomized TrialuL/NWCabbcilnidipineh0LWamlodipinen0NOw\O(u0kY000?\-N00000-000000kUACR6q[pe$P n0000000K0012K0g_~0g0n0 YScilnidipineR"amlodipine0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23935398?report=DocSum&format=html52W|?\u'`N[0TuOY00ؚ@'W`k0J0Q00Cabbcilnidipinen0NOwRgk0Y00kfSALMANT%`'`_K{h^XAMI k0[Y00PCIeLMRn0b@hmonteplaseNO(uϑYlJ00s0K0000SnicorandilYlk000][XKR9eURgh0[hQ'`n0i0SALT6Study of Ascending Levels of Tolvaptan in Hyponatremia{L}Sxbv000000V<sub>2</sub>S[SObbtolvaptann0 gR'`0i01eS__00n0@n00000o^f} NbMzn0000000BfK004e_J00s030e_n0 YS00000o^o0tolvaptann0eL0000000 gak0ؚD00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17105757?report=DocSum&format=htmlSwedish Aspirin Low-Dose Trial0b@\gNO(uϑaspirinbNk0003RS-N0{kNN2Rg0i0aspirin0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1682734?report=DocSum&format=htmlSALTIREGScottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression:atorvastatink000MzuivNO NBvlo0wppS'YR_rzn02U\0b6RY00S0h00.~U0[00S0h00j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15944423?report=DocSum&format=htmlSAMI5Streptokinase Angioplasty Myocardial Infarction TrialY%`'`_K{h^X_n0rzh0][_jk0[Y00PTCAh0@hn㉬streptokinaseSK n0Rg0k0QsPTCAR"SK0kX[rzb6R0rz9eURgPTCASK*01986t^03gDhttp://www.ncbi.nlm.nih.gov/pubmed/2936956?report=DocSum&format=htmlSAMMPRIScStenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial StenosisN;egB}N=30e_n03RS-N {kNb6RRgMzuivQylBvPTASL}vv@{b_bSJ00s00000 MzuivQylBv*0S0n0P}go0]0n0_2t^N Nc}0Nhttp://www.ncbi.nlm.nih.gov/pubmed/24168957,21899409?report=DocSum&format=htmlcOutcome of Patients in the SAMMPRIS Trial Who Had Failed Antithrombotic Therapy at Study EnrollmentCzvuBfn0b@hBvln0 g!q0OU0Z0 ;NP}gh0 Tik0MzuivQylBvo0L}vv@{b_bS 00000RW0_04XT000 gRj0S'`L0:yU0000 SAMURAI-ICHeStroke Acute Management with Urgent Risk-factor Assessment and Improvement - Intracerebral Hemorrhage%`'`gzvu_3Bf*gn n0CabbnicardipineYlk000M'WlBvvjS.~g@'W;SBP=160mmHg n0[hQ'`h0[LS'`0i<0M'WlBv_n0TbSBPؚ$Po0rzW0f00^ Noh0#/ zvu_24Bf}}Y00M'WlBvk0000^L09eUY00S'`/ SBPn0 YRo0 ^yL}f[vX`J00s00^ Noh0rzW0f0#0Whttp://www.ncbi.nlm.nih.gov/pubmed/< 23704107,24425118,24968929?report=DocSum&format=html SAMURAI-NVAFJStroke Acute Management with Urgent Risk-factor Assessment and Improvement^_u'`_?b0}R0 gY003RS-N`k0[Y00bQVBvl0SANDS.Stop Atherosclerosis in Native Diabetics StudyNLDL-CJ00s0SBPn0MzuivNO NlBvk0008Rn0Q--NSL0.~ ][K{͑ϑL0'YM0O0NO NW0_0L0 聊^0000o0\j0O0jnlBvh0n0]o0000j0K0c0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/18398080?report=DocSum&format=htmlSAPAT%Swedish Angina Pectoris Aspirin Trial7b@\gaspirinn0_K{h^XMI N!kN2Rg0i0MI0{kNN2Rgaspirin0000*01992t^12gDhttp://www.ncbi.nlm.nih.gov/pubmed/1360557?report=DocSum&format=htmlSAPPHIRETStenting and Angioplasty with Protection in Patients at High Risk for EndarterectomyF30eNQn0{kN 3RS-N _K{h^X 31e^1t^_n0{kN TtP'`3h^Xb6Rk0J0D0f0 0000 ^XhOw0000o0@{QdSSk0R0j0D00Nhttp://www.ncbi.nlm.nih.gov/pubmed/15470212,18403765?report=DocSum&format=htmlUStenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Sattar N, et al.r0000lBvk000|?\uzvu000o00Z0K0k0 NfW0_00n0n0 ]0n0v}[v000o0NOO0 Q0000b6Rn00000000 NV0{0i0g0o0j0K0c0_00 -NI{^^ؚ000` _@{u`TuOOk0J0D0f0 sLn00000lBv0 YfY0y0M0g0o0j0D00o2W|?\u`k0J0D0f0 PCSK9;[evolocumab*g000000ub00ˆ}vo00000 ezetimibek0O00y0f0Wfk0NO NW0_00NO Nso0^2W|?\u`h0 Y00Z0 000000k000]0000j0K0c0_00 * PCSK9proprotein convertase subtilisin/kexin type 9 o0000000000n0N.zg0 Ӂg0TbU00@-Nk0RlU000ˆ}vg0B000LDLS[SOk0P}TW0 LDLS[SOn0R㉒0O2Y00ˆ}vh0W0f0w00f0J00 PCSK9n0_jrs_W Ypu00c0_0HQ)Y'`u`L0~0U0k0[e'`ؚ0000000@uh0hsWL0 TNg0B00S0h0K00zvU00_00 evolocumabo0S0n0ˆ}vk0[Y000000000bSOdRg0 ,{IIvfk0J0D0f0LDL-Cn0 gaj0NO Nh0o}Yj0[hQ'`L0:yU00f0D000SATURNbStudy of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin_g'Y(uϑn00000rosuvastatinh0atorvastain n000000'`RlxSuk0[Y00Rg0kY00000000[MzsrosuvastatinR"atorvastain0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22085316?report=DocSum&format=html@QRu``k0J0D0f0 g'Y(uϑn0rosuvastatinh0atorvastatinn000000'`RlxSu2U\b6RRgo0 TI{0Savarese G, et al.$ؚ@'W`k0J0D0f0 6RikLݍn09eUo0聊^0^n09eU0S fW0j0D002ؚ000n0^_ NhQ`k0J0D0f0 ACE;[ ARBo0D0Z000_@{00000000 gak0b6RY000SAVE*Survival and Ventricular Enlargement TriallzvuegK00n0ACE;[captoprilbNL0wgN_09eUY00K0 __jn0`S0N2Y00K00i0hQ{kN0_@{{k0͑u_ NhQ0%`'`_K{h^XQzv0^{k'`_@{0000N2Rgcaptopril0000*0qhttp://www.ncbi.nlm.nih.gov/pubmed/1386652,15569840,15172406,12732606,12208801,11985906?report=DocSum&format=html$Sleep Apnea Cardiovascular Endpoints[c}}'W|T8TCPAP BvlRk000_@{0000b6RRg0i<0_@{{k _K{h^X 3RS-N _ NhQ0%`'`QuP0TIAk000eQbn0T0000000CPAPR"8^000Nhttp://www.ncbi.nlm.nih.gov/pubmed/27571048,27571490?report=DocSum&format=html SAVE PACebSearch AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction TrialbS[:Ro0g\S_[n01 TgS0N2 Y00NT00000L0_egn0NT00000k0ky0_?b0}Rn00000NO NU0[00K00i0c}'`_?b0}Rb6RRgg\S_[00000_egNT00000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17804844?report=DocSum&format=htmlSAVEDSaphenous Vein de novo TrialU0000lBv~0_0o00000@LQ^lBvn0聊^vJ00s0@{ q_ Nn0Rg0k0@{QT_b5_0_0000b6RRg00000000*0Qrzb6RRg0000000001997t^09gDhttp://www.ncbi.nlm.nih.gov/pubmed/9287229?report=DocSum&format=html SAVOR-TIMI 53Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) Thrombolysis in Myocardial Infarction (TIMI) 53<DPP-4;[saxagliptink000Z@0000n0XR0 n\0000j0K0c0_0L0 _ NhQk000eQbo0XRW0_00`http://www.ncbi.nlm.nih.gov/pubmed/23992601,23992603,27222508,25189213?report=DocSum&format=html_Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-TIMI 53lCVDؚ000n02W|?\u`k0J0D0f0 Nn0|?\ulBvx0n0DPP-4;[00000000saxagliptin Rn00000k0[Y002.1t^_-N.Y$P n0_@{0000g0n0^R'`L00000,{IVvf 0SCAAR5Swedish Coronary Angiography and Angioplasty Registry?dRnQ'`0000DES h0000000000BMS n0wg0^0kY000}{kN _K{h^Xb6RRgDESR"BMS0{http://www.ncbi.nlm.nih.gov/pubmed/17296822,24998123,23500325,22947610,19406341,19420363,19371822?report=DocSum&format=html24t^_n0{kN _K{h^Xn0zvuk0J0D0f0 dRnQ'`0000h0000000000k0]o0000j0K0c0_00SCAF-Stockholm Cohort-study on Atrial FibrillationbQVwarfarink000lBv;^0ACC/AHA/ESC0000000Wk0UO ~0_0warfarinO(uk0q_Y00V0fxk0Y0003RS-NN2L0 NASRg0 3RS-Nn0qSzVP[k000000d\%RSL0warfarinlBvk0NH00q_o0\U0D0h0`0000N\lBvo0zv\O'`AFJ00s081skN Nn0`g0ؚ;^k0000 Vv000000k0We0O0lBveݑn09eUL0_0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16847008?report=DocSum&format=html SCANDSTENT:Stenting Coronary Arteries in Non-stress/Benestent DiseaseGsirolimusnQ0000SES n0 gR'`h0[hQ'`0iY0006K0g_n0[ϑvQR q_k000jvu Yg\@{_SESBMS*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/164< 12876,18498953?report=DocSum&format=htmlCStenting of Coronary Arteries in Non-Stress/Benestent Disease Trial1іu Yk0J0D0f0 Cypher0000o0000000k0ky0Qrz jvu Y@LQ^S0 gak0b6R0SCAST&Statin and Coronary Artery Spasm TrialzQR0000sLlBvCabb k0HMG-CoA reductase;[fluvastatin0RW0_04XTk0U00k00000L0b6RU000K00iY0006K0g_n00000000zvQR0000b6RRgfluvastatin[gq*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/18452779?report=DocSum&format=html+Scandinavian Candesartan Acute Stroke TrialARB candesartank000Na͑j0M'WlBvn0 gR'`0iY000gRn06K0gk0J0Q00@{{k ^{kv_K{h^XMI ^{kv3RS-Nn0T0000000candesartanR"0000 modified Rankin Scaleg0UOW0_06K0g_n0_jv0^candesartann0{0F0L0 NoPT0Whttp://www.ncbi.nlm.nih.gov/pubmed/21316752,21316753,23660849?report=DocSum&format=htmlSCAT4Simvastatin/Enalapril Coronary Atherosclerosis TrialHMG-CoA reductase;[simvastatink000NO NBvlJ00s0ACE;[enalapriln0QR00000RlxSuk0S|0Y0Rg0i0rz0PTCAb6Rsimvastatin0000*0{kN _K{h^X 3RS-Nb6Renalapril00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/11023927?report=DocSum&format=htmlSCATIOStudio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'InfartohbQVcalcium-heparinn0Rg0i0NN'`Z@zv\OheparinR"[gq0SKbNOn0_K{Z@QzvJ00s0{kNN2Rgheparin[gq*0SK^bNOg0o0heparin[gq0Dhttp://www.ncbi.nlm.nih.gov/pubmed/2568520?report=DocSum&format=htmlSCD-HeFT+Sudden Cardiac Death in Heart Failure TrialYN_k0[Y00b NteamiodaroneJ00s0 i0Wd0}RhVICD n0 gR'`0i0hQ{kNb6RRgICD0000* amiodaroneR"0000p0.53 0http://www.ncbi.nlm.nih.gov/pubmed/15659722,24747100,24727258,23541974,18955671,18768944,18768943,18687249,18371559,17485579,16818817?report=DocSum&format=htmlTCost-effectiveness of ICD therapy in the Sudden Cardiac Death in Heart Failure Trial=[[_ NhQ`k0J0D0f0 amiodaroneo00000000000ؚj0L00 gR'`g0R0 ICDo0000 gR'`h00k0ؚD004ij0lBv0SQ0f0D00_ NhQ`J0D0f0 ICDo0{kN0b6RW0_0L0 amiodaroneo0b6RW0j0K0c0_00Schneider MP, et al.}RASb6Rn0_?b0}RN!k0N!kN2lBvn0exbh0W0f0n0a0/ecY00P}gg0B00L0 N!kN2fn0P}gk0o0_NQ0㉐gk0000n0L0eQc0f0D000RASb6Rn0dRn0UD00b Nteh0n0vN\O(uB00D0o0vWN\O(un0S'`j0i0 ~0`0 Nfj0pL0\j0O0j0D00SCIPIOEffect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial Up to 2 Years After TherapykCABG0eLY00Z@'`_K{u`k0J0Q00]_Ӂy^0}ހc-kit}'` QRQleQo0[hQg0 h^X000L0.~\ uX[_K{L0XRW0 ][ƙQs QOLL09eUW0_0,{1 vf: lBv20O0[gq13O02t^ 0SCOPE/Study on Cognition and Prognosis in the ElderlyAIIS[SObbcandesartank000M'WlBvL0_@{0000 w_jNO N uFT0b6RY00K00i0M'Wcandesartan0000*0_@{{k ^{kv_K{h^X 3RS-NcandesartanR"000003RS-Nb6RRgcandesartan00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/12714861,15364316?report=DocSum&format=html9Study on Cognition and Prognosis in Elderly HypertensivesSCORE=Study to Compare Restenosis Rate Between QueST and QuaDDS-QP2[paclitaxel\SOg0B007-hexanoyltaxolؚ(uϑnQ0000o0euQXk0 gak0b6RW0_00n0n0 0000@hu g[_0000n0000L0 NfW0fo0-NbkU00_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/15464315,12356631?report=DocSum&format=htmlSCORESStent Comparative Restenosis_self-expanding]b5_W SE0000h0balloon-expandable0000b5_W BE0000n0 gR'`0k0;N g[_0000zvus QrzsSER"BE0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11472703?report=DocSum&format=htmlSCORPIUSGerman Multicenter Randomized Single Blind Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery LesionsDeu Yx0n0sirolimusnQ0000o01t^n0[hQ'`J00s0ؚD0 gR'`0:yW0 000000000k0ky0ifgQT d1Y0 gak0b6RW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/17950142?report=DocSum&format=html SCOT-HEART)Scottish COmputed Tomography of the HEARTSNO--NI{^000n0u00000Yeg`k0J0Q00jn00ig ECG KRwfj0i0 x0n0QRCT@{ q_ wppS000 Rk000CADk000r_un0:e0SCREAM project)Stockholm CREAtinine Measurements projectBeGFR 60 mL/R/m&sup2;n0-NI{^^͑^n0ba'`NӁuo0 'YR_rzuzvun0rzW0_0qSzVP[g0B00S0h0L0:yUU00_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/30678761?report=DocSum&format=htmlSCRIP+Stanford Coronary Risk Intervention ProjectkQRu`n0000VP[0n\U0[00S0h0k00000000RlxSn02L0bH00S0h0L0g0M00K0i0F0K00 T`n0K0K00d0Q0;Sk000_egn0lBvlh0k09eU0KR0@{rzb6RRg000VP[n\_eglBv*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/8124838?report=DocSum&format=htmlSCRIPPSIScripps Coronary Radiation to Inhibit Intimal Proliferation Post Stentingg0000 i0_n0QXk0n\U0[00_00n000000k000QRQ000}gq\00000192Ir-192 n0[hQ'`J00s0 gR'`0i0g\@{_b5_0ifgQT_ d1Yb6RRgIr-1920000*0Mhttp://www.ncbi.nlm.nih.gov/pubmed/9180087,10468078?report=DocSum&format=htmlSDTS&Syncopoe Diagnosis and Treatment Study7!N[8lEN0000000< lBvh0irBvln0 gR'`0k0-Nzvh gR'`o0!N[8lEN0000000lBvirBvl*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11435337?report=DocSum&format=htmlSEARCHSStudy of the Effectiveness of Additional Reductions in Cholesterol and HomocysteineHMG-CoA reductase;[simvastatink000MzuivNO Nn0 gR'`h0 @{u`000n0rzW0_00000g0B000n0n0VgSOL0f0K0k0j0c0f0D0j0D00000000n0NO Nn0 gR'`0i12</sub>R"00000Whttp://www.ncbi.nlm.nih.gov/pubmed/21067805,21067806,20571015?report=DocSum&format=html>_K{h^X_n0`k0J0D0f0 simvastatinMzuilBv 0000000NO NBvlk000;N@{0000b6RRgo0000Z00SEAS,Simvastatin and Ezetimibe in Aortic StenosisHMG-CoA reductase;[h0\x000000000000000;[n0uO(usimvastatin-ezetimibe n0 gR'`0i0_@{{k 'YR_rzu#0000Z@'`0000eQb0Y000000 ^Q@'`3RS-Nn0Tsimvastatin-ezetimibeR"00000rhttp://www.ncbi.nlm.nih.gov/pubmed/18765433,27486164,23770175,22440214,21321152,18765432?report=DocSum&format=htmlu^-NI{un0!quP'`'YR_rzuk0J0D0f0 simvastatin/ ezetimibeHMG-CoA reductase;[ 000000000000000;[ k0007_RNO NlBvo0;Nj0_@{0000'YR_rzu#00000+T0 n0 gaj0b6RRgo0000j0K0c0_0L0 Z@'`_@{0000o0 gak0b6RU00_00SECURESECURITYpSecond Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Dual Antiplatelet TherapyX2dRuO(ub@\gBvlDAPT g6K0gh012K0gn0聊^0^0kY00^R'`f 012K0g_n0;NCVD 0000@hu Q@n0T00000006K0gR"12K0g0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25236346,25443707?report=DocSum&format=htmlSEEDS4Syncope Evaluation in the Emergency Department StudyUQe%`k01Y^y\0000syncope unit 0-Q00S0h0k000 :en0xzL0 gak09eUW0 1Y^yn0Qzv {kN0XRU0[00S0h0j0O0eQbpe }eQbepe0 gak0NO NW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/15536093?report=DocSum&format=html5Qe}TQe%`[k01Y^y0000syncope unit 0-Q00h0 :en0xz eQbepe wgu}TN_L09eU0 SELECT-ACS\Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes TriallPCI0eLY00NSTEMI`k0J0D0f0 zOP[D}cH0bP-000000000000bSOinclacumabL0_K{[0b6RY00S'`L0 24BfMRXSVleQ20mg/kg g016-24Bf_n000000I$PNO N0 SENDCAPNSt. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention_egn0|?\ulBvk0NeQlBv0RW0_04XTn0_@{0^k0S|0Y0q_0i09eURgؚ@u(ubezafibrate0000*0R'`u`2Lb6RRgbezafibrate00000Z@ YS0_K{h^Xb6RRgbezafibrate0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9571357?report=DocSum&format=htmlSENIORHwgDAPT[ek000geNNDESh0BMS0kY0001t^_n0;N_3@{ g[0000b6RRgDESBMS<sup>*</sup>0Ehttp://www.ncbi.nlm.nih.gov/pubmed/29102362?report=DocSum&format=htmlSENIORSnStudy of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Senoirs with Heart Failure>1xb'`nenebivololn0 gR'`0i0hQ{kN _@{0000k000eQbb6RRgnebivolol0000*0`http://www.ncbi.nlm.nih.gov/pubmed/15642700,21138861,19497441,16443607?report=DocSum&format=htmlSENTINEL=Cerebral Protection in Transcatheter Aortic Valve ReplacementUL}00000v'YR_ncSTAVR eL-Nn0L}00000v3^XhOwTCEP o0[hQk0[eg0M0 99%n0`g0^Xh0000UcIcW0_0L0 ^yL}w_jk0 YSo0j0K0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/27815101,28126163?report=DocSum&format=htmlSEPIA-ACS1-TIMI 42Study Program to Evaluate the Prevention of Ischemia with direct Anti-Xa inhibition in Acute Coronary Syndromes 1 Thrombolysis in Myocardial Infarction 42botamixabann0(uϑzl[fL0B}N 0.105-0.140mg/kg/BfL0N_n0,{IIIvfn0P܈k0  *gR;u0000 eptifibatidek0O00y0_@{00000b6RU0[00S'`0SERAPHINkStudy with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcomezdual 000000S[SObbg0B00macitentann0wg gR'` [hQ'`0iY000ؚ@'Wun0X` 0000000n0Yl/v Nln0Y y i _?b-NˆS hQ{kNn0T0000000b6RRgmacitentan0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/23984728?report=DocSum&format=html SES-SMARTRSirolimus-Eluting Stent in the Prevention of Restenosis in Small Coronary ArteriesAsirolimusnQ0000n08K0g_n0Qrzb6RRg0000000BS h0k0sirolimusnQ0000BS*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15585732?report=DocSum&format=htmlRandomized Comparison of a Sirolimus-Eluting Stent and a Standard Stent in the Prevention of Restenosis in Small Coronary Arteries2\@{u Yk0J0D0f0 sirolimusnQ0000o0^00 0000k0ky0Qrz0 gak0b6R0SESAMFStudy in Europe with Saruplase and Alteplase in Myocardial Infarction?@hn㉬saruplaseh0alteplasen0Rg0i0X[Rg ^Xb6RRgsaruplaseR"alteplase0Dhttp://www.ncbi.nlm.nih.gov/pubmed/9070549?report=DocSum&format=htmlSESAMINSirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial In< farctionLsirolimusnQ0000SES h0000000000BMS n0Qrzb6RRg0k01t^_n0binaryQrzb6RRgSESBMS*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/17498576?report=DocSum&format=htmlSeshasai SR, et al.uaspirinn0N2bNk000^{kv_K{h^Xo0n\W0_0L0 _@{{k Lv{kn0N!kN2Rgo0:yU00Z00aspirinn0 gR'`o0]000 NV0Q@0000k000vkU000S0h0K00 N!kN2h0W0f0n0aspirinn00000bNo0YS_g0j0D00Seven Countries Study-puj00eSWk0J0D0f0}0000000h0QR_u`k000wg{kNsh0n0#0iY00uf[0pu8^u uf[ Z@'`_u`Uhttp://www.ncbi.nlm.nih.gov/pubmed/10620642,8610299,7596000?report=DocSum&format=html SHARE Program5Save Hearts in Arizona Registry and Education Program5t^n0'Wn00n0_uCOCPR 000000k000 E\T0[0_0Nk000_uCPR n0[esJ00s0`n0uX[bsL09eUY00K00iY00s|V00000]n00000xvz0E\T0[0_0Nk000CPR[eso0Wfk0XRW0 COCPR[eOo0_egn0CPR[eO0CPR^[eOk0ky0f0uX[sL0ؚK0c0_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/20924010,20924019?report=DocSum&format=htmlSharma M, et al.bؚbn0@hu000{tk0J0D0f0 vc\O(uWL}SbQV4dRn0 gR'`o0\j0O0h000000Kbbh0 TI{g0B00L0 Q@0000o0dRk000puj000yrk0 dabigatrano0mS{Q@000L0ؚD00SHARP#Study of Heart and Renal ProtectionNO(uϑ0000simvastatin 20mg/e h000000008TS;[ezetimiben0uO(uBvlk000LDL-CNO NBvln0 gR'`h0[hQ'`0UOY00000000'`RlxS'`0000n0Rzvb6RRgsimvastatin ezetimibe0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21663949?report=DocSum&format=htmlSHEAFSSelf-Measurement of Blood Pressure at Home in the Elderly: Assessment and Follow-upnN_N,nVP[h0W0f0n0[^@'Wh0:[[@'WYeg@'W 0k0Yeg@'Wo0ck8^`0L0[^@'Wo0 NfY00Nbؚ@'Wn0_@{TuOu000o0000000o}Yn0}2 Pg0B00 [^@'Wo0Yeg@'W000 g(uj0N,nVP[g0B00h0`0000Ehttp://www.ncbi.nlm.nih.gov/pubmed/15026401?report=DocSum&format=html Shen L, et alK聊^fk0{v2U00_0S.~'`_ NhQYeg`k0J0Q00z6q{kL0L}Bfvk0NO NW0_0L0 S00o0{kVk0[Y0000000k0We0O0lBvn0/}Mz000000h0NW0f0D0_00SHEP,Systolic Hypertension in the Elderly Program&M'WlBvL03_@{TuOu0N2Y00K0&TK0i0N2RgM'W0000*01991t^06ghttp://www.ncbi.nlm.nih.gov/pubmed/2046107,24325609,22187278,18391094,15619390,11703993,11497197,11451282,10954008,10904510,9554680,9218667?report=DocSum&format=htmlSHIELD*Shock Inhibition Evaluation with AzimilideThQ0000 b;b00000k00c0f0\PbkW0_0uP'`_[;bb6RRgIIIb Nteazimilide0000* hQ0000b6RRgazimilide00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/15533855,18848141?report=DocSum&format=html*Shock Inhibition Evaluation with AzimiLiDe=ICD i0Ok0J0D0f0 IIIb Nteazimilideo00000 000000_h0Y00_[;bn0Qzv0 gak0b6R0SHIFTRSystolic Heart Failure Treatment with the I<sub>f</sub>0Inhibitor Ivabradine TrialhxbvI<sub>f</sub>00000;[ivabradinen0jnlBvx0n0RbNn0 gR'`0iY000_@{{k _ NhQ`Sk000eQbn0T0000000b6RRgivabradine0000*0ihttp://www.ncbi.nlm.nih.gov/pubmed/20801500,23536611,22927555,22617188,20801495?report=DocSum&format=htmlSHIfTGSystolic Heart failure treatment with the If inhibitor ivabradine Trialp][S.~_jL0NO NW0_0-NI{^^͑^0_bpeg"70b/Rn0ba'`_ NhQ`k0J0D0f0 xbv0000000Am;[ivabradinen0jnlBvx0n0RbNk000 _@{{k _ NhQ`Sk000eQbn0T0000000L0b6RU000 SHIP-DINER:Shiga Progression of Diabetes, Nephropathy and Retinopathy22W|?\u`k0J0Q00L}S|?\ulBvx0n000000bb'`9eUpioglitazone NWN[0Rg0SHOCKLShould We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock<eg@LQ^n0Rg0i030e{kNN2Rgeg@LQ^SR"QylBv06K0g{kNN2Rgeg@LQ^SQylBv*0 http://www.ncbi.nlm.nih.gov/pubmed/10460813,16757723,16186436,16022953,15261929,14563577,14563578,12727150,12706920,12538428,11691514,11376311,11176812,10985707,10985708,10985709,10985711,10985712,10985713,10985714,10985715,10985706,10985710?report=DocSum&format=htmlSHSStrong Heart Study00000000000k0J0D0f0_@{u`030WW12eg0i0!kn03ib1. _@{{kNs1984t^^'88t^ 35^74sk 2. _K{h^XJ00s03RS-N3@{u` k000Rzv eQbn0RzvJ00s0QzvUOk000yus1984^'88t^ 45^74sk 3. _@{u`yush0000VP[n0O45^74sk 0http://www.ncbi.nlm.nih.gov/pubmed/21852681,21788631,18772065,17576870,17210838,16769914,16750694,16116058,15936607,15161777,14732744,14970108,12475459,12392827,11997279,11839627,11587163,11376315,11231443,11171789,10618305,10318659,8970414,2260546?report=DocSum&format=htmlSIAM IIIDSouthwest German Interventional Study in Acute Myocardial Infarctionmimmediate0000@hnBvlv_n00000 h0_eglBv__jv0000j0i0 0k6K0g_n0{kN Qh^X Z@0000 jvu Yx0n0Q@LQ^Sb6RRgimmediate0000__jv0000*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/12932593?report=DocSum&format=htmlSIDIAPBInformation System for the Development of Research in Primary Careh0000lBvh0;N g[_@{0000MACE J00s0{kNn0#0i<010t^CVD000L0NOD0ƖVg0B0c0_0k00K000Z0 0000lBvn0eY~0_0o0Qo03.6t^_n0MACEJ00s0hQ{kN000n0NO Nh0#0Ehttp://www.ncbi.nlm.nih.gov/pubmed/26868687?report=DocSum&format=htmlSiemieniuk RA, et a< l.YO0n0` h0O0k0YO}TL0wD0`B00D0o0wg_RS000n0͑'`L0NOD0`g0o0 L}'YR0000k000TAVI n0{0F0L0SAVR00cksTn0)RvL0'YM0D0S'`L0:yU00_00_0`0W0 L}'Y00000L0 Ni_n0`g0o0SAVRn0{0F0L0L}_\00000k000TAVI0000^o0o}Yg0B000SIGNIFYStudy Assessing the Morbidity Mortality Benefits of the I<sub>f</sub> Inhibitor Ivabradine in Patients with Coronary Artery DiseasefjnlBvk0_bpe0NO NU0[00I<sub>f</sub> Am;[ivabradine0RW0_04XTn0 gR'`0iY000_@{{k ^{kv_K{h^Xn0T0000000ivabradineR"00000Nhttp://www.ncbi.nlm.nih.gov/pubmed/25176136,25176137?report=DocSum&format=htmlSilverman MG, et al.yLDLS[SOn0000000000000NW0f0LDL-C0NO NU0[000000lBvh0^0000lBvg0o0 LDL-C 38.7mg/dLNO NT0h0n0;N@{0000n0v[000o0 TI{g0B0c0_00TbLDL-C$PL0NOD0{0i0;NQ0000000o0NOK0c0_00SIMPLEShockless Implant Evaluation[d0}R0000L0j0D04XTn0 gR'`h0[hQ'`0 0000LF0jnv i0h0k0 Nte{k iR0000n0 NbRn0T0000000 30e_n0{kN CVDj0i0000^[eR"[e0Ehttp://www.ncbi.nlm.nih.gov/pubmed/25715991?report=DocSum&format=htmlSingapore Chinese Health Study. m_0000000n0kvؚ;^j0BdSo02W|?\un0zvu QRu`{kn0000X'Yh0#0Ehttp://www.ncbi.nlm.nih.gov/pubmed/22753304?report=DocSum&format=htmlSingh M, et al.?_Ӂ@{YyKbSn0g0M0j0D0e-g0n0PCIeLk000 g0M00e-g0n0PCIeLk0ky0eQb-Nn0{kN }%`CABGeLn0XRo0j0D00 SINGLEKISS Single Stent and Kissing Balloon R\u Yk0J0Q00lBv&beuSiontis GC, et al.28lENv0000000 i0o017%07u'` 000000Bfn0O\[ Kbb-Nn0?b[0000L0N,nVP[0Sipahi I, et al.MRؚ@'Wn03RS-Nzvu000o0M'WlBvk000 gak0NO NY000SIPS>Strategy for Intracoronary Ultrasound-Guided PTCA and StentingI0000QRQ000lICUS k000000000000o00^09eUY00K00i02t^_n00^o0ICUS-guided 0000g09eUW0_00Ehttp://www.ncbi.nlm.nih.gov/pubmed/11076823?report=DocSum&format=htmlSIRIUStSirolimus-Eluting Baloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary-Artery LesionsUsirolimusnQ0000n0 gR'`0i0Qrz 270eNQ_Ӂ{k _K{h^X jv@{@LQ^SQeLb6RRgsirolimusnQ0000jn0000*0http://www.ncbi.nlm.nih.gov/pubmed/14523139,18036446,16580520,15655127,15123524,14769686,15249503,15596568,15262844,15172398?report=DocSum&format=html SIRIUS IIU Perindopril and Remodelling in Elderly with Acute Myocardial Infarction phase IIf 6%`'`n0^NQ'`_ NhQ`k0J0D0f0 00000)R?\0000ularitideo0@LRKaJ00s0ur 0^09eU0SIRS!Steroids In caRdiac Surgery Trial\_0000CPB 0Y00_ӁKbS0eLN[n0ؚ000`k0J0D0f0 0000000000n0S-NbNk00030e_n0{kNb6Ro0000Z0 _K{h^XCK-MB[ 000L0XRW0_00SIRTAX]Sirolimus-Eluting Stent Compared with Paclitaxel-Eluting Stent for Coronary RevascularizationasirolimusnQ0000Cypher h0paclitaxelnQ0000Taxus n0 gR'`h0[hQ'`0k09K0g_n0;Nj0 g[_0000b6RRgCypherTaxus*0`http://www.ncbi.nlm.nih.gov/pubmed/16105989,21646500,20298923,17868802?report=DocSum&format=htmlNine-Months Results from the SIRTAX Trial: A Randomized Comparison of a Sirolimus with a Paclitaxel Eluting Stent for Coronary RevascularizationIuP'`QRu``k0J0D0f0 Cypher0000o0Taxus0000k0ky090g_n0_Ӂ{k _K{h^X Z@k000jvu Y@LQ^S0 gak0b6R0SISAStent In Small Arteries7Qrzg"50% zvus00000L00000@{b_bSk0ky0f0b6RY00K00i0Qrzs0000R"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/11673341?report=DocSum&format=htmlSISCA#Stenting In Small Coronary ArteriesH__jv0000n0 gR'`0_egn0L}vvQRb_bSPTCA h0k0聊^ Nn00^0000PTCA*0QR q_ Nn00^0000PTCA0Ehttp://www.ncbi.nlm.nih.gov/pubmed/11704369?report=DocSum&format=htmlSISR/Sirolimus-Eluting Stent for In-Stent RestenosisQsirolimusnQ0000SES h0QRQ>e\}lBvVBT h00kY0009K0g_n0_Ӂ{k _K{h^X jv@{@LQ^Sb6RRgSESVBT*0Ehttp://www.ncbi.nlm.nih.gov/pubmed/16531619?report=DocSum&format=html SITS-ISTRVSafe Implementation of Treatments in Stroke International Stroke Thrombolysis RegistryizvuK003^4.5Bf_n0@hn㉬alteplasebNn0Rgo03BfNQn0bNh0 Tig0B00h0D0F0N0iSafe Implementation of Thrombolysis in Stroke-Monitoring Study\0000Skfg01XJTU00f0D00@hn㉬alteplaseYlo0 @hn㉬O(un0L}L0j0D0e-g00[hQk0O(ug0M0 K0d0 gR24BfNQn0uP'`3QQ@ 3K0g_n0{kN g0B000Nhttp://www.ncbi.nlm.nih.gov/pubmed/17258667,18927461?report=DocSum&format=htmlSixty-Plus Reinfarction StudyMbQVAC n0L}SbNk0002t^_n0}{kNsL0NO NY00K00i0{kN0_K{h^XQzvN2RgAC0000*0-˄Q0000b6RRgAC000001980t^11gDhttp://www.ncbi.nlm.nih.gov/pubmed/6107674?report=DocSum&format=htmlSMART;Surgical Management of Arterial Revascularization TherapiesF00000QR0000SOPCAB h0_egn0_0000k000CABG0k0X[s TIMILpAm 0^ QOLOPCABR"CABG0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15100202?report=DocSum&format=htmlh<span sty< le="font:1.1em;color:#ff0000">%S0n0֊eo0dVU00~0W0_0</span><!--Shiga Microalbuminuria Reduction Trial-->֊edV<!--ARB valsartann0_ϑ00000?\n09eURg0Cabbamlodipineh0kY00000000/000000k9eUvalsartanamlodipine*0?\-N00000clϑn0ck8^Sremission svalsartanamlodipine*0-->Nhttp://www.ncbi.nlm.nih.gov/pubmed/17363751,18716365?report=DocSum&format=html&Shiga MicroAlbuminuria Reduction Trialh2W|?\uؚ@'W`k0J0D0f0 AIIS[SObbARB valsartanh0Cabbamlodipinen0D0Z000 gak0M'W0_ϑ00000?\n0cQo0ARBXSrj0D0W0ACE;[h0n0uO(ubNL0U00k0b6R0&Shiga Microalbuminuria Reduction TrialX2W|?\u _ϑ00000?\04OF0ؚ@'W`k0J0D0f0 _ϑ00000?\n0ck8^S0valsartanh0amlodipineg0UOW0 TdRn0ACE;[x0n0 NWN[0Rg0kY000SMART-AF\THERMOCOOL SMARTTOUCH Catheter for Treatment of Symptomatic Paroxysmal Atrial FibrillationGCF0000NM0000000000000n0[hQ'`h0 gR'`0UOY00012K0g_n0uP'`_?b0}R _?b'`;b _?b|Rn0QzvVso072.5%0Nhttp://www.ncbi.nlm.nih.gov/pubmed/25125294,25125295?report=DocSum&format=htmlSMART-AVwSmartDelay Determined AV Optimization: A Comparison to Other AV Delay methods Used in Cardiac Resynchronization TherapyY?b[E^AV0000 n0giSn0 g(u'`0iY000][S.~+gg[Mz:AV00000120msk0V[R"000000g0Rvk0AV00000giSR"_000g0AV00000giS0Ehttp://www.ncbi.nlm.nih.gov/pubmed/21098426?report=DocSum&format=htmlSMART AVwSmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapyi_ӁQ TgBvlk0J0D0f0 ?b_E^AV0000 0SmartDelay000000k000giSW0_04XTn0][S.~+gg[Mzn0 YSo0_000k000giSW0_04XT N[Bf120msec k0V[W0_04XTh0 Y00Z00SMARTTESerial Markers, Acute Myocardial Infarction and Rapid Treatment Triala@n0000000000 CK-MB n00000egk0eQKbY00S0h0o0 ij0@hnBvl0XRU0[00K00i0@hnBvln0[ek0q_[0Z0 %`'`_K{X{kn0x2</sub> Lp-PLA<sub>2</sub> ;[0000000darapladib n0iirlBvx0n0RbNn0[hQ'` gR'`0iY000;NQ0000darapladibR"00000Ehttp://www.ncbi.nlm.nih.gov/pubmed/25173516?report=DocSum&format=htmlSOLO7nn02W|?\u`k0J0Q00xbv0000000-1CB1 S[SObbrimonabantn0 gR'`n0i0SOLVD Prevention Trial9Studies of Left Ventricular Dysfunction Prevention TrialZACE;[enalapriln0_ NhQzvu eQb {kNk0S|0Y0Rg0i0hQ{kN0_@{{kN2Rgenalapril00000_ NhQ eQbn0zvuenalaprilR"00000http://www.ncbi.nlm.nih.gov/pubmed/1463530,15028361,12932605,12771010,12788569,12628950,12106937,11583864,11571241,11499733,11345383,11333991?report=DocSum&format=htmlSOLVD Treatment Trial7Studies of Left Ventricular Dysfunction Treatment Trial?ACE;[enalapriln0N_9eURg0i0hQ{kN0_@{{k0_ NhQk000eQbN2Rgenalapril00000http://www.ncbi.nlm.nih.gov/pubmed/2057034,12932605,12771010,12788569,11583864,11571241,11499733,11345383,11333991?report=DocSum&format=htmlSOPAT,Suppression of Paroxysmal Atrial Tachycardia);00000=000g0O(u;^n0ؚD02.z^n0b Nten0 gR'`J00s0[hQ'`0k0Ehttp://www.ncbi.nlm.nih.gov/pubmed/10355069?report=DocSum&format=htmlSORCanStroke Out< comes Research Canada`{kNn0N,nVP[0 T[W0 S:Bfk0聊^;SL08^eQKbSj0`1Xk0We0D0_0{kN000n0N,n000n0\Obh0i<0LF00S:_peBfQk0 T[Sj0VP[0(uD0f030e_ 1t^_n0{kN0N,nY00S0h0o0S0Nhttp://www.ncbi.nlm.nih.gov/pubmed/21300951,21300950?report=DocSum&format=html SORT OUT II>Danish Organization on Randomized Trials with Clinical Outcome29K0g_n0 g[_0000o0 sirolimusnQ0000h0paclitaxelnQ0000o0 Ti0Nhttp://www.ncbi.nlm.nih.gov/pubmed/18230778,28183505?report=DocSum&format=html SORT OUT IIICDanish Organisation for Randomised Trials with Clinical Outcome III_zotarolimusnQ0000ZES h0sirolimusnQ0000SES n0 gR'`h0[hQ'`0kY00all-comerf09K0g_n0;N g[0000b6RSESZES*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/20231034,20231035?report=DocSum&format=htmlA prospective randomized comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with coronary artery diseaseFzotarolimusnQ0000ZES n0sirolimusnQ0000SES 00*Q0_018K0g_n0_@{0000b6Ro0000Z00 SORT OUT IVHScandinavian Organization for Randomized Trials with Clinical Outcome IV,{NNNDESn0everolimusnQ0000EES n0[hQ'`h0 gR'`0 ,{NNNDESn0sirolimusnQ0000SES h0k09K0g_n0[hQ'` gR'`,{NNNDESn0,{NNNk0[Y00^R'`L0:yU00_02012t^ 03t^_n0MACEEESR"SES2014t^ 5t^_n0MACEb6RRgEESSES<sup>*</sup>2016t^ 0`http://www.ncbi.nlm.nih.gov/pubmed/22308301,26892409,26892410,25086842?report=DocSum&format=html SORT OUT VGScandinavian Organization for Randomized Trials with Clinical Outcome VbuSO8TS'`00000biolimusnQ0000n0 gR'` [hQ'`0EN'`00000sirolimusnQ0000h0kY00^R'`f09K0g_n0CVD 0000@hu TVRn0^R'`o0000Z00Ehttp://www.ncbi.nlm.nih.gov/pubmed/23374649?report=DocSum&format=html SORT OUT VIHScandinavian Organization for Randomized Trials with Clinical Outcome VI,{ NNNdRnQ'`0000g0B00uSOiT'`EN'`0000O(uzotarolimusnQ0000EN'`0000ZES n0[hQ'`h0 gR'`0 uR'`0000O(ubiolimusnQ0000uR'`0000BES h0kY00all-comerf012K0g_n0[hQ'`h0 gR'`k0J0D0f0 EN'`0000ZESn0uR'`0000BESk0[Y00^R'`L0:yU00_00Nhttp://www.ncbi.nlm.nih.gov/pubmed/25601789,25601787?report=DocSum&format=htmlSoSStent or Surgery Trialostent-assisted percutaneous coronary interventionPCI h0CABGn0 gR'`0k0@LQ^SQeLb6RRgCABGPCI*0{kN ^{k'`Qlh^XCABGR"PCI0`http://www.ncbi.nlm.nih.gov/pubmed/12383664,18606919,15557380,12975252?report=DocSum&format=html SOS-KANTORSurvey of Survivors of Out-of-Hospital Cardiac Arrest in the Kanto Region of JapanME\T0[0_0Nk000SF0d0W0|T8Tj0W0n0_Ӂ00000n00n0uSo0 yrk0!q|T8TuO _[0}R0;b _\PbkK00n0BfL0wD0uOk0[Y0000 gRj0Qng0B000Ehttp://www.ncbi.nlm.nih.gov/pubmed/17368153?report=DocSum&format=htmlSPAF.Stroke Prevention in Atrial Fibrillation Study|3h^Xh0hQ'`^XhuN2Rg0b@\gaspirin~0_0o0bQVwarfaring0k03h^X0hQ'`^Xhub6RRgaspirin0000* warfarin0000*03h^X hQ'`^Xh {kNb6RRgwarfarinaspirin0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1860198?report=DocSum&format=htmlSPAF II1Stroke Prevention in Atrial Fibrillation II StudyTbQVwarfarinh0b@\gaspirink000Z@'`zv\O3h^X hQ'`^Xhu k0[Y00N2Rg0k0Z@'`zv\Ob6RRgwarfarinaspirin0Dhttp://www.ncbi.nlm.nih.gov/pubmed/7907677?report=DocSum&format=htmlSPAF III2Stroke Prevention in Atrial Fibrillation III Studyh@h^Xhun0ؚ000n0_?b0}R`k0J0D0f0 00[hQK0d0!|Oj0lBvl0i03h^X0hQ'`^Xhu03RS-NzvuL0warfarin aspirinuO(ug0warfarin(uϑte00 gak0ؚO0fo0-NbkU00_00hhttp://www.ncbi.nlm.nih.gov/pubmed/8782752,15477396,12796127,12370220,10463708?report=DocSum&format=htmlSPAN-CHF-Specialized Primary and Networked Care in CHFY3K0gn0 ww+^k000_ NhQu`{theart failure disease management k000 90e_n0_ NhQk000eQbJ00s0`S__00n0eQbepeL0 gak0NO N0Ehttp://www.ncbi.nlm.nih.gov/pubmed/15313938?report=DocSum&format=htmlSpanish ABPM RegistryM'WlBvk000:[[@'Wo0000000U00f0D00140/90mmHg 0n0n0 24Bf@'Wn0000000o0 NASRn0masked uncontrolled hypertensionMUCH n0 gush0yr_0i<0MUCHo031.1%g0 7u'` 65sk UYqO |?\u ؚ000 XLuW:[[@'W CabbbNOk0YD00Ehttp://www.ncbi.nlm.nih.gov/pubmed/24497346?report=DocSum&format=htmlSPARCL?Stroke Prevention by Aggressive Reduction in Cholesterol LevelsXHMG-CoA reductase;[atorvastatinn03RS-NN!kN2Rg0iY000{kv0^{kv3RS-Nn0Qzvb6RRgatorvastatin0000*0Nhttp://www.ncbi.nlm.nih.gov/pubmed/16899775,17962589?report=DocSum&format=htmlVHMG-CoA reductase;[atorvastatinn0 gu[sL0ؚO0LDL-CL050%N NNO NW0_0Og0o0Q@'`3RS-NL0XRY00S0h0j0O03h^XL0g0b6RU00_00Spaulding C, et al. <{kN _K{h^X 0000@hun0zvuk0J0D0f0 sirolimusnQ0000h0000000000k0 ga]o0000Z00SPECIAL~Secondary Protective Effect of Ca-antagonist for Ischemic Heart Attack Randomized Parallel Comparison with Beta-blocker TrialZ@'`_u`k0J0Q00Cabbn0N!kN2Rgn0iSPINAF5Stroke Pre< vention in Nonrheumatic Atrial Fibrillation;warfarink000bQVBvlL03RS-Nn00000n\U0[00K0&TK0i03h^Xb6RRgwarfarin0000*0Dhttp://www.ncbi.nlm.nih.gov/pubmed/1406859?report=DocSum&format=htmlSPIRE Cardiovascular OUTCOMEWStudies of PCSK9 Inhibition and the Reduction of Vascular Events Cardiovascular OUTCOME~;egB}Nf=00NO000n0`